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Cardiovascular disease remains the commonest cause of death worldwide. The 
majority of deaths are caused by atherosclerotic plaque rupture with resultant 
myocardial infarction or stroke, or rupture of abdominal aortic aneurysms. 
Conventional imaging modalities have consistently failed to identify atherosclerotic 
plaques or aneurysms with high-risk pathological features that are at highest risk of 
rupture or progression. The development of modern molecular imaging techniques 
targeted at these features could lead to the identification of such high-risk plaques 
and aneurysms in vivo and guide the development of novel treatment strategies.  The 
aim of this thesis was to evaluate whether novel molecular modalities have a role in 
providing new insights into biological disease processes, and identify high-risk 
plaques and aneurysms. Using positron emission tomography-computed tomography 
(PET-CT), 18F-fluorodeoxyglucose and 18F-fluoride were utilised as markers of 
metabolic inflammation and active calcification. Cellular inflammation was assessed 
using ultrasmall superparamagnetic particles of iron oxide (USPIO) enhanced 
magnetic resonance imaging (MRI). 
 
In a prospective trial, 80 patients with myocardial infarction (n=40) and stable angina 
(n=40) underwent 18F-fluoride and 18F-fluorodeoxyglucose PET-CT, and invasive 
coronary angiography (Chapter 3). Intense 18F-fluoride uptake localised to recently 
ruptured plaque in patients with acute myocardial infarction. In patients with stable 
coronary artery disease, 18F-fluoride uptake identified coronary plaques with high-
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risk features on intravascular ultrasound. 18F-fluoride PET-CT is the first non-
invasive imaging method to identify and localise ruptured and high-risk coronary 
plaques.  
 
Aortic vascular uptake of 18F- fluorodeoxyglucose was studied in patients with 
myocardial infarction and stable angina (Chapter 4). In a separate outcome of 1,003 
patients enrolled in the Global Registry of Acute Coronary Events, we further 
evaluated whether infarct size predicted recurrent coronary events. Patients with 
myocardial infarction had higher remote atherosclerotic tracer uptake that correlated 
with the degree of myocardial necrosis, and exceeded that observed in patients with 
stable coronary disease. The outcome cohort demonstrated that patients with higher 
degree of myocardial necrosis had the highest risk of early recurrent myocardial 
infarction. This supports the hypothesis that acute myocardial infarction exacerbates 
systemic atherosclerotic inflammation and remote plaque destabilization: myocardial 
infarction begets myocardial infarction. 
 
In a prospective imaging cohort, the role inflammation and calcification was assessed 
in 63 patients with abdominal aortic aneurysms and 19 age and sex matched patients 
with atherosclerosis (Chapter 5). Compared to non-aneurysmal segments, enhanced 
inflammation and calcification was observed within the wall of aortic aneurysmal 
segments. In comparison to matched controls with atherosclerosis, the entire aorta in 
those with aortic aneurysm appears more highly inflamed, suggesting presence of a 
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global aortopathy rather than a disease confined only to the abdominal region of the 
aorta. Aortic aneurysms have greater active inflammation and calcification than 
atherosclerotic controls suggesting a more intense, destructive and transmural 
pathological process. A subgroup of fifteen patients with aortic aneurysms 
underwent imaging with both PET-CT with 18F-fluorodeoxyglucose, and T2*-
weighted MRI before and 24 h after administration of USPIO (Chapter 6). Whilst 
there was a moderate correlation between the two tracers, there were distinct 
differences in the pattern and distribution of uptake suggesting a differential 
detection of macrophage glycolytic and phagocytic activity respectively.  
 
These studies provide novel insights into vascular biological processes involved in 
the initiation, progression and rupture of atherosclerotic plaques and aortic 
aneurysms. Future longitudinal studies are needed to establish whether these 
techniques have a role in improving the clinical management and treatment of 
patients with coronary artery disease and aortic aneurysms. 
 
 	








18F-FDG = 18F-flurodeoxyglucose 
18F-NaF = 18F-sodium fluoride  
AAA = abdominal aortic aneurysm 
CAC = coronary artery calcium  
CAD = coronary artery disease  
CHD = coronary heart disease  
CI = confidence interval  
CT = computed tomography  
CTA = computed tomography aortogram 
CVA = cerebrovascular accident  
CVD = cardiovascular disease  
HASTE = Half Fourier Acquisition Single Shot Turbo Spin Echo 
MACE = major adverse cardiovascular events  
MI = myocardial infarction  
MRI = magnetic resonance imaging 
PET = positron emission tomography  
PET-CT = positron emission tomography-computed tomography 
ROI = region of interest 
SI = signal intensity 
SUV = standardised uptake value 
T2*W = T2* weighted 
T2W = T2 weighted 
TBR = tissue-to-background ratio 
TE = Echo time 
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TR = repetition time 
USPIO = ultrasmall superparamagnetic particles of iron oxide  
ΔR2* = change in R2* (1/T2*) 
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Cardiovascular diseases are the leading cause of death and illness worldwide 
(Lozano et al., 2012, Mozaffarian et al., 2014). Atherosclerosis — a progressive 
disease characterized by the accumulation of lipids and fibrous elements in the large 
arteries — constitutes the single most important contributor to this burden, and has 
been intensely studied over the past century. Our understanding of the 
pathophysiology underlying this important disease has evolved substantively over 
this period. Previously it was considered to be a bland lipid storage disorder, with 
passive deposition of lipid encapsulated within the intima and separated from the 
vessel lumen by a capsule of smooth muscle cells. More recently substantial 
advances in basic and translational science have highlighted the role of 
inflammation, lipid oxidization, cell death, matrix metalloproteinase activity, 
calcification and angiogenesis (Tahara et al., 2014, Otsuka et al., 2014, Golestani and 
Sadeghi, 2014, Thompson et al., 2013). In particular compelling evidence has 
emerged with respect to the importance of inflammation at both the basic and clinical 
level, indicating that better understanding the link between inflammation and 
atherosclerosis might yield predictive and prognostic information of considerable 
clinical utility (Falk et al., 2013b, Budoff et al., 2013, Palombo et al., 2012a, Kataoka 
et al., 2012). 
 
Atherosclerosis has origins in childhood and by middle age subclinical atheroma is 
almost ubiquitous (Libby et al., 2010, Jaffer et al., 2009, Jaffer et al., 2007, Naghavi 
et al., 2003). Indeed, atherosclerosis has one of the longest incubation periods among 
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human disease, offering the tantalizing opportunity to prevent clinical events via 
timely detection and treatment of subclinical disease. Whilst anti-atherosclerotic 
agents of increasing efficacy are evolving constantly, identification of those in need 
of preventive therapy remains a real challenge.    
 
Atherosclerosis is a true systemic disease characterised by widespread development 
of its localized manifestation: the atherosclerotic plaque. Atherosclerosis has a 
particular predilection for medium and large sized arteries, with the coronary 
arteries, carotid arteries, ilio-femoral arteries, and aorta being particularly 
susceptible. The location of the plaque and its stability largely determines the clinical 
manifestation of the disease process. These manifestations can be diverse. At one end 
of the spectrum fixed obstructive stenoses results in demand ischemia leading to 
classical symptoms of exertional angina and leg claudication (Falk et al., 1995, 
Hackett et al., 1988, Falk et al., 1995, Ambrose et al., 1988). However, the most 
dreaded consequences of atherosclerotic disease – stroke and myocardial infarction- 
instead occur as a result of abrupt atherosclerotic plaque rupture and subsequent 
thrombosis. Whilst angiographic techniques can identify lesions likely to cause 
angina, we lack the ability to identify high-risk atherosclerotic plaques at risk of 
rupture and causing myocardial infarction. This is seen as a major goal in cardiology 
because if these plaques could be identified and subsequent rupture and thrombosis 
averted, then atherosclerosis would be rendered a much more benign disease.  	




Atherosclerotic lesions are focal thickenings of the innermost arterial layer, the 
intima. The content of these lesions typically consists of connective tissue, lipids and 
inflammatory and smooth muscle cells (Stary et al., 1995). This chronic 
inflammatory process preferentially occurs at sites of disturbed laminar flow, such as 
branch points and bifurcations, most likely due to the effects of reduced shear stress 
(Moore and Tabas, 2011). Endothelial cells in these regions appear to be more 
permeable due to their polygonal shape, allowing large molecules such as low-
density lipoproteins (LDL) to accumulate beneath the endothelium (Gimbrone, 
1999).  This accumulation appears to be greatest in cases of hypercholesterolemia as 
a result of excess levels of circulating LDL. Indeed, the earliest stages of lesion 
development are characterised by subendothelial accumulation and retention of 
apolipoprotein B-containing lipoproteins (Williams and Tabas, 1995). LDL retained 
within the vessel wall undergoes a series of modifications including oxidation, 
lipolysis, proteolysis and aggregation (Skalen et al., 2002, Goldstein et al., 1979). 
Initially this results in the formation of minimally oxidised LDL which has a 
stimulatory effect on the endothelial cells to produce a variety of growth factors, 
chemotactic proteins and adhesion molecules. These pro-inflammatory molecules 
allow leukocytes entry into the arterial wall.  
  
Adhesion, the ‘rolling’ of leukocytes along the endothelial surface, is mediated by 
selectins, which bind to carbohydrate ligands on leukocytes. Studies of mice 
deficient in P- and E-selectins or the cell adhesion molecule ICAM, has revealed the 
role of these adhesion molecules in atherosclerosis (Dong et al., 1998, Collins et al., 
Novel Molecular Imaging of Cardiovascular Disease in Man 
 
27 
2000). In particular, adhesion of monocytes and T cells has been shown to be 
controlled by the interaction of the integrin VLA-4 with VCAM-1 on the endothelial 
surface (Shih et al., 1999). Following the passage of these monocytes in to the vessel 
wall the growth factor M-CSF promotes their proliferation and differentiation to 
macrophages. Normally, LDL is not taken up by macrophages quickly enough to 
produce heavily lipid-laden foam cells. Further modification of LDL is first required 
by reactive oxygen species and the enzymes myeloperoxidase, sphingomyelinase and 
secretory phospholipase 2. This modification process produces a highly oxidised 
form of LDL, which is rapidly taken up by macrophages, resulting in the generation 
of foam cells (Falk, 2006, Hansson, 2005). This process appears to be mediated by a 
group of receptors which recognise a wide array of ligands. Two such “scavenger 
receptors”, SR-A and CD-36, are thought to be of particular importance (Suzuki et 
al., 1997, Febbraio et al., 2000). As the lesion progresses there is formation of a 
fibrous cap mainly consisting of smooth muscle cells (SMC) and a proteoglycan-
collagen matrix which covers an underlying lipid pool (Virmani et al., 2000b). In 
time the cells present within this lipid pool undergo apoptosis or necrosis, ultimately 
leading to the formation of a necrotic core consisting primarily of cellular debris 
(Littlewood and Bennett, 2003).   
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 STAGES	OF	PLAQUE	PROGRESSION		1.2.1.
Atherosclerosis is a dynamic process with multiple stages: intimal thickening, fibrous 
cap atheroma (fibroatheroma) formation, thin-cap fibroatheroma, and plaque rupture 
(Virmani et al., 2000b). To understand the process of plaque rupture better, it is 
useful to review these different stages of plaque development. 
 
Intimal thickening and intimal xanthomas  
The flow mediated adaptive, intimal thickening is observed at bifurcation points soon 
after birth. While some plaques may begin as fatty-streaks, evidence suggests that the 
intimal thickening is the likely precursor to symptomatic atherosclerotic disease 
since these lesions occur in children at similar locations as advanced plaques in 
adults, although fatty streaks are known to regress (Velican, 1981). However 
considerable debate exists as to whether these lesions should be classified as 
atherosclerosis per se (Getz, 2000). Intimal thickening primarily consists of smooth 
muscle cells and proteoglycan-collagen matrix without significant infiltrating 
inflammatory cells. Fatty streaks, which are predominantly observed at branch 
points, correspond to the accumulation of macrophages within the intima and regress 
with age (McGill et al., 2000). 
 
Pathologic intimal thickening  
The stage in between intimal thickening and fatty streaks and more advanced lesions 
known as fibroatheromas is referred to as pathologic intimal thickening and is 
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characterized by presence of lipid pools containing proteoglycans typically without 
necrosis (Virmani et al., 2000b). The lipid pools are located in the deeper intimal 
layers near the arterial media but in contrast the macrophage infiltrates are present in 
the luminal surface away from the area of accumulated lipid. Early calcification may 
be seen and likely results from the death of smooth muscle cells and as a healing 
response to early inflammation (Kolodgie et al., 2007). Pathologic intimal thickening 
can be associated with plaque erosion and subsequent acute coronary syndromes. 
 
Fibrous cap atheroma  
Fibrous cap atheroma or fibroatheromas represents the earliest of the advanced 
coronary lesions (Virmani et al., 2000b). Typically, the fibroatheromas consist of 
lipid-rich necrotic core consisting of macrophage infiltration within lipid pool and 
encapsulated by fibrous tissue. There is loss of proteoglycans and collagen without 
much free cholesterol in the early phases. The later phases of fibroatheromas are 
characterized by increased free cholesterol, cellular debris and an expanding necrotic 
core. Such plaques may expand outwardly (positive remodeling) or inwards often 
due to progressive fibrosis and calcification (negative remodeling). The latter may 
lead to significant luminal stenosis and the development of anginal symptoms.  
 
The thin-cap fibroatheroma is a subtype of fibroatheromas characterised by a large 
necrotic core (typically > 25% of total plaque volume) that is separated from the 
lumen by a thin fibrous cap (typically < 65 µm). Usually, the fibrous cap tends to be 
heavily infiltrated with macrophages (Virmani et al., 2000b). This well-characterized 
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lesion is considered to be the plaque sub-type most likely to result in plaque rupture 
and is therefore a key imaging target for both invasive and non-invasive approaches 
(Virmani et al., 2000b) (Figure 1-1). 
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Figure 1-1 Photomicrographic cross-section of human coronary artery with 
varying degree of luminal stenosis. 
(A to C) Plaque rupture with mild, moderate, and severe luminal stenosis, respectively. Non-occlusive 
thrombus (Thr) is observed in the microphotograph A whereas occlusive thrombus is occupying the 
lumen in the image B and C. (D to F) Thin Fibrous Cap Atheroma (TCFA) with mild, moderate, and 
severe luminal stenosis. Necrotic Core (NC) is covered by a thin fibrous cap, and thrombus is not 
present in the lumen. (G to I) Stable plaque or FA with mild, moderate, and severe luminal stenosis, 
respectively. The size of necrotic core is relatively small when present, and calcification (Ca++) is 
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 THE	 LINK	 BETWEEN	 INFLAMMATION	 AND	 CALCIFICATION	 IN	 ATHEROSCLEROSIS:	1.2.2.
INFLAMMATION	DEPENDENT	CALCIFICATION	PARADIGM	
Inflammation plays a critical role in the formation, progression and rupture of 
atherosclerotic plaques and is typically characterised by the presence of macrophages 
within the plaque lipid core (Figure 1-2) (Burke et al., 1997a, Burke et al., 2001, Falk 
et al., 2013a, Finn et al., 2010, Virmani et al., 2006b, Virmani et al., 2000a).  In an 
attempt to clear lipid from the vessel intima, these macrophages set up an 
inflammatory cycle that ultimately proves difficult to contain, leading to progressive 
matrix degradation and plaque destabilization. Indeed ongoing macrophage 
infiltration and cell death along with accelerated lipid accumulation contribute to an 
enlarging necrotic core that becomes progressively more inflamed and hypoxic. 
Moreover these cells secrete pro-inflammatory cytokines (including interleukin-1, 
monocyte chemotactic protein-1 and tumour necrosis factor-alpha) and matrix 
metalloproteinases, which actively weaken the fibrous cap: the only barrier between 
this highly thrombogenic lipid core and the vessel lumen. Fortunately this is where 
body defence mechanisms are believed to respond, triggering a calcific healing 
response that attempts to subdue and wall off this inflamed necrotic environment, 
thereby reducing the risk of plaque rupture. 
 
Calcification occurs widely in the body and frequently occurring as a healing 
response to intense necrotic inflammation. This is perhaps best exemplified by 
tuberculosis where the body attempts to wall off the intense necrotic inflammation 
associated with caseating granulomata using calcification. Similar mechanisms are 
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believed to occur within coronary atheroma, with calcification occurring as a healing 
response to intense inflammation within the necrotic core. However within the 
atheroma, calcification appears to have a bi-phasic response, with each stage 
associated with markedly different plaque characteristics and clinical consequences. 
The latter phase of macroscopic calcification is readily imaged using standard x-ray 
angiography and CT, and is widely believed to impart stability to the plaque. Indeed 
by this stage the healing process has often successfully subdued inflammation within 
the vessel wall and separated it from the contents of the vascular lumen. By contrast 
the earlier phase of micro-calcification is not visible using standard non-invasive 
imaging techniques and is associated with plaque instability and an increased risk of 
rupture (Aikawa et al., 2007, Otsuka et al., 2013).  The likely explanation is that at 
this early time-point the healing process has not yet been effective and that the 
inflamed necrotic environment triggering calcification still exists within the plaque. 
This risk of plaque rupture related to inflammation therefore persists. However 
recent data have indicated that micro-calcification might itself increase the 
propensity to rupture, acting as a focal point that intensifies mechanical stresses on 
the surface of the cap (Vengrenyuk et al., 2006a).  
 
Although there have been significant advances in our understanding as to why 
atherosclerotic plaques calcify, the exact molecular mechanisms underpinning this 
observation still remain unclear. Multiple potential pathways have been proposed 
although often these have been established using models of vascular medial 
calcification. Calcification in the coronary arteries is almost uniquely intimal, with 
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medial and adventitial involvement occurring only rarely in conditions such as renal 
failure. Calcification activity in the intima appears to be closely related to 
inflammation and cell death within the necrotic core. Several putative pathways have 
been proposed linking these entities (New and Aikawa, 2011, Tintut et al., 2000, 
Radcliff et al., 2005, Demer and Tintut, 2008, Proudfoot et al., 2000, Shanahan, 
2007). First and most obviously, necrosis of foam cells, vascular smooth muscle cells 
and other cells in the inflammatory plaque milieu leads to the release of large 
quantities of phosphate and calcium which may lead to spontaneous dystrophic 
calcification (as observed in infarctions, haematomas and scars). Second, 
inflammation may trigger osteogenic metaplasia in a variety of cell types (VSMC, 
endothelial cells, etc.) which make a phenotypic switch to osteoblast like cells under 
the influence of RUNX-2 transcription and become capable of roughly recapitulating 
skeletal osteogenesis in the plaque matrix. Third, circulating osteoprogenitors may be 
recruited to the plaque before undergoing maturation to classical osteoblasts. Fourth, 
cells undergoing programmed cell death within the plaque may provide calcifying 
substrate through the release of apoptotic bodies. Fifth and finally, macrophages 
may, themselves, provide the substrate for calcification by directly releasing matrix 
vesicles (the key and final executors of ordered tissue mineralization) into the 
extracellular matrix. Aikawa et al. have published the key and highly elegant 
longitudinal experiments in a mouse model that have demonstrated the link between 
inflammation and calcification (Aikawa et al., 2007).  They showed that macrophage 
infiltration is closely associated with osteogenic activity (as assayed by accumulation 
of Osteosense; a bisphosphonate-conjugated to a fluorescent reporter).  They have 
also shown that apoptotic bodies and matrix vesicles that contain calcium 
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orthophosphate nanocrystals execute this early calcific process (Bobryshev et al., 
2007, Golub, 2011, Proudfoot et al., 2000). 
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 THE	VULNERABLE	ATHEROSCLEROTIC	PLAQUE:	WHAT	EXACTLY	DEFINES	A	HIGH-RISK	1.2.3.
PLAQUE?	
The concept of the vulnerable plaque was first introduced by James Muller in 1989 
when he described ‘hemodynamically insignificant, albeit dangerous lesions’(Muller 
et al., 1989), that he believed were at high risk of rupturing and causing myocardial 
infarction. Since then multiple observational studies have confirmed that most of the 
plaques causing myocardial infarction are non-flow limiting at the time of antecedent 
coronary arteriography or myocardial stress testing. However pioneering work over 
the last two decades has now established that ruptured plaques do have certain key 
histopathological features including: the presence of a large necrotic core, a thin 
fibrous cap (<65 µm), a positively remodelled vessel, macrophage infiltration 
resulting in plaque inflammation, hypoxia leading to neovascularization and finally 
early stage microcalcification (Figure 1-2) (Burke et al., 1997a, Burke et al., 2001, 
Falk et al., 2013a, Finn et al., 2010, Virmani et al., 2006b, Virmani et al., 2000a). 
Moreover it is widely postulated that intact high-risk plaques are likely to 
demonstrate the same pathophysiological features immediately before a clinical 
plaque rupture event, so that identification of these characteristics may be of use 
prospectively. Recent technological advances, coupled with the failure of 
percutaneous coronary intervention to reduce myocardial infarction in patients with 
stable angina (Boden et al., 2007) has renewed interest in detecting these plaques in 
vivo. Indeed, this has been described by many as the ‘holy grail’ of clinical 
cardiology (Calvert et al., 2011, Naghavi et al., 2003, Stone et al., 2011a, Kato et al., 
2012a). 
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Two distinct plaque morphologies have been implicated in majority of acute 
coronary events: plaque rupture and plaque erosion. A few cases (2% to 7%) are 
attributable to a third plaque morphology called calcified nodule (Virmani et al., 
2006a).  It is believed that 60-75% of acute coronary syndromes are initiated by 
plaque rupture (Davies, 1992).  Plaque erosion or denudation of the coronary arterial 
endothelium with an intact fibrous cap is responsible for acute coronary syndromes 
in most of the remainder cases, and is typically observed in young, female smokers 
(Virmani et al., 2000b). 
 
Traditionally, the term vulnerable plaque has been used for all plaque types that have 
been associated with luminal thrombosis (Virmani et al., 2006a). However recently 
attention has focused on the thin fibrous cap atheroma as the most common precursor 
of plaque rupture. In particular virtual histology intravascular ultrasound (VH-IVUS) 
has been used to identify such plaque in the recent Providing Regional Observations 
to Study Predictors of Events in the Coronary Tree (PROSPECT) and the VH-IVUS 
in Vulnerable Atherosclerosis (VIVA) studies (Calvert et al., 2011, Stone et al., 
2011b). Whilst most of the clinical events in these studies were attributable to 
TCFAs, what was also clear is the vast majority of these lesions are clinically silent.  
 
Pioneering work over the last two decades has established that plaques that go on to 
rupture demonstrate several histological features that differentiate them above and 
beyond the classical infact TCFA.  These include a large necrotic core, high 
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macrophage infiltration of the fibrous cap and plaque micro-calcification (Virmani et 
al., 2006a, Kolodgie et al., 2001). This would suggest that there is an intermediate 
stage between a thin-capped fibrous atheroma and a ruptured plaque, which appears 
characterised by advanced plaque metabolism.
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 ABDOMINAL	AORTIC	ANEURYSMS		1.3.
Abdominal aortic aneurysms (AAA) have a prevalence of 5% in adults 65-74 years 
and when ruptured, are associated with a mortality of up to 90% (Scott, 2002). 
Ruptured aortic aneurysms are a common cause of death in the United Kingdom, 
being the thirteenth commonest cause of death and accounting for 6,800 deaths each 
year in England and Wales (Scott, 2002). Open surgical or endovascular intervention 
to prevent rupture is considered when the diameter exceeds 55 mm or expansion 
rates are greater than 10 mm/year (Lederle et al., 2002, UKSAT 1998, Powell et al., 
2007).  Population screening has been shown to halve the mortality associated with 
abdominal aortic aneurysms (Scott, 2002)  and has led to the establishment of a 
national screening and surveillance programme (Lederle et al., 2002, UKSAT 1998). 
Currently, abdominal aortic aneurysm surveillance is complex because of the non-
linearity and unpredictability of expansion rates (Brady et al., 2004), although the 
best predictor of aneurysm expansion is the baseline aneurysm diameter (Golledge et 
al., 2006a). However, up to one fifth of ruptured abdominal aortic aneurysm are less 
than 55 mm in diameter (Darling et al., 1977), and many patients present with 
diameters considerably greater than 55 mm without prior symptoms or rupture 
(Powell et al., 2008). Apart from the simple measurement of aneurysm diameter, 
there are currently no methods of predicting which patients are at risk of further 
aneurysm growth and rupture.  
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 ANEURYSMAL	DISEASE	AND	ATHEROSCLEROSIS	1.3.1.
Aortic aneurysms and atherosclerosis have traditionally been regarded to have a 
common background. This is because AAA is invariably associated with 
atherosclerotic wall damage, supported by the presence of risk factors such as age, 
male gender, smoking, hypercholesterolemia, hypertension and a positive family 
history (Reed et al., 1992). However, during the last decade, evidence has emerged 
highlighting the differences between AAA and atherosclerosis (Golledge and 
Norman, 2010). Atherosclerotic lesions are pre-dominantly intimal in location, 
whereas the media and adventitia are primarily involved in aneurysms (Weintraub, 
2009). Aneurysmal disease is also much more closely associated with smoking and 
hypertension, and has a particular predilection for the abdominal aorta. Furthermore, 
whilst diabetes mellitus is positively associated with atherosclerosis, it is negatively 
associated with AAA (Golledge et al., 2006b). Although aggressive management of 
hypertension and hyperlipidemia is recommended in patients with AAA, therapies 
for these conditions have little effect on aneurysmal growth and rupture (Weintraub, 
2009). Whether this association between AAA and atherosclerosis is causal or 
simply due to common risk factors is unknown. 
 
One possibility is that AAA develops as a pathological response to aortic 
atherosclerosis. This theory was first suggested more than half a century ago 
(Eiseman and Hughes, 1956), when the term “atherosclerotic aneurysms” was 
commonly used (Kaschina et al., 2009). Arterial remodelling is thought to be central 
to this theory. It has been proposed that arterial luminal stenosis leads to 
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compensatory changes in media in response to shear stress alterations (Ward et al., 
2000). The subsequent remodeling of the extracellular matrix compensates for the 
shear stresses (Ward et al., 2000). Although this theory explains severe medial 
thinning observed in AAA, it fails to explain the inflammation observed in the 
biopsies of the walls of advanced AAA. Elastin breaks, stimulated by medial 
proteolysis and the diffusion of pro-inflammatory cytokines from inflammatory cells 
present within atheroma or associated thrombosis could, however, provide the 
stimulation for the chronic inflammatory response seen (Golledge et al., 2006b, 
Golledge and Norman, 2009, Ward et al., 2000). A unique feature of the arterial wall 
in aneurysmal disease is degradation of the connective tissue (Sakalihasan et al., 
2005). Moreover, an increased proteolytic activity has been demonstrated in the wall 
of abdominal aortic aneurysm (AAA) (Sakalihasan et al., 1996, Thompson and 
Parks, 1996).  
 
An alternative theory suggests that the development of AAA and atherosclerosis are 
independent. Shared environmental and genetic risk factors may promote the 
development of both atherosclerosis and AAA in some patients, but the mechanisms 
involved are distinct (Golledge and Norman, 2010). Perhaps, it is obvious that the 
inflammation either due to atheroma or the thrombus holds the vital clue to the 
underlying pathological processes.  
 
The AAA wall usually becomes laminated with thrombus and its intraluminal 
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diameter often appears relatively normal by angiography (Shimizu et al., 2006). 
There is now increasing evidence that this intraluminal non-occlusive thrombus plays 
a key role in AAA evolution (Kazi et al., 2003). Recent studies demonstrate that 
inhibition of thrombus formation via the prevention of platelet aggregation limit 
AAA enlargement in a model of experimental aneurysm in rats (Touat et al., 2006). 
These findings suggest that thrombus formation compromises the structural integrity 
and stability of the arterial wall (Houard et al., 2006). The thrombus mass itself is 
biologically active (Adolph et al., 1997, Fontaine et al., 2002a) with fibrin generation 
demonstrable at the luminal interface (Touat et al., 2006, Houard et al., 2007).  
 
The formation, growth and rupture of aneurysms is now recognised to be the result of 
a complex interplay between biological and mechanical factors. 
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 INFLAMMATION	AND	ANEURYSMAL	DISEASE	1.3.2.
Aneurysmal tissue is characterised by excessive medial neovascularisation, 
infiltration of inflammatory cells (principally macrophages and B-lymphocytes) and 
irreversible remodelling of the extracellular matrix. These pathological processes are 
focal and do not affect the aorta uniformly. Shear wall stress varies spatially within 
the aneurysm (Raghavan et al., 2000) and tensile strength varies in different parts of 
the aneurysm sac (Vallabhaneni et al., 2004). Focal neovascularisation is present at 
the site of rupture only (Choke et al., 2006) and its presence corresponds to the 
degree of inflammation (Thompson et al., 1996). These biological ‘hotspots’ 
represent sites of potential rupture and are targets of developing imaging strategies to 
assess the aneurysm expansion and the risk of rupture. 
 
In contrast to the thoracic aorta, the tunica media of the abdominal aorta is not 
normally supplied by vasa vasorum and the presence of microvasculature in the 
abdominal aortic wall is a pathological finding (Wolinsky and Glagov, 1969). 
Hypoxia of the inner layer of the media, resulting from the presence of intraluminal 
thrombus, is thought to attract inflammatory cells and induce the secretion of 
angiogenic factors promoting neovascularisation (Vorp et al., 2001). These new 
vessels not only supply oxygen and nutrients to the arterial wall but also amplify the 
pathological process by promoting further inflammatory infiltration. The 
inflammatory infiltrate in aneurysm disease is characterised by macrophages and B 
lymphocytes that may be attracted, in part, by the products of extra-cellular matrix 
degradation. Inflammatory cells secrete matrix metalloproteinases that leads to 
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degradation of elastin and then collagen, thus disrupting the structural integrity of the 
aortic wall and rendering it vulnerable to aneurysm formation and rupture.     
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 NOVEL	 IMAGING	 MODALITIES	 TO	 IDENTIFY	 HIGH	 RISK	 ATHEROSCLEROTIC	 AND	1.4.
ANEURYSMAL	DISEASE	
Over the last few years, advances in basic cardiovascular research coupled with 
improvement in novel imaging technology has resulted in improved understanding of 
biological processes underlying formation, progression, and complications of 
atherosclerosis that in turn has renewed interest in detecting the high-risk plaques 
and aneurysms in vivo prior to rupture. (Calvert et al., 2011, Naghavi et al., 2003, 
Stone et al., 2011a, Kato et al., 2012a).  
 
Traditionally the assessment of cardiovascular diseases is evaluated using anatomical 
and physiological modalities. Undoubtedly, these techniques have a significant role 
in assessing the severity of coronary stenosis and are indeed routinely used in 
diagnosis of coronary disease in patients with stable and unstable symptoms. 
Modalities such as stress perfusion and X-ray contrast angiography help identify high 
risk patients by identifying disease severity by assessment of plaque stenosis, burden 
and ischaemia, and guide the need to revascularisation in a certain subset of patients. 
Similarly, routine ultrasound assessment of AAAs is undertaken to assess 
progression of aneurysmal size. However, these modalities primarily focus on 
anatomical and structural element of the disease and give very little insight into the 
molecular or biological processes within the vasculature.  In contrast to approaches, 
molecular and cellular imaging target specific biochemical and cellular processes to 
provide unique insights into the etiology, biology and pathogenesis of the disease. 
Indeed by harnessing recent imaging advances, many believe that it is possible to 
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develop imaging approaches beyond traditional domains and move towards a more 
refined technique that allow identification of more complex molecular, cellular and 
metabolic components of atherosclerotic and aneurysmal disease (Jaffer et al., 2009, 
Jaffer et al., 2007, Choudhury and Fisher, 2009, Tawakol et al., 2006, Rudd et al., 
2002, Tahara et al., 2006b, Nahrendorf et al., 2011). 
 
The common aims of novel molecular imaging are to inform molecular and 
biological processes within a tissue, help refine the diagnosis and risk-stratification, 
and assess responses to specific therapeutic interventions (Jaffer et al., 2009, Jaffer et 
al., 2007, Choudhury and Fisher, 2009, Nahrendorf et al., 2011). Indeed, the 
molecular imaging modailities could act as surrogate end points to study and monitor 
the response of specific interventions.  A number of invasive and non-invasive 
modalities have been developed across various platforms and have shown 
considerable promise to fulfil these goals. The novel imaging modalities can be 
broadly divided into non-invasive modalities such as PET-CT, CT coronary 
angiography, MRI and catheter based invasive modalities such as IVUS and OCT. 
Each of these modalities will be briefly discussed in the following sections, with 
primary focus on metabolic and cellular imaging with PET-CT and ultrasmall 
superparamagnetic particles of iron oxide (USPIO) - enhanced MRI. 
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 POSITRON	EMISSION	TOMOGRAPHY	IMAGING		1.5.
Combined positron emission and computed tomography (PET/CT) is a modern non-
invasive imaging technique that combines molecular information from PET with the 
fine anatomical detail provided by CT, allowing study of biochemical processes 
within small structures. This technique has been widely used in the clinical 
assessment of patients with cancer for many years, resulting in the widespread 
availability of PET/CT scanners (Lardinois et al., 2003). Recent technological 
advances including ECG-gating alongside improved PET resolution has allowed 
translation of this technology in cardiovascular imaging. Theoretically, a limitless 
number of pathological processes can be studied subject to appropriate radiotracer 
being developed, and therefore in principle any high-risk plaque characteristics can 
be potentially targeted.  
 
Using a cyclotron, a positron emitting atom is generated using an isotope with a 
relatively short life such as  11C, 13N, 15O and 18F (Zanzonico, 2012).  Other less 
commonly used radioisotopes include 64Cu, 76Br, 82Rb, 68Ga and 124I. The 
positron emitting atom is bound to a specific protein or sugar that can be translocated 
into the tissue of interest within the body where the isotope decays releasing a  
positron that interact with surrounding electrons, resulting in complete annihilation 
of particles and resulting in two diametrically opposite photons that can be detected 
by the PET detector. The photons detected by the PET scanner are processed and the 
tomographic images define the tracer distribution within the body using a specialized 
algorithm. Corrections for attenuation, dead time, scatter, and random coincidences 
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are applied. This information is then superimposed upon anatomical CT images and 
regions of interest are drawn to determine standardized uptake values (SUV) and 
tissue-to-background ratio (TBR) (Dweck et al., 2012a, Dweck et al., 2012b, Fayad 
et al., 2011a, Rudd et al., 2002, Tawakol et al., 2006). Typically, radioisotopes with 
short half-lives are used for PET tracers, because they decay at a predictable rate 
after intravenous administration, and keep patient radiation dose low. Furthermore, 
many of these isotopes can be incorporated into biological substrates (glucose, H2O, 
NH3, CO2, O2, etc.) and pharmaceuticals, without altering their biological activity. 
One of the major challenges and expenses is reliable and efficient production of 
novel and complex PET tracers to a Good Manufacturing Practices standard. 
 
Within the atherosclerotic tissue, specific pathological processes can be targeted to 
assess inflammation, calcification and other related processes such as macrophage 
activity, hypoxia and neoangiogenesis. To date the most promising studies 
investigating atherosclerosis have utilised the tracers 18F-fluorodeoxyglucose (18F-
FDG) as a marker of inflammation and 18F-fluoride as a marker of micro-
calcification.  
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 18F-	FLUORODEOXYGLUCOSE	1.5.1.
18-Fluorine-labelled 2-deoxy-2-fluoro-D-glucose (18F-FDG) is used extensively to 
image metabolically active cells with PET-CT. Indeed it has been employed very 
successfully to identify metastases in patients with high-grade poorly differentiated 
tumours (Lardinois et al., 2003). The first study to evaluate 18F-FDG in human was 
undertaken at the University of Pennsylvania, Philadelphia in 1976 with the aim of 
demonstrating cerebral and total body glucose utilisation (Reivich et al., 1977). 18F-
FDG identifies metabolically active tissue by directly competing with glucose for 
transportation by GLUT receptors and then undergoes phosphorylation to 18F-FDG-
6-phosphate by hexokinase.  However, once bound to phosphoglucose isomerase, 
18F-FDG-phosphate is unable to progress down the glycolytic pathway and is 
effectively trapped within the cell and can be targeted with PET imaging. By this 
virtue, 18F-FDG is able to identify cells with high glucose requirements, and not 
specific to one cell type it be taken by the cells with high energy and metabolic 
demand e.g. neurons, active muscle cells, neoplastic cells and activated inflammatory 
cells.  
 
Vascular imaging with 18F-FDG PET was pioneered by Rudd at Cambridge 
University in 2002 (Rudd et al., 2002). Within the vascular bed, it is thought that 
macrophages have the highest metabolic requirement and therefore its uptake has 
become synonymous with macrophage activity (Rudd et al., 2002, Tawakol et al., 
2006). Indeed, several studies have demonstrated a close association between 18F-
FDG and tissue macrophage burden in the carotid arteries (Satomi et al., 2013b).  
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Furthermore, 18F-FDG uptake is associated with traditional cardiovascular risk 
factors including age, male gender and metabolic syndrome as well as inflammatory 
biomarkers (Yun et al., 2002, Tahara et al., 2007). Moreover, vascular 18F-FDG 
uptake is elevated in patients infected with human immunodeficiency virus 
(Subramanian et al., 2012)  and with rheumatoid arthritis (Maki-Petaja et al., 2012), 
perhaps accounting for the increased cardiovascular events in these patient 
populations.  Indeed, 18F-FDG has become a widely used measure of vascular 
inflammation, and employed to demonstrate the anti-inflammatory effects of statins 
and other lipid lowering agents (Tahara et al., 2006b, Fayad et al., 2011a). However, 
recent data have suggested that the mechanisms underlying vascular 18F-FDG 
activity may be more complex, implicating hypoxia as an important driver of 18F-
FDG uptake by both macrophages and vascular smooth-muscle cells (Folco et al., 
2011). Recent data have also suggested that 18F-FDG preferentially labels M1 type 
proinflammatory macrophages rather than the anti-inflammatory M2 type (Satomi et 
al., 2013b). 
 
Whilst 18F-FDG uptake has been validated in large vessels such as the aorta, carotid, 
iliac and femoral arteries, attempts to utilise this tracer in the coronary arteries have 
been less successful. Increased 18F-fluorodeoxyglucose in the coronary arteries has 
been described in patients with coexisting malignancy (Dunphy et al., 2005, 
Wykrzykowska et al., 2009). Since then, three prospective studies have examined the 
feasibility and reproducibility of assessing uptake of this tracer in the coronary 
vasculature (Rogers et al., 2010, Dweck et al., 2012a, Cheng et al., 2012). Whilst two 
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early studies (Cheng et al., 2012, Rogers et al., 2010) suggested that 18F-
fluorodeoxyglucose might identify some inflamed coronary plaques in patients with 
recent myocardial infarction, others have more recently demonstrated that in 50% of 
patients with acute myocardial infarction, there was no uptake of 18F-
fluorodeoxyglucose in the culprit plaque (Cheng et al., 2012).     
 
18F-FDG Imaging in aneurysmal disease 
The feasibility of assessing 18F-FDG uptake within the AAA has been assessed in 
several studies with variable results (Morel et al., 2015, Palombo et al., 2012b) 
(Tegler et al., 2012, Kotze et al., 2011a, Barwick et al., 2014, Nchimi et al., 2014). 
Uptake of 18F-FDG has been shown to be higher in the aneurysmal region of the 
aorta as compared to controls (Truijers et al., 2008, Kotze et al., 2009), and is 
associated with inflammation, aortic wall instability and symptomatic disease (Reeps 
et al., 2008). However, others have reported low and variable 18F FDG uptake in 
aneurysms below the cut off for surgical intervention (Palombo et al., 2012b, Marini 
et al., 2012, Tegler et al., 2012). Indeed it has been suggested that there is waxing 
and waning of inflammation within the aneurysmal tissue due to cyclical metabolic 
pattern of aneurysmal growth (Morel et al., 2015). Important limitation of these 
studies was small sample size and variable parameters to define tracer activity. 
Larger prospective studies are required to understanding the relationship between 
18F-FDG uptake and different stages of aneurysms. 
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 18F-FLUORIDE	1.5.2.
18F-Fluoride is a PET tracer with favourable pharmacokinetic properties, first 
introduced by Blau and coworkers in 1962 for the study of bone disease (Blau et al., 
1962, Blau et al., 1972, Hawkins et al., 1992). After an intravenous injection, 
approximately 70% of 18F-fluoride is plasma based with the remaining 30% found 
in erythrocytes. Because of its small size and negligible protein binding, 18F-fluoride 
demonstrates almost complete clearance from the blood stream on first pass, (Blake 
et al., 2001, Wootton and Dore, 1986, Hoh et al., 1993) resulting in low blood-pool 
activity. This coupled with its specificity for bone and vascular calcification ensures 
that it provides excellent signal to noise in these tissues with little contamination 
from adjacent structures.  
 
The mechanism of 18F-fluoride uptake in bone is well established. First it diffuses 
via the capillary network into the bone extracellular fluid. Then it exchanges with 
hydroxyl groups on exposed regions of hydroxyapatite crystal on the bone surface, 
forming fluoroapatite. The intensity of the signal depends both on the bone blood 
flow but also upon the surface area of exposed hydroxyapatite, which is increased in 
regions of new bone formation and remodelling (Blau et al., 1962, Blau et al., 1972, 
Hawkins et al., 1992). As a consequence 18F-fluoride has been extensively utilized 
as a marker of bone turnover and used to study various bone related clinical 
conditions such as Paget’s disease (Cook et al., 2002, Installe et al., 2005) 
osteoporosis (Frost et al., 2004, Messa et al., 1993) renal osteodystrophy (Messa et 
al., 1993), fracture healing (Hsu et al., 2007) and osteonecrosis . Moreover, 18F-
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fluoride PET has become widely established as the most sensitive imaging modality 
for the detection of malignant bone involvement, leading to its widespread and 
commercial availability (Petren-Mallmin et al., 1998, Schirrmeister et al., 1999, 
Hetzel et al., 2003, Even-Sapir et al., 2006, Beheshti et al., 2008). 
 
The mechanism underlying 18F-fluoride in the vascular tissue is similar to bone 
uptake. Hydroxyapatite is also the key structural component of vascular calcium, so 
that arterial 18F-fluoride uptake is likely to relate closely to the available surface area 
of this crystal.   Transmission electron microscopy studies have demonstrated that 
during the early stages of calcification hydroxyapitate crystals are nanosized, very 
thin and long (Rey et al., 2009). This results in a much larger surface area of 
hydroxyapatite for 18F-fluoride binding in the early stages of microcalcification 
compared to macroscopic calcification in which much of the hydroxyapatite is 
internalised and not accessible to the tracer. Indeed recent pre-clinical work 
performed by our collaborators at Cambridge University has confirmed that 18F-
fluoride adsorbs to calcified deposits within plaque with high affinity and is selective 
and specific and distinguishes between areas of macro- and microcalcification 
(Agnese Irkle, 2013, Irkle et al., 2015) (Figure 1-3) 
 
Derlin et al. first described the vascular uptake of 18F-fluoride in 2010 in a 
retrospective analysis of patients with malignancy (Derlin et al., 2010). The authors 
noted increased 18F-fluoride uptake in large vessels such as the aorta, carotids and 
Novel molecular imaging of cardiovascular diseases in man 
  55 
femoral vessels in about three quarters of the patients studied. Interestingly, only a 
fifth of all calcified plaques on CT demonstrated increased 18F-fluoride uptake, 
highlighting even at this early stage that 18F-fluoride provides different information 
to the presence of calcium on CT. Subsequent work by the same group 
retrospectively compared the distribution of 18F-fluoride and 18F-FDG uptake in 
oncology patients (Derlin et al., 2011a) and suggested that 18F-fluoride signal in the 
femoral vessels correlated with the calcified plaque burden and cardiovascular risk 
factors (Janssen et al., 2013). Beheshti and colleagues first described 18F-fluoride 
activity localizing to the heart (Beheshti et al., 2011) whilst we and other groups 
have confirmed increased 18F-fluoride activity in the aorta and importantly in the 
valves of patients with aortic stenosis, (Dweck et al., 2011, Dweck et al., 2013b) 
where it acts as a marker of calcification activity and predicts disease progression 
(Dweck et al., 2014). 
 
We first described 18F-fluoride uptake in the coronary arteries as a novel marker of 
plaque biology in subjects with and without aortic valve disease (Dweck et al., 
2012a). This demonstrated the feasibility and excellent reproducibility of this tracer 
in the coronary vasculature. Moreover increased uptake of this tracer localised to 
individual coronary plaques and importantly identified patients at increased 
cardiovascular risk, with those subjects having increased Framingham risk scores and 
prior MACE event rates. This study also confirmed that, as in the aorta, 18F-fluoride 
provided different information to the presence of coronary calcium on CT. Indeed we 
observed that >40% of patients with coronary artery calcium scores >1000 Agatston 
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Units did not have 18F-fluoride uptake, suggesting the ability of 18F- fluoride to 
distinguish between dormant pacified calcific disease and metabolically active 
ongoing micro-calcification (Table 1-1). 
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Figure 1-3 The relationship between inflammation, biphasic calcific response 
and adverse cardiovascular events         
(A) Typical features of a vulnerable plaque: The initial stages of plaque inflammation and 
vulnerability are associated with macrophage influx into a large lipid core. By this stage, other 
features of plaque vulnerability such as positive remodelling, thinning of the fibrous cap, are 
observed. (B) Microcalcification within the necrotic core: Cell death occurring within the lipid core 
as a consequence of necrosis and apoptosis triggers microcalcification. This is a high risk plaque type 
that is ripe to rupture. This can have two consequences: successful plaque calcification by walling off 
the inflamed area, or initiation of plaque rupture with subsequent thrombotic occlusion. This is the 
plaque type that is believed to be have avid 18F-fluoride uptake on PET/CT. (C) Plaque stabilization 
with successful healing of the necrotic core with obvious macrocalcification that can be detected with 
conventional imaging modalities such as computed tomography and X-ray angiography. (D) Plaque 
rupture with thrombotic occlusion of the lumen resulting in myocardial infarction 
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Table 1-1 Key differences between micro and macrocalcification 
 Microcalcification Macrocalcification 
Size <5µm >5µm 
Stage of calcification Early Late 
Inflammation Persistent Healed 
Surface area High Low 
Exposed hydroxyapatite High  Low 
Risk of rupture High risk of rupture Low risk of rupture 
Computed Tomography/ X-ray 
angiography 
Undetectable Detectable 
18F-fluoride binding on 
Positron Emission Tomography 
Avid binding  Low binding 
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 ALTERNATIVE	NOVEL	TRACERS	1.5.3.
The great strength of PET imaging is that tracers can ultimately be developed to 
target any pathological process of interest and can therefore be directed to any of the 
features that characterise high-risk plaques. Whilst this is an expensive process, the 
studies using 18F-fluoride have clearly demonstrated that metabolic plaque imaging 
in the coronary arteries is now feasible, making an expansion of activity in this area 
likely.   
 
Given its pathophysiological importance, inflammation would appear to be the prime 
potential target. As discussed 18F-FDG, whilst an excellent tracer for measuring 
inflammation in the aorta and carotids arteries, is of limited use in the coronary 
arteries, the metabolic activity of which governs the majority of clinical events. 
There is therefore an urgent need to develop more macrophage-specific tracers that 
crucially do not demonstrate increased activity in adjacent structures as the 
myocardium.  
 
There has been significant interest in inflammation imaging with 68Ga-
DOTATATE, a novel tracer with receptor binding specificity to somatostatin 2. 
Although primarily overexpressed in malignancies, in particular neuro-endocrine 
tumors, somatostatin receptors are thought to be preferentially expressed in damaged 
and proliferating endothelium and by activated macrophages (Armani et al., 2007, 
Adams et al., 2005, Dalm et al., 2003). Indeed murine data has shown good 
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correlation between tracer activity and macrophage density in atherosclerotic lesions 
(Li et al., 2013). Observational data from oncology patients has reported uptake for 
this tracer in large vessels, again demonstrating a good correlation with calcific 
plaque burden. Interestingly, in this study, 18F-FDG uptake did not colocalise with 
68Ga-DOTATATE suggesting labeling of distinct process within vascular 
inflammation. (Li et al., 2012a) Furthermore, uptake has been described in the 
coronaries with modest correlation with calcific plaque burden and previous 
cardiovascular events. (Rominger et al., 2010, Mojtahedi et al., 2015).  
 
Other tracers that have shown early promise in atherosclerotic inflammation imaging 
include 11C-PK11195, 18F-FMCH and 11C-choline (Laitinen et al., 2009, 
Gaemperli et al., 2012, Pugliese et al., 2010). Furthermore, tracers aimed at other 
important features of plaque vulnerability such as hypoxia (18F-
Fluoromisonadazole) (Mateo et al., 2014) and neoangiogenesis (18F-Galacto and 
18F-fluciclatide) (Brooks et al., 1994, Beer et al., 2006) have also shown promise 
and studies to assess their role in patients with atherosclerosis are underway. 
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 MAGNETIC	RESONANCE	IMAGING	1.6.
Magnetic resonance imaging (MRI) has emerged as a powerful investigation for 
cardiovascular disease offering high-resolution images without radiation, thus 
allowing serial imaging to monitor disease progression and regression. Similar to 
PET-CT, various processes within plaque biology remain legitimate targets for 
development of specific MRI contrast agents (Winter et al., 2003, Burtea et al., 2008, 
Nahrendorf et al., 2006, Briley-Saebo et al., 2008). MRI evaluates response of a 
tissue subjected to transient electromagnetic radiofrequency pulses when placed in a 
strong static magnetic field. It uses different contrast weightings — T1, T2, proton-
density, and time-of-flight providing insights into biophysical and biochemical 
properties including physical state, chemical composition and concentration, water 
content, molecular motion, or diffusion. In atherosclerotic disease, MRI can 
distinguish different plaque components including the fibrous cap, the lipid core and 
areas of calcification (Cai et al., 2005, Yuan et al., 2001). For instance, on the T1-
weighted images, plaque fibrous tissue and lipid core appears iso to hypointense 
where as on T2-weighted images, fibrous tissue has a high intensity signal intensity 
while the lipid content may appears hypointense. In contrast, calcific areas appears 
hypointense on both  T1- and T2-weighted images. Furthermore, MRI provides a 
high degree of spatial resolution and soft tissue contrast yielding excellent anatomic 
detail. However, it is of inherently low sensitivity for molecular imaging 
applications. Given low temporal resolution, MR imaging is best suited for the study 
of large or relatively “static” arteries, such as the carotid arteries and the aorta. 
Because of their small dimensions and their continuous motion during data 
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acquisition, coronary arteries remain a particular challenge (Vancraeynest et al., 
2011). 
 
MRI has been shown to identify plaque ruptures (Yuan et al., 2002) and hemorrhages 
(Chu et al., 2004) in carotid atherosclerosis with a good correlation between the 
plaque components with histopathology (Yuan et al., 2001). However, one of the 
main limitations with MRI in identification of high-risk vulnerable plaques is poor 
reproducibility, especially in context of necrotic core and fibrous cap (Touze et al., 
2007). Alternative imaging strategies have therefore been developed to overcome 
this limitation with use of contrast media that enables signal enhancement of the 
tissues and this expands the overall assessment of the plaque. Indeed novel MR 
contrasts allows targeted imaging of the cellular mediators of plaque components  in 
atherosclerosis. In comparision to the picomolar range of the tracers for PET 
imaging, MRI contrast requires relatively large quantities of contrast agents to the 
site of interest at micromolar range. These could be gadolinium-based ions chelated 
to small molecules leading to bright appearance or positive contrast on T1-weighted 
images or iron oxides based contrast, causing signal drop out and an intense negative 
contrast on T2*-weighted images.  
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 ULTRASMALL	SUPERPARAMAGNETIC	PARTICLES	OF	IRON	OXIDE	ENHANCED	MRI	1.6.1.
Recently a novel class of MRI contrast agents containing superparamagnetic 
particles of iron oxide (SPIO) has been developed that provides additional biological 
and functional information through the detection of cellular inflammation within 
tissues. The initial focus of SPIO development was imaging of the 
reticuloendothelial system and oncology imaging. Subsequent studies have 
demonstrated incorporation of SPIOs into aortic atherosclerotic plaques in rabbits 
(Schmitz et al., 2000). In comparison to SPIOs, the smaller ultrasmall SPIOs 
(USPIO) have additional property to extravasate via tight capillary pores that makes 
them an attractive option for cellular MR imaging. With a particle size in the range 
10-30 nm, USPIOs escape immediate recognition by the reticulo-endothelial system 
and persist for longer in the bloodstream allowing them to be used to assess the 
accumulation of macrophages within vascular and lymphatic tissues (Harisinghani et 
al., 2003, Heesakkers et al., 2008, Kooi et al., 2003a, Trivedi et al., 2006a, Tang et 
al., 2009a). Capitalising on these effects, USPIOs have been used in the diagnosis of 
diseases of the liver, spleen and lymph nodes in oncology imaging.  Current 
preparations are biodegradable and safe for clinical administration (Bernd et al., 
2009, Bourrinet et al., 2006, Muller et al., 2007). The safety of USPIOs as a contrast 
agent in humans is well established (Ersoy et al., 2004, Li et al., 2007, Li et al., 2005, 
Prince et al., 2003, Neuwelt et al., 2007). Most of these studies have examined and 
confirmed its utility as a blood-pool contrast agent. However, it has also been 
assessed for its use in lymph node imaging for cancer staging. In a study of patients 
with prostate cancer, USPIOs were administered after baseline scan and further was 
performed at 5, 8 and 24 hours using a 1.5 T scanner. Maximum signal to noise ratio 
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was observed in lymph nodes at 24 hours on T2*-weighted MR imaging 
(Harisinghani et al., 2007).   
 
USPIO have also been shown to accumulate in the aortae of hypercholesterolemic 
rabbits (Ruehm et al., 2001, Herborn et al., 2006)  and in murine models of AAAs 
(Turner et al., 2009). Susceptibility artefacts were detected in the aortic wall at day 2 
to 3 post administration of contrast and signal voids were observed as a result of 
T2/T2* effects. Histology confirmed the accumulation of iron particles under the 
endothelium and into the medial layer of diseased vessels (Herborn et al., 2006). 
USPIOs have been shown to reduce T2*-weighted MRI signal within the carotid 
plaques in patients undergoing carotid endarterectomy, and it is suggested that 
USPIO signal effect correlates with the propensity for plaque rupture. Indeed, the 
presence of intracellular USPIO in plaque macrophages has been demonstrated in the 
carotid plaque (Kooi et al., 2003b, Trivedi et al., 2006b).  The ATHEROMA 
(Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) study 
evaluated the effects of low and high-dose statin therapy on carotid plaque 
inflammation as determined by ultrasmall superparamagnetic iron oxide (USPIO)-
enhanced carotid magnetic resonance imaging (MRI). Using serial USPIO-enhanced 
MR imaging over a 3-month period, a significant reduction in carotid plaque 
inflammation with high-dose statin-lowering therapy was reported (Tang et al., 
2009a).  
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 USPIO	IN	ANEURYSMAL	DISEASE	1.6.2.
The cellular uptake of USPIO in aneurysms was first reported in 2009 in patients 
with malignancies (Truijers et al., 2009). Since then prospective studies have 
demonstrated the feasibility of this technique using T2* qualitative and quantitative 
analysis (Sadat et al., 2011a, Richards et al., 2011b). Richards et al. conducted a 
series of MRI studies in patients with AAA and shown that uptake of USPIO in AAA 
correlates with macrophage activity and identifies cellular inflammation. Using 3T 
MRI scanner, asymptomatic AAA patients (n=29; aneurysm diameter 4.0-6.6 cm) 
from surveillance program were imaged before and 24-36 h after administration of 
USPIO. Histological examination of aneurysm tissue has confirmed co-localization 
and uptake of USPIO in areas with macrophage infiltration ( Richards et al., 2010). 
Furthermore, patients with deep-seated mural uptake had 3-fold higher aneurysm 
growth rate as compared to patients with peri-luminar or diffuse patchy uptake. 
Uptake of USPIOs therefore, may identify rapidly expanding AAA and possible 
rupture. If future studies confirm these findings, this technique holds major promise 
in risk-stratifying patients with abdominal aortic aneurysms. 
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 CORONARY	CALCIUM	AND	COMPUTED	TOMOGRAPHY	CORONARY	ANGIOGRAPHY	1.7.
Ever since Agatston et al. described the calculation of the total calcific burden using 
coronary artery calcium (CAC) scoring in 1990,  this method has become a reliable 
and reproducible non-invasive technique to quantify coronary atherosclerosis 
(Agatston et al., 1990). Total CAC score is derived by multiplying individual areas 
of calcified plaque by a factor derived from the maximal plaque density (CT 
attenuation) in Hounsfield Units, and then adding the values obtained for all coronary 
plaques identified. Subsequent studies have established CT calcium scoring to be one 
of the most powerful predictors of future cardiovascular events in asymptomatic 
individuals irrespective of ethnicity (Detrano et al., 2008, Greenland et al., 2004), 
(Budoff et al., 2007, Arad et al., 2005, Taylor et al., 2005). Moreover risk prediction 
can be further refined by examining the progression of coronary calcification (Raggi 
et al., 2004b). 
 
CT calcium scoring quantifies macroscopic calcification in the coronary arteries. 
These plaques are believed to be stable, healed and unlikely to rupture. Indeed, it is 
well established that calcific fibroatheromas and calcified nodules are very rarely 
responsible for coronary thrombosis (Virmani et al., 2006b). Why then does calcium 
scoring predict cardiovascular risk related to rupture? The likely explanation is that is 
provides a surrogate of plaque burden. The more calcified stable plaques you have 
the more unstable non-calcified plaques you are also likely to have in addition 
(Otsuka et al., 2013, Mauriello et al., 2013).  
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Due to its wide availability and adoption, one of the most important noninvasive 
techniques for the evaluation of the coronary vasculature is CTCA. Indeed, recent 
studies and guidelines support the utility of this modality for assessment of patients 
with new onset anginal chest pain for evaluation of coronary stenosis (SCOT-
HEART investigators, 2015, Douglas et al., 2015, Skinner et al., 2010).  
 
Assessment of plaque morphology with CT allows identification of several high-risk 
features on CTCA primarily because of its ability to assess not only the lumen but 
also the vessel wall. Indeed, several studies have reported on the correlation between 
CTCA plaque features with invasive coronary imaging modalities, such as IVUS, 
IVUS-VH, and OCT. Identification of spotty calcification using CTCA has been 
associated with high-risk plaque type (Motoyama et al., 2007). Furthermore, 
Motoyama et al reported that positive remodeling and low attenuation plaque on 
CTCA predict a higher likelihood of future plaque rupture (Motoyama et al., 2009b). 
Others have described features such as the “Napkin ring” or the “Signet ring” sign 
for identification of plaque vulnerability (Maurovich-Horvat et al., 2010). However, 
interpretation of such features on CTCA comes with significant limitations. 
Suboptimal resolution does not allow precise definition of the vascular boundary, 
and the extent of positive remodelling may be over or underestimated. Similarly, low 
attenuation plaque is defined based on specific thresholds in the Hounsfield unit 
measurements which may be influenced by various imaging and technical parameters 
in regions of non-calcified plaque.  	
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 INTRAVASCULAR	ULTRASOUND	IMAGING	1.8.
Intravascular ultrasound (IVUS) was one of the earliest invasive techniques to allow 
imaging of the lumen and vessel wall and despite the development of novel 
techniques, IVUS still remains the standard method for assessing plaque burden. This 
technique also allows us to assess many other structural features within the plaques, 
including positive remodelling, thrombi, plaque length, lumen narrowing, spotty and 
macroscopic calcification and the presence of a lipid-rich core (Yamagishi et al., 
2000, Kotani et al., 2003, Fujii et al., 2003, Ehara et al., 2004, Garcia-Garcia et al., 
2014). Moreover recent advances make the use of ultrasound backscatter (VH-IVUS) 
thus providing even more information with respect to plaque morphology and 
characteristics (Garcia-Garcia et al., 2009a). Various plaque contents such as 
calcium, fibrous tissue, fibrofatty tissue and necrotic core can be resolved. Moreover 
as discussed VH-IVUS can classify plaque types such as pathological intimal 
thickening, thick and thin capped fibroatheromas with a high degree of accuracy 
(Garcia-Garcia et al., 2009a). 
 
VH-IVUS has become widely available and has been the subject of intense 
investigation, having to date been tested in 3 major prospective clinical studies: 
Providing Regional Observations to Study Predictors of Events in the Coronary Tree 
(PROSPECT)(Stone et al., 2011b) VH-IVUS in Vulnerable Atherosclerosis 
(VIVA)(Calvert et al., 2011)  and the European Collaborative Project on 
Inflammation and Vascular Wall Remodeling in Atherosclerosis (ATHEROREMO- 
IVUS) study (Cheng et al., 2014). However, the prospects of identifying patients or 
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indeed plaques that will cause future cardiovascular events, using radiofrequency 
IVUS, have been rather disappointing. Indeed amongst 697 patients enrolled in the 
PROSPECT study, 595 thin- cap fibroatheromas were identified by IVUS across the 
cohort, only 26 of these plaques were sites of subsequent events at 3 years, and the 
majority of events were related to rehospitalization for angina rather than myocardial 
infarction. Plaque burden greater than 70%, minimal luminal area less than 4 mm2 
and presence of thin capped fibroatheromas were thought to be the primary drivers. 
However when all these three factors were present in the same lesion, the positive 
predictive value of an event was only 18 %. Consistent with these findings, the 
VIVA and ATHEROREMO- IVUS studies suggested that whilst identification of 
thin fibrous cap athermas identified subsequent MACE, it did not predict future MI 
per se, and once again the vast majority of these lesions did not result in clinical 
sequelae (Calvert et al., 2011, Cheng et al., 2014).  
 
One of the important limitations of VH-IVUS is its limited axial resolution of 100 to 
150 microns (Rodriguez-Granillo et al., 2005), which means that it will tend to 
overestimate the number of plaques with a thin fibrous cap (traditionally defined by a 
thickness of < 60µm). This may account for the low event rate associated with VH-
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 AIMS	AND	HYPOTHESIS	1.9.
The overall aims of these studies are to assess the role of novel molecular imaging 
techniques in human atherosclerotic and aneurysmal disease. A multimodality 
approach for assessment of atherosclerotic plaques and aneurysms will be undertaken 
with 18F-FDG and 18F-fluoride PET-CT as markers of inflammation and active 
calcification. We will gain complementary information regarding plaque 
inflammation, vulnerability and rupture in patients with stable and unstable coronary 
artery disease in the culprit and remote atherosclerotic plaques. Role of inflammation 
and calcification will be assessed in patients with AAA and compared with patients 
with atherosclerosis.  
 
In Chapter 3, utilising cardiac gated PET-CT imaging, we will develop the 
methodology for assessing coronary uptake of PET tracers. The tracer activity will be 
assessed in patients with acute myocardial infarction and patients with stable angina. 
The plaque characteristics will be assessed using multi-modality imaging with CTCA 
and VH-IVUS  in patients with stable angina and histopathological analysis of 
atheromatous tissue from endartectomy specimens will be analysed to assess 18F-
Fluoride uptake in patients with symptomatic carotid disease.  
 
In Chapter 4, systemic atherosclerotic plaque inflammation will be assessed in 
patients with acute myocardial infarction and will be compared to those with stable 
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angina. The clinical relevance of infarct size, remote plaque inflammation and the 
risk of recurrent myocardial infarction will also be evaluated.  
 
In Chapter 5, the relationship between the size of aneurysm and inflammation will be 
studied. Using 18F-FDG as a marker of metabolic inflammation, uptake will be 
quantified in patients will smaller aneurysms and compared to patients with 
atherosclerosis. 
 
In Chapter 6, the relationship between metabolic imaging of inflammation will be 
assessed against the cellular inflammation with USPIO, using AAA as a model of 
inflammation. Multimodality hybrid imaging will be used to register the PET and 
R2* color maps to derive the similarities and differences on PET and MR platforms. 
 
The following hypothesis will be addressed: 
i) Plaque inflammation and calcification with 18F-FDG and 18F-fluoride 
will be higher in patients with ruptured and unstable coronary 
atherosclerotic plaques as compared to those with stable plaques. 
(Chapter 3). 
ii) Patients with recent myocardial infarction will have higher remote 
atherosclerotic plaque inflammation as compared to patients with stable 
coronary disease. (Chapter 4). 
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iii) Patients with abdominal aortic aneurysms will have higher inflammation 
in the aneurysmal part of the aorta as compared to the non-aneurysmal 
part of the aorta and patients with atherosclerosis (Chapter 5).	
iv) Using AAA as a model of vascular inflammation, cellular inflammation 
as assessed by USPIO enhanced MRI will concur with metabolic activity 
using 18F-FDG PET. (Chapter 6).	
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Chapter	2. METHODS	
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 OVERVIEW	2.1.
The specific study designs and methodology for each of the cohorts are described in 
detail in relevant chapters. The following sections will provide the overview of the 
patient populations and the novel imaging modalities utilised in these studies.   
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 PATIENT	POPULATION	2.2.
 PATIENTS	WITH	CORONARY	AND	CAROTID	ATHEROSCLEROSIS	2.2.1.
Patients were recruited from the Edinburgh Heart Centre, Royal Infirmary of 
Edinburgh in three cohorts: patients with acute ST- or non-ST-segment elevation 
myocardial infarction, patients with stable angina pectoris undergoing elective 
invasive coronary angiography, and patients undergoing carotid endartectomy for 
symptomatic carotid artery disease.  
 
Consecutive patients with myocardial infarction were approached and recruited if 
they fulfilled the criteria for type 1 myocardial infarction according to the Universal 
Definition of Myocardial Infarction (Thygesen et al., 2012). ST segment elevation 
myocardial infarction was defined as new ST segment elevation at the J point in two 
contiguous leads with the cut-points: ≥0.1 mV in all leads except V2-V3 where the 
thresholds were ≥0.2 mV for men ≥40 years and ≥0.25 mV for women (Thygesen et 
al., 2012). 
 
Consecutive patients with stable angina pectoris were recruited if they had typical 
symptoms of exertional anginal chest pain, previously documented coronary artery 
disease (>70% stenosis of at least one major epicardial coronary artery), and had 
been scheduled for invasive coronary angiography. Patients were excluded if they 
had suffered an acute coronary syndrome within the last 3 months.  
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Patients with typical symptoms and signs of an acute transient ischemic attack, 
amaurosis fugax or stroke were recruited within 1-14 days of symptom onset. All 
patients underwent clinical evaluation and carotid Doppler assessment. Inclusion 
criteria were carotid stenosis >50% (North American Symptomatic Carotid 
Endarterectomy Trial, 1991)  consistent with clinical presentation, and planned 
carotid endarterectomy.  
 
Exclusion Criteria 
Exclusion criteria were age <50 years, insulin-dependent diabetes mellitus, women 
of childbearing age not taking contraception, severe renal failure (serum creatinine 
>250 µmol/L), known contrast allergy and inability to provide informed consent. 
Only patients older than 50 years were recruited in the study to reduce any long-term 
risks associated with radiation exposure. Uncontrolled diabetes and high blood 
glucose concentrations (>11 mmol/L) interfere with image quality of 18F-FDG PET 
imaging due to competition between glucose and 18F-fluorodeoxyglucose for 
cellular entry. It has therefore been a convention to exclude such patients from 
vascular 18F-fluorodeoxyglucose positron emission tomography studies (Dweck et 
al., 2012a, Dweck et al., 2011, Rudd et al., 2002, Tawakol et al., 2013, Elkhawad et 
al., 2012, Maki-Petaja et al., 2012). Studies were performed with the approval of the 
local research ethics committee, in accordance with the Declaration of Helsinki, and 
with the written informed consent of each participant. 
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 PATIENTS	WITH	ATHEROSCLEROSIS	AND	ANEURYSMAL	DISEASE	2.2.2.
Patients were recruited from Addenbrooke’s Hospital, Cambridge and the Royal 
Infirmary of Edinburgh in two cohorts: (i) A study cohort consisting of patients with 
abdominal aortic aneurysm and (ii) a control cohort of age- and sex- matched 
atherosclerotic patients. All control subjects were recruited in Cambridge, and the 
study patients were recruited across both sites. Consecutive patients presenting at 
both institutions were considered for enrolment. The inclusion criteria for the study 
cohort were age >50 years and presence of an aneurysm between 3.0 and 5.5 cm. The 
inclusion criteria for the control cohort were clinically stable (>6 months) 
cardiovascular disease (defined as previous myocardial infarction, stroke, or 
peripheral vascular disease). Exclusion criteria for both cohorts were insulin 
dependent diabetes, type 2 diabetes with a fasting glucose of >11 mmol/L, 
illness/condition that may result in a life expectancy <2 years, women of 
childbearing age not taking contraception, severe renal failure (serum creatinine 
>250 µmol/L), hepatic cirrhosis (Child Pugh score B or C), planned AAA surgery 
within 6 months of screening or a contra-indication to magnetic resonance imaging, 
known contrast allergy or the inability to provide informed consent. Baseline clinical 
characteristics and cardiovascular risk factors were recorded. Full blood count, renal 
and lipid profiles were measured. The study was performed in accordance to the 
protocol approved by the local research ethics committee and the Declaration of 
Helsinki. All subjects provided written informed consent. 
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 POSITRON	EMISSION	TOMOGRAPHY	-	COMPUTED	TOMOGRAPHY	IMAGING	2.3.
Patients underwent combined PET-CT scanning using validated PET-CT imaging 
protocols (Dweck et al., 2012a, Dweck et al., 2011, Rudd et al., 2002, Tawakol et al., 
2013, Elkhawad et al., 2012, Maki-Petaja et al., 2012). In Edinburgh, Siemens PET 
CT scanner (Biograph mCT, Siemens Medical Systems, Erlangen, Germany) was 
used while in Cambridge, an equivalent GE Discovery 690 PET/CT scanner was 
utilized for scanning. The detailed scanning protocol has been described in relevant 
sections. Briefly, after consenting to participate in the study, patients were invited to 
undergo a PET-CT scan. Patients were asked to follow a low-carbohydrate, high-
protein and high-fat diet for at least 24 h prior to undergoing 18F-FDG PET-CT 
(Elkhawad et al., 2012, Maki-Petaja et al., 2012) and refrain from alcohol and 
caffeine on the day of the scan prior to 18F-FDG scan to minimise myocardial 
uptake.  There were no restrictions for 18F-fluoride scan.  A 20 G cannula was 
inserted in a large peripheral vein and blood was drawn for analysis. Patients were 
then administrated radioactive tracer and rested in a quiet environment. Based on 
previous studies (Rudd et al., 2002, Dweck et al., 2012a, Dweck et al., 2011), the 
tracer uptake times were 90 minutes for 18F-FDG and 60 minutes for 18F-fluoride 
scan to produce optimal contrast between the tissue of interest and the blood pool.  
 
Image Acquisition and reconstruction 
Patients were transferred onto the PET-CT scanner and a non-contrast-enhanced 
attenuation correction CT scan was performed followed by a PET scan. The PET 
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data were reconstructed using standard time of flight reconstruction algorithms. 




Anonymized PET-CT datasets were analyzed using OsiriX workstation (64 bit; 
version 5.5.1 OsiriX Imaging Software, Geneva, Switzerland) (Joshi et al., 2013, 
Maki-Petaja et al., 2012). Readers were blinded to the patients’ clinical status and 
presented images in a random order. PET images were fused with the CT, and 
regions of interest (ROIs) drawn around the tissue of interest. The general principles 
of coronary and aortic PET image analysis have been illustrated in the examples 
below (Figure 2-1 and Figure 2-2).  Within these regions, tracer activity was 
measured using standard uptake values (SUV; the decay corrected tissue 
concentration of the tracer divided by the injected dose per body weight) and 
corrected for blood pool activity in the superior vena cava to provide tissue-to-
background ratios (TBRs).  
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Figure 2-1 Tracer uptake in coronary arteries. 
The tracer uptake within the tissue of interest was analysed by fusing the CT image (A) with PET 
image (C). Region of interests were then drawn on the CT (B) and fused PET-CT (D) image to 
calculate standardised uptake values.  
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Figure 2-2 Tracer uptake in the aneurysmal tissue 
In this illustration, tracer uptake is visualised within the shoulder region of the aortic aneurysm on 
fused sagittal PET-CT scan (A). The uptake within the aneurysmal tissue was analysed by drawing 
regions of interest along the aneurysmal  adventitial border (B). These were then applied to the PET 
image to derive the standardised uptake values (C). Panel D represents fused PET-CT image. 
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 REPRODUCIBILITY	OF	PET-CT	IMAGING		2.3.1.
Several studies have assessed the reproducibility of PET CT imaging in multiple 
vascular beds (Rudd et al., 2007, Rudd et al., 2008).  The scan re-scan reproducibility 
of PET imaging within the aorta and carotids over a 2-week period is excellent 
(Rudd et al., 2007, Rudd et al., 2008). Furthermore, the intra-observer agreement is 
very high with intra-class correlation coefficients values ranging between 0.93 and 
0.98. Similarly, the results from our previously reported studies have shown an 
excellent intra-observer agreement of PET-CT imaging in the coronary vasculature 
(Dweck et al., 2012a). 
 
The reproducibility of vascular PET signal is comparable to more established 
imaging modalities (Rudd et al., 2007, Rudd et al., 2008) that includes the magnetic 
resonance imaging (MRI)(Varghese et al., 2005), intra-vascular ultrasound 
(Hagenaars et al., 2000), and computed tomography (Budoff et al., 2006) 
Additionally, the high sensitivity of FDG-PET might allow detection of small 
metabolic changes within plaque that occur before structural alterations can be 
detected by other modalities (Rudd et al., 2007, Rudd et al., 2008). 
  
Novel molecular imaging of cardiovascular diseases in man 
  83 
 COMPUTED	TOMOGRAPHY	2.4.
Patients underwent coronary artery calcium and CT angiography or aortography 
following acquisition of PET/CT images. In patients undergoing CT coronary 
angiography, oral metoprolol 50 mg was administered in patients with a heart rate of 
greater than 60 beats/min. If necessary, patients were given further intravenous 
metoprolol. Patients with a contraindication to beta-blockade were considered for 
oral verapamil 80 mg followed by intravenous verapamil 2.5 mg. For the acquisition 
of CTCA, following setting were used: 330 ms rotation time, 100 (body mass index 
[BMI] <25 kg/m2) or 120 (body mass index >25 kg/m2) kV tube voltage, 160-245 
mAs tube current, 3.8 mm/rotation table feed, prospective (heart rate regular and 
<60/min), or retrospective (heart rate >60 / min) electrocardiogram-gated. Depending 
on the BMI, a bolus of 80-100 mL of contrast (400 mgI/mL; Iomeron, Bracco, 
Milan, Italy) was injected intravenously at 5 mL/s, after determining the appropriate 
trigger delay with a test bolus of 20 mL contrast material.   
 
Off-line analyses using automated computerised software programmes that employ 
the Agatston scoring method using 130 HU thresholds was used to determine degree 
of coronary calcification. Computed tomography scans were reported by two trained 
observers (radiologist and cardiologist). Vitrea software (Vital Images Inc, 
Minnetonka) was be used to visualise computed tomography coronary angiography 
data and perform region of interest measurements on particular slices and objects.  	
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 INTRA-VASCULAR	ULTRASOUND	2.5.
Intravascular ultrasound analysis was performed as described previously (Calvert et 
al., 2011) using dedicated VIAS software (Volcano Corp, USA) by operators blinded 
to the positron emission tomography data (Figure 2-3). Briefly, in patients 
undergoing coronary angiography, grey-scale and radiofrequency intravascular 
ultrasound was acquired with a dedicated IVUS catheter (20 MHz Eagle Eye 
Platinum Catheters [Volcano Corp, San Diago, CA, USA]), passed over coronary 
guidewire after injecting intracoronary nitrates with a motorized catheter pullback. 
The analysis was performed offline and was not used for procedural guidance. 
Regions of interest were drawn around the external elastic membrane and luminal 
borders, and plaque area and composition (dense calcium, necrotic core, fibro-fatty 
tissue and fibrous tissue) calculated (Calvert et al., 2011), (Mintz et al., 2001). The 
presence of microcalcification (spotty calcification in the absence of acoustic 
shadowing on ≥3 consecutive frames) and the maximum frame necrotic core (the 
highest percentage of necrotic core on a single frame) were recorded. The remodeling 
index was defined as the ratio between the external elastic membrane cross-sectional 
area of the lesion and a proximal reference region in the same vessel. Plaques were 
classified as thin-cap fibroatheroma, thick-cap fibroatheroma, pathologic intimal 
thickening or fibrocalcific plaque as defined previously (Garcia-Garcia et al., 2009b). 
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Figure 2-3: Grey-scale and radiofrequency intravascular ultrasound analysis  
The grey-scale intravascular ultrasound (A) was used to identify the lumen (B) and the external 
elastic lamina (C). This allowed assessment of plaque dimensions such as plaque burden (D). 
Radiofrequency ultrasound was then used to assess plaque characteristics (E). Finally the 
composition of the plaque elements such as fibrous, fibro-fatty tissue, necrotic core and calcium were 








We used immunohistochemistry to investigate macrophage infiltration (CD68), 
calcification activity (tissue non-specific alkaline phosphatase and osteocalcin), and 
cell death (apoptosis, cleaved caspase 3; presence of necrotic core).  
 
Inflammation is a key feature of human atherosclerosis and is thought to precede the 
early stages of calcification (Aikawa et al., 2007). CD68 is expressed by 
macrophages and has been closely correlated with the 18F-FDG signal in the carotid 
arteries. Apoptotic cell death is a recognized phenomenon in atherosclerotic plaque 
and is thought to be detrimental to plaque stability (Kockx and Herman, 2000). 
Cleaved caspase 3 is a critical executioner of apoptosis, being responsible for the 
proteolytic cleavage of many key proteins, such as the nuclear enzyme poly (ADP-
ribose) polymerase (PARP). Its expression has been previously demonstrated in 
atherosclerotic plaque (Fernandes-Alnemri et al., 1994).    
 
During propagation of atherosclerosis, vascular smooth muscle cells undergo 
osteogenic differentiation (New and Aikawa, 2011). Additionally, matrix vesicles 
released from living cells and apoptotic bodies from dying macrophages and smooth 
muscle cells are thought to provide a nidus for microcalcification(Proudfoot et al., 
2000, Shanahan, 2007). Tissue non-specific alkaline phosphatase (TNAP) is an 
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enzyme that plays a key role in atherosclerotic calcification by increasing availability 
of inorganic phosphate levels through the hydrolyzing   pyrophosphate, a key 
inhibitor of mineralization (Demer and Tintut, 2008). Unlike dyes such as alizarin 
red that directly stains tissue calcium, TNAP provides information about calcification 
activity and gives information distinct from mere anatomical calcium.  
 
Osteocalcin, or bone Gla protein, is a small protein secreted by osteoblasts that can 
undergo γ-carboxylation (Kapustin and Shanahan, 2011). The γ-carboxylated form 
binds hydroxyapatite and is abundant in bone extracellular matrix. Osteocalcin is 
thought to be a regulator of osteochondrogenic differentiation of pathologically 
mineralizing vascular smooth muscle cells (Kapustin and Shanahan, 2011). The 
presence of osteocalcin is therefore suggestive of up regulated vascular 
mineralization (Idelevich et al., 2011). 
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 CAROTID	ATHEROMA		 	2.6.2.
Intact atherosclerotic plaques were retrieved at the time of carotid endarterectomy 
and scanned using ex-vivo PET-CT to allow precise anatomical co-localisation of 
18F-fluoride activity with pathological evidence of plaque rupture. Plaques were 
divided into 18F- fluoride positive and negative areas, and histological sections were 
assessed using Movat’s pentachrome and immunohistochemistry to investigate both 
calcification activity (tissue non-specific alkaline phosphatase and osteocalcin), 
macrophage infiltration (CD68) and cell death (apoptosis, cleaved caspase 3; 
presence of necrotic core). 
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 EX-VIVO	18F-FLUORIDE	PET		2.6.3.
Carotid plaques were retrieved intact at the time of carotid endarterectomy, and 
photographed before being wrapped in foil and frozen at -80 °C. Subsequently, they 
were thawed in a batch and immersed in 18F- fluoride solution diluted with 
phosphate buffered saline (PBS) to a total activity of 10 MBq/mL. After 60 min, 
plaques were rinsed 3 times in PBS before being oriented and placed in a PET-CT 
hybrid scanner (64-multidetector Biograph mCT, Siemens Medical Systems, 
Erlangen, Germany). After an attenuation correction CT scan, PET imaging was 
undertaken over a single bed for 15 min.  
 
Histology and Immunohistochemistry    
Immediately following scanning, plaques were fixed in 4% paraformaldehyde for 24 
hours before transfer to 70% ethanol. Plaques were decalcified in 
ethylenediaminetetraacetic acid before being divided into segments with or without 
18F-Fluoride uptake that were paraffin-embedded, and 5-µm sections were prepared 
and stained with Movat’s pentachrome. Immunohistochemical staining for CD68 
expression (mouse anti-human CD68 mAb, M087601-2, Dako), cleaved caspase 3 
(anti-human rabbit mAb #9664, Cell Signalling Technology) and tissue non-specific 
alkaline phosphatase (anti-human rabbit pAb CAT#LF PA50004, Abfrontier) was 
then undertaken following heat induced epitope retrieval (HIER) using 0.01 M citrate 
buffer at pH 6.0 in a decloaking chamber. Osteocalcin staining (anti-human mouse 
mAb ab13418, Abcam) required no HIER. Sections were stained using a Leica 
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Vision Biosystems Bond x immunostaining robot. Optimization of antibody dilution 
was undertaken by determining positive and negative controls. Positive controls for 
CD68 were generated using human kidney, cleaved caspase 3 using sections of 
normal human tonsil and spleen, and for tissue non-specific alkaline phosphatase and 
osteocalcin using decalcified human bone to determine optimal antibody dilutions. 
Negative controls were generated by omitting the primary antibody. After blocking 
in peroxide for 10 min, sections were incubated with the specific anti-human 
antibodies for 2 hours at room temperature at the following dilutions: CD68 1:100, 
osteocalcin 1:200, cleaved caspase 3 1:150, and tissue non-specific alkaline 
phosphatase 1:100. All incubation steps were followed by washing in TBS/Tween.  
Sections for osteocalcin were incubated for 15 min with pre-polymer/post primary 
followed by 15 min with polymer (HRP) for all antibodies prior to DAB (3,3'-
Diaminobenzidine) visualization and haematoxylin counterstaining. Sections were 
dehydrated in graded ethanol, cleared in xylene before cover slipping in Pertex.   
 
Images were taken on a Zeiss Axioskop2 fitted with an Axiocam MRc digital camera 
using Axiovision software. Total vessel and plaque cross-sectional area was 
calculated using Image Pro Plus 5 (Rockville, MD, USA).  Staining was quantified 
by automated colour-coded segmentation.  Immunohistochemical markers were 
expressed as number of cells per mm2 or percentage staining of total cross-sectional 
area.  
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 MAGNETIC	RESONANCE	IMAGING	2.7.
Patients with aneurysmal disease (Chapter 6)  underwent MRI in a whole body 3T 
scanner (Magnetom Verio, Siemens, Erlangen, Germany) before and 24 h after 
intravenous administration of USPIO contrast agent (Ferumoxytol; Advanced 
Magnetics Inc., Cambridge, MA, USA; dose 4 mg/kg at a rate of 1 mL/s) as 
described previously (Richards et al., 2011b, Alam et al., 2012). Briefly, coronal and 
sagittal breath-held T2-weighted multi-slice HASTE localizer sequences were used 
to identify the position and extent of the aneurysm following which a respiratory-
gated, electrocardiographically-triggered T2 weighted (T2W) turbo-spin echo 
sequence was used to acquire detailed anatomical data. (TR/TE 2R-R intervals/72 
ms; flip angle 180°; matrix 192 × 256; field of view 400 × 400 mm; slice width 5 
mm, zero slice-gap). A multi-echo, gradient-echo T2*W sequence (TE 4.9, 7.7, 10.5, 
13.3 ms; TR 133 ms; flip angle 15°; matrix 192 × 256; field of view 400 × 400 mm; 
slice width 5 mm, zero slice-gap) was used to acquire axial images of the entire 
aneurysm with slice positions corresponding to those of the T2W images. When 
performing the post-contrast scans, axial acquisitions were positioned to match those 
of the pre-contrast scan by reference to the vertebral bodies. Pre- and post- contrast 
T2*W images were utilized to generate R2* color maps (Matlab, Maths works) for 
quantification of USPIO uptake (Alam et al., 2012, Richards et al., 2011b). 
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 IMAGE	REGISTRATION	AND	ANALYSIS		2.7.1.
The MRI dataset was registered to the PET dataset using a semi-automatic rigid 3D 
voxel registration protocol  (Analyze 11.0, Mayo Clinic).  The accuracy of PET-CT 
to CTA registration was confirmed by visual assessment and minor intra-scan patient 
movement was corrected. Registration of the MRI data allowed both the excellent 
anatomical detail on the T2W images and the high sensitivity of T2*W images for 
iron to be utilized.  All the images were registered to the pre-contrast T2W image 
using the same semi-automatic 3D voxel registration protocol (Analyze 11.0, Mayo 
Clinic). The CTA and T2W MRI datasets were co-registered. At the end of the 
registration process, the pre-USPIO T2*W MRI, the post-USPIO T2*W MRI, the 
CTA and the PET-CT were all co-registered to enable direct comparison. 
USPIO quantification 
Using validated in-house software (Matlab, Mathworks, USA), four echoes in the 
multi-echo T2*W sequence were combined to generate a T2* map in which the 
magnitude of each voxel represented the T2*value (S(t)=S(0)exp-(t/T2*).  The T2* 
value is the decay constant for the exponential decay of signal intensity with time.  In 
the presence of USPIO, the signal decays more rapidly because of local magnetic 
field inhomogeneities and the T2* value is reduced. A 3×3 voxel Gaussian filter was 
applied to the individual echoes to reduce noise.  An experimentally determined 
threshold for the coefficient of determination (r2>0.85) was used to exclude data that 
did not have an acceptable exponential decay when signal intensity (SI) was plotted 
against echo time. USPIO uptake was detected using the change in T2* (or R2*; 
R2*=1/T2*) following USPIO administration. A previously defined threshold of 
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significance (59% increase in T2*) was used to distinguish USPIO accumulation 
from artefactual changes in T2* (Richards et al., 2012, Richards et al., 2011c). To 
enable the spatial distribution of USPIO uptake within the aneurysm to be assessed, 
colour maps were generated in which each voxel represented the change in T2* 
(ΔT2*) or R2* (ΔR2*) following USPIO administration.  
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 STATISTICAL	ANALYSIS		2.8.
Specific statistical analysis has been described in each chapter separately. Statistical 
analysis was performed with Graph Pad Prism version 6 (GraphPad Software Inc., 
California USA) or SPSS 19.0 (SPSS Inc., Chicago, Illinois) where appropriate. 
Continuous data were checked for normality using the D’Agostino-Pearson omnibus 
test. Parametric variables were expressed as mean ± standard deviation and 
compared using Student’s t-tests or repeat measure one-way ANOVA with Tukey’s 
multiple comparison test when appropriate. Non-parametric data were presented as 
median [interquartile range] and compared with Mann-Whitney test, Wilcox 
matched-pairs signed rank, or Friedman test as appropriate. Inter-observer 
reproducibility was estimated using the Bland Altman method and presented as mean 
bias ± 2 standard deviation, and intra-class correlation coefficients with 95% 
confidence intervals were also calculated. A two-sided P<0.05 was taken as 
statistically significant.  Inter-observer reproducibility was calculated by the Bland 
Altman method and presented as mean bias ± 2 standard deviation, and intra-class 
correlation coefficients with 95% confidence intervals were calculated. 
 
The primary end-point of the study in patients with atherosclerosis (Chapter 3) was 
the comparison of 18F-fluoride tissue-to-background ratios of culprit and non-culprit 
coronary plaques of patients with acute myocardial infarction. The main secondary 
endpoints were comparative imaging and histological characterisation of 18F-
fluoride positive and negative atherosclerotic plaques in patients with carotid and 
coronary artery disease. Based on our previous data (Dweck et al., 2012a), we 
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required 36 patients with myocardial infarction to detect a difference of 0.23 in the 
tissue-to-background ratio between culprit and non-culprit plaques at 90% power and 
two-sided p<0.05. We recruited 40 patients to account for incomplete data and 
recruited a similar sized (n=40) comparator group of patients with stable angina.  As 
a pre-specified end-point (ClinicalTrials.gov: NCT01749254), we explored 18F-FDG 
uptake in remote aortic atheroma of patients with recent myocardial infarction or 
stable coronary heart disease.  
 
Patients in the registry cohort were divided into tertiles according to their peak 
troponin concentration (Chapter 4). Kaplan Meier curves were used to estimate the 
distribution of early recurrent myocardial infarction across the tertiles. Univariate 
analysis was undertaken to identify associations with early (≤30 days) and late (>30 
days) recurrent myocardial infarction that were then entered into the multivariate 
logistic regression model based on univariate association of p<0⋅1. In addition, age 
and sex were included in the model.  Statistical analysis was performed with Graph 
Pad Prism version 6 (GraphPad Software Inc., California USA) and SPSS 19.0 
(SPSS Inc., Chicago, Illinois) where appropriate. Unless stated, a two-sided P<0.05 
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Chapter	3. 18F-FLUORIDE	 POSITRON	 EMISSION	
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Non-invasive imaging to identify ruptured or high-risk coronary atherosclerotic 
plaque would represent a major clinical advance. Using combined positron emission 
tomography (PET) and computed tomography (CT), we investigated the 
identification of ruptured and high-risk atherosclerotic plaque using 18F-fluoride and 
18F-fluorodeoxyglucose (18F-FDG). 
 
In this prospective clinical trial, patients with myocardial infarction (n=40) and stable 
angina (n=40) underwent 18F-fluoride and 18F-FDG PET-CT, and invasive coronary 
angiography. 18F- fluoride uptake was compared with histology in carotid 
endarterectomy specimens from patients with symptomatic carotid disease, and with 
intravascular ultrasound in patients with stable angina. 
 
In 37 (93%) of the patients with myocardial infarction, the highest coronary 18F- 
fluoride activity was observed in the culprit plaque (maximum tissue-to-background 
ratio: culprit 1.66 [1.40-2.25] versus highest non-culprit 1.24 [1.06-1.38], p<0.001). 
In contrast, coronary 18F-FDG uptake was commonly obscured by myocardial 
uptake and where discernible, there were no differences between culprit and non-
culprit plaques (1.71 [1.40-2.13] versus 1.58 [1.28-2.01], p=0.34).  Marked 18F- 
fluoride uptake occurred at the site of all carotid plaque ruptures and was associated 
with histological evidence of active calcification, macrophage infiltration, apoptosis 
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and necrosis. Eighteen (45%) patients with stable angina had plaques with focal 18F-
Fluoride uptake (maximum tissue-to-background ratio: 1.90 [1.61-2.17]) that were 
associated with more high-risk features on intravascular ultrasound than those 
without uptake:  positive remodeling (remodeling index: 1.12 [1.09-1.19] versus 1.01 
[0.94-1.06]; p<0.001), microcalcification (73 versus 21%, p=0.002) and necrotic core 
(25 [21-29] versus 18 [14-22] %, p=0.001).  
 
18F- fluoride PET-CT is the first non-invasive imaging method to identify and 
localise ruptured and high-risk coronary plaque. Future studies are needed to 
determine whether this can improve the management and treatment of patients with 
coronary artery disease.  
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 INTRODUCTION		3.2.
Coronary atherosclerotic plaque rupture is the principal aetiological precipitant of 
acute myocardial infarction and an important cause of sudden cardiac death. It is 
challenging to predict because most plaques that subsequently rupture are non-
obstructive and are not identified by stress testing or coronary angiography (Naghavi 
et al., 2003, Virmani et al., 2000a). Atherosclerotic lesions at risk of rupture have 
certain histopathological characteristics that include positive remodeling, 
microcalcification and a large necrotic core (Naghavi et al., 2003, Virmani et al., 
2000a, Virmani et al., 2006b). The development of modern molecular imaging 
techniques targeted at these features could lead to the identification of such high-risk 
plaques in vivo and guide the development of novel treatment strategies (Rogers and 
Tawakol, 2011). 
 
Combined positron emission tomography (PET) and computed tomography (CT) is a 
non-invasive imaging technique that brings functional molecular imaging together 
with precise anatomical information. We have recently reported preliminary PET-CT 
data using the tracer 18F-fluoride (18F-Fluoride) as a marker of valvular and 
vascular calcification activity in patients with aortic stenosis (Dweck et al., 2013b, 
Dweck et al., 2013a, Dweck et al., 2012a). Other studies have demonstrated the 
utility of 18F-flurodeoxyglucose (18F-FDG) as a surrogate of vascular inflammation 
and macrophage burden (Rogers et al., 2010, Tawakol et al., 2006, Rudd et al., 2002, 
Wykrzykowska et al., 2009, Cheng et al., 2012). We therefore sought to investigate 
whether, in comparison to the current non-invasive gold-standard of 18F-FDG, 18F-
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Fluoride uptake could identify ruptured and high-risk atherosclerotic plaques in 
patients with symptomatic coronary and carotid artery disease.  
  




Patients were recruited from the Royal Infirmary of Edinburgh between February 
2012 to January 2013 in three cohorts : 40 patients with acute ST- or non-ST-
segment elevation myocardial infarction (Thygesen et al., 2012) 40 patients with 
stable angina pectoris undergoing elective invasive coronary angiography, and 12 
patients undergoing carotid endartectomy for symptomatic carotid artery disease. 
Studies were performed with the approval of the local research ethics committee, in 
accordance with the Declaration of Helsinki, and with the written informed consent 
of each participant. 
 
Consecutive patients with myocardial infarction were approached and recruited if 
they fulfilled the criteria for type 1 myocardial infarction according to the Universal 
Definition of Myocardial Infarction (Thygesen et al., 2012), ST segment elevation 
myocardial infarction was defined as new ST segment elevation at the J point in two 
contiguous leads with the cut-points: ≥0.1 mV in all leads except V2-V3 where the 
thresholds were ≥0.2 mV for men ≥40 years and ≥0.25 mV for women. 
Consecutive patients with stable angina pectoris were recruited if they had typical 
symptoms of exertional anginal chest pain, previously documented coronary artery 
disease (>70% stenosis of at least one major epicardial coronary artery), and had 
been scheduled for invasive coronary angiography. Patients were excluded if they 
had suffered an acute coronary syndrome within the last 3 months.  
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Patients with typical symptoms and signs of an acute transient ischemic attack, 
amaurosis fugax or stroke were recruited within 1-14 days of symptom onset. All 
patients underwent clinical evaluation and carotid Doppler assessment. Inclusion 
criteria were carotid stenosis >50% (NASCENT Criteria, 1991) consistent with 
clinical presentation, and planned carotid endarterectomy.  
 
Exclusion Criteria 
Exclusion criteria were age <50 years, insulin-dependent diabetes mellitus, women 
of childbearing age not taking contraception, severe renal failure (serum creatinine 
>250 µmol/L), known contrast allergy and inability to provide informed consent. 
Only patients older than 50 years were recruited in the study to reduce any long-term 
risks associated with radiation exposure. Uncontrolled diabetes and high blood 
glucose concentrations (>11 mmol/L) interfere with image quality of 18F-FDG PET 
imaging due to competition between glucose and 18F-fluorodeoxyglucose for 
cellular entry. It has therefore been the convention to exclude such patients from 
vascular 18F-fluorodeoxyglucose positron emission tomography studies (Tawakol et 
al., 2006, Wykrzykowska et al., 2009, Williams and Kolodny, 2008, Cheng et al., 
2012).  
All patients underwent a comprehensive baseline clinical assessment including 
evaluation of their cardiovascular risk factor profile. Plasma troponin I 
concentrations were measured in patients with stable angina using the ARCHITECT 
STAT high-sensitivity troponin I assay (Abbott Laboratories, Abbott Park, Illinois; 
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lower limit of detection, 1.2 ng/L; 99th percentile diagnostic threshold, 26 ng/L).  
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 PET-CT	IMAGING	AND	ANALYSIS	3.3.2.
Patients with a heart rate exceeding 65 beats/min received oral beta-blockade (50 or 
100 mg metoprolol orally) 1 h before the computed tomography (CT) examination. 
All patients received sublingual glyceryl trinitrate (300 µg) just prior to the CT 
coronary angiography (CTCA). Patients were asked to refrain from alcohol and 
caffeine on the day of the scan.  
 
Visit 1: 18F-Fluoride 
All patients underwent dual cardiac and respiratory-gated positron emission 
tomography (PET)-CT imaging of the coronary arteries with a hybrid scanner (64-
multidetector Biograph mCT, Siemens Medical Systems, Erlangen, Germany). Study 
subjects were administered a target dose of 125 MBq 18F-fluoride (18F-Fluoride) 
intravenously and subsequently rested in a quiet environment for 60 min. An 
attenuation correction CT scan (non-enhanced 120 kV and 50 mA) was then 
performed, followed by PET imaging of the thorax in list-mode for 20 min.  
Coronary artery calcium and CTCA were undertaken in the same visit as the 18F-
Fluoride scan. With the patient lying still on the scanner after acquisition of the PET, 
an electrocardiogram-gated breath-hold CT scan (non-contrast-enhanced, 40 
mAs/rotation, 120 kV; CareDose, Siemens Medical Systems) of the coronary arteries 
was performed. CTCA was performed using the following settings: 330 ms rotation 
time, 100 (body mass index [BMI] <25 kg/m2) or 120 (body mass index >25 kg/m2) 
kV tube voltage, 160-245 mAs tube current, 3.8 mm/rotation table feed, prospective 
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(heart rate regular and <60/min), or retrospective (heart rate >60 /min) 
electrocardiogram-gated. Depending on the BMI, a bolus of 80-100 mL of contrast 
(400 mgI/mL; Iomeron, Bracco, Milan, Italy) was injected intravenously at 5 mL/s, 
after determining the appropriate trigger delay with a test bolus of 20 mL contrast 
material.  
 
Although the PET scans were acquired with the potential for dual motion correction, 
inclusion of respiratory gating led to significant loss of signal with increased noise. 
Therefore, only electrocardiogram-gated cardiac motion correction was undertaken. 
The PET scans were reconstructed in multiple phases of the cardiac cycle, with the 
diastolic phase (50-75%) used for analysis. The CTCA scans were reconstructed at 
0.75 x 0.7 mm and 0.6 x 0.3 mm for retrospective and prospective acquisitions 
respectively at 60%, 65% and 70% of the cardiac cycle. Additional reconstructions 
were undertaken if necessary. Although the PET scans were acquired with the 
potential for dual motion correction, inclusion of respiratory gating led to significant 
loss of signal with increased noise. Therefore, only electrocardiogram-gated cardiac 
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Visit 2: 18F-Fluorodeoxyglucose 
Intense uptake of 18F-fluorodeoxyglucose (18F-FDG) by the left ventricle leads to 
difficulties in discriminating between activity in the coronary arteries and the 
myocardium. All patients in our cohort were asked to observe a low-carbohydrate, 
high-protein and high-fat diet for 24 hours before their 18F-FDG scan because this 
suppresses myocardial uptake as the heart switches from glucose to free fatty acid 
metabolism (Tawakol et al., 2006, Wykrzykowska et al., 2009, Cheng et al., 2012, 
Williams and Kolodny, 2008).Patients were provided with a list of food and drink to 
avoid and reminded of these restrictions the day before their scan. Dietary diaries 
were recorded for all patients. 
 
Subjects were administered a target dose of 200 MBq 18F-FDG intravenously and 
subsequently rested in a quiet environment for 90 min. Combined PET-CT imaging 
was then performed as described for the 18F-Fluoride scan.  
 
Patients with myocardial infarction and stable angina underwent 18F- fluoride and 
18F-FDG PET-CT, CT coronary angiography and CT calcium scoring (Dweck et al., 
2012a). To minimize myocardial uptake, patients were instructed to adhere to a low-
carbohydrate, high-protein and high-fat diet for at least 24 h prior to undergoing 18F-
FDG PET-CT. 
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Electrocardiogram-gated PET images were reconstructed in diastole (50-75% of the 
R-R interval, Ultra-HD, time of flight x True X), fused with the CT coronary 
angiogram, and analysed by experienced observers blinded to the clinical diagnosis 
(NJ, MD, FC) using an OsiriX workstation (OsiriX version 5.5.1 64-bit; OsiriX 
Imaging Software, Geneva, Switzerland). Two-dimensional regions of interest 
(ROIs) were drawn around all major (diameter >2 mm) epicardial vessels on 3-mm 
axial slices just beyond the discernible adventitial border. The maximum standard 
uptake value (SUV; the decay corrected tissue concentration of the tracer divided by 
the injected dose per body weight) was measured and corrected for blood pool 
activity in the superior vena cava to provide tissue-to-background ratios (TBRs) 
measurements. Using this methodology, we have previously demonstrated excellent 
reproducibility for 18F-Fluoride TBR measurements in the coronary arteries with an 
intraclass correlation coefficient of 0.99 (Dweck et al., 2012a). 
 
We used a previously established 95% lower reference limit to categorise coronary 
plaques into 18F-Fluoride positive lesions (focal uptake with a TBR >25 % higher 
than a proximal reference lesion) and negative plaques if these criteria were not 
achieved. This was based on our previous study, where plaques with high 18F-
Fluoride uptake had maximum TBRs that were 44% (95% confidence intervals, 26-
62%) higher than a proximal quiescent reference lesion (Dweck et al., 2012a). In 
patients with acute myocardial infarction, 18F- fluoride uptake in the culprit plaque 
was compared with the highest value in any of the non-culprit vessels.  
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Quantification of 18F-FDG uptake was performed as for 18F- fluoride uptake but 
restricted to the proximal and mid-portions of the coronary arteries, and to regions 
where myocardial uptake and spillover could be confidently excluded (Dweck et al., 
2012a). Again 18F-FDG positive plaques were defined using the >25% threshold as 
described for 18F-Fluoride. Effective myocardial suppression of 18F-FDG was 
predefined as SUV ≤5.0 in the basal ventricular septum as per published data 
(Wykrzykowska et al., 2009). 
 
Image Analysis Repeatability 
Thirty patients were selected randomly to test the repeatability of image analysis in 
between two trained readers (NVJ, MRD). Fifteen patients from each of the 18F-
FDG and 18F-Fluoride cohorts were selected and each reader repeated the analysis 
of these patients independently in random order to avoid recall bias. 
  




In patients with stable angina, PET-CT imaging was prospectively used to direct 
gray-scale and radiofrequency intravascular ultrasound (20 MHz Eagle Eye Platinum 
Catheters [Volcano Corp, USA], motorized pull-back 0.5 mm/s) to the 18F-Fluoride 
positive and negative plaques. The interventional cardiologist acquiring the 
intravascular ultrasound data was blinded to the PET-CT status of the plaque. 
 
Intravascular ultrasound analysis was performed as described previously using 
dedicated VIAS software (Volcano Corp, USA) by operators blinded to the positron 
emission tomography data (Calvert et al., 2011). Regions of interest were drawn 
around the external elastic membrane and luminal borders, and plaque area and 
composition (dense calcium, necrotic core, fibro-fatty tissue and fibrous tissue) 
calculated (Calvert et al., 2011, Stone et al., 2011a, Murray et al., 2013). The 
presence of microcalcification (spotty calcification in the absence of acoustic 
shadowing on ≥3 consecutive frames) and the maximum frame necrotic core (the 
highest percentage of necrotic core on a single frame) were recorded (Ehara et al., 
2004). The remodeling index was defined as the ratio between the external elastic 
membrane cross-sectional area of the lesion and a proximal reference region in the 
same vessel (Mintz et al., 2001). Plaques were classified as thin-cap fibroatheroma, 
thick-cap fibroatheroma, pathologic intimal thickening or fibrocalcific plaque as 
defined previously (Stone et al., 2011a, Garcia-Garcia et al., 2009b). 
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CT analysis was performed on a dedicated cardiovascular workstation (Vital Images, 
Minnetonka, Minnesota, USA). Vessel-specific and total Agatston calcium scores 
were calculated as described previously (Dweck et al., 2012a). An independent 
experienced and blinded observer  determined stenosis severity, plaque composition 
(calcified, non-calcified, mixed plaque) and the presence of high-risk CT features 
(positive remodeling, microcalcification, necrotic core) according to standard 
definitions in plaques with and without increased 18F-fluoride activity (Motoyama et 
al., 2009a). 
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 CAROTID	ATHEROMA		 	3.3.4.
Intact atherosclerotic plaques were retrieved at the time of carotid endarterectomy 
and scanned using ex-vivo PET-CT to allow precise anatomical co-localisation of 
18F-fluoride activity with pathological evidence of plaque rupture. Plaques were 
divided into 18F- fluoride positive and negative areas, and histological sections were 
assessed using Movat’s pentachrome and immunohistochemistry to investigate both 
calcification activity (tissue non-specific alkaline phosphatase and osteocalcin), 
macrophage infiltration (CD68) and cell death (apoptosis, cleaved caspase 3; 
presence of necrotic core). 
 
Rationale for Immunohistochemistry of Carotid Atheroma  
We used immunohistochemistry to investigate macrophage infiltration (CD68), 
calcification activity (tissue non-specific alkaline phosphatase and osteocalcin), and 
cell death (apoptosis, cleaved caspase 3; presence of necrotic core).  
 
Inflammation is a key feature of human atherosclerosis and is thought to precede the 
early stages of calcification (Aikawa et al., 2007). CD68 is expressed by 
macrophages and has been closely correlated with the 18F-FDG signal in the carotid 
arteries. Apoptotic cell death is a recognized phenomenon in atherosclerotic plaque 
and is thought to be detrimental to plaque stability (Kockx and Herman, 2000). 
Cleaved caspase 3 is a critical executioner of apoptosis, being responsible for the 
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proteolytic cleavage of many key proteins, such as the nuclear enzyme poly (ADP-
ribose) polymerase (PARP). Its expression has been previously demonstrated in 
atherosclerotic plaque (Fernandes-Alnemri et al., 1994).    
 
During propagation of atherosclerosis, vascular smooth muscle cells undergo 
osteogenic differentiation (New and Aikawa, 2011). Additionally, matrix vesicles 
released from living cells and apoptotic bodies from dying macrophages and smooth 
muscle cells are thought to provide a nidus for microcalcification(Proudfoot et al., 
2000, Shanahan, 2007). Tissue non-specific alkaline phosphatase (TNAP) is an 
enzyme that plays a key role in atherosclerotic calcification by increasing availability 
of inorganic phosphate levels through the hydrolyzing   pyrophosphate, a key 
inhibitor of mineralization (Demer and Tintut, 2008). Unlike dyes such as alizarin 
red that directly stains tissue calcium, TNAP provides information about calcification 
activity and gives information distinct from mere anatomical calcium.  
 
Osteocalcin, or bone Gla protein, is a small protein secreted by osteoblasts that can 
undergo γ-carboxylation (Kapustin and Shanahan, 2011). The γ-carboxylated form 
binds hydroxyapatite and is abundant in bone extracellular matrix. Osteocalcin is 
thought to be a regulator of osteochondrogenic differentiation of pathologically 
mineralizing vascular smooth muscle cells (Kapustin and Shanahan, 2011). The 
presence of osteocalcin is therefore suggestive of up regulated vascular 
mineralization (Idelevich et al., 2011). 
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Ex-vivo 18F-Fluoride Positron Emission Tomography  
Carotid plaques were retrieved intact at the time of carotid endarterectomy, and 
photographed before being wrapped in foil and frozen at -80 °C. Subsequently, they 
were thawed in a batch and immersed in 18F- fluoride solution diluted with 
phosphate buffered saline (PBS) to a total activity of 10 MBq/mL. After 60 min, 
plaques were rinsed 3 times in PBS before being oriented and placed in a PET-CT 
hybrid scanner (64-multidetector Biograph mCT, Siemens Medical Systems, 
Erlangen, Germany). After an attenuation correction CT scan, PET imaging was 
undertaken over a single bed for 15 min.  
 
Histology and Immunohistochemistry    
Immediately following scanning, plaques were fixed in 4% paraformaldehyde for 24 
hours before transfer to 70% ethanol. Plaques were decalcified in 
ethylenediaminetetraacetic acid before being divided into segments with or without 
18F-Fluoride uptake that were paraffin-embedded, and 5-µm sections were prepared 
and stained with Movat’s pentachrome. Immunohistochemical staining for CD68 
expression (mouse anti-human CD68 mAb, M087601-2, Dako), cleaved caspase 3 
(anti-human rabbit mAb #9664, Cell Signalling Technology) and tissue non-specific 
alkaline phosphatase (anti-human rabbit pAb CAT#LF PA50004, Abfrontier) was 
then undertaken following heat induced epitope retrieval (HIER) using 0.01 M citrate 
buffer at pH 6.0 in a decloaking chamber. Osteocalcin staining (anti-human mouse 
mAb ab13418, Abcam) required no HIER. Sections were stained using a Leica 
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Vision Biosystems Bond x immunostaining robot. Optimization of antibody dilution 
was undertaken by determining positive and negative controls. Positive controls for 
CD68 were generated using human kidney, cleaved caspase 3 using sections of 
normal human tonsil and spleen, and for tissue non-specific alkaline phosphatase and 
osteocalcin using decalcified human bone to determine optimal antibody dilutions. 
Negative controls were generated by omitting the primary antibody. After blocking 
in peroxide for 10 min, sections were incubated with the specific anti-human 
antibodies for 2 hours at room temperature at the following dilutions: CD68 1:100, 
osteocalcin 1:200, cleaved caspase 3 1:150, and tissue non-specific alkaline 
phosphatase 1:100. All incubation steps were followed by washing in TBS/Tween.  
Sections for osteocalcin were incubated for 15 min with pre-polymer/post primary 
followed by 15 min with polymer (HRP) for all antibodies prior to DAB (3,3'-
Diaminobenzidine) visualization and haematoxylin counterstaining. Sections were 
dehydrated in graded ethanol, cleared in xylene before cover slipping in Pertex.   
 
Images were taken on a Zeiss Axioskop2 fitted with an Axiocam MRc digital camera 
using Axiovision software. Total vessel and plaque cross-sectional area was 
calculated using Image Pro Plus 5 (Rockville, MD, USA).  Staining was quantified 
by automated colour-coded segmentation.  Immunohistochemical markers were 
expressed as number of cells per mm2 or percentage staining of total cross-sectional 
area.  
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 STATISTICAL	ANALYSIS		3.3.5.
The primary end-point of the study was the comparison of 18F-fluoride tissue-to-
background ratios of culprit and non-culprit coronary plaques of patients with acute 
myocardial infarction. The main secondary endpoints were comparative imaging and 
histological characterisation of 18F-fluoride positive and negative atherosclerotic 
plaques in patients with carotid and coronary artery disease. Based on our previous 
data (Dweck et al., 2012a), we required 36 patients with myocardial infarction to 
detect a difference of 0.23 in the tissue-to-background ratio between culprit and non-
culprit plaques at 90% power and two-sided p<0.05. We recruited 40 patients to 
account for incomplete data and recruited a similar sized (n=40) comparator group of 
patients with stable angina.  
 
Continuous data were tested for normality with the D’Agostino and Pearson 
Omnibus test.  Continuous parametric variables were expressed as mean ± standard 
deviation and compared using Student’s t-tests. Non-parametric data were presented 
as median [interquartile range] and compared using Mann-Whitney U test or 
Wilcoxon signed-rank test as appropriate. Fisher’s exact test or Chi-Squared test was 
used for analysis of categorical variables. Statistical analysis was performed with 
Graph Pad Prism version 5 (GraphPad Software Inc., California USA). A two-sided 
p<0.05 was taken as statistically significant.  
 
The study was registered with ClinicalTrials.gov number NCT01749254.  
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 RESULTS	3.4.
Patients were predominantly middle-aged men and had multiple cardiovascular risk 
factors (Table 3-1). They underwent both 18F-fluoride (60±9 min after 123±5 MBq) 
and 18F-FDG (90±7 min after 192±11 MBq) PET-CT scanning within a median of 6 
[3-9] days. The median duration between PET-CT scanning and coronary 
angiography was 7 [1-12] days. The total effective radiation dose from study 
participation was 13.7±3.0 mSv (conversion factor of 0.014 mSv/mGy.cm): 18F-
Fluoride (3.8±0.3 mSv) and 18F-FDG (4.9±0.5 mSv) PET-CT, CT coronary 
angiogram (3.7±2.1 mSv) and calcium score (1.3±0.5 mSv). 
The total time spent in the imaging centre for each patient was ~100 min for visit 1 
(18F-Fluoride PET-CT scans) and ~120 min for visit 2 (18F-FDG PET-CT scans). 
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 REPEATABILITY	OF	IMAGE	ANALYSIS	3.4.1.
The repeatability for measurements of coronary 18F-FDG and 18F- fluoride activity 
in the present study were excellent, with no fixed or proportional biases for 
measurements of the maximum tissue-to-background ratios for either tracer. The 
limits of agreement for maximum coronary 18F-FDG tissue to background ratios 
were 0.04±0.23 (mean bias±2SD) with intraclass correlation coefficient values of 
0.97 after exclusion of uninterpretable segments [95% CI 0.90-0.99]. For 18F- 
fluoride limits of agreement were 0.01±0.11 with intraclass correlation coefficient 
values of 0.99 [95% CI 0.99-1.00].  	
Novel molecular imaging of cardiovascular disease in man 
 119 
 PATIENTS	WITH	MYOCARDIAL	INFARCTION	3.4.2.
The culprit vessel was the left anterior descending artery in 17 (42%) patients, the 
left circumflex artery in seven (18%) and the right coronary artery in 16 (40%). 
Patients underwent 18F-Fluoride scans 6 [3-10] days following hospitalization for 
myocardial infarction (symptoms to 18F- fluoride scan, 8 [3-10] days). 18F- fluoride 
activity in the culprit plaque was 34% higher than the maximum activity recorded 
anywhere else in the coronary vasculature (maximum TBR, 1.66 [1.40-2.25] versus 
1.24 [1.06-1.38] respectively, p<0.001; Figures 3-1, 3-2 and 3-3). In 37 of the 40 
patients (93%), increased 18F-Fluoride uptake was observed in the culprit plaque 
(Figure 3-1). In the three patients without uptake, two were younger smokers and, in 
the third, the culprit lesion was adjudicated as the right coronary artery although 
focal increased activity was observed in the left circumflex artery. In five patients, 
increased 18F-fluoride activity was observed at multiple sites within the coronary 
circulation.  
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Table 3-1: Baseline characteristics of patients with coronary artery disease 
	 Myocardial	Infarction	 Stable	Angina	
	 All	(n=40)	 STEMI	(n=26)	 NSTEMI	(n=14)	 All	(n=40)	
Age	(years)	 62±8	 63±9	 60±8	 67±8	
Male	sex	 37	(93%)	 24	(92%)	 13	(93%)	 36	(90%)	
BMI	(kg/m2)	 28±5	 27±5	 30±4	 30±5	
Antecedent	angina	(active)	 9	(23%)	 5	(19%)	 4	(29%)	 40	(100%)	
Heart	rate	(per	min)	 56±7	 56±7	 56±7	 59±9	
Systolic	blood	pressure	(mmHg)	 132±21	 131±20	 121±21	 134±14	
Diastolic	blood	pressure	(mmHg)	 76±9	 76±9	 76±8	 77±10	
Cardiovascular	History	 	 	 	 	
Previous	MI	 5	(13%)	 1	(4%)	 4	(29%)	 15	(38%)	
Previous	CVA/TIA	 2	(5%)	 1	(4%)	 1	(7%)	 4	(10%)	
Previous	PCI	 5	(13%)	 2	(8%)	 3	(21%)	 19	(48%)	
Previous	CABG	 2	(5%)	 2	(8%)	 0	 11	(28%)	
Risk	Factors	 	 	 	 	
Smoking	Habit	(ex	or	current)	 25	(63%)	 19	(73%)	 6	(43%)	 24	(60%)	
Non-insulin	dependent	diabetes	 8	(20%)	 7	(27%)	 1	(7%)	 13	(33%)	
Hypertension	 17	(43%)	 11	(42%)	 6	(43%)	 36	(90%)	
Hypercholesterolemia	 19	(48%)	 11	(42%)	 8	(57%)	 39	(98%)	
Medications	 	 	 	 	
Aspirin	 40	(100%)	 26	(100%)	 14	(100%)	 33	(83%)	
Clopidogrel	 39	(98%)	 25	(96%)	 14	(100%)	 5	(13%)	
Statin	 39	(98%)	 26	(100%)	 13	(93%)	 36	(90%)	
β-Blocker	 32	(80%)	 20	(77%)	 12	(86%)	 28	(70%)	
ACEI/ARB	 35	(88%)	 25	(96%)	 10	(71%)	 20	(50%)	
Calcium	channel	blockers	 2	(5%)	 2	(8%)	 0	 16	(40%)	
Other	Anti-hypertensive	 3	(8%)	 1	(4%)	 2	(14%)	 6	(15%)	
Oral	Nitrates	 1	(3%)	 0	 1	(7%)	 15	(38%)	
Serum	Biochemistry	 	 	 	 	
Cholesterol	(mmol/L)	 4.7±1.2	 4.7±1.3	 4.8±1.1	 3.9±0.8	
HDL	Cholesterol	(mmol/L)	 1.1±0.3	 1.1±0.3	 1.0±0.3	 1.1±0.3	
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*Heart rate at the time of CTCA;
 † 
Medications at the time of scan 
STEMI ST elevation myocardial infarction, NSTEMI non-ST elevation myocardial infarction, BMI body mass index, MI myocardial infarction, 
CVA cerebrovascular accident, TIA transient ischemic attack, PCI percutaneous coronary intervention, ACEI angiotensin converting enzyme 
inhibitor, ARB angiotensin receptor blocker, CABG coronary artery bypass graft, HDL high-density lipoprotein, LDL low-density lipoprotein, 
TG Triglycerides. AU Agatston Units  
 
  
LDL		Cholesterol	(mmol/L)	 2.9±1.1	 2.8±1.1	 3.1±1.0	 2.1±0.7	
Triglycerides	(mmol/L)	 1.6±0.8	 1.7±0.7	 1.5±0.7	 1.6±0.7	
Creatinine	(µmol/L)	 84±27	 86±29	 82±24	 85±23	
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Figure 3-1: Focal 18F-fluoride and 18F-fluorodeoxyglucose uptake in patients 
with myocardial infarction and stable angina 
Patient with acute ST-segment elevation myocardial infarction with (A) proximal occlusion (red 
arrow) of the left anterior descending artery on invasive coronary angiography and (B) intense focal 
18F-fluoride (18F-Fluoride; tissue-to-background ratios, culprit 2.27 versus reference segment 1.09 
[108% increase]) uptake (yellow-red) at the site of the culprit plaque (red arrow) on the combined 
positron emission and computed tomogram (PET-CT). Corresponding 18F-fluorodeoxyglucose PET-
CT image (C) showing no uptake at the site of the culprit plaque (18F-FDG tissue-to-background 
ratios; 1.63; versus 1.91 reference segment; 15% decrease). Note the significant myocardial uptake 
overlapping with the coronary artery (yellow arrow) and uptake within the oesophagus (blue arrow).  
Patient with anterior non-ST-segment elevation myocardial infarction with (D) culprit (red arrow; left 
anterior descending artery) and bystander non-culprit (white arrow; circumflex artery) lesions on 
invasive coronary angiography that were both stented during the index admission. Only the culprit 
lesion had increased 18F- fluoride uptake (18F-Fluoride, tissue-to-background ratios; culprit 2.03 
versus reference segment 1.08 [88% increase]) on PET-CT (E) following percutaneous coronary 
intervention. Corresponding 18F-fluorodeoxyglucose PET-CT showing no uptake either at the culprit 
(18F-FDG, tissue-to-background ratios; culprit 1.62 versus reference segment 1.49 [9% increase]) or 
the bystander stented lesion. Note intense uptake within the ascending aorta.  
In a patient with stable angina with previous coronary artery bypass grafting, invasive coronary 
angiography (G) demonstrated non-obstructive disease in the right coronary artery.  Corresponding 
PET-CT scan (H) showed a region of increased 18F- fluoride activity (positive lesion, red line) in the 
mid-right coronary artery (tissue-to-background ratio, 3.13) and a region without increased uptake in 
the proximal vessel (negative lesion, yellow line). Radiofrequency intravascular ultrasound shows that 
the 18F-Fluoride negative plaque (I) is principally composed of fibrous and fibrofatty tissue (green) 
with confluent calcium (white with acoustic shadow) but little evidence of necrosis. On the contrary, 
the 18F- fluoride positive plaque (J) demonstrates high risk features such as a large necrotic core 
(red) and microcalcification (white).  
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Figure 3-2: 18F-fluoride and 18F-fluorodeoxyglucose uptake in patients with 
myocardial infarction 
18F-fluoride activity (maximum tissue-to-background ratio, TBR) was increased in the culprit plaque 
(red) compared to the maximum uptake in any of the non-culprit plaques (blue).  By contrast there 
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Pre-defined myocardial suppression of 18F-FDG uptake was achieved in 28 (70%) 
patients (median myocardial SUV=3.92 [2.71-5.55]). However, coronary 18F-FDG 
uptake could not be distinguished from patchy myocardial uptake in 22 patients 
affecting 52% of vessel territories. Increased uptake of 18F-FDG was observed in the 
culprit vessels of 6 (33%) of the remaining 18 patients.  Overall, no significant 
differences could be demonstrated between the maximum TBRs in the culprit 
plaques and those recorded elsewhere in the coronary vasculature (1.71 [1.40-2.13] 
versus 1.58 [1.28-2.01], p=0.34: Figure 2) with a mean difference of 0.09 (95% 
confidence interval, -0.07 to 0.24).  
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Figure 3-3: Patients with myocardial infarction and 18F- fluoride uptake. 
Panels A-D, invasive coronary angiograms of patients admitted with myocardial infarction with red 
arrows highlighting the culprit stenosis. Panels E-H, corresponding fused positron emission 
tomograms and computed tomography coronary angiograms showing intense coronary 18F-fluoride 
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 PATIENTS	UNDERGOING	CAROTID	ENDARTERECTOMY	3.4.3.
The median duration between clinical symptoms to carotid endarterectomy was 17 
[10-27] days (Table 3-2). Carotid endarterectomy specimens (Figure 3-4 and 3-5) 
were collected in 12 patients although three specimens could not be excised intact 
and were discarded. Ex vivo 18F- fluoride PET-CT was undertaken in nine 
specimens and uptake was localized to the site of macroscopic plaque rupture in all 
patients (Figure 3-4). In comparison to sections of tissue without uptake (n=15), 
those with increased 18F- fluoride uptake (n=24) had increased calcification activity 
(tissue non-specific alkaline phosphatase, 4.07±3.42 versus 0.76 ±0.51 %, p<0.001; 
osteocalcin, 1.88 [0.58-4.10] versus 0.25 [0.11-0.58] %, p<0.001), macrophage 
infiltration (CD68, 350 [172-840] versus 145 [24-362] cells/mm2, p=0.013) and cell 
death (apoptosis, cleaved-caspase-3, 1.23 [0.69-1.91] versus 0.09 [0.04-1.38] %, 
p=0.005; necrotic core, 22/24 versus 4/15; p<0.0001). 
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Figure 3-4: Carotid 18F-fluoride uptake and carotid plaque rupture 
In-vivo (A and B) and ex vivo (C and D) positron emission and computed tomograms showing co-
localization of 18F-fluoride (18F-Fluoride) uptake (yellow-orange) to the site of plaque rupture with 
adherent thrombus on excised carotid endarterectomy tissue (E and F). Histology of the 18F- fluoride 
-positive region demonstrates a large necrotic core (Movat’s pentachrome, magnification 4x, G), 
within which increased staining for tissue non-specific alkaline phosphatase can be observed as a 
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Figure 3-5:Histological comparison of 18F-fluoride positive and negative 
regions of carotid endarterectomy specimens 
Histological sections of carotid endarterectomy specimens in regions with (A-C) and without (D-F) 
18F-fluoride (18F-Fluoride) uptake. Movat’s pentachrome (A and D) showing a large necrotic core 
in a plaque with increased 18F- fluoride uptake (A; arrows). Calcification activity (non-specific 
alkaline phosphatase) and apoptosis (cleaved caspase-3) are increased in the necrotic core and its 
shoulder region of 18F-Fluoride positive plaque (B and C respectively; brown staining) compared to 
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Table 3-2 Baseline characteristics of patients with symptomatic carotid disease 






































BMI body mass index, MI myocardial infarction, CVA cerebrovascular accident, TIA transient ischemic attack, PCI percutaneous 
coronary intervention, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CABG coronary artery 
bypass graft, HDL high-density lipoprotein, LDL low-density lipoprotein. 
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 PATIENTS	WITH	STABLE	ANGINA	3.4.4.
Patients with stable angina were older (67±8 versus 62±8 years, p=0.006) and had 
more severe coronary artery disease (coronary artery calcium score 599 [60-1302] 
versus 159 [42-456] Agatston Units, p=0.006) than those with myocardial infarction 
(Table 3-1). Focal 18F- fluoride uptake was noted in 18 patients (45%) that did not 
appear related to percutaneous coronary intervention and stent deployment. The 
maximum TBR for 18F- fluoride positive plaques was 1.90 [1.61-2.17] and for 18F- 
fluoride positive plaques was 1.02 [0.82-1.17].  18F-fluoride positive plaques were 
predominantly (72% of patients) non-obstructive (<70% luminal stenosis) on 
coronary angiography and demonstrated multiple high-risk features on 
radiofrequency intravascular ultrasound (positive remodeling [remodeling index: 
1.12 [1.09-1.19] versus 1.01 [0.94-1.06]; p<0.001, microcalcification (73 versus 
21%, p=0.002) and necrotic core (24.6 [20.5-28.8] versus 18.0 [14.0-22.4]) %, 
p=0.001), with similar observations for CT (Figure 3-1, 3-6 and 3-7; Table 3-3 and 
3-4). Multi-vessel uptake was commonly observed: 2-vessel uptake in six (15%) and 
3-vessel uptake in five (13%) patients. Patients with 18F- fluoride positive lesions 
had higher baseline plasma troponin concentrations (3.35 [2.35-10.20] versus 2.45 
[1.85-4.02] ng/L; p=0.047) with one individual having a concentration (35 ng/L) 
above the 99th percentile diagnostic threshold. 
 
Although pre-defined myocardial suppression of 18F-FDG uptake was achieved in 
34 (85%) patients (median myocardial SUV=2.60 [1.83-3.83]), coronary 18F-FDG 
uptake could not be confidently interpreted in 45% of vessel territories. Increased 
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focal 18F-FDG uptake was noted in just four patients: three at the site of recent 
coronary stenting and one at the ostium of a saphenous vein graft. 
 
Percutaneous Coronary Intervention With Stent Implantation 
Seven patients with myocardial infarction underwent 18F- fluoride scanning prior to 
percutaneous coronary intervention with stent implantation (6 non-ST elevation 
myocardial infarction and 1 late presentation ST elevation myocardial infarction). 
Focal 18F- fluoride uptake was observed at the site of culprit plaque in all 7 patients 
(culprit lesion tissue to background ratios 1.74 [1.40-1.95] versus maximum non-
culprit lesion 1.25 [1.07-1.29], p=0.007). Furthermore at the time of their PCI, two 
patients with myocardial infarction underwent additional coronary stenting to a 
bystander non-culprit stenosis (Figure 3-1). Although intense 18F- fluoride uptake 
was observed at the site of culprit lesion, none was observed at the site of the 
bystander lesions. Amongst patients with stable angina, 5 patients underwent 18F-
Fluoride PET imaging shortly after elective coronary stenting (24 [12-29] days). 
There was no uptake noted at the site of the percutaneous coronary intervention in 
these patients (TBR stented lesion 1.07 [0.78-1.16] versus reference lesion 0.98 
[0.81-0.98], p=0.92). Taken together, these data indicate that 18F-Fluoride uptake 
does not appear to occur as a response to stent implantation.  
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Figure 3-6: Lesions with and without 18F-fluoride uptake, and gray-scale and 
radiofrequency intravascular ultrasound in patients with stable angina. 
Panels A and B: Proximal left anterior descending artery lesion showing intense 18F-fluoride uptake 
(tissue-to-background ratio 2.81; arrows) on combined positron emission tomography and computed 
tomography images (A). The radiofrequency and grey-scale intravascular ultrasound of this lesion (B) 
shows significant necrotic core (red arrow) and microcalcification (white arrow). 
Panels C and D: Proximal left anterior descending artery lesion with no 18F-fluoride uptake. The 
radiofrequency and grey-scale intravascular ultrasound shows that this lesion is principally 
composed of fibrous and fibro-fatty tissue (green arrow) with minimal necrotic core. 
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Table 3-3 Gray-scale and radiofrequency intravascular ultrasound 









Lumen	 	 	 	
Area	(mm2)	 9.0	[5.7-13.5]	 6.7	[4.7-9.7]	 0.078	
Minimal	Diameter	(mm)	 2.6	[1.7-3.1]	 1.9	[1.7-2.6]	 0.165	
Maximum	Diameter	(mm)	 4.9	[4.1-5.3]	 3.6	[3.1-4.6]	 0.006	
Vessel	 	 	 	
Area	(mm2)	 24.1	[17.2-27.1]	 14.5	[11.9-18.1]	 0.002	
Minimal	Diameter	(mm)	 4.4	[3.4-5.2]	 3.6	[3.0-4.1]	 0.057	
Maximum	Diameter	(mm)	 6.5	[6.0-7.1]	 5.2	[4.7-5.9]	 <0.001	
Plaque	 	 	 	
Length	(mm)	 14.2	[6.2-23.5]	 15.2	[6.7-25.0]	 0.941	
Volume	(mm3)	 152.9	[99.6-289.7]	 91.0	[45.8-158.2]	 0.032	
Burden	(%)*	 55.6	[48.6-64.4]	 54.2	[46.3-57.3]	 0.174	
Remodeling	Index	 1.12	[1.09-1.19]		 1.01	[0.94-1.06]	 <0.001	
Plaque	Composition	 	 	 	
Fibrous	Tissue	(%)	 51.0	[46.3-56.6]	 58.1	[51.6-65.5]	 0.015	
Fibro-Fatty	(%)	 10.9	[6.0-13.8]	 12.6	[9.3-17.8]	 0.092	
Necrotic	Core	(%)	 24.6	[20.5-28.8]	 18.0	[14.0-22.4]	 0.001	
Max	Frame	Necrotic	Core	(%)	 35.5	[34.2-40.5]	 29.2	[23.9-42.1]	 0.009	
Dense	Calcium	(%)	 12.6	[9.1-18.1]	 10.2	[4.0-14.9]	 0.092	
Microcalcification	 11	(73%)	 5	(21%)	 0.002	
Plaque	Classification	 	 	 	
Thin-cap	fibroatheroma	 7	(47%)	 4	(16%)	 0.068	
Thick-cap	fibroatheroma	 5	(33%)	 9	(38%)	 1.0	
Pathological	intimal	thickening	 0		 7	(29%)	 0.003	
Fibrocalcific	plaque	 3	(20%)	 4	(16%)	 1.0	
Median [IQR] maximum frame necrotic core: refers to maximum necrotic core in any single frame in the plaque.*Plaque burden 
calculation: (average vessel area-average lumen area) /average vessel area. IQR Interquartile Range. 
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Table 3-4 Plaque characteristics on invasive and computed tomography 







Lesion	stenosis*	 	 	 	
>70%	 9	(28%)	 8	(15%)	 0.99	
50%	to	70%	 11	(39%)	 23	(43%)	 0.67	
10%	to	50%	 6	(19%)	 10	(19%)	 1.00	
<10%	 6	(19%)	 12	(23%)	 1.00	
Type	of	Plaque†	 	 	 	
Non-calcified	 2	(6	%)	 11	(21%)	 0.97	
Mixed	 23	(72%)	 28	(53%)	 0.98	
Calcified	 7	(22%)	 14	(26%)	 1.00	
Plaque	Analysis	 	 	 	
Positive	remodeling‡	 16	(50%)	 30	(57%)	 0.650	
Necrotic	core§	 10	(31%)	 9	(17%)	 0.179	
Microcalcification¶	 20	(63%)	 15	(28%)	 <0.001	
Dense	calcification	 21	(66%)	 34	(64%)	 1.000	
*On invasive coronary angiogram.  †On CT Coronary Angiogram. ‡Positive Remodeling: diameter at the plaque site was at   least 
10% larger than the proximal reference segment. §Necrotic core: Based on Hounsfield Units of less than 30 within the 
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Figure 3-7: Patients with stable angina and 18F-fluoride uptake 
Representative examples for 18F-fluoride uptake in patients with stable angina. Panels A-D, 
computed tomography coronary angiograms; panels E-H, 18F-fluoride positron emission tomograms; 
and panels I-L, fused positron emission tomograms and computed tomography coronary angiograms 
(tissue-to-background ratios 2.80, 3.84, 1.80 and 2.38 respectively).  
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 DISCUSSION	3.5.
We report the first non-invasive imaging technique to identify ruptured and high-risk 
coronary atherosclerotic plaque. We have demonstrated that intense 18F- fluoride 
uptake localises to recent plaque rupture in patients with acute myocardial infarction 
and those with symptomatic carotid disease. Moreover, in patients with stable 
coronary artery disease, 18F- fluoride uptake appears to identify coronary plaques 
with high-risk features on intravascular ultrasound. This technique holds major 
promise as a means of identifying high-risk and ruptured plaque, and potentially 
informing the future management and treatment of patients with stable and unstable 
coronary artery disease.  
 
Over 90% of our patients with myocardial infarction had increased 18F- fluoride 
uptake at the site of their culprit ruptured plaque with TBR values that were a third 
higher than the maximum activity anywhere else in the coronary vasculature. These 
findings were not unique to the coronary circulation since we also observed 
increased focal 18F- fluoride uptake at the site of plaque rupture in all excised 
carotid endarterectomy specimens from patients with symptomatic carotid disease. 
However, we do acknowledge that this was not a universal finding. Of the three 
patients with myocardial infarction who had no uptake, two were younger smokers 
with only mild underlying irregularities on coronary angiography, implicating plaque 
erosion and thrombosis as the mechanism of their infarction rather than plaque 
rupture (Burke et al., 1997b). The third patient sustained an infero-lateral non-ST 
segment elevation myocardial infarction and had a lesion in the right coronary artery 
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stented. Increased 18F- fluoride activity was observed in the co-dominant circumflex 
artery that could have equally explained the clinical presentation, raising the 
intriguing possibility that 18F- fluoride may have a clinical role for patients in whom 
the culprit lesion is not readily apparent.  
 
Focal regions of increased 18F- fluoride activity were observed in almost one half of 
our patients with stable coronary artery disease. In order to understand the 
mechanism of uptake in these patients, we sought to compare plaque characteristics 
of lesions with and without increased 18F- fluoride uptake. Because histology of the 
coronary arteries in this population is not feasible, we undertook gray-scale and 
radiofrequency intravascular ultrasound; a widely used and validated tool that 
provides detailed characterization of plaque composition (Garcia-Garcia et al., 
2009b). This demonstrated that lesions with increased 18F- fluoride uptake were 
associated with greater positive remodeling, more microcalcification and a larger 
necrotic core. These findings were corroborated by, and consistent with, the findings 
of plaque analysis performed using CT coronary angiography. Intriguingly, plasma 
troponin concentrations measured by a novel high-sensitivity assay were also higher 
in those patients with 18F- fluoride positive plaques: perhaps implicating sub-clinical 
plaque rupture with embolization and micro-infarction.  
 
Why does 18F- fluoride bind to ruptured or high-risk plaque? Similar to the caseating 
granulomata of tuberculosis, atherosclerotic vascular calcification is a controlled 
Novel molecular imaging of cardiovascular disease in man 
 140 
cellular response to an intense, necrotic and chronic inflammatory stimulus. Indeed, 
direct links between inflammatory cells and osteoblastic metaplasia in the 
vasculature are well described (Aikawa et al., 2007, New et al., 2013a). 
Hydroxyapatite is the central structural component of vascular calcification and is 
laid down during the very earliest and active stages of mineralization (Aikawa et al., 
2007): hydroxyapatite nanocrystals nucleate, propagate and mineralize the 
extracellular matrix. Fluoride ions are incorporated into the hydroxyapatite by ion 
exchange with hydroxyl groups at the crystal surface. This is critically dependent on 
the crystal surface area that will be greatest in the earliest and most active 
nanocrystalline stages of mineralization associated with plaque inflammation and 
necrosis. We believe that this is responsible for the observed 18F- fluoride uptake 
and is consistent with our data demonstrating 18F- fluoride uptake in regions of 
necrosis, macrophage infiltration, apoptosis, microcalcification and alkaline 
phosphatase and osteocalcin staining. Moreover, mathematical modeling indicates 
that microcalcification at the surface of thin-capped atheroma can intensify and 
double incident stresses (Vengrenyuk et al., 2006b). Microcalcification is therefore 
not only a marker of acute plaque rupture but is implicated in its precipitation. 
 
Coronary arterial calcification is considered pathognomonic of atherosclerosis and is 
a powerful independent risk predictor for cardiovascular events that can be further 
refined by the rapidity of its progression (Raggi et al., 2004a, McEvoy et al., 2010). 
Why then not rely on CT coronary calcium scoring alone as a biomarker? 
Microcalcification cannot be detected on CT and confluent coronary 
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macrocalcification develops slowly taking many months or years to become apparent 
on CT and can become dormant once inflammation in the plaque has subsided. By 
identifying areas of nascent and ongoing calcification activity, 18F- fluoride uptake 
allows us to detect regions of metabolically active plaque, thus providing 
complementary information to CT (Derlin et al., 2010, Li et al., 2012b, Beheshti et 
al., 2008). Indeed, we observed large areas of coronary CT calcium in the absence of 
increased 18F-Fluoride uptake whereas other regions with minimal or no CT calcium 
had intense 18F-Fluoride uptake  in keeping with previous observations by Derlin et 
al. in the aorta (Derlin et al., 2010, Derlin et al., 2011b). Moreover given that 18F-
Fluoride appears more closely aligned with the process of necrotic inflammation and 
plaque metabolic activity, we believe that it potentially offers major improvements to 
the prediction of cardiovascular risk compared to calcium scoring.  
 
Our data have already established that 18F- fluoride identifies plaque with multiple 
high-risk features but prospective studies are now required in a broad range of 
patients to assess whether increased coronary 18F- fluoride activity will ultimately 
translate into future adverse events.  If the results prove confirmatory then this 
technique has the potential to alter fundamentally the way we treat coronary artery 
disease: moving us away from the current paradigm based on lesion severity and 
ischemia to one focused on plaque metabolism and inflammation. It could, for 
example, permit the identification of the “vulnerable patient” with single or multiple 
high-risk or silently ruptured plaques, providing an opportunity to treat and modify 
their risk to prevent future adverse cardiovascular events.  
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In contrast to 18F- fluoride, 18F-FDG imaging was hampered by problems related to 
tracer uptake in the myocardium. Our stringent dietary recommendations resulted in 
suppression of myocardial activity in 70-85% of patients: a rate that compares 
favorably with previous studies (57-84%) (Rogers and Tawakol, 2011, Cheng et al., 
2012, Wykrzykowska et al., 2009). However, this suppression resulted in a patchy 
distribution of myocardial uptake that frequently obscured activity in one or more 
coronary vessels. It remains a possibility that 18F-FDG uptake is increased in the 
culprit plaque and we failed to demonstrate this because of incomplete data or the 
delay in scanning. However, given its limitations, we believe that 18F-FDG is 
unlikely to become sufficiently robust to permit its clinical application to the 
coronary circulation. In contrast, 18F-FDG uptake remains an important measure of 
more general vascular inflammation in the aorta and carotid arteries, providing 
complementary and distinct metabolic information to that of 18F- fluoride uptake.  
 
We do acknowledge that there are limitations of our study that include a lack of 
respiratory gating, potential partial volume artifacts and the use of surrogate 
measures for coronary histology (Garcia-Garcia et al., 2009b). However, we believe 
that the totality of our comprehensive evidence using multiple approaches and 
imaging modalities, provides a robust and cogent argument to support our contention 
that 18F-fluoride uptake identifies vulnerable and high-risk plaques in patients with 
stable and unstable coronary heart disease. Further work is now needed to establish 
whether 18F- fluoride PET-CT will provide a clinically useful technique capable of 
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improving risk stratification, monitoring disease progression, guiding therapeutic 
interventions and assessing novel anti-atherosclerotic therapies.  
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Chapter	4. SYSTEMIC	 ATHEROSCLEROTIC	
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 SUMMARY		4.1.
In murine models, acute myocardial infarction exacerbates atherosclerotic 
inflammation and progression. Using combined positron emission and computed 
tomography (PET-CT), we investigated whether this phenomenon occurs in humans.  
 
Forty patients with recent myocardial infarction and 40 with stable angina pectoris 
underwent thoracic 18F-fluorodeoxyglucose (18F-FDG). Radiotracer uptake was 
measured in aortic atheroma and non-vascular tissue (para-spinal muscle). In 1,003 
patients enrolled in the Global Registry of Acute Coronary Events, we assessed 
whether infarct size predicted early (≤30 days) and late (>30 days) recurrent 
coronary atherothombotic events. 
 
Compared to patients with stable angina, patients with myocardial infarction had 
higher aortic 18F-FDG uptake (mean TBRmax 2⋅15±0⋅30 versus 1⋅84±0⋅18, P<0⋅0001) 
and plasma C-reactive protein concentrations (6⋅50 [2⋅00-12⋅75] versus 2⋅00 [0⋅50-
4⋅00] mg/dL, P=0⋅0005), despite having similar aortic (aortic Agatston score: 135 [0-
805] versus 538 [4-1870] AU, P=0⋅12) and less coronary (coronary Agatston score: 
599 [60-1302] versus 159 [42-456] AU, P=0⋅006) atherosclerotic burden, and similar 
para-spinal muscular 18F-FDG uptake (0⋅79±0⋅25 versus 0⋅75±0⋅21, P=0⋅52). 
Patients with ST-segment elevation myocardial infarction had larger infarcts (peak 
plasma troponin concentration 32,300 [10,200->50,000] versus 3,800 [1,000-9,200] 
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ng/L, P<0⋅0001) and greater aortic 18F-FDG uptake (2⋅24±0⋅32 versus 2⋅02±0⋅21, 
P=0⋅03) than those with non-ST elevation myocardial infarction. Peak plasma 
troponin concentration correlated with aortic 18F-FDG uptake  (r=0⋅43, P=0⋅01) in 
patients with myocardial infarction. On multivariate analysis, peak troponin I 
concentrations were an independent predictor of early recurrent myocardial 
infarction (tertile-3 versus tertile-1: relative risk 4⋅30 [95% CI, 1⋅85-9⋅96], p=0⋅001) 
but did not predict late re-infarction. 
 
The presence and extent of myocardial infarction is associated with increased aortic 
atherosclerotic inflammation and early recurrent myocardial infarction. This supports 
the hypothesis that acute myocardial infarction exacerbates and promotes systemic 
atherosclerotic inflammation and remote plaque destabilisation. 
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 INTRODUCTION		4.2.
Despite recent advances, prognosis following acute myocardial infarction remains 
poor (Roger et al., 2011, Naghavi et al., 2003, Virmani et al., 2000a) because of a 
considerable risk of recurrent infarction (Milonas et al., 2010) and ischemia 
(Goldstein et al., 2000). Such recurrent events are as likely to occur at the site of non-
culprit plaques as the original culprit lesion (Stone et al., 2011a). Indeed, in post-
mortem studies of patients dying after acute myocardial infarction, there is evidence 
of multiple plaque-related thrombotic events: on average 2.4 per patient (Mann and 
Davies, 1999). Moreover, there is an increased incidence of ischemic stroke 
following myocardial infarction (not exclusively as a consequence of embolic 
events) suggesting systemic as well as localized destabilization of remote 
atherosclerotic plaque (Witt et al., 2006, Mooe et al., 1997).   
 
Myocardial infarction occurs predominantly as a consequence of acute 
atherosclerotic plaque rupture (Virmani et al.,2000, Burke et al. 1997), with 
inflammation believed to be a key precipitant (Libby, 2013, Swirski and Nahrendorf, 
2013). Macrophages infiltrate high-risk plaque and secrete matrix metalloproteinases 
that weaken the fibrous cap and predispose the plaque to rupture (Libby, 2013, 
Swirski and Nahrendorf, 2013). Recent pre-clinical murine data have indicated that 
myocardial infarction induced by coronary artery ligation causes a systemic 
inflammatory response that involves macrophage mobilization, a generalized 
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increase in atherosclerotic inflammation and accelerated plaque progression (Dutta et 
al., 2012). However, this phenomenon has not been directly observed in humans.   
Positron emission tomography (PET) combined with computed tomography (CT) 
allows the in vivo assessment of atherosclerotic disease in humans. 18F-fluorine-2-
deoxy-D-glucose (18F-FDG) is a glucose analogue that is taken up by cells with high 
metabolic requirements. It has become a widely used as a measure of acute vascular 
inflammation, correlating with atherosclerotic macrophage burden, response to drug 
therapy and symptomatic status (Rogers et al., 2010, Tawakol et al., 2006, Rudd et 
al., 2002, Satomi et al., 2013b). Indeed, its generalized uptake within large arteries is 
a powerful predictor of subsequent adverse cardiovascular events (Rominger et al., 
2009).  
 
In this prospective clinical trial, we determined whether systemic atherosclerotic 
plaque metabolism is increased in patients with myocardial infarction compared to 
those with stable coronary disease, and whether this is more marked in those with 
larger infarctions. Furthermore, we explored whether this might be of clinical 
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 METHODS	4.3.
The study comprised two cohorts of patients: an imaging cohort consisting of 
subjects with stable angina and myocardial infarction, and an outcome cohort 
comprising patients enrolled in the Global Registry of Acute Coronary Events 
(GRACE)(Fox et al., 2006). 
 
 IMAGING	COHORT	4.3.1.
Consecutive patients with acute ST- or non-ST-segment elevation myocardial 
infarction (Thygesen et al., 2012) and stable angina pectoris scheduled for invasive 
coronary angiography were recruited from the Royal Infirmary of Edinburgh. 
Patients with myocardial infarction fulfilled the criteria for type 1 myocardial 
infarction according to the Universal Definition of Myocardial Infarction (Thygesen 
et al., 2012). ST segment elevation myocardial infarction was defined as new ST 
segment elevation at the J point in two contiguous leads with the cut-points: ≥0.1 mV 
in all leads except V2-V3 where the thresholds were ≥0.2 mV for men ≥40 years and 
≥0.25 mV for women. Consecutive patients with stable angina pectoris were 
recruited if they had typical symptoms of exertional anginal chest pain, previously 
documented coronary artery disease (>70% stenosis of at least one major epicardial 
coronary artery), and had been scheduled for invasive coronary angiography. Patients 
were excluded if they had suffered an acute coronary syndrome within the last 3 
months.  
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Other exclusion criteria were age <50 years, insulin-dependent diabetes mellitus, 
women of childbearing age not taking contraception, severe renal failure (serum 
creatinine >250 µmol/L), known contrast allergy and inability to provide informed 
consent. Studies were performed with the approval of the local research ethics 
committee, in accordance with the Declaration of Helsinki, and with the written 
informed consent of each participant. All patients underwent a comprehensive 
baseline clinical assessment including evaluation of their cardiovascular risk factor 
profile. Blood was drawn from all participants for evaluation of plasma C-reactive 
protein (CRP) concentrations that were measured using the MULTIGENT CRP 




All patients underwent PET-CT imaging of the thorax with a hybrid scanner 
(Biograph mCT, Siemens Medical Systems, Erlangen, Germany) using 18F-FDG as 
well as coronary calcium scoring and CT angiography of the aorta and coronary 
arteries (Joshi et al., 2013, Dweck et al., 2012a, Dweck et al., 2011). 
 
Image Analysis 
Anonymized PET-CT datasets were presented in a random order on an OsiriX 
workstation (64 bit; version 5.5.1 OsiriX Imaging Software, Geneva, Switzerland) to 
trained observers blinded to the patient’s clinical status. To aid image analysis, PET 
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images were fused with the CT angiograms, and regions of interest (ROIs) drawn 
around the thoracic aorta on serial 3-mm axial slices. Within these regions, mean and 
maximum tracer activities were measured using standard uptake values (SUV) and 
corrected for blood pool activity in the superior vena cava to provide tissue-to-
background ratios (TBRs) (Joshi et al., 2013, Dweck et al., 2012a, Dweck et al., 
2011, Wong et al., 2009, Dweck et al., 2013c). The ascending aorta was defined as 
the segment of the aorta from the lower level of the right pulmonary artery up to the 
last slice where the aorta maintained its circular cross-sectional appearance. The 
descending aorta was defined similarly as the region extending up from the tip of the 
diaphragm to the last circular slice. The aortic arch was defined as the region of aorta 
connecting the ascending and descending aorta (Figure 4-1). Aortic radiotracer 
uptake was quantified using the method of Fayad et al. (Fayad et al., 2011a).  In 
brief, the following measures of uptake were measured on axial slices across the 
aorta as a whole and within each region: TBRmax, the average of the maximum TBR 
values measured on each axial slice; TBRmean, the average of the mean TBR values 
measured on each slice; max TBR, the maximum uptake TBR value in any axial 
section and TBRMDS, the most diseased segment, defined as the highest maximal 
TBR value averaged over 3 consecutive slice (Fayad et al., 2011a) . Thirty patients 
were selected randomly to test the repeatability of 18F-FDG measurements in the 
aorta. Fifteen patients from each cohort were selected and two trained readers (NVJ, 
SPL) quantified aortic activity independently. Activity within non-vascular tissue 
was assessed using oval-shaped ROIs drawn within paraspinal muscle (area ~7 cm2) 
on 5 consecutive axial slices. 
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CT analysis was performed on a dedicated cardiovascular workstation (Vitrea,Vital 
Images, Minnetonka, Minnesota, USA). Vessel-specific and total Agatston calcium 
scores were calculated as described previously (Dweck et al., 2012a) for the coronary 
arteries, the aorta and its different regions using a threshold of 130 Hounsfield units 
(Santos et al., 2010).  
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Figure 4-1: Measurement of radiotracer uptake in the aorta 
The aorta was divided into ascending (A), arch (B) and descending aorta (C) as shown. Regions of 
interest were drawn around the aorta on axial slices to provide measures of radiotracer uptake. 
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 OUTCOME	COHORT	4.3.2.
Full details of the GRACE methods have been published previously (Fox et al., 
2007, Steg et al., 2002). The Edinburgh cohort of the prospectively maintained 
GRACE database was used to identify 1,003 patients admitted with an acute 
coronary syndrome between 20th January 2003 to 9th June 2009 (Fox et al., 2010). To 
be eligible, patients (>18 years) had to be admitted with an acute coronary syndrome 
as a presumptive diagnosis and have at least 1 of the following: electrocardiographic 
changes consistent with acute coronary syndrome, serial increases in biomarkers of 
cardiac necrosis or documented coronary artery disease. For consistency, only 
patients who had plasma troponin I concentrations quantified (Abbott Laboratories, 
Abbott Park, IL, USA) in a standardized accredited laboratory were included. 
Exclusion criteria were secondary myocardial injury precipitated or accompanied by 
a significant comorbidity, trauma, or surgery. Information regarding patient 
demographic characteristics, medical history, timing and occurrence of acute 
coronary symptoms, clinical characteristics, electrocardiographic findings, treatment 
approaches, and in-hospital outcomes is collected through completion of a 
standardized proforma (Fox et al., 2007, Steg et al., 2002). The baseline and peak 
troponin I concentrations during admission were recorded and patients divided into 
tertiles based on their peak troponin I to reflect the degree of myocardial injury and 
the size of their infarct (Younger et al., 2007).  
 
The primary endpoint of the analysis was early recurrent myocardial infarction 
following the index admission, defined as recurrent type 1 myocardial infarction 
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within 30 days of index admission (Fox et al., 2006). To avoid confounding with the 
index presentation, only those patients having recurrent myocardial infarction 
beyond the first 24 hours after presentation were analyzed as described previously 
(Fox et al., 2006). We also examined the factors associated with late recurrent 
myocardial infarction as an exploratory end-point, defined as a recurrent type 1 
myocardial infarct >30 days following index admission.  
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 STATISTICAL	ANALYSIS		4.3.3.
As a pre-specified end-point of our previously reported trial (ClinicalTrials.gov: 
NCT01749254), we explored 18F-FDG uptake in remote aortic atheroma of 
patients with recent myocardial infarction or stable coronary heart disease. 
Continuous data were tested for normality with the D’Agostino and Pearson 
Omnibus test.  Continuous parametric variables were expressed as mean±standard 
deviation and compared using Student’s t-tests. Non-parametric data were 
presented as median [interquartile range] and compared using Mann-Whitney U 
test or Wilcoxon signed-rank test as appropriate. Interobserver reproducibility was 
calculated by Bland Altman method and intraclass correlation coefficients with 
95% confidence intervals. Fisher’s exact test or chi-squared test was used for 
analysis of categorical variables. Corelations were performed using Pearson’s and 
Spearman’s rank correlation coefficient for parametric and non-parametric data 
respectively. 
 
Patients in the registry cohort were divided into tertiles according to their peak 
troponin concentration. Kaplan Meier curves were used to estimate the distribution 
of early recurrent myocardial infarction across the tertiles. Univariate analysis was 
undertaken to identify associations with early (≤30 days) and late (>30 days) 
recurrent myocardial infarction that were then entered into the multivariate logistic 
regression model based on univariate association of p<0⋅1. In addition, age and sex 
were included in the model.  Statistical analysis was performed with Graph Pad 
Prism version 6 (GraphPad Software Inc., California USA) and SPSS 19.0 (SPSS 
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Inc., Chicago, Illinois) where appropriate. Unless stated, a two-sided P<0.05 was 
taken as statistically significant. 
  




A total of 40 patients with stable angina and 40 with myocardial infarction 
underwent 18F-FDG PET imaging. The median time between hospitalization and 
18F-FDG PET imaging was 11 [8-17] days in patients with myocardial infarction. As 
compared to patients with stable angina, patients with myocardial infarction were 
younger and had less extensive coronary artery disease (Table 4-1), and lower 
coronary artery calcium scores (coronary artery calcium score: stable angina 599 [60-
1302] versus myocardial infarction 159 [42-456] Agatston Units, P=0.006; Tables 4-
1 and 4-2). Although apparently higher aortic calcium scores were noted in patients 
with stable angina, this did not reach statistical significance (aortic calcium scores; 
stable angina 538 [4-1870] versus myocardial infarction 135 [0-805] Agatston Units; 
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Table 4-1 Baseline characteristics of patients with coronary artery disease 
	 Stable	angina	 Myocardial	infarction	
	 All	(n=40)	 All	(n=40)	 STEMI	(n=26)	 NSTEMI	(n=14)	
Age	(years)	 67±8	 62±8	 63±9	 60±8	
Male	sex	 36	(90%)	 37	(93%)	 24	(92%)	 13	(93%)	
BMI	(kg/m2)	 30±5	 28±5	 27±5	 30±4	
Antecedent	angina	(active)	 40	(100%)	 9	(23%)	 5	(19%)	 4	(29%)	
Heart	rate	(/min)	 59±9	 56±7	 56±7	 56±7	
Systolic	BP	(mmHg)	 134±14	 132±21	 131±20	 121±21	
Diastolic	BP	(mmHg)	 77±10	 76±9	 76±9	 76±8	
Cardiovascular	History	 	 	 	 	
Previous	MI	 15	(38%)	 5	(13%)	 1	(4%)	 4	(29%)	
Previous	CVA/TIA	 4	(10%)	 2	(5%)	 1	(4%)	 1	(7%)	
Previous	PCI	 19	(48%)	 5	(13%)	 2	(8%)	 3	(21%)	
Previous	CABG	 11	(28%)	 2	(5%)	 2	(8%)	 0	




24	(60%)	 25	(63%)	 19	(73%)	 6	(43%)	
Diabetes	Mellitus	 13	(33%)	 8	(20%)	 7	(27%)	 1	(7%)	
Hypertension	 36	(90%)	 17	(43%)	 11	(42%)	 6	(43%)	
Hypercholesterolaemia	 39	(98%)	 19	(48%)	 11	(42%)	 8	(57%)	
Medications	 	 	 	 	
Aspirin	 33	(83%)	 40	(100%)	 26	(100%)	 14	(100%)	
Clopidogrel	 5	(13%)	 39	(98%)	 25	(96%)	 14	(100%)	
Statin	 36	(90%)	 39	(98%)	 26	(100%)	 13	(93%)	
β-Blocker	 28	(70%)	 32	(80%)	 20	(77%)	 12	(86%)	
ACEI/ARB	 20	(50%)	 35	(88%)	 25	(96%)	 10	(71%)	
Calcium	channel	blockers	 16	(40%)	 2	(5%)	 2	(8%)	 0	
Other	Anti-hypertensive	 6	(15%)	 3	(8%)	 1	(4%)	 2	(14%)	
Oral	Nitrates	 15	(38%)	 1	(3%)	 0	 1	(7%)	
Serum	Biochemistry	 	 	 	 	
Cholesterol	(mg/dL)	 151±31	 181±46	 181±50	 185±43	
HDL-Cholesterol	(mg/dL)	 43±12	 43±12	 43±12	 39±12	
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LDL-Cholesterol	(mg/dL)	 81±27	 112±43	 108±43	 120±39	
Triglycerides	(mg/dL)	 62±27	 62±31	 66±27	 58±27	













Medications at the time of scan 
STEMI ST elevation myocardial infarction, NSTEMI non-ST elevation myocardial infarction, BMI body mass index, MI myocardial 
infarction, CVA cerebrovascular accident, TIA transient ischemic attack, PCI percutaneous coronary intervention, ACEI angiotensin 
converting enzyme inhibitor, ARB angiotensin receptor blocker, CABG coronary artery bypass graft, HDL high-density lipoprotein, 
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Table 4-2 Aortic calcium scores and 18F-FDG tissue-to-background ratios in 













CT	Aortic	Calcium	 	 	 	 	 	 	
Agatston	Units	(AU)	 538	[4-1870]	 135	[0-805]	 0.12	 183	[0-377]	 55	[0-2523]	 0.91	
Volume	(mm3)	 532	[7-1718]	 149	[0-717]	 0.12	 192	[0-387]	 94	[0-2263]	 0.85	
Mass	(mg)	 131	[2-517]	 31	[31-1415]	 0.07	 131	[2-517]	 43	[0-86]	 0.9	
18F-	FDG	 	 	 	 	 	 	
Thoracic	aorta	
mean	TBRmax	
1.84±0.18	 2.15±0.30	 <0.0001	 2.24±0.32	 2.02±0.21	 0.03	
Thoracic	aorta	
mean	TBRmean	
1.41±0.14	 1.60±0.17	 <0.0001	 1.51±0.16	 1.66±0.17	 0.01	
Thoracic	aorta	max	
TBR	
2.22±0.31	 2.64±0.52	 <0.0001	 2.78±0.57	 2.40±0.35	 0.02	
Thoracic	aorta	
TBRMDS*	
2.11±0.23	 2.54±0.49	 <0.0001	 2.66±0.53	 2.34±0.33	 0.04	
Aortic	sub-regions	 	 	 	 	 	 	
Ascending	aorta		
mean	TBRmax	
1.84±0.20	 2.21±0.35	 <0.0001	 2.35±0.35	 2.03±0.26	 0.01	
Arch	of	aorta	mean	
TBRmax	
1.88±0.22	 2.26±0.34	 <0.0001	 2.35±0.35	 2.11±0.26	 0.03	
Descending	aorta	
mean	TBRmax	
1.82±0.18	 2.10±0.30	 <0.0001	 2.17±0.32	 1.98±0.21	 0.08	
 
STEMI: ST elevation myocardial infarction, NSTEMI: non ST elevation myocardial infarction,  mean TBRmax average of the maximum tissue to 
background ratios across all slices in the segment,  mean TBRmean average of the mean tissue to background ratios all slices in the segment, max TBR 
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Positron Emission Tomography 
The reproducibility of TBR measurements in the aorta for tracer activity was 
excellent, with no fixed or proportional biases and narrow limits of agreement. In 
contrast to the calcium scores, 18F-FDG uptake was 20% higher in the aortae of 
patients with recent myocardial infarction than those with stable coronary artery 
disease (Table 4-2, Figure 4-2). This was a consistent finding in all regions of the 
aorta assessed (entire thoracic aorta, ascending aorta, aortic arch, descending aorta; 
all P<0.0001) and with all measures of tracer activity (mean TBRmax, mean TBRmean, 
max TBR, TBRMDS, all P<0.001). Furthermore 18F-FDG activity was higher in 
patients with ST-segment elevation compared to those with non-ST-segment 
elevation myocardial infarction (TBR max 2.24±0.32 versus 2.02±0.21 respectively, 
P=0.03; Table 4-2) consistent with the former having sustained larger myocardial 
infarctions (peak plasma troponin concentration 32,300 [10,200-50,000] versus 3,800 
[1,000-9,200] ng/L; P<0.0001). Indeed, aortic 18F-FDG activity correlated with peak 
plasma troponin I concentrations (r=0.43, P=0.01). 
 
In patients with stable angina and those with myocardial infarction, paraspinal uptake 
of 18F-FDG (mean TBRmax 0.79±0.25 versus 0.75±0.21 respectively, P=0.52) was 
similar.  
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Figure 4-2: Uptake of 18F-fluorodeoxyglucose by aortic atherosclerosis in 
patients with stable and unstable coronary heart disease 
Aortic mean  of the maximum tissue-to-background ratios (mean TBRmax) for 18F-flurodeoxyglucose 
uptake in patients with stable angina, ST elevation myocardial infarction (STEMI) and non-ST 
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C-reactive Protein 
Compared to patients with stable angina, patients with myocardial infarction had 
higher plasma C-reactive protein concentrations (6.50 [2.00-12.75] versus 2.00 
[0.50-4.00]) mg/dL, P=0.0005). Amongst patients with myocardial infarction, 
patients with ST-segment elevation myocardial infarction appeared to have higher 
plasma C-reactive protein concentrations (7.50 [2.00-13.75] versus 2.50 [1.75-9.50] 
mg/dL) but this did not reach statistical significance (P=0.22). There was a modest 
correlation between peak troponin I concentrations and C-reactive protein (r=0.35, 
P=0.03).  
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 	OUTCOME	COHORT	4.4.2.
One thousand and three patients enrolled in the GRACE database were followed up 
for a median follow up period of 34 [18-50] months. Early recurrent myocardial 
infarction occurred in 54 patients following index admission, whilst late recurrent 
myocardial infarction occurred in 89 patients.  
 
Patients were classified into tertiles according to their peak plasma troponin I 
concentrations measured during the index admission (tertile 1, ≤ 220; tertile 2, 230-
6,130; and tertile 3, ≥6,140 ng/L; Table 4-3). On univariate analysis, the risk of early 
recurrent infarction (≤30 days) was more than four-fold higher amongst patients in 
the highest troponin tertile compared to the lowest, whilst it was double in the middle 
tertile compared to the lowest (Table 4-4 and Figure 4-3). The variables with 
univariate association of p<0⋅1 were Killip score ≥2, ST segment deviation, 
multivessel disease and troponin I concentrations. On multivariate analysis, troponin 
emerged as an independent predictor of early myocardial infarction on multivariate 
analyses after adjustment for other relevant variables (tertile 3 versus tertile 1: 
relative risk 4.30 [95% CI, 1.85-9.96], P=0.001; tertile 2 versus tertile 1: relative risk 
2.48 [95% CI 1.02-6.05], P=0.05). The only other independent predictor being Killip 
class 2 (1.79 [95% CI, 1.02 - 3.15], P=0.04). 
 
By contrast, recurrent late myocardial infarction was not associated with troponin 
tertiles on univariate analysis (tertile 1 versus tertile 2: relative risk 1⋅07 [95%CI 
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(0⋅64 –1⋅79)], P=0⋅79; tertile 1 versus tertile 3: relative risk 0⋅80 [95%CI, (0⋅46–
1⋅39)], P=0⋅43), instead being more closely related to traditional predictors of 
myocardial infarction (Table 4-4).   
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Table 4-3 Baseline Characteristics of Patients From the GRACE Cohort 
	 Tertile	1	 Tertile	2	 Tertile	3	 P	value	
	 (n=332)	 (n=336)	 (n=335)	 	
Peak	Troponin	I	(range)	 ≤220	 230	–	6130	 ≥6140	 -	
Age	(years)	 65	±	12	 66	±	12	 63	±	13	 0.02	
GRACE	score	 124	±	47	 197	±	49	 218	±	41	 <0.0001	
Male	sex	 212	(63.9%)	 226	(67.3%)	 254	(75.8%)	 0.003	
Smoking	Habit		 214	(64.5%)	 243	(72.3%)	 235	(70.1%)	 0.08	
Previous	MI	 149	(44.9%)	 91	(27.1%)	 51	(15.2%)	 <0.0001	
Killip	score	≥2	 82	(24.7%)	 114	(33.9%)	 98	(29.3%)	 0.03	
Previous	CABG	 61	(18.4%)	 25	(7.4%)	 12	(3.6%)	 <0.0001	
Previous	heart	failure	 26	(7.8%)	 25	(7.4%)	 13	(3.9%)	 0.07	
Diabetes	 53	(16.0%)	 47	(14.0%)	 47	(14.0%)	 0.71	
ST	deviation	 77	(23.2%)	 142	(42.3%)	 275	(82.1%)	 <0.0001	
Multi-vessel	disease	 92	(27.7%)	 141	(42.0%)	 125	(37.3%)	 <0.0001	
Recurrent	MI	≤30	days	 7	(2.1%)	 18	(5.4%)	 29	(8.7%)	 0.001	
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 Table 4-4: Univariate predictors of early (≤30 day) and late (>30 day) recurrent 






Age	(yrs)	 1.02	(0.99	–	1.04)	 0.14	 1.04	(1.02	–	1.06)	 <0.0001	
Male	gender	 1.30	(0.70	–	2.43)	 0.45	 0.89	(0.56	–	1.41)	 0.63	
Smoker	 0.82	(0.46	–	1.46)	 0.55	 1.04	(0.65	–	1.67)	 0.91	
Previous	MI	 0.69	(0.36	–	1.32)	 0.28	 3.81	(2.43	–	5.95)	 <0.0001	
Killip	score	≥2	 1.86	(1.06	–	3.24)	 0.03	 1.79	(1.14	–	2.82)	 0.01	
Previous	CABG	 0.94	(0.37	–	2.42)	 0.99	 2.91	(1.66	–	5.10)	 <0.0001	
Previous	heart	failure	 0.86	(0.26	–	2.82)	 0.99	 2.77	(1.40	–	5.45)	 0.008	
Diabetes	 0.72	(0.30	–	1.71)	 0.56	 1.41	(0.80	–	2.48)	 0.27	
ST	deviation	 1.81	(1.03	–	3.19)	 0.05	 1.18	(0.76	–	1.82)	 0.5	
Multi-vessel	disease	 1.73	(0.99	–	2.99)	 0.06	 1.57	(1.01	–	2.44)	 0.05	
Troponin	Tertiles	 	 	 	 	
Tertile	2	versus	Tertile	1	 2.63	(1.08–6.38)	 0.03	 1.07	(0.64	–	1.79)	 0.79	
Tertile	3	versus	Tertile	1	 4.40	(1.90–10.19)	 0.001	 0.80	(0.46	–	1.39)	 0.43	
Linear	trend	across	tertiles	 -	 <0.0001	 -	 0.57	
Risk Ratios (95% Confidence Interval), CABG: coronary artery bypass surgery, MI: 
myocardial infarction.	
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Figure 4-3: Kaplan–Meier curves demonstrating survival free from early 
recurrent myocardial infarction at 30 days 
Patients were divided into tertiles according to their peak plasma troponin I concentrations (tertile 1, 
≤ 220; tertile 2, 230-6,130; and tertile 3, ≥6,140 ng/L).  
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 DISCUSSION	4.5.
Using 18F-FDG PET imaging, we have demonstrated increased metabolic activity in 
remote aortic atherosclerotic plaques in patients with recent myocardial infarction 
that correlated with the degree of myocardial necrosis, and exceeded that observed in 
patients with stable coronary disease who had a greater atherosclerotic burden. Using 
the GRACE registry, we explored the clinical relevance of these findings to assess 
whether infarct size and the associated increase in atherosclerotic inflammation could 
predict recurrent coronary atherothombotic events in every day clinical practice. 
Intriguingly, patients with the largest infarcts had more than a four-fold increase in 
the risk of early recurrent myocardial infarction, with baseline tertiles of plasma 
troponin concentration emerging as an independent predictor of these events. We 
therefore provide clinical data to support the hypothesis that myocardial infarction 
exacerbates systemic atherosclerotic inflammation, destabilizes remote atheromatous 
plaque, and causes an increase in early recurrent atherothrombotic events.  
 
Pre-clinical data have indicated that myocardial infarction induces a macrophage-
driven pro-inflammatory state (Ono et al., 1998), that directly increases inflammation 
in remote atheroma and induces further atherosclerosis (Dutta et al., 2012,  Takaoka 
et al., 2006, Wright et al., 2010).In a mouse model, myocardial infarction induced by 
coronary artery ligation increased splenic monocyte motility (Dutta et al., 2012), with 
these cells exiting the spleen en masse and migrating both to the injured myocardium 
and crucially to remote atherosclerotic plaque (Swirski et al., 2009). In addition 
sympathetic stimulation following infarction increased the production and liberation 
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of hematopoietic stem and progenitor cells from the bone marrow, resulting in 
further increases in circulating monocytes and the accumulation of macrophages 
within regions of remote atheroma. The net result was a marked accumulation of 
macrophages in remote atherosclerotic plaque following myocardial infarction that 
resulted in acceleration of the disease process in these areas. The first aim of the 
current study was to test whether this pro-inflammatory phenomenon also occurs in 
humans using 18F-FDG as a marker of vascular macrophage inflammatory activity. 
Because we cannot measure 18F-FDG uptake before and after myocardial infarction, 
we prospectively compared uptake between patients with stable coronary heart 
disease and those with recent myocardial infarction. Despite a comparable or lower 
overall aortic and coronary plaque burden, aortic 18F-FDG uptake was 20% higher 
in patients who had sustained a recent myocardial infarction. Indeed, the aortic 18F-
FDG uptake was consistently increased across all regions of the thoracic aorta. In 
contrast, para-spinal muscle uptake was similar between the cohorts indicating a 
specific vascular and atherosclerotic response rather than a generalized non-specific 
inflammation across all tissues. Based on clinical factors and the peak plasma 
troponin concentration, patients with ST-segment elevation myocardial infarction 
had larger infarcts and demonstrated greater increases in aortic 18F-FDG uptake than 
those with non-ST elevation myocardial infarction. Indeed we observed a good 
correlation between peak plasma troponin I concentrations and aortic 18F-FDG 
activity suggesting that the association may be causal.  
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Next we investigated whether the observed increases in vascular inflammatory 
activity were of clinical importance in real life practice. Our imaging cohort was not 
large enough to address this question so we turned to data from the well-established 
GRACE registry. In more than 1,000 patients, we demonstrated that the size of the 
initial myocardial infarction emerged as an independent predictor of early recurrent 
myocardial infarction over and above traditional risk factors, with a four-fold 
increase in these events amongst those with the biggest infarcts. This would indicate 
that the increased vascular inflammation associated with myocardial infarction 
translates into adverse clinical events, perhaps due plaque destabilization and the 
associated increased risk of rupture. Interestingly our data also suggest that the 
clinical effects of this systemic inflammatory response are only transitory, with no 
association between infarct size and later recurrent events after 30 days, by which 
time the inflammation will have subsided and plaques begun to stabilise once more. 
Our data are also consistent with those of the smaller (n=378) EValuation Of MCC-
135 for Left VEntricular Salvage in Acute Myocardial Infarction (EVOLVE) 
randomised controlled trial (Chia et al., 2008) that also observed an increased early 
event rate in patients with the highest tertile of troponin concentration with a trend 
for an increase in recurrent myocardial infarction. Moreover our findings are 
supported by recently reported studies (Kim et al., 2014, Han et al., 2014, Wald et 
al., 2014, Kato et al., 2012b).  Patients with acute coronary syndromes have 
increased plaque vulnerability in non-culprit lesions with increased incidence of thin-
capped fibroatheromas and adherent thrombus (Kato et al., 2012b). Furthermore, 
patients with ST elevation myocardial infarction have accelerated plaque progression 
in non-culprit lesions, on follow up angiography (Han et al., 2014), whilst stenting of 
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such lesions at the same time as culprit lesions reduces adverse cardiovascular events 
(Wald et al., 2014). Moreover, patients with unstable coronary disease have higher 
metabolic carotid plaque activity as compared to patients with stable disease thereby 
suggesting a pan-vascular inflammatory process as indicated by our study (Kim et 
al., 2014). 
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Figure 4-4: Schematic representation showing remote atherosclerotic 
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Taken together, our data offer clear support for the hypothesis that myocardial 
infarction begets early recurrent myocardial infarction due to up regulated 
macrophage-mediated inflammation in remote atherosclerotic plaque (Figure 4-4). It 
would also offer an explanation for the increased incidence of ischemic stroke 
following myocardial infarction and explain why immediate reperfusion for ST-
segment elevation myocardial infarction and the resultant limitation in myocardial 
injury, confers a greater reduction in the risk of recurrent events, than 
revascularisation after infarct completion (Ioannidis and Katritsis, 2007, Libby, 
2013).  
 
Although our data support the hypothesis that myocardial infarction results in remote 
arterial inflammation, it could also be argued that more widespread and intense 
atherosclerotic inflammation occurs prior to the precipitation of myocardial 
infarction and this is the explanation for the association. The correlation between 
infarct size and the inflammatory signal would support the former explanation, 
however to resolve this issue, 18F-FDG imaging would be required both before and 
after myocardial infarction, which given the unpredictable nature of these events is 
extremely challenging in the clinical context. We also acknowledge that we did not 
directly measure myocardial infarct size and have used peak plasma troponin 
concentration as a surrogate measure. However, peak plasma troponin concentration 
has a strong correlation with infarct size (r=0.740, p<0.001)(Younger et al., 2007, 
Chia et al., 2008) and is a valid surrogate marker especially when applied to large 
datasets such as the registry cohort used here. Finally, we were unable to measure 
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systemic markers of inflammation such as C-reactive protein in our outcome cohort. 
However, C-reactive protein is well known to correlate with troponin release after 
myocardial infarction (Anzai et al., 1997, Orn et al., 2009, Brunetti et al., 2006) and 
indeed this was observed in our imaging cohort.  
 
In summary we have demonstrated that the presence and extent of myocardial 
infarction is associated with increased aortic atherosclerotic inflammation and early 
recurrent myocardial infarction supporting the hypothesis that myocardial infarction 
begets myocardial infarction in humans.  
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Chapter	5. DIFFERENTIAL	AORTIC	INFLAMMATION	AND	
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 SUMMARY		5.1.
The vascular biology of both abdominal aortic aneurysms (AAAs) and 
atherosclerosis remains incompletely understood. We aimed to investigate the role of 
inflammation and calcification in AAAs, and to test the hypothesis that these 
processes contribute differently in AAAs compared to atherosclerosis. 
 
In 63 patients (mean age 76.12±6.75 years; 89% male) with asymptomatic 
aneurysms (mean size 4.33±0.73 cm) and 19 age- and sex-matched patients with 
atherosclerosis, we measured inflammation and calcification using 18F-
fluorodeoxyglucose (18F-FDG) positron emission tomography and computed 
tomography (PET-CT). Inflammation and calcification were quantified using 18F-
FDG tissue-to-background ratios (TBR) and Agatston scores respectively.  
 
18F-FDG uptake was higher within aneurysms than in non-aneurysmal aorta (mean 
TBRmax 2.23±0.46 vs. 2.12±0.46, p=0.02). Compared to controls with atherosclerosis 
only, both aneurysmal and non-aneurysmal aorta in patients with AAA showed 
higher 18F-FDG uptake (total aorta mean TBRmax 2.16±0.51 vs. 1.70±0.22, p=0.001; 
abdominal aortic mean TBRmax 2.23±0.45 vs. 1.68±0.21, p<0.0001). There was no 
correlation between aneurysm size and 18F-FDG uptake (Pearson’s r=0.12, p=0.36), 
although smaller aneurysms (≤4.33 cm, n=32) trended to higher 18F-FDG uptake 
than larger ones (≥4.34 cm, n=30), mean TBRmax 2.36±0.45 vs. 2.14±0.45, p=0.065). 
Patients without aneurysmal thrombus has higher tracer activity within the 
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aneurysmal wall compared to those with thrombus (mean TBRmax aneurysm wall 
2.43±0.45 versus 2.14±0.43, p=0.018) with the thrombus itself demonstrating very 
low levels of uptake (mean TBRmax within thrombus 1.30±0.48 vs. aneurysm wall 
2.23±0.46, p<0.0001).  Calcification in the aneurysmal segment of the aorta was 
higher than in non-aneurysmal segments in patients with AAA (Agatston 4918 
[2901-8008] vs. 1017 [139-2226], p<0.0001) and equivalent regions in patients with 
atherosclerosis (442 [304-920] vs. 166 [80-374] Agatston units per cm, p=0.0042).  
 
This prospective imaging study has demonstrated enhanced active inflammation and 
calcification within the wall of aortic aneurysms suggesting an intense, destructive 
and transmural pathological process. As compared to atherosclerotic controls, 
patients with AAA have inflammation involving the entire aorta, supporting a 
hypothesis of global aortopathy in these subjects.  
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 INTRODUCTION		5.2.
Abdominal aortic aneurysm (AAA) is a vascular disorder resulting in localized aortic 
dilatation (diameter >3cm)(Shimizu et al., 2006). Aneurysms have a prevalence of 
around 5% in adults aged 65-74 years and are frequently asymptomatic until rupture 
(Scott, 2002). If rupture occurs, death results in 60-90% of patients(Scott, 2002). 
National ultrasound screening programs for high-risk patients have significantly 
reduced deaths from rupture by identifying asymptomatic subjects with large 
aneurysms for elective repair (Scott, 2002, Lederle et al., 2002, UKSAT, 1998) 
However, screening also identifies many patients with small aneurysms, below the 
threshold for intervention, and in this group the rate of future expansion and risk of 
rupture are difficult to predict. 
 
The treatment of AAA is either open or endovascular repair to prevent aneurysm 
rupture, recommended when the diameter exceeds 5.5cm (Powell et al., 2007). There 
are no medical treatments with proven prognostic benefit for AAA (Golledge et al., 
2006b, Norman et al., 2004),  and therefore continued surveillance is the only option 
for those who do not fulfil criteria for AAA repair. Repeat ultrasound frequency is 
currently determined by baseline aneurysm size. The rate of AAA rupture is around 
1% per year in smaller aneurysms (3.0-5.5cm), although they still account for about a 
fifth of all ruptures. Some aneurysms can exceed 5.5cm without rupture, suggesting 
aneurysm size is not the only determinant of rupture (Darling et al., 1977, Powell et 
al., 2008). To improve risk stratification in patients with AAA, a better 
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understanding of the pathology leading to AAA growth and rupture is needed 
(Golestani and Sadeghi, 2014). 
Pathologically, aneurysms are associated with inflammatory infiltration of the aortic 
wall, smooth muscle cell apoptosis and matrix degradation (Nordon et al., 2011). 
These changes lead to weakening of the wall, allowing expansion and rupture to 
occur. Although aneurysms are most common in the abdominal aorta, it has been 
suggested that the entire arterial system is abnormal in susceptible subjects (Ward, 
1992), with dilatation of the carotid arteries being a common finding in these patients 
(Makita et al., 2000, Vorp et al., 2001). 
 
18-fluorine-labelled 2-deoxy-2-fluoro-D-glucose (18F-FDG) positron emission 
tomography - computed tomography (PET-CT) is commonly used to image 
metabolically active cells in patients with cancer as a means of diagnosis and risk-
stratification. This technique has been adapted to measure vascular metabolic activity 
and provides a reproducible, non-invasive measure of arterial inflammation 
(Tawakol et al., 2006, Rudd et al., 2002), reflecting glucose uptake by macrophages 
and other plaque cells. Consequently, 18F-FDG PET has been demonstrated to 
predict future cardiovascular events in several studies and can be used to test the 
efficacy of anti-inflammatory drugs (Tahara et al., 2006a, Fayad et al., 2011b, 
Tawakol et al., 2013, Kotze et al., 2009). 
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This study set out to determine the extent of inflammation and calcification in these 
two diseases. We hypothesized that both aortic inflammation and calcification would 
be greater in aneurysm subjects than in matched controls with atherosclerosis. We 
also sought to investigate the relationship between baseline aneurysm size, 









Patients were recruited from the Royal Infirmary of Edinburgh and Addenbrooke’s 
Hospital, Cambridge and in two cohorts: (i) patients with asymptomatic abdominal 
aortic aneurysm and (ii) age- and sex- matched control patients with atherosclerosis 
but no aortic aneurysm disease. Control subjects were originally recruited and 
imaged as part of a drug trial (Elkhawad et al., 2012, Maki-Petaja et al., 2012); only 
their baseline PET data was used in this study. All control subjects were recruited in 
Cambridge, whereas study patients were recruited across both sites. Consecutive 
patients presenting at both institutions were considered for enrolment. The inclusion 
criteria for the study cohort were age >50 years and presence of an aneurysm 
between 3.0 and 5.5cm on ultrasound. The inclusion criteria for the control cohort 
were clinically stable (>6 months) cardiovascular disease (defined as previous 
myocardial infarction, stroke, or peripheral vascular disease). Exclusion criteria for 
both cohorts were type 1 diabetes, type 2 diabetes with a fasting glucose of 
>11mmol/L, renal impairment (serum creatinine >250 µmol/L), known contrast 
allergy or the inability to provide informed consent. The study was performed in 
accordance to the protocol approved by the local research ethics committee and the 
Declaration of Helsinki. All subjects provided written informed consent. 
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 POSITRON	EMISSION	TOMOGRAPHY	AND	COMPUTED	TOMOGRAPHY	IMAGING	5.3.2.
All patients underwent 18F-FDG PET-CT imaging of the entire aorta. In addition, 
patients in the study group underwent contrast-enhanced CT imaging of the 
abdominal aorta. We used validated, reproducible, previously published PET 
imaging protocols (Elkhawad et al., 2012, Maki-Petaja et al., 2012). 
Patient preparation 
Patients were asked to fast for 6 hours prior to PET imaging.  
Image Acquisition and reconstruction 
In Cambridge, a GE Discovery 690 PET-CT scanner was used. In Edinburgh, an 
equivalent Siemens machine was used (Biograph mCT, Siemens Medical Systems, 
Erlangen, Germany). A target dose of 240MBq 18F-FDG was injected intravenously 
after which patients rested in a quiet environment for 90 min before being transferred 
to the scanner. A non-contrast-enhanced attenuation correction CT scan (40mAs per 
rotation [CareDose], 100 kV) was then performed followed by PET scan covering 
three bed positions from the arch of aorta to the aortic bifurcation over 30 min (10 
min per bed position). Tracer circulation times were based on previous studies using 
18F-FDG in atherosclerosis (Rudd et al., 2002, Dweck et al., 2012a, Dweck et al., 
2011) and aimed to produce optimal contrast between the aortic wall and the blood 
pool. With the patient in the same position, a CT aortogram from the diaphragm to 
the aortic bifurcation was performed using 75-100mL of iodinated contrast 
(400mgI/mL; Iomeron, Bracco, Milan, Italy), followed by 50mL of 0.9% saline 
flush. The PET data were reconstructed using standard time of flight reconstruction 
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Anonymized PET-CT datasets were analysed using the OsiriX workstation (64 bit; 
version 5.5.1 OsiriX Imaging Software, Geneva, Switzerland) (Joshi et al., 2013, 
Maki-Petaja et al., 2012). Readers were blinded to the patients’ clinical status (study 
group or control). PET images were fused with corresponding CT datasets, and 
regions of interest (ROIs) drawn on serial axial slices. Within these regions, mean 
and maximum tracer activities were measured using standard uptake values (SUV; 
the decay corrected tissue concentration of the tracer divided by the injected dose per 
body weight) and corrected for blood pool activity in the superior vena cava to 
provide tissue-to-background ratios (TBRs) (Joshi et al., 2013, Maki-Petaja et al., 
2012). The average of the maximum TBR values within each slice was expressed as 
the mean TBRmax. 
 
The aorta was divided into 5 distinct segments for further comparisons: ascending 
aorta, descending thoracic aorta, abdominal non-aneurysmal aorta, aneurysm 
shoulder and aneurysm sac. The ascending aorta was defined as the segment of the 
aorta from the lower level of the right pulmonary artery up to the last slice where the 
aorta maintained its circular cross-sectional appearance. The descending thoracic 
aorta was defined as the region extending down from the circular slice below the 
arch of aorta to the slice where the diaphragm was first visible. The non-aneurysmal 
abdominal aorta was defined as the region between the descending aorta and the start 
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of the aneurysm. The aortic aneurysm was defined as the region of abdominal aorta 
with all slices having a diameter of at least 3cm. The aneurysm shoulder was defined 
as that segment of aorta bordering the first slice of aneurysmal aorta (2 slices above 
and below the first 3 cm diameter slice). The aneurysm sac comprised the region 
between the aneurysm shoulder and the inferior aspect of the aneurysm. 
 
Thrombus within the aneurysm was identified on the contrast CT aortogram using 
previously published Hounsfield unit definitions (Golledge et al., 2008) and 
sequential ROIs were drawn, avoiding over-spill both from the lumen and aneurysm 
wall.  
 
CT Calcium Scoring 
Calcium scoring was performed using a cardiovascular workstation (Vital Images, 
Minnetonka, Minnesota, USA). Total Agatston scores were recorded for the entire 
aorta, using a threshold of 130 Hounsfield units for calcium, on the non-contrast 
attenuation CT scan (Santos et al., 2010). In addition, arterial calcium scores 
corrected for length of artery evaluated (in Agatston units per centimeter) (Criqui et 
al., 2014) were generated to allow comparison of aneurysmal segments in the study 
group and equivalent length segments of non-aneurysmal aorta in control subjects. 
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 REPRODUCIBILITY	STUDIES	5.3.4.
PET-CT data from 10 patients were selected at random to test the reproducibility of 
the 18F-FDG PET analyses. Two trained readers analysed the scans independently to 
provide a measure of the inter-observer bias and variation for 18F-FDG uptake in 
each region of the aorta.  
  
Novel molecular imaging of cardiovascular disease in man 
 191 
 	STATISTICAL	ANALYSIS	5.3.5.
Statistical analysis was performed with Graph Pad Prism version 6 (GraphPad 
Software Inc., California USA) or SPSS 19.0 (SPSS Inc., Chicago, Illinois) where 
appropriate. Continuous data were checked for normality using the D’Agostino-
Pearson omnibus test. Parametric variables were expressed as mean ± standard 
deviation and compared using Student’s t-tests or repeat measure one-way ANOVA 
with Tukey’s multiple comparison test when appropriate. Non-parametric data were 
presented as median [interquartile range] and compared with Mann-Whitney test, 
Wilcox matched-pairs signed rank, or Friedman test as appropriate. Inter-observer 
reproducibility was estimated using the Bland Altman method and presented as mean 
bias ± 2 standard deviation, and intra-class correlation coefficients with 95% 
confidence intervals were also calculated. A two-sided P<0.05 was taken as 
statistically significant.   
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 RESULTS	5.4.
Sixty-three patients with abdominal aortic aneurysms and 19 age-and sex matched 
subjects with atherosclerosis were recruited (Table 5-1). In one patient, PET-CT data 
were acquired only for the abdominal aorta and was excluded from final analysis. 
The mean age was 76.1±6.8 years, and 89% of the study group was male. The mean 
baseline AAA size was 4.33±0.73cm. 
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Table 5-1: Baseline characteristics of patients with AAA  
	 Total	(n=63)	 Cambridge	(n=33)	 Edinburgh	(n=30)	
Average	Age	(years)	 76.1±6.8	 77.6±7.2	 74.5±5.9	
Male	sex	 56	(89%)	 31	(94%)	 25	(83%)	
BMI	(kg/m2)	 25.7±3.4	 26.2±2.5	 25.2±4.1	
Systolic	blood	pressure	(mmHg)	 137±19	 137±20	 138±18	
Diastolic	Blood	Pressure	(mmHg)	 79±12	 80±12	 76±12	
Average	Size	of	AAA	Baseline	 4.33±0.72	 4.07±0.65	 4.62±0.70	
Risk	Factors	 	 	 	
Current	Smoker	 14	(22.2%)	 3	(9.1%)	 11	(36.7%)	
Ex-Smoker	 33	(52.3%)	 16	(48.4%)	 17	(56.7%)	
Hypertension	 26	(41.6%)	 9	(27.3%)	 17	(56.7%)	
Past	Medical	History	 	 	 	
Diabetes	Mellitus	 5	(7.9%)	 3	(9.1%)	 2	(6.7%)	
Previous	Myocardial	Infarction	 14	(22.2%)	 6	(18.2%)	 8	(26.7%)	
Stroke	 8	(12.7%)	 2	(6.1%)	 6	(20%)	
Peripheral	Vascular	Disease	 9	(14.3%)	 6	(18.2%)	 3	(10%)	
Medications	Prior	to	Admission	 	 	 	
Aspirin	 48	(76.2%)	 25	(75.8%)	 23	(76.7%)	
Statin	 53	(84.1%)	 28	(84.8%)	 25	(83.3%)	
β-Blocker	 21	(33.3%)	 11	(33.3%)	 10	(33.3%)	
ACEI/ARB	 30	(47.62%)	 14	(42.4%)	 16	(53.3%)	
Thiazide	Diuretic	 6	(9.5%)	 3	(9.1%)	 3	(10%)	
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 INFLAMMATION	IN	ABDOMINAL	AORTIC	ANEURYSM	5.4.1.
Average 18F-FDG accumulation was higher within aortic aneurysms than non-
aneurysmal aortae (mean TBRmax 2.23±0.46 vs. 2.12±0.46, p=0.024, Figures 5-1 and 
5-2 and Table 5-2). Exploring further, 18F-FDG uptake was consistently higher in 
both the sac and shoulder regions of the aneurysm than any non-aneurysmal segment 
of the aorta (p=0.0004, Table 5-2). Within the aneurysm itself, there were no 
significant differences in 18F-FDG uptake between the sac and the shoulder 
(p=0.89).  
 
Comparison between aneurysm and control groups 
The two groups were well matched for age and sex. Most subjects were taking 
statins. Compared to age- and sex-matched patients with atherosclerosis (n=19, mean 
age 69.4±5.8 years, 89.5% males), patients with AAA (n=19, mean AAA diameter 
4.3±0.7cm) had higher aortic 18F-FDG uptake (mean TBRmax 2.16±0.51 vs. 
1.70±0.22, p=0.001).  This higher FDG uptake was not confined to the aneurysm, but 
noted in all non-aneurysmal aortic segments (Table 5-2). 
 
Association between 18F-FDG uptake and clinical parameters in aneurysms 
There was no correlation between aneurysm size and 18F-FDG uptake within it 
(r=0.12, p=0.36). However, when divided into two groups by size, the 32 smaller 
aneurysms (below the mean cohort size of 4.33cm) trended towards 18F-FDG 
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accumulation than the 30 larger aneurysms above the mean cohort size (mean 
TBRmax 2.36±0.45 vs. 2.14±0.45, p=0.065).  
 
18F-FDG uptake within aneurysm thrombus 
Aneurysmal thrombus was present in 43 of the 63 aneurysm patients. Patients 
without aneurysmal thrombus has higher 18F-FDG uptake within the aneurysmal 
wall as compared to those with thrombus (mean TBRmax aneurysm 2.43±0.45 versus 
2.14±0.43, p=0.018). 18F-FDG uptake within the thrombus itself was consistently 
lower than in any region of the aortic wall in these subjects (mean TBRmax within 
thrombus 1.30±0.48 vs. aneurysm wall 2.23±0.46, p<0.0001).  
  
Novel molecular imaging of cardiovascular disease in man 
 196 
Table 5-2 Inflammation and calcification in aortic aneurysm 
Inflammation (mean TBRmax) and calcification (Agatston score) data for all aneurysm subjects. 




Mean	TBR	max	 2.23±0.46	 2.12±0.46	 0.024	
Agatston	score	(median	[IQR])	 4918	[2901-8008]	 1017	[139-2226]	 <0.0001	
 
Table 5-2b  displays the values for each individual region of the aorta. 
	 Shoulder	 Sac	 Ascending	 Descending	 Abdominal	 p	value	
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 Figure 5-1: Aneurysmal 18F-FDG uptake.      
Coronal and transaxial fused PET and contrast CT images demonstrating focal 18F-FDG uptake 
within the aneurysmal wall (white arrowheads). Note also the calcified lateral aspect of the aneurysm. 
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 CALCIFICATION	IN	ABDOMINAL	AORTIC	ANEURYSM	5.4.2.
In the aneurysm group, calcification was greater within the aneurysmal aortic wall 
than in the non-aneurysmal segments of aorta (4918 Agatston units [2901-8008] vs. 
1017 [139-2226], p<0.0001). This calcification was highest within the aneurysm sac 
compared to the other aortic regions (p<0.0001, Table 5-2b). Consistent with these 
findings, aortic aneurysms were more calcified than the corresponding regions of 
abdominal aorta in atherosclerotic controls (442 Agatston units per cm [304-920] vs. 
166 [80-374], p=0.0042). Of note, no differences in calcification were detected 
between aneurysm subjects and controls in any other aortic region. No significant 
relationships were observed between aneurysm diameter and extent of calcification 
(r=0.08, p=0.53). No differences were observed in the calcification in patients 
without or with intraluminal thrombus within the aneurysm (5310 [2748-9165] 
versus 4903 [2952-7856], p=0.574). 
 
Relationship between inflammation and calcification in AAA and atherosclerosis 
There was no relationship between inflammation and calcification within aneurysms 
(r=-0.153, p=0.235). Similarly, in the control group, there was no correlation 
between aortic inflammation and calcification (total aorta: r=-0.19, p=0.45; 
abdominal aorta: r=-0.13, p=0.6). 
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Figure 5-2: 18F-FDG uptake in AAA       
Coronal contrast CT, 18F-FDG PET and fused images of a subject with a large (4.5cm) aneurysm 
demonstrating focal 18F-FDG uptake within the aneurysmal wall (golden color on PET images). Note 
also the presence of intra-luminal thrombus and calcification. 
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 REPRODUCIBILITY	OF	18F-FDG	MEASUREMENTS	5.4.3.
The inter-observer reproducibility for 18F-FDG measurements was excellent across 
all regions of the aorta, including aneurysmal regions, and consistent with previous 
studies in atherosclerosis. Across the aorta as a whole, the limits of agreement for 
mean TBRmax were 0.04±0.07. All intra-class correlation values were >0.90, with the 
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 DISCUSSION	5.5.
18F-FDG PET imaging of aortic aneurysm was first reported in 2002 (Sakalihasan et 
al., 2002). This present work is the largest series to measure both 18F-FDG uptake 
and calcification, and to compare these with well-characterised controls with 
atherosclerosis. 
 
 We have presented evidence that subjects with asymptomatic aortic aneurysms have 
excessive inflammation within the aneurysmal segment of the aorta. In comparison 
to matched controls with atherosclerosis, the entire aorta in those with abdominal 
aortic aneurysm appears more highly inflamed. This suggests the presence of a 
global aortopathy rather than a disease confined only to the abdominal region of the 
aorta. We also noted that the intra-luminal thrombus, frequently seen in conjunction 
with aneurysms, was metabolically inert with low 18F-FDG uptake in most of our 
cases. 
 
There was no linear relationship between baseline aneurysm size and 18F-FDG 
uptake, but, consistent with a previous report (Kotze et al., 2011a), small aneurysms 
appeared more 18F-FDG-avid than larger examples. This might be explained in a 
scenario where intense early inflammation causes mechanical weakening of the 
aortic wall, allowing expansion to occur. Inflammation then reduces as the wall 
becomes more calcified. 
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In terms of calcification, as with inflammation, this appeared greatest within the 
aortic aneurysm itself in the study group. Compared with atherosclerotic controls, 
calcification was more prevalent in the aneurysms than in control abdominal aortas. 
But, in contrast to the pattern of inflammation described above, aneurysm patients 
did not exhibit more calcification than controls in other regions of their aortae. 
 
Aortic aneurysms frequently occur in patients with atherosclerosis. The two disease 
processes share several common risk factors, notably cigarette smoking (Brady et al., 
2004). The underlying pathologies of the two conditions overlap to an extent, with 
inflammation and calcification being common to both. Nevertheless, there are 
important differences. While aneurysms are characterised by weakening of the media 
of the aorta by chronic inflammation and degradation of the extracellular matrix 
(Hellenthal et al., 2009), in atherosclerosis the main insult is to the intima of the 
artery, at least initially. In atherosclerosis, a fibrous cap is typical over the necrotic 
core of the lesion, whereas in aneurysm, there is very often a large adherent 
thrombus, variously described as protective against expansion in some studies 
(Thubrikar et al., 2003) and encouraging destabilization in others (Hinnen et al., 
2005, Fontaine et al., 2002b). Our results lend more support to the former hypothesis, 
thrombus being metabolically inactive with respect to glucose usage. The role of 
calcification is also debated in both conditions (Buijs et al., 2013). In atherosclerosis, 
macro-calcification is thought to be a healing response conferring plaque stability 
(Joshi et al., 2013, Aikawa et al., 2007, New et al., 2013b), but micro-calcification 
appears to be associated with a risk of plaque rupture (Libby and Aikawa, 2002). On 
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a patient level, a non-zero calcium score, derived from CT imaging of the coronary 
arteries, is strongly associated with future vascular events and overall mortality 
(Budoff et al., 2013). In aneurysms, the role of calcification is less understood than in 
atherosclerosis with fewer large prospective studies. One recent paper (Buijs et al., 
2013) showed that more calcium was present within the walls of aneurysms that had 
ruptured compared to those repaired electively, although numbers in both groups 
were small with several confounding factors. In another publication (Lindholt, 2008) 
the authors reported the opposite, namely that calcification within the aneurysm (this 
time measured by ultrasound) was protective and associated with slower annual 
mean growth rates (1.72mm vs. 2.97mm, p=0.001).  
 
Our study group consisted of patients with aneurysms below the size limit for 
surgery, and therefore tissue harvesting for testing of the relationship between 18F-
FDG uptake and inflammation was not possible. Nevertheless, the degree of 18F-
FDG uptake in the aortic wall, measured by PET, has correlated strongly with 
histologically-proven inflammation in tissue removed during aneurysm repair 
surgery in several prior studies (Reeps et al., 2008, Courtois et al., 2013, Sakalihasan 
et al., 2002, Truijers et al., 2008). We therefore believe that our 18F-FDG data are at 
least partly reflective of underlying inflammation. It may be that imaging agents 
more specific for inflammation, such as 68Ga-DOTATATE PET, 11C-PK11195 
PET or USPIO-MRI might provide differing insights into the pathology of the 
disease. 
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No partial volume correction methods were applied to the PET data presented here, 
which might have affected quantification of the 18F-FDG signal. However, a recent 
publication by Reeps and colleagues addressed this question, concluding that such 
corrections were not needed when imaging vascular structures as relatively large as 
aortic aneurysms (Reeps et al., 2013).  
 
In terms of whether 18F-FDG uptake predicts future aneurysm behavior, published 
work presents a mixed picture. There is evidence to suggest that 18F-FDG can 
discriminate between asymptomatic and symptomatic aneurysms, but its potential as 
a marker of aneurysm expansion and rupture has yet to be established (Reeps et al., 
2008, Truijers et al., 2008, Reeps et al., 2013, Nchimi et al., 2010, Kotze et al., 
2011a, Sakalihasan et al., 2004). There also appear to be positive correlations 
between 18F-FDG uptake and the degree of mechanical wall stress within an 
aneurysm (Xu et al., 2010). Considerably more work is needed to determine whether 
data derived from advanced imaging, such as inflammation and calcification, can 
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Chapter	6. POSITRON	 EMISSION	 TOMOGRAPHY	 AND	
MAGNETIC	 RESONANCE	 IMAGING	 OF	 CELLULAR	
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 SUMMARY	6.1.
Inflammation is critical in the pathogenesis of abdominal aortic aneurysm (AAA). 
Combined positron emission tomography and computed tomography (PET-CT) with 
18F-flurodeoxyglucose (18F-FDG) and ultrasmall superparamagnetic particles of 
iron oxide (USPIO)-enhanced magnetic resonance imaging (MRI) are non-invasive 
methods of assessing tissue inflammation.  The aim of this study was to compare 
18F-FDG PET-CT with USPIO-enhanced MRI in patients with AAA. 
 
Fifteen patients with asymptomatic AAA with diameter 46±7 mm underwent PET-
CT with 18F-FDG and T2*-weighted MRI before and 24 h after administration of 
USPIO. The PET-CT and MRI data were co-registered. Standardized uptake values 
(SUV) were calculated to measure 18F-FDG uptake, and USPIO uptake was 
determined using change in R2*.  Comparisons between the techniques were made 
using a quadrant analysis and on a voxel-by-voxel evaluation. 
 
Maximum SUV was lower in patients with mural USPIO uptake. When all areas of 
the aneurysm were evaluated, there was a modest correlation between the SUV on 
PET-CT and the change in R2* on USPIO-enhanced MRI (n=70,345 voxels; r=0.30; 
p<0.0001).   Co-localization of 18F-FDG and USPIO uptake was poor (kappa 
statistic 0.074; 95% CI, 0.026 - 0.122). 
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Both 18F-FDG PET-CT and USPIO-MRI uptake identify vascular inflammation 
associated with AAA.  Whilst they demonstrate a weak correlation, there are distinct 
differences in the pattern and distribution of uptake suggesting a differential 
detection of macrophage glycolytic and phagocytic activity respectively.  
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 INTRODUCTION	6.2.
Recent advances in imaging modalities have generated considerable interest in novel 
molecular and cellular techniques. In contrast to anatomical and structural 
approaches, molecular and cellular imaging targets the activity of specific 
biochemical and cellular processes to provide insight into the etiology, biology and 
pathogenesis of diseased states. Moreover, this has the potential to refine the 
diagnosis and risk-stratification of cardiovascular disease as well as to assess 
responses to specific therapeutic interventions (Jaffer et al., 2009, Jaffer et al., 2007, 
Choudhury and Fisher, 2009, Tawakol et al., 2006, Rudd et al., 2002, Tahara et al., 
2006b). 
 
18F-Fluorodeoxyglucose (18F-FDG) is used extensively to image metabolically 
active cells with positron emission tomography (PET) combined with computed 
tomography (CT). It accumulates in cells and tissues with increased metabolic 
activity, and in vascular tissue, 18F-FDG uptake correlates with the degree of 
inflammation (Lardinois et al., 2003).  Indeed, 18F-FDG uptake correlates with acute 
plaque events and cardiovascular risk factors, and has being used as a biomarker to 
demonstrate the anti-inflammatory effects of statins (Tawakol et al., 2006, Rudd et 
al., 2002, Tahara et al., 2006b, Fayad et al., 2011a). 18F-FDG also accumulates in 
the wall of abdominal aortic aneurysms (AAA) and appears to identify active aortic 
inflammation. However, its potential use as a marker of aneurysm expansion, 
progression and rupture has yet to be established.  
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Magnetic resonance imaging (MRI) with ultrasmall superparamagnetic particles of 
iron oxide (USPIOs) is an alternative approach for detecting cellular inflammation. 
(Ruehm et al., 2001) (Alam et al., 2012, Richards et al., 2012). Due to their small 
particle size (diameter 10-30 nm), USPIOs escape immediate recognition by the 
reticulo-endothelial system, persist in the bloodstream and accumulate at sites of 
vascular inflammation. Here they are phagocytosed by tissue-resident macrophages 
within which they accumulate and are detectable on T2- and T2*-weighted MRI 
sequences. Within atheromatous plaques, USPIO uptake correlates with macrophage 
density, distinguishes stable from unstable carotid plaques, and is reduced following 
high-dose atorvastatin therapy (Trivedi et al., 2006a, Tang et al., 2009b, Morishige et 
al., 2010). We have previously demonstrated USPIO uptake in the wall of AAAs 
where it co-localizes with macrophages and is associated with a three-fold higher 
AAA growth rate (Richards et al., 2012).   
 
Given that both 18F-FDG PET and USPIO-enhanced MRI have been used to assess 
vascular inflammation in patients with AAA, the aim of this study was to compare 
18F-FDG PET and USPIO-enhanced MRI in patients with AAAs. Specifically, we 
assessed the spatial distribution and intensity of the inflammatory process using both 
techniques to determine whether they provide unique or common insights into the 
pathogenesis and disease progression of AAAs. 
 
  




Patients with asymptomatic AAA (diameter 30-55 mm on duplex ultrasound 
examination) were recruited from the outpatient aneurysm surveillance clinic at the 
Royal Infirmary of Edinburgh. Exclusion criteria were age <50 years, active systemic 
inflammatory or malignant disease, insulin-dependent diabetes mellitus, renal 
dysfunction (estimated glomerular filtration rate <30 mL/min), hepatic cirrhosis 
(Child Pugh score B or C), planned AAA surgery within 6 months of screening and a 
contra-indication to MRI. Studies were performed with the approval of the local 
research ethics committee, in accordance with the Declaration of Helsinki, and with 
the written informed consent of each participant. All patients underwent a 
comprehensive baseline clinical assessment including evaluation of their 
cardiovascular risk factor profile and recording of an abdominal ultrasound scan. 
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 POSITRON	EMISSION	TOMOGRAPHY	AND	COMPUTED	TOMOGRAPHY	AORTOGRAM		6.3.2.
PET-CT scans were performed followed by a CT aortogram (CTA) using a hybrid 
scanner (Biograph mCT, Siemens Medical Systems, Erlangen, Germany). Patients 
were asked to fast for 6 h prior to the scan. A target dose of 240 MBq 18F-FDG was 
injected intravenously after which patients rested in a quiet environment for 90 min 
before scanning. An attenuation correction CT scan (non-enhanced, 40 mAs per 
rotation [CareDose], 100 kV) was then performed followed by a PET scan covering 
three bed positions from the arch of aorta to the aortic bifurcation over 30 min. 
Tracer circulation times were based on previous studies using 18F-FDG in 
atherosclerosis (Dweck et al., 2012a, Dweck et al., 2011, Rudd et al., 2002, Tawakol 
et al., 2013) and aimed to allow for optimal contrast between the aortic wall and the 
blood pool. With the patient lying in the same position, a CT aortogram from the 
diaphragm to the aortic bifurcation was performed using 75 mL of iodine contrast, 
followed by 50 mL of 0.9% saline flush. The PET data were reconstructed using the 
Siemens Ultra-HD (time of flight +True X) reconstruction algorithm. Corrections 
were applied for attenuation, dead time, scatter and random coincidences. Image 
acquisition and reconstructions for CTA were undertaken as per pre-specified 
protocol (voltage 120kV, ref mAs 145, slice thicknesses 1 and 3 mm, field of view 
300 x 400 mm). 
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 USPIO	ENHANCED	MAGNETIC	RESONANCE	IMAGING	6.3.3.
Participants underwent MRI in a whole body 3T scanner (Magnetom Verio, Siemens, 
Erlangen, Germany) before and 24-36 h after intravenous administration of the 
USPIO contrast agent (ferumoxytol; Feraheme, Advanced Magnetics Inc., 
Cambridge, MA, USA; dose 4 mg/kg at a rate of 1 mL/s). Routine clinical coronal 
and sagittal breath-held T2-weighted multi-slice HASTE localizer sequences were 
used to identify the position and extent of the aneurysm following which a 
respiratory-gated, electrocardiographically-triggered T2 weighted (T2W) turbo-spin 
echo sequence was used to acquire detailed anatomical data (TR/TE 2R-R 
intervals/72 ms; flip angle 180°; matrix 192 × 256; field of view 400 × 400 mm; slice 
width 5 mm). A multi-echo, gradient-echo T2*W sequence (TE 4.9, 7.7, 10.5, 13.3 
ms; TR 133 ms; flip angle 15°; matrix 192 × 256; field of view 400 × 400 mm; slice 
width 5 mm) was used to acquire axial images of the entire aneurysm with slice 
positions corresponding to those of the T2W images. When performing the post-
contrast scans, axial acquisitions were positioned to match those of the pre-contrast 
scan by reference to the vertebral bodies (Richards et al., 2012, Richards et al., 
2011c). 
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 IMAGE	ANALYSIS	6.3.4.
Registration of PET and MRI images  
The accuracy of PET-CT to CTA registration was confirmed by visual assessment 
and minor intra-scan patient movement was corrected using a semi-automatic rigid 
3D voxel registration protocol  (Analyze 11.0, Mayo Clinic).  
Registration of the MRI data allowed both the excellent anatomical detail on the 
T2W images and the high sensitivity of T2*W images for iron to be utilized.  All the 
images were registered to the pre-contrast T2W image using the same semi-
automatic 3D voxel registration protocol (Analyze 11.0, Mayo Clinic). The CTA and 
T2W MRI datasets were co-registered. At the end of the registration process, the pre-
USPIO T2*W MRI, the post-USPIO T2*W MRI, the CTA and the PET-CT were all 
co-registered to enable direct comparison. 
 
18F-FDG quantification 
The maximum standardized uptake value (SUV) was used to assess 18F-FDG 
activity in the aneurysm. The SUV is the decay corrected tissue uptake divided by 
the injected dose per unit body weight and is a semi-quantitative dimensionless unit 
that has been previously validated and is commonly used measure of tissue 18F-FDG 
activity (Dweck et al., 2012a, Dweck et al., 2011, Rudd et al., 2002, Tawakol et al., 
2013). The SUV in vascular structures can be heavily influenced by variability of 
18F-FDG activity in the blood pool.  Therefore, the tissue-to-background ratio (TBR) 
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was also calculated by dividing the tissue maximum SUV by the mean SUV in the 
blood pool (average of five randomly selected regions in the descending thoracic 
aorta).  An area of 18F-FDG uptake was defined as significant if the maximum SUV 
or TBR was >125% of the value obtained from non-aneurysmal descending thoracic 
aorta (average of five randomly selected areas). 
 
USPIO quantification 
Using validated in-house software (Matlab, Mathworks, USA), four echoes in the 
multi-echo T2*W sequence were combined to generate a T2* map in which the 
magnitude of each voxel represented the T2*value (S(t)=S(0)exp-(t/T2*).  The T2* 
value is the decay constant for the exponential decay of signal intensity with time.  In 
the presence of USPIO, the signal decays more rapidly because of local magnetic 
field inhomogeneities and the T2* value is reduced. A 3×3 voxel Gaussian filter was 
applied to the individual echoes to reduce noise.  An experimentally determined 
threshold for the coefficient of determination (r2>0.85) was used to exclude data that 
did not have an acceptable exponential decay when signal intensity (SI) was plotted 
against echo time. USPIO uptake was detected using the change in T2* (or R2*; 
R2*=1/T2*) following USPIO administration. A previously defined threshold of 
significance (59% increase in T2*) was used to distinguish USPIO accumulation 
from artefactual changes in T2* (Richards et al., 2012, Richards et al., 2011c). To 
enable the spatial distribution of USPIO uptake within the aneurysm to be assessed, 
colour maps were generated in which each voxel represented the change in T2* 
(ΔT2*) or R2* (ΔR2*) following USPIO administration. 
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We chose to analyze the correlation between 18F-FDG uptake and USPIO 
distribution using three methods: first we compared these signals in different regions 
of the aneurysm by drawing regions of interests around the wall and thrombus, and 
second we studied co-localization across the whole aneurysm using a voxel-by-voxel 
analysis. Finally, a previously defined aneurysm classification system based on 
USPIO uptake on MRI (Richards et al., 2011c) was compared to the SUV and TBR 
for each aneurysm. 
 
Colour maps 
Two independent observers, blinded to patient demographics and aneurysm size 
reviewed the ΔT2* colour maps and the fused PET-CT data. Each axial slice was 
divided into quadrants and each quadrant was defined as positive if it included at 
least one region of increased USPIO or 18F-FDG uptake, or negative if it did not. On 
the ΔT2* colour maps, regions were defined as consisting of at least ten contiguous 
voxels with ΔT2* above the threshold of 59%.16 On the PET-CT scans, regions of 
interest were drawn around areas of maximum uptake in the wall and thrombus of 
the aneurysm and defined as positive if the maximum SUV was >125% of the mean 
SUV.  
 
In order to define the area of the aneurysm where there was increased uptake of 
either USPIO or 18F-FDG, the aneurysm was divided in the axial plane into three 
distinct regions; on MRI the shoulder region extended 1 slice (5 mm) above and 
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below the point at which the aorta dilated to 30 mm and on PET-CT, 2 slices (6 mm) 
were considered.  The bifurcation region was defined in an identical way but from 
the point where the aneurysm reduced in diameter to 30 mm.  The area between these 
two points was defined as the main body of the aneurysm. 
 
Voxel-by-voxel analysis 
The MRI images were reconstructed by down-sampling to achieve equivalent voxel 
sizes on MR and PET images. A region of interest (ROI) encompassing the entire 
aortic wall and thrombus was drawn on each slice of the pre-contrast T2W image. 
These ROI were then applied to the PET images and to the ΔR2* colour maps. This 




We have previously shown that mural USPIO uptake predicts expansion therefore 
aneurysms were classified into three pre-defined groups by two independent blinded 
observers: Group 1, no mural or thrombus USPIO uptake, except for isolated 
periluminal enhancement; Group 2, diffuse USPIO uptake, distinct from the 
periluminal thrombus and aortic wall; and Group 3, focal areas (with at least 10 
contiguous voxels) of USPIO uptake within the aortic wall of the aneurysm, distinct 
from the periluminal area and thrombus (Richards et al., 2011c). The classification of 
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each aneurysm was then compared to the maximum SUV and TBR of each 
aneurysm. 
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 STATISTICAL	ANALYSIS	6.3.5.
Normally distributed continuous variables were expressed as mean ± standard 
deviation. Non-parametric data were presented as median with interquartile 
ranges. Correlations between normally distributed data were performed using 
Pearson’s correlation. Comparisons were undertaken with paired or unpaired 
Student’s t-tests as appropriate. A two-sided P<0.05 was regarded as 
statistically significant. Statistical analysis was performed with the use of Graph 
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 RESULTS	6.4.
Fifteen predominantly elderly men with multiple cardiovascular risk factors and 
a mean AAA diameter of 46 mm (range 36-54 mm) participated in the study 
(Table 6-1).  All patients were asymptomatic and had fusiform aneurysms 
confined to the abdominal aorta.  18F-FDG PET-CT and USPIO-enhanced MRI 
scans were performed a median of 7 days apart.  PET imaging of the abdomen 
was undertaken a median of 92 min (IQR, 89-97 min) after injection of 237±16 
MBq of 18F-FDG. The effective radiation from participation in the study was 
10.8 mSv using a conversion factor of 0.014 mSv/mGy.cm.  The administration 
of 18F-FDG and USPIO was well tolerated with no adverse events.  
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*Angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) 
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 18F-FDG	UPTAKE	6.4.1.
There was demonstrable 18F-FDG activity within the wall of the AAA and 
increased activity was present in 13 of the 15 aneurysms.  All areas of increased 
activity of 18F-FDG were diffuse and involved the wall (Table 6-2).  There was 
increased activity in the peri-luminal zone around the thrombus but the 
thrombus itself was metabolically inert. The majority of areas of increased 18F-
FDG uptake occurred in the shoulder region of the aneurysm (25/42, 60%), 
with a third (14/42) occurring within the main body of the aneurysm and the 
remainder in close proximity to the bifurcation (3/42).  
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 USPIO	UPTAKE	6.4.2.
All aneurysms had focal areas of USPIO uptake involving the wall of the 
aneurysm and most of these areas were confined to the main body of the 
aneurysm (146/271, 54%), with 28% (75/271) located in the shoulder region 
and 19% (50/271) adjacent to the bifurcation (Table 2).  In keeping with the 
peri-luminal effect seen in previous studies, all patients had USPIO uptake in 
the periluminal area, representing a movement of particles directly into the 
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Figure 6-1: A. Comparison of standard uptake value (SUV) and absolute change 
in R2* in the wall of the abdominal aortic aneurysm (AAA).     
When the thrombus and wall of the aneurysm are considered there is a modest correlation between 
the SUV and the absolute change in R2* (r2 value = 0.09).  B. MRI group classification compared to 
maximum absolute change in R2*, maximum SUV and tissue-to-background ratio (TBR) in the wall of 
the AAA.  There was no significant difference between the absolute change in R2* (p=0.4123, 95% CI 
-86.99 – 37.98), maximum SUV (p=0.4696, 95% CI -1.682 – 0.8194) or TBR (p=0.7884, 95% CI -
2.181 – 1.690) of patients in group 1 and 2 and those in group 3. 
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 COMPARISON	BETWEEN	18F-FDG	AND	USPIO	UPTAKE	6.4.3.
Based on USPIO uptake, 4 patients were classified into Group 3 and 11 into 
Groups 1 and 2.  Maximum SUV and TBR appeared to be lower in those 
classified as Group 3 than in those in Groups 1 and 2, but this did not reach 
statistical significance (p=0.7884, 95% CI -2.181–1.690; Figure 6-1).  There 
was no correlation between the grouping classification and the maximum 
absolute change in R2* (p=0.4123, 95% CI -86.99 – 37.98).    When all areas of 
the aneurysm were considered, there was a modest correlation between the 
SUV on PET-CT and the absolute change in R2* on MRI (r=0.30; 95% CI 
0.29–0.31, p<0.0001; Figure 6-1).  
 
On occasion, MRI and fused PET-CT scans co-localized to the same area of 
increased USPIO and 18F-FDG uptake in the aortic wall, although regions of 
USPIO uptake without corresponding 18F-FDG activity were also commonly 
seen (Figure 6-2).  Focal and discrete uptake of USPIO can be readily discerned 
on MRI, whereas there was more diffuse and ill-defined uptake of 18F-FDG 
involving both the wall and the thrombus on PET-CT. Co-localization of areas 
of increased uptake of USPIO on MRI and 18F-FDG activity on PET-CT was 
poor (kappa statistic 0.074; 95% CI, 0.026-0.122) and there were more areas of 
increased uptake identified on MRI, than on PET-CT (Table 6-3). 
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Table 6-2: Quadrant analysis of USPIO enhanced MRI and 18F-FDG PET-CT 
uptake           
Regions of uptake identified in the MRI wall versus PET-CT wall.  Kappa statistic = 0.074 (95% C.I. 
0.026 – 0.122), representing a poor strength of agreement. 
  
                                           18F-FDG PET-CT 
   
   
   
   
   
   











  Regions of uptake No regions 
of uptake 
Total 
Regions of uptake 70 353 423 
No regions of uptake 69 613 682 





Classification of AAA according to 18F-FDG activity or USPIO uptake using 
the quadrant technique was consistent and reproducible with excellent inter-
observer agreement and a kappa statistic of 0.87 for 18F-FDG and 0.85 for 
USPIO.   
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Figure 6-2: A & B: Representative MRI (A) and fused PET-CT (B) scans from 
the same patient with an abdominal aortic aneurysm (AAA).      
USPIO uptake, defined by percentage change in T2* is demonstrated using a color scale. Changes in 
T2* value over the threshold (59%) are presented on a graduated (yellow-red) color scale and data 
below the threshold appears blue.  Corresponding 18F-FDG activity (red arrow) can be seen in 
image B.  Differences in the location of regions of uptake between the techniques are apparent, as 
marked by the white arrow.  Image C & D are corresponding MRI and fused PET-CT slices from the 
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Table 6-3: Qualitative evaluation of 18F-FDG uptake on PET-CT versus USPIO uptake on MRI 
 18F-FDG PET-CT USPIO MRI 
Spatial resolution 5-6mm  3-4mm 
Periluminal enhancement Present Present 
Region of uptake Predilection for shoulder 
region 
Predilection for sac of 
aneurysm 
Definition of uptake >125% mean SUV (5 
randomly selected regions 
of descending thoracic 
aorta)  
10 contiguous voxels with 
% change in T2* ≥59% 
 
Functional assessment Glycolytic activity Phagocytic activity 
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 DISCUSSION	6.5.
In comparing 18F-FDG PET-CT with USPIO-enhanced MRI in patients with AAA, 
we have identified a modest correlation between these two imaging modalities, yet a 
number of key differences. In particular activity detected with these two techniques 
appears to be concentrated in different regions of the aneurysm: largely in the 
shoulder region with 18F- FDG and in the body of the aneurysm using USPIOs. We 
believe that this reflects the different elements of inflammatory activity detected by 
these two approaches, with PET-CT providing information related to glycolysis and 
USPIO information on phagocytosis. Further studies are now required to assess 
which modality will have the greatest predictive power to determine aneurysm 
growth and clinical outcome. 
 
Inflammatory cells have a key role in the development and progression of abdominal 
aortic aneurysms (Courtois et al., 2013). Histopathologically, the aneurysmal aortic 
wall is characterised by focal medial neovascularisation, infiltration of inflammatory 
cells (principally macrophages and lymphocytes) and fragmentation of elastin and 
collagen fibres within the extracellular matrix. Both 18F-FDG and USPIO imaging 
aim to detect and quantify the inflammatory cellular component and it is therefore 
encouraging that a modest correlation between these two measures was observed in 
this study, confirming that ultimately both identify vascular inflammation, albeit 
through differing pathways. 
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Vascular inflammatory cells are metabolically active and take up 18F-FDG in an 
insulin- insensitive manner. Therefore, 18F-FDG uptake in the fasted state has been 
proposed as a marker of risk for aneurysm progression and rupture with higher 
uptake associated with inflammation, aortic wall instability, and clinical symptoms 
(Reeps et al., 2008). However, recent data have suggested that vascular 18F-FDG 
activity may relate to more than simply macrophage burden, implicating hypoxia as 
an important driver to 18F-FDG uptake (Folco et al., 2011). Furthermore, although 
several small studies have demonstrated the ability of 18F-FDG to discriminate 
between symptomatic and asymptomatic AAA (Reeps et al., 2012, Reeps et al., 
2013, Reeps et al., 2008, Courtois et al., 2013, Sakalihasan et al., 2002,  Truijers et 
al., 2008), one report showed an inverse relationship between 18F-FDG uptake and 
future aneurysm growth rates (Kotze et al., 2011b). USPIO-enhanced MRI has been 
used to explore a number of inflammatory conditions, including atherosclerotic 
plaques and abdominal aortic aneurysms (Sadat et al., 2011b, Richards et al., 2011b, 
Trivedi et al., 2006a, Morishige et al., 2010). USPIOs are taken up by inflammatory 
phagocytic cells, particularly macrophages, and accumulate at sites of cellular 
inflammation at sufficient concentrations to cause signal changes on MRI. In 
addition, histological examination of excised tissue, including aneurysm tissue, has 
confirmed the co-localisation and uptake of USPIO in areas of macrophage 
infiltration (Richards et al., 2011b, Trivedi et al., 2006a, Kooi et al., 2003a, Schmitz 
et al., 2001). We speculate that USPIO and 18F-FDG uptake represent distinct 
markers of vascular inflammation that correspond to differing inflammatory and 
macrophage activities. Clearly, USPIO uptake is a measure of ongoing phagocytic 
activity of tissue-resident macrophages and potentially neutrophils, whereas 18F-
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FDG reflects glucose utilisation by cells with high metabolic requirements including 
the cells implicated in vascular inflammation (Millon et al., 2013). Moreover there is 
evidence that the two techniques target different macrophage subsets. Macrophages 
exist in varying polarised states and have different roles in vascular tissue. M1 
macrophages are considered more destructive, promoting the destabilisation and 
rupture of atherosclerotic plaques, whereas phagocytosis is more important in the 
role of M2 macrophages stimulating reparative processes, mediated by the 
production of anti-inflammatory cytokines and the suppression of pro-inflammatory 
signaling (Mosser and Edwards, 2008). It has been suggested that 18F-FDG and 
USPIO uptake may be able to differentiate these two distinct M1 and M2 
macrophage sub- populations respectively (Satomi et al., 2013a). In our study the 
majority of 18F-FDG uptake was identified in the shoulder region of the aneurysm, 
an area of high biomechanical stress (Nchimi et al., 2014, Xu et al., 2010), with a 
particular tendency to rupture: perhaps related to a destructive macrophage 
phenotype in this area. Even though it has been demonstrated that our USPIO 
aneurysm classification identifies aneurysms likely to progress and dilate (Group 3; 
distinct mural USPIO uptake) we found no correlation between this classification and 
18F-FDG uptake nor the maximum absolute change in R2*. This supports the 
suggestion that it is the location of USPIO uptake that is crucial, rather than the 
degree of USPIO uptake. However, the modest correlation that was demonstrated 
between maximum absolute change in R2* and SUV on a voxel-by-voxel basis 
supports the contention that these imaging modalities are both detecting elements of 
macrophage activity, namely phagocytosis and glucose metabolism. 
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There are important study limitations and technical considerations when interpreting 
our findings. We acknowledge that co-registration of the MRI and PET-CT datasets 
was challenging and cannot exclude partial or incomplete co-registration. Moreover 
the limited in-plane resolution of PET-CT makes definition of the wall more difficult 
and therefore challenging to locate the exact site of activity. Indeed this may also 
explain the increased 18F-FDG uptake observed in the shoulder region, which is 
more prone to partial volume effects due to its angulation through the slice. 
Additionally, there is no consensus or validated definition of quantitative 
significance values for 18F-FDG or USPIO uptake and despite the excellent 
interobserver reproducibility demonstrated in this study, this may contribute to the 
differences observed. This is also a small study population that will require 
prospective evaluation in larger patient cohorts. Given this limited sample size, we 
were unable to assess the relationship between uptake of either 18F-FDG or USPIOs 
with AAA growth rates or clinical outcome. A number of small studies have 
demonstrated the ability of 18F-FDG’s ability to differentiate between symptomatic 
and asymptomatic AAA (Reeps et al., 2012, Reeps et al., 2013, Courtois et al., 2013, 
Sakalihasan et al., 2002, Truijers et al., 2008) and a recent study has suggested an 
association between 18F-FDG activity and future clinical events (Nchimi et al., 
2014). We have previously demonstrated in a pilot study of 29 patients that USPIO 
uptake in the wall of AAA is associated with accelerated expansion rates (Richards et 
al., 2011c). Further datasets are therefore required to undertake more complete 
evaluation of these promising imaging approaches. 
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In conclusion, the correlation between 18F-FDG PET-CT and USPIO-enhanced MRI 
to detect vascular inflammation in AAAs is modest and reflects the differing 
elements of macrophage activity that they detect: glycolysis and phagocytosis 
respectively. Whether the identification of this varying activity will impact on 
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 SUMMARY	OF	FINDINGS	7.1.
Despite significant advances in our understanding, cardiovascular diseases still 
remain the commonest cause of death worldwide (Lozano et al., 2012, Mozaffarian 
et al., 2014). Majority of these deaths are sudden and are caused by atherosclerotic 
plaque rupture with resultant myocardial infarction or cerebrovascular accident and 
ruptured aortic aneurysms. Conventional imaging modalities such coronary 
angiography and stress echocardiography have consistently failed to identify plaques 
at risk of rupture (Stone et al., 2011a, Libby, 2013, Boden et al., 2007) and an ever-
expanding repertoire of cardiovascular imaging techniques are currently being 
investigated in detecting the so-called vulnerable plaques. Similarly, AAA growth 
and rupture are highly unpredictable and current imaging modalities are unable to 
guide early interventions (Scott, 2002,  Lederle et al., 2002, Golledge et al., 2006b, 
Norman et al., 2004). Recent advances in imaging modalities that target biochemical 
and cellular processes have generated considerable interest in novel molecular and 
cellular techniques (Jaffer et al., 2009, Jaffer et al., 2007, Choudhury and Fisher, 
2009, Tawakol et al., 2006, Rudd et al., 2002, Tahara et al., 2006b).  These 
techniques have a potential to provide novel biological insights, risk-stratify patients, 
and allow assessment of responses to specific therapeutic interventions (Jaffer et al., 
2009, Jaffer et al., 2007, Choudhury and Fisher, 2009, Nahrendorf et al., 2011)  
 
The aims of the studies presented in this thesis were to develop and evaluate the role 
of novel molecular imaging techniques in human atherosclerotic and aneurysmal 
disease. A multimodality approach for assessment of atherosclerotic plaques and 
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aneurysms was utilised, with 18F-FDG PET and USPIO enhanced MRI as markers 
metabolic and cellular inflammation and 18F-fluoride PET as a marker of active 
calcification. From the series of studies presented in this thesis, we can conclude that 
the molecular imaging techniques hold major promise in identifying patients with 
high-risk vulnerable atherosclerotic plaques (chapter 3), provide novel insights into 
atherosclerotic disease process and risk of future recurrent cardiovascular events 
(chapter 4), and aid our understanding of pathobiological processes in vascular 
disease (chapter 5 and 6).  
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 FLUORIDE	 PET	 IMAGING	 CAN	 IDENTIFY	 HIGH	 RISK	 AND	 VULNERABLE	 CORONARY	7.1.1.
ATHEROSCLEROSIS	
We assessed the potential of 18F-fluoride positron emission tomography to become 
the first practical non-invasive method of identifying ruptured or high-risk coronary 
atherosclerotic plaque in patients with symptomatic stable and unstable coronary 
artery disease. The study provides a robust and cogent argument to support the 
contention that 18F-fluoride uptake identifies vulnerable and high-risk plaques in 
patients with stable and unstable coronary heart disease.  
 
18F-fluoride identified the culprit plaque in patients with acute ST-segment and non 
ST-segment elevation myocardial infarction. Histologic evaluation of patients with 
symptomatic carotid disease undergoing carotid endarterectomy confirmed 18F-
fluoride uptake at the site of plaque rupture and correlates with histologically 
confirmed areas of active calcification, apoptosis and necrosis. We extended our 
findings to patients with stable symptomatic coronary artery disease and compared 
18F-fluoride uptake with plaque characteristics defined by gray-scale and 
radiofrequency intravascular ultrasound, and computed tomography coronary 
angiography. 18F-fluoride uptake is associated with coronary plaques that have high-
risk features including positive remodeling, microcalcification and necrosis. 
 
18F-fluoride PET-CT holds major promise as a means of identifying high-risk and 
ruptured plaque, and potentially informing the future management and treatment of 
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patients with stable and unstable coronary artery disease. Further work is now needed 
to establish whether 18F- fluoride PET-CT will provide a clinically useful technique 
capable of improving risk stratification, monitoring disease progression, guiding 
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 MYOCARDIAL	INFARCTION	BEGETS	MYOCARDIAL	INFARCTION.		7.1.2.
Pre-clinical data suggest an acute inflammatory response following myocardial 
infarction accelerates systemic atherosclerosis (Dutta et al., 2012). Using combined 
positron emission and computed tomography (PET-CT), we investigated whether 
this phenomenon occurs in humans. 
 
Using an imaging cohort, we have demonstrated increased metabolic activity in 
remote aortic atherosclerotic plaques in patients with recent myocardial infarction 
that correlated with the degree of myocardial necrosis. Using the well-validated 
prospective GRACE registry (Fox KA at al., 2007), we showed that the patients with 
the largest infarcts had more than a four-fold increase in the risk of early recurrent 
myocardial infarction.  
 
We therefore provide clinical data to support the hypothesis that myocardial 
infarction exacerbates systemic atherosclerotic inflammation, destabilizes remote 
atheromatous plaque, and causes an increase in early recurrent atherothrombotic 
events. The presence and extent of myocardial infarction is associated with increased 
aortic atherosclerotic inflammation and early recurrent myocardial infarction 
supporting the hypothesis that myocardial infarction begets myocardial infarction in 
humans.  
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 IN-VIVO	ASSESSMENT	OF	INFLAMMATION	AND	CALCIFICATION	IN	ABDOMINAL	AORTIC	7.1.3.
ANEURYSMS	AND	ATHEROSCLEROSIS	
Despite recent advances, the pathobiological processes underlying aneurysmal 
expansion remain poorly understood. Using 18F –FDG as a marker of vascular 
inflammation, we sought to evaluate the extent of inflammation and calcification in 
patients with AAA and atherosclerosis. We hypothesized that both aortic 
inflammation and calcification would be greater in aneurysmal subjects than in 
matched controls with atherosclerosis.  
 
We showed that there was increased aortic and aneurysmal inflammation in patients 
with AAA as compared to patients with atherosclerosis.   Furthermore the aneurysms 
displayed higher degree of calcification as compared to atherosclerotic controls, 
suggesting an intense, destructive and trans-mural pathological process involving the 
aneurysmal aorta. 
 
We conclude that patients with AAA have enhanced active inflammation and 
calcification within the aortic aneurysmal wall.  As compared to atherosclerotic 
controls, patients with AAA have inflammation involving the entire aorta, supporting 
a hypothesis of global aortopathy in these subjects.  Prospective studies are now 
underway to evaluate whether the degree of aneurysmal inflammation is associated 
with rate of progression of aneurysmal size, growth and rupture. 
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 IN	VIVO	ASSESSMENT	OF	CELLULAR	AND	METABOLIC	INFLAMMATION	IN	AAA	7.1.4.
Using two contemporary molecular imaging techniques:  USPIO enhanced MRI and 
18F-FDG PET, we assessed cellular and metabolic inflammation in patients with 
aneurysmal disease. 
 
We showed that there was modest correlation between the 18-FDG and USPIO 
uptake, although there were importance differences in distribution of molecular 
agents, suggesting a differential detection of macrophage glycolytic and phagocytic 
activity respectively. In particular activity detected with these two techniques appears 
to be concentrated in different regions of the aneurysm: largely in the shoulder region 
with 18F- FDG and in the body of the aneurysm using USPIOs. 
 
Further studies are now underway to assess which modality will have the greatest 
predictive power to determine aneurysm growth and clinical outcome. 
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 FUTURE	DIRECTIONS	7.2.
The conclusions of this thesis raises questions on whether cardiovascular molecular 
imaging techniques will aid risk stratification, monitoring of disease progression, 
guide therapeutic interventions, and assess novel anti-atherosclerotic therapies in 
patients with stable and unstable atherosclerotic and aneurysmal diseases. 
 
A number of studies are now ongoing to evaluate:  
i) whether 18F- fluoride PET will aid in identifying patients with coronary disease at 
high risk of future cardiovascular events.  
ii) the role of 18F-fluoride in identifying patients who benefit from potent anti-
thrombotic therapy.  
iii) the role of molecular imaging in predicting AAA progression and rupture. 
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 PREDICTION	OF	RECURRENT	EVENTS	WITH	18F-FLUORIDE	TO	IDENTIFY	RUPTURED	7.2.1.
AND	 HIGH-RISK	 CORONARY	 ARTERY	 PLAQUES	 IN	 PATIENTS	 WITH	 MYOCARDIAL	
INFARCTION	(THE	PRE18FFIR	STUDY)	
In patients with myocardial infarction, will coronary 18F-fluoride uptake predict 
future disease progression and clinical outcomes? The PRE18FFIR study 
(ClinicalTrials.gov number: NCT02278211) is a multicentric outcome based study 
that aims to confirm our preliminary findings (chapter 3) in a larger cohort of 
patients with recent myocardial infarction. A total of 700 patients with recent 
myocardial infarction and multi-vessel coronary heart disease will be recruited from 
four UK centres. The primary end point is cardiovascular death or non-fatal recurrent 
myocardial infarction at two years. Additional sub-studies will assess the 
reproducibility, natural history and further in vivo plaque characterization techniques 
with 18F-fluoride PET (Appendix). 
 
These series of studies will evaluate the role of a surrogate non-invasive marker of 
high-risk vulnerable plaque in patients with acute myocardial infarction, over and 
above standard prognostic markers for future cardiovascular events.  
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 DUAL	 ANTIPLATELET	 THERAPY	 TO	 INHIBIT	 CORONARY	 ATHEROSCLEROSIS	 AND	7.2.2.
MYOCARDIAL	 INJURY	 IN	 PATIENTS	WITH	NECROTIC	HIGH-RISK	 CORONARY	PLAQUE	
DISEASE	(THE	DIAMOND	STUDY)	
Myocardial infarction is initiated by coronary atherosclerotic plaque rupture and 
subsequent thrombosis (Burke et al., 1997a, Burke et al., 2001, Falk et al., 2013a, 
Finn et al., 2010, Virmani et al., 2006b, Virmani et al., 2000a). Given the central role 
of thrombosis in progression of atherosclerosis, anti-thrombotic interventions have 
major potential to impact on the consequences and progression of atherosclerotic 
disease (Williams et al., 1997, Rioufol et al., 2004). With the advent of more potent 
platelet inhibition with newer P2Y12 receptor antagonist such as ticagrelor 
(Wallentin et al., 2009), there is now the opportunity to assess whether dual anti- 
platelet therapy can improve markers of myocardial injury and disease progression. 
 
Will aggressive secondary treatment with potent P2Y12 inhibitor ticagrelor reduce 
biomarkers of myocardial injury and inhibit disease progression in patients with 
stable coronary heart disease and evidence of high-risk coronary plaque defined by 
18F-fluoride uptake on positron emission tomography? The DIAMOND study is a 
randomised double blind placebo-controlled trial in patients with angiographically 
proven multivessel disease that will aim address this question. The primary end point 
of the study is to determine whether ticagrelor will influence the degree of 
myocardial injury in patients with stable coronary heart disease and high-risk 
coronary atheroma as compared to placebo (Appendix). 	
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 USPIO-ENHANCED	MRI	AND	18F-FLUORIDE	PET	CT	IN	AAA	7.2.3.
The imaging modalities used in our studies (chapters 5 and 6) provide important 
pathobiological insights into vascular inflammation and calcification. Specifically, 
the aneurysmal wall had more pronounced calcification as compared to other areas 
thereby suggesting an intense, destructive and transmural pathological process 
involving AAA (chapter 5). Furthermore, a distinct distribution of cellular vascular 
inflammation was noted with USPIO enhanced MRI in AAA patients (chapter 6). 
Whether uptake of these tracers using novel imaging techniques translates to 
important clinical events or progression of disease remains unknown.  We have 
designed two prospective observational studies to evaluate the role of these tracers in 
AAA.  
 
The MRI Abdominal Aortic Aneurysms to predict Rupture or Surgery (The MA3RS 
trial) is a prospective multicentre observational cohort study across 350 patients 
evaluating the role of USPIO enhanced MRI in patients with AAA. The study aims 
to assess whether mural uptake of USPIO provides incremental risk prediction in 
addition to standard risk markers such as aneurysm diameter, smoking and blood 
pressure. The primary end-point of the study will be the composite of aneurysm 
rupture or aortic aneurysm repair, with the rates of surgical repair and aneurysmal 
growth as secondary endpoints.   
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18F-Sodium Fluoride PET-CT in Abdominal Aortic Aneurysms  (The SoFIA3 
Study) is a prospective study to evaluate the role of 18F-fluoride PET-CT in patients 
with abdominal aortic aneurysms. The aim of the study is to explore whether 18F- 
fluoride uptake in the aortic wall correlates with aneurysm expansion.  
 
These studies will provide insights into how molecular imaging relate to both 
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 PERSPECTIVE	7.3.
The ability to identify high-risk vulnerable atherosclerotic plaques has been 
described as the ‘holy grail’ of clinical cardiology (Naghavi et al., 2003). Similarly, 
an ability to identify high-risk aneurysmal disease at highest risk of progression and 
rupture will transform the way we manage patients with aneurysmal disease 
(Shimizu et al., 2007). Novel molecular imaging techniques by targeting the 
biological processes driving disease progression have shown a great potential to 
fundamentally in identifying the diseases in vivo. The studies described in this thesis 
represent a major step in achieving the aim of identifying high-risk coronary and 
aneurysmal disease. Further studies are now needed to assess if these techniques can 
identify vulnerable patients at highest risk of having future coronary events and 
aneurysmal progression and rupture.  
 
The discovery of 18F-fluoride in assessment of coronary heart disease represents a 
new frontier in cardiovascular imaging (Thomas and Haraszti, 2014, van der Wall, 
2014, Mearns, 2014). It represents a step change in our scientific understanding of 
atherosclerosis, in particular the mechanisms underlying calcification (George, 
2012). We already know that CT coronary calcium scoring is one of the most 
powerful predictors for cardiovascular events (Budoff et al., 2007). However, unlike 
established macrocalcification visible on CT, 18F-fluoride uptake identifies actively 
calcifying atherosclerotic plaques that, similar to the caseating granulomata of 
tuberculosis, occurs as a healing response to intense inflammation either within the 
necrotic core or related to the plaque rupture event itself. Given that such inflamed 
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lesions are at the highest risk of rupture, there is therefore a clear rationale for why 
18F-fluoride uptake should predict myocardial infarction and why this technique also 
has important potential clinical applications.  
 
The discovery of fluoride PET as a marker of high-risk plaques has many potential 
and wide reaching applications. It might prove a useful tool to test the effectiveness 
of new treatments. In the clinical setting, this technique holds hope as a means of 
defining and selecting the best treatments for our patients with coronary heart 
disease. Future studies aimed to assess which patient group will derive the most 
benefit from this technique are now needed. If this is established then 18F-fluoride 
PET is likely to fundamentally alter the way we assess and treat coronary artery 
disease – moving us away from the current paradigm based on lesion severity and 
ischemia to one based on plaque metabolism and vulnerability.  
 
The concept of systemic inflammation following myocardial infarction provides 
fascinating insight into remote plaque inflammation and destabilization following 
myocardial infarction, thus explaining the clinical observations of early recurrent 
infarction and ischaemia in patients post myocardial infarction. This supports the 
concept of “myocardial infarction begets myocardial infarction”.  
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The studies on abdominal aortic aneurysms provide unique perspective on this 
common and deadly condition. The current clinical practice involves patients with 
AAA participating in national screening and surveillance programs designed to 
detect and monitor aneurysmal progression. However, the AAA expansion rates are 
non-linear and unpredictable, and more refined techniques are necessary to predict 
AAA growth and rupture. The molecular imaging studies on AAA provide novel 
insights into plaque biology of atherosclerosis and aneurysmal disease. This is the 
first step in adapting novel molecular imaging techniques in refining the approach 
taken to evaluate the progression of disease and identifying patients at risk of future 
adverse events.  
 
In undertaking these studies, we have developed robust methodologies to ultimately 
study large cohorts of patients with coronary atherosclerotic and aneurysmal disease. 
Prospective outcome based studies with these molecular imaging techniques are now 
required in a range of cardiovascular disease with an aim to identify the vulnerable 
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1 INTRODUCTION 
1.1 BACKGROUND 
1.1.1 Pathogenesis of Coronary Artery Disease 
Coronary plaque rupture of mildly stenotic coronary atherosclerosis is the 
commonest cause of acute coronary thrombosis, myocardial infarction and 
death [Davies, 2000]. It is closely linked to hypercholesterolaemia and has a 
dominant inflammatory phenotype. Classical histological features include a 
lipid-rich pool, thin fibrous cap, paucity of vascular smooth muscle cells and 
an intense inflammatory cell infiltrate [Davies, 2000]. 
Plaque rupture does not invariably lead to thrombotic occlusion of the 
coronary artery. Coronary plaque events are very common and the majority of 
such events do not cause coronary occlusion [Mann & Davies, 1999; Davies, 
2000]. Here, plaque rupture and thrombosis is organised, remodelled and 
incorporated into the atherosclerotic plaque itself. Indeed, 80% of plaques that 
cause over 50% diameter stenosis have evidence of old healed plaque 
rupture with incorporation of thrombus into the atheroma [Mann & Davies, 
1999]. This process contributes to the progression of coronary atherosclerosis 
and explains the first appearance, or step change in severity, of angina 
pectoris. 
Coronary plaque events are often not isolated. Plaque rupture can occur 
throughout the body and is not confined to a single vascular bed. Moreover, in 
patients with acute coronary syndromes, it is common for multiple plaque 
events to occur simultaneously and beyond the culprit lesion itself. Post-
mortem studies indicate that, on average, 2.4 coronary thrombotic events 
occur in each patient who presents with fatal coronary heart disease [Mann & 
Davies, 1999; Davies, 2000]. This suggests that systemic and generalised 
mechanisms and mediators play an important role in addition to local factors 
within the coronary artery wall. 
In summary, coronary atherosclerosis is characterised by multiple and 
recurrent plaque rupture events that are often sub-clinical and cause step-
wise growth of the plaque as it heals and remodels. Patients undergoing 
repeated plaque rupture events are likely to be at increased risk of myocardial 
infarction. 
1.1.2 Non-invasive Imaging of the Vulnerable Plaque 
In the study of coronary artery disease, many researchers have searched for 
a non-invasive imaging biomarker of plaque vulnerability and rupture. For the 
first time, we have demonstrated that 18F-fluoride positron emission 
tomography can detect high-risk coronary plaque in patients with stable 
coronary artery disease [Joshi et al, 2014].  
In the vasculature, 18F-fluoride acts as a marker of novel calcification activity 
[Dweck et al, 2012a; Dweck et al, 2013]. Similar to other conditions, 
calcification in coronary atheroma occurs as a healing response to intense 
necrotic inflammation, making 18F-fluoride a useful marker of high-risk 
atherosclerotic plaque. We have previously demonstrated increased uptake of 
PRE18FFIR 
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this tracer in the coronary vasculature localizing to individual coronary lesions 
and identifying patients with increased cardiovascular risk factor profiles 
[Dweck et al, 2012b]. More recently we have conducted a prospective study of 
40 patients with myocardial infarction in whom 18F-fluoride localised to the 
culprit plaque (Figure 1) in over 90% of patients [Joshi et al, 2014]. This 
finding was confirmed in 12 patients with a recent stroke undergoing carotid 
endartectomy where 18F-fluoride uptake was observed at the site of plaque 
rupture in 100% of patients and this uptake correlated with increased 
calcification activity and areas of necrosis on histology. Finally we studied 40 
patients with stable coronary artery disease. Increased uptake was observed 
in 45% of these patients and this again localized to individual coronary 
plaques (Figure 2). Interestingly these lesions were associated with multiple 
high-risk markers on radiofrequency and gray-scale intravascular ultrasound 
(necrotic core, positive remodeling and microcalcification). Importantly, 
plasma high-sensitivity troponin concentrations were much higher in patients 
with 18F-fluoride positive plaques compared to patients without evidence of 
uptake (7.89±9.34 versus 3.10±1.89 ng/L, P=0·047). The latter observation is 
of particular interest as it supports the hypothesis that 18F-fluoride is detecting 
subclinical plaque rupture in those with stable disease, similar to its 
mechanism of activity following myocardial infarction. Moreover plasma 
troponin concentrations measured by a high-sensitivity assay also predict an 
adverse outcome amongst patients with stable coronary artery disease 
[Omland et al, 2013] and provide a useful surrogate biomarker of therapeutic 
efficacy. 
1.1.3 Recurrent Events Following Acute Myocardial Infarction 
Myocardial infarction and stroke are two of the commonest causes of 
hospitalisation, major disability and death in the United Kingdom. However, 
despite many billions of pounds being spent each year on their treatment, 
recurrent cardiovascular events are common. Indeed, within one year of acute 
myocardial infarction, one in five patients have recurrent events despite 
optimal medical therapy [Mills et al, 2011], and one half of these recurrent 
events occur at sites not felt to have caused their initial presentation [Stone et 
al, 2011]. 
Coronary calcification is pathognomonic of atherosclerosis and recent studies 
in Egyptian mummies have demonstrated that it has been present in humans 
for millennia [Thompson et al, 2013]. Despite this, the mechanisms of its 
formation have yet to be precisely defined. Furthermore, the nature and extent 
of vascular calcification may vary according to the pathophysiological setting 
and underlying disease process. Given that it is independently associated with 
a 3 to 4-fold increased risk of death [Detrano et al, 2008], a better 
understanding of the pathophysiology and mechanisms of vascular 
calcification will be critical to our understanding of cardiovascular disease. 
This is particularly important if we are to determine its role in the initiation, 
progression and consequences of atherosclerosis. This may provide novel 
insights into the pathophysiology of atherosclerosis as well as identify new 
and as yet unexplored pathways that could be the target for future life-saving 
therapeutic interventions. For example, although highly successful in treating 
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cardiovascular disease, statins only prevent 25% of recurrent cardiovascular 
events, and have no effect on the progression of vascular calcification. The 
majority of recurrent events therefore remain unchecked and we urgently 
need more effective and comprehensive interventions. 
Non-invasive imaging techniques to detect early active vascular calcification in 
atherosclerosis have the potential to identify high-risk and ruptured 
atherosclerotic plaques, thereby providing a major novel biomarker of plaque 
vulnerability. This will provide a platform to explore and follow the in vivo 
pathogenesis of atherosclerosis, as well as assess novel anti-atherosclerotic 
interventions. This will also facilitate the more accurate identification of culprit 
atherosclerotic plaque in the precipitation of myocardial infarction and stroke, 
allowing better delivery and targeting of our therapies at both the lesion and 
patient level. This approach would potentially be a major advance for the 
treatment of unstable atherosclerotic disease. 
1.1.4 Stratified Medicine and Intervention 
Current treatment decisions for patients with acute myocardial infarction are 
based on a large number of major multi-centre international randomised 
controlled trials. These trials demonstrate major secondary preventative 
benefits with the use of anti-platelet therapy, statins, angiotensin-converting 
enzyme inhibition and beta-blockade following acute myocardial infarction. 
However, all patients are treated with the same combination of medications 
with little attempt to risk stratify patients and select those who have the most 
to benefit from such therapies.  
Emergency or immediate coronary angiography with a view to coronary 
revascularisation is now recommended in the vast majority of patients 
presenting with acute myocardial infarction. Indeed, 80% of patients admitted 
with non-ST segment elevation myocardial infarction in the United Kingdom 
undergo coronary angiography with a view to coronary revascularisation 
during their index hospital admission [MINAP, 2013]. However, coronary 
revascularisation following myocardial infarction focuses on treating flow-
limiting stenoses (≥70% luminal stenosis) with coronary revascularisation 
strategies such as percutaneous coronary intervention and coronary artery 
bypass graft surgery. However, we know that the majority of plaque rupture 
events occur on non-flow limiting stenoses (see section 1.1), and this 
questions whether we are over treating a large number of patients and indeed 
coronary artery lesions without actually tackling the future potential culprit 
lesions. Using 18F-fluoride, we have “the opportunity to better assess the 
commonly accepted belief that most myocardial infarctions are caused by 
rupture of previously non-obstructive plaques” [Thomas & Haraszti, 2014]. 
 
1.2 RESEARCH HYPOTHESIS 
The central hypothesis of the PRE18FFIR study is that coronary 18F-fluoride 
uptake can identify high-risk and ruptured atherosclerotic plaque in patients 
with recent myocardial infarction. This has the potential to assist in the 
diagnosis, risk stratification, investigation, management and treatment of 
patients with acute myocardial infarction. 
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1.3 RATIONALE FOR THE STUDY  
We have investigated and described the use of 18F-fluoride positron emission 
tomography and computed tomography coronary angiography to identify high-
risk or ruptured coronary atherosclerotic plaque [Joshi et al. Lancet 2014]. 
This is the first non-invasive imaging technique to achieve this and it has been 
heralded as a major advance with wide reaching ramifications for the 
diagnosis, investigation, and treatment of coronary artery disease [Thomas & 
Haraszti, 2014]. Importantly, it may provide the basis of a new paradigm in the 
treatment and management of patients with myocardial infarction by tailoring 
therapy to the presence and extent of plaque inflammation and rupture rather 
than the anatomical severity of luminal stenoses. More targeted and focused 
investigations and interventions have the potential to shorten hospital stay, to 
avoid the indiscriminate application of expensive therapies, and to focus and 
to maximize the impact of our current successful therapies to reduce recurrent 
major adverse cardiac events. 
The study rationale is therefore to confirm our preliminary findings in a broad 
range of patients across different centres throughout the United Kingdom. 
Specifically, the study is intended to confirm whether coronary 18F-fluoride 
uptake identifies high-risk or ruptured coronary atherosclerotic plaque, and to 
determine if coronary 18F-fluoride uptake is predictive of disease progression 
and clinical outcome.  We have also planned two sub-studies to assess the 
reproducibility and natural history of 18F-fluoride uptake and an additional 
sub-study to provide correlation with in vivo plaque characterization tests.  
These sub-studies are described in more detail in separate protocols.  
2 STUDY OBJECTIVES 
2.1 OBJECTIVES 
2.1.1 Primary Objective 
• To determine whether coronary 18F-fluoride uptake is associated with 
recurrent coronary thrombotic events in patients with multi-vessel 
coronary artery disease and recent myocardial infarction. 
2.1.2 Secondary Objectives 
In patients with multi-vessel coronary artery disease and recent myocardial 
infarction, to determine whether coronary 18F-fluoride uptake: 
• Is associated with secondary clinical outcomes including all-cause 
death, recurrent major adverse cardiac events defined as cardiac 
death, recurrent myocardial infarction, and rehospitalization for acute 
coronary syndrome, unscheduled coronary revascularization, and 
healthcare resource utilization. 
• Can identify areas of high-risk or ruptured atherosclerotic plaque in a 
large broad population of patients across multiple sites. 
• Can predict the territory of subsequent myocardial reinfarction. 
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• Can identify areas of future progression of coronary atherosclerotic 
plaque (volume and calcification) 
• Is sufficiently repeatable and reproducible for clinical application. 
• Changes with time and establish what are the determinants of 
increasing or decreasing activity. 
2.1.3 Safety Objective 
• To determine the radiation exposure and effective dose associated with 
18F-fluoride positron emission tomography and computed tomography 
coronary angiography 
2.1.4 Exploratory Objectives 
We will initially explore whether the identification of 18F-fluoride positive 
coronary atherosclerotic plaque has the potential to guide patient 
management. Here positron emission tomography and computed tomography 
coronary angiography results will be compared with the subsequent 
application of coronary revascularization and optimal medical therapy. 
Importantly, we will also explore the feasibility of using the identification of 
18F-fluoride positive coronary atherosclerotic plaque to guide coronary 
revascularisation and intervention. For example, how many stenotic but 18F-
fluoride negative lesions undergo intracoronary stenting, and how many 18F-
fluoride positive lesions are left untreated and are responsible for recurrent 
cardiovascular events?  
 
2.2 ENDPOINTS 
2.2.1 Primary Endpoints 
• Cardiac death or non-fatal recurrent myocardial infarction at 2 years. 
2.2.2 Secondary Endpoints 
These will include: 
• All-cause death 
• Recurrent major adverse cardiac events defined as cardiac death, 
recurrent myocardial infarction, and rehospitalization for acute coronary 
syndrome and unscheduled coronary revascularization,  
• Healthcare resource utilization of patients with and without focal 18F-
NaF uptake in coronary plaques unrelated to index myocardial 
infarction 
• Each individual component end-point of the composite end-point of 
major adverse cardiac event. 
• 18F-NaF uptake localisation to culprit plaque causing the index 
myocardial infarction 
• Territory of subsequent myocardial reinfarction. 
• Coronary artery plaque progression by computed tomography coronary 
angiography. Plaque volume, composition and calcification. 
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3 STUDY DESIGN 
This is a multicentre observational cohort study of an investigational medical 
product with longitudinal follow-up for disease progression and clinical 
outcomes. 
3.1 RATIONALE FOR STUDY DESIGN 
We wish to confirm our preliminary single centre findings in a larger 
multicentre study of patients with recent myocardial infarction. We therefore 
will undertake an observational study in patients with recent myocardial 
infarction who will undergo coronary 18F-fluoride positron emission 
tomography and computed tomography coronary angiography immediately 
following hospitalisation. However at present, we have no data to determine 
whether coronary 18F-fluoride can predict disease progression or clinical 
outcome: a key determinant of its potential clinical utility. The study will 
therefore have a longitudinal cohort follow-up component where participants 
will undergo clinical follow-up of at least 2 years duration when repeat 
computed tomography coronary angiography will be performed.  
Before conducting a randomised controlled trial using coronary 18F-fluoride 
uptake to stratify and guide treatment, it is imperative that we confirm the 
diagnostic and prognostic importance of coronary 18F-fluoride uptake within a 
large multicentre observational cohort study. 
4  STUDY POPULATION 
4.1      Number of Participants 
We will recruit 700 patients with recent myocardial infarction and multi-vessel 
coronary heart disease. 
4.2        Inclusion Criteria 
For inclusion in the study subjects will fulfil the following criteria: 
1. Patients aged ≥50 years with recent (<21 days) type 1 myocardial 
infarction and angiographically proven multi-vessel coronary artery 
disease defined as at least two major epicardial vessels with any 
combination of either (a) >50% luminal stenosis, or (b) previous 
revascularization (percutaneous coronary intervention or coronary 
artery bypass graft surgery). 
2. Provision of informed consent prior to any study specific procedures 
4.3       Exclusion Criteria 
Subjects will not enter the study if any of the following exclusion criteria are 
fulfilled: 
 
1. Inability or unwilling to give informed consent 
2. Women who are pregnant, breastfeeding or of child-bearing potential 
(women who have experienced menarche, are pre-menopausal and 
have not been sterilised) will not be enrolled into the trial 
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3. Major intercurrent illness with life expectancy <2 year 
4. Renal dysfunction (estimated glomerular filtration rate ≤30 mL/min/1.73 
m2) 
5. Contraindication to iodinated contrast agent, positron emission 
tomography or computed tomography 
6. Permanent or persistent atrial fibrillation 
7. Previous screening as part of the trial  
4.4       Co-enrolment 
Co-enrolment with a non-CTIMP or another CTIMP clinical trial may be 
allowed provided this is not expected to place an undue burden upon 
participants and their families, and will not compromise the primary end-point 
of either trial.  Consideration will also be given to the total exposure to ionising 
radiation should additional studies require further exposure. 
Co-enrolment with another CTIMP will only be permitted with agreement of 
the Sponsors, Trial Steering Committees, and Chief Investigators of both 
studies. 
 
5   PARTICIPANT SELECTION AND ENROLMENT 
5.1 IDENTIFYING PARTICIPANTS 
Patients presenting with myocardial infarction will be approached for study 
recruitment by their usual care team. This will normally be undertaken during 
their index hospital admission. Patients will be provided with a Patient 
Information Sheet and given an opportunity to ask questions about 
participation in the trial.  
5.2 CONSENTING PARTICIPANTS 
After a minimum of 24 hours, patients willing to participate in the study will be 
asked to consent and undergo screening. Written informed consent will be 
obtained by a suitably qualified member of the research team before any 
study related procedures are performed. 
5.3 SCREENING FOR ELIGIBILITY 
Screening for eligibility based on pre-existing clinical investigations (i.e. 
standard clinical biochemical and haematological investigations and coronary 
angiographic findings) will be performed by a member of the research team 
and will only take place once written consent has been obtained.  Once a 
patient has agreed to participate and is deemed eligible they will be invited to 
attend the baseline 18F-fluoride positron emission tomography and computed 
tomography coronary angiogram scan. 
5.4 INELIGIBLE AND NON-RECRUITED PARTICIPANTS 
Ineligible and non-recruited patients will receive standard medical care. An 
anonymised log will be kept of patients who were screened for the study and 
subsequently found to be ineligible or not recruited.   
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5.5 PROCEDURES FOR HANDLING PARTICIPANTS INCORRECTLY 
ENROLLED 
Patients identified as being incorrectly enrolled prior to their initial CT-PET 
scan will be excluded from the primary study analysis and replaced. Patients 
who are identified as incorrectly enrolled but have undergone their initial CT-
PET will be included in the primary analysis and we will endeavour to continue 
to collect study data without involving the participant in any further study 
related procedures. 
5.6 WITHDRAWAL OF STUDY PARTICIPANTS 
Participants are free to withdraw from the study at any point or a participant 
can be withdrawn by the investigator. If withdrawal occurs, the primary reason 
for withdrawal will be documented in the participant’s case record form, if 
possible. The patient will have the option of withdrawal from (i) all or specific 
further study procedures but continued collection of routine clinical and safety 
data, (ii) all further aspects of the study with no further collection of any data, 
and (iii) all aspects of the trial with removal of all previously collected data.   
6 INVESTIGATIONAL MEDICINAL PRODUCT  
6.1 STUDY DRUG 
Investigational 
product 
Dosage form and 
strength 
Manufacturer 
[18F] Sodium Fluoride 250 MBq See 6.1.2 
6.1.1 Study Drug Identification 
[18F] Sodium Fluoride (18F-NaF) sterile solution for injection 
 
6.1.2 Study Drug Manufacturers 
Manufacturing will be performed by: 
 
 Clinical Research Imaging Centre (CRIC) 
 University of Edinburgh 
 47 Little France Crescent  
 Edinburgh 
 EH16 4TJ 
 Licence: MIA (IMP) 1384  
 
PETNET Solutions 
Lesley Harrison Building 
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Licence: MIA (IMP) 21750 
 
6.1.3 Marketing Authorisation Holder 
There is currently no Marketing authorisation for [18F] Sodium Fluoride (18F-
NaF) 
6.1.4 Labelling and Packaging 
Labelling and packaging of the [18F] Sodium Fluoride (18F-NaF) will be 
carried out by: 
 
 Clinical Research Imaging Centre (CRIC) 
 University of Edinburgh 
 47 Little France Crescent  
 Edinburgh 
 EH16 4TJ 
 Licence: MIA (IMP) 1384  
 
PETNET Solutions 
Lesley Harrison Building 




Licence: MIA (IMP) 21750 
 
6.2 DOSING REGIME 
Single intravenous injection 
6.3 OVERDOSE 
Given that the 18F-fluoride will be administered as a single intravenous 
injection by trained personnel, accidental or unintentional overdose is not 
anticipated to occur. Moreover the doses and quantities of sodium fluoride are 
very low (<430 µg) and >1,000-fold below the dose (3-5 mg/kg) where toxicity 
symptoms may appear and >1,000,000-fold below the anticipated lethal dose 
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(5-10 g). However, if an overdose of sodium fluoride were to occur then 
radiation exposure and sodium fluoride toxicity will be the primary 
considerations.  Excretion should be accelerated in order to reduce the dose 
taken by the patient.  For this reason, forced diuresis (furosemide and fluid) 
should be applied to the patient. 
 
For radiation overexposure, the patient will be contained within a safe 
environment to allow radioactive decay to occur to acceptable levels. 
Monitoring for the consequences of excess radiation exposure (such as bone 
marrow toxicity) will be undertaken as required. Symptoms of sodium fluoride 
toxicity include abdominal pain, abnormal taste (salty or soapy taste), 
convulsions, diarrhoea, drooling, headache, arrhythmia, nausea, hypopnea, 
bradycardia, tremors, vomiting, and weakness. For an intravenous overdose, 
there are no specific antidotes and supportive measures will be undertaken as 
clinically indicated, such as hydration and anti-emetic therapy. Consideration 
will be given to intravenous calcium supplementation to compete with the 
excess fluoride ions especially in the presence of problematic arrhythmias. 
6.4 OTHER MEDICATIONS 
6.4.1 Non-Investigational Medicinal Products 
At the time of positron emission tomography and computed tomography 
coronary angiography, patients may receive oral and/or intravenous beta-
blockade, such as metoprolol 5-100mg, to slow the heart rate to below 65 
beats per minute to maximise image quality and reduce radiation exposure. 
Glyceryl trintrate spray or tablet will be administered sublingually (200-400 µg) 
to induce coronary vasodilatation to enhance image quality of the coronary 
angiogram. 
6.4.2 Permitted Medications 
As per the standard of care for treatment of myocardial infarction, unless 
contraindicated, all patients will be encouraged to be maintained on aspirin 75 
mg once daily and maximally tolerated doses of statin, angiotensin-converting 
enzyme inhibition and beta-blocker therapy as clinically indicated and in 
accordance with local guidelines. Patients will be encouraged to be 
maintained on a P2Y12 receptor antagonist for at least 1 year. 
 
There are no study specific prohibited medications. 
7 STUDY ASSESSMENTS 
Trial participants will undergo 3 study visits (Table 1). During their initial 
hospital admission, medical notes will be screened prior to consent and 
potentially eligible patients will be approached to take part in the study. Those 
patients who are potentially eligible and wish to participate will be consented 
and routine clinical data will be collected following consent (screening visit). 
The participants will attend a second visit where they will have a baseline 18F-
fluoride positron emission tomography, computed tomography (CT) calcium 
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scan and CT coronary angiography (CTCA) scan performed (baseline visit) 
before attending for a final clinical review and 2-year computed tomography 
calcium scan and CT coronary angiogram (2-year visit) when further routine 
clinical data will be collected. In order to assess for clinical cardiac events and 
AEs/SAEs participants will contacted by telephone 1 year after their baseline 
PET and CTCA scans were performed.  Following the 2-year visit, data on 
study outcomes will continue to be collected until study completion (last 
patient, last visit) via periodic review of the electronic health record and 
additional annual telephone review as required.  This will ensure that late 
study outcomes can be evaluated over the duration of the study.  In order to 
detect long-term outcome data we will continue to monitor clinical events via 
annual review of patient electronic clinical records for a period of 5 years 
following the completion of the participant’s final study visit. 
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7.1 SAFETY ASSESSMENTS 
The dose-length product and effective radiation dose will be recorded for all 
study scans: baseline 18F-fluoride positron emission tomography and 
computed tomography coronary angiography scan, and the final 2-year 
computed tomography coronary angiogram. 
7.2 STUDY ASSESSMENTS 
This is a prospective multi-centre observational cohort study. Subjects will 
attend for clinical assessments at the screening visit (review of clinical records 
and confirmation of eligibility), baseline visit (18F-fluoride positron emission 
tomography, computed tomography calcium scan and CT coronary 
angiography scan), and at 2 years (repeat computed tomography calcium 
scan and CT coronary angiogram). Clinical outcome data will be obtained 
from routinely collected clinical data in the electronic health record and, where 
appropriate, annual telephone calls to the patients or General Practitioners. 
7.2.1 Screening Assessment 
Screening visit assessments will include clinical history, review of patient 
records to confirm study eligibility and record clinical profile, standard clinical 
biochemical and haematological variables, 12-lead electrocardiogram, the 
Global Registry of Acute Coronary Events (GRACE) score and the invasive 
coronary angiogram findings and percutaneous coronary interventional 
procedures.  
7.2.2 Baseline Assessment 
Baseline visit assessments will include 18F-fluoride positron emission 
tomography, computed tomography calcium scan and CT coronary 
angiography scan. AE/SAE’s will also be recorded. 
7.2.3 Follow Up Assessments 
Participants will be contacted by telephone at 12 months and periodically 
thereafter until the last recruited patient has completed their 2 year follow-up 
visit. The purpose of the telephone interview is to review any clinical 
cardiovascular events or AE/SAE that may have occurred in the intervening 
period.  They will attend for a final study visit 2 years after their initial CT-PET 
scans. At the final study visit, patients will undergo a repeat computed 
tomography calcium scan and CT coronary angiogram. On-going periodic 
review of the electronic health records will continue throughout the study and 
for a period of 5 years after study completion in order to assess long-term 
outcomes.  
7.2.4 Positron Emission and Computed Tomography Coronary 
Angiography 
Patients may receive oral and/or intravenous beta-blockade, such as 
metoprolol 5-100 mg, to slow the heart rate to below 65 beats per minute to 
maximise image quality and reduce radiation exposure. Glyceryl trintrate 
spray or tablet will be administered sublingually (200-400 µg) to induce 
coronary vasodilatation to enhance image quality of the coronary angiogram. 
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All patients will undergo dual cardiac and respiratory-gated positron emission 
and computed tomography imaging of the coronary arteries. Study subjects 
will be administered a target dose of 250 MBq 18F-fluoride intravenously and 
subsequently rested in a quiet environment for 60 min. An attenuation 
correction computed tomography scan will then be performed, followed by 
positron emission tomography imaging of the thorax in list-mode for 30 min.  
Computed tomography coronary calcium scan and angiography will be 
undertaken in the same visit as the 18F-fluoride scan and again at 2 years. 
With the patient lying still on the scanner after acquisition of the positron 
emission tomography scan, an electrocardiogram-gated breath-hold 
computed tomography scan of the coronary arteries will be performed. A 
bolus of contrast (BMI adjusted) will be injected intravenously after 
determining the appropriate trigger delay with a test bolus.  Because the use 
of contrast is required for the CT scan study participants may require pre-
procedural check of eGFR according to local study site imaging protocols. 
The positron emission tomography scans will be reconstructed in multiple 
phases of the cardiac cycle, with the diastolic phase (50-75%) used for 
analysis. Additional reconstructions will be undertaken as necessary. Positron 
emission tomography scans will correct for cardiac motion correction using 
electrocardiogram-gated images. 
Further technical details of the specific CT-PET scanning procedures and how 
inter-site imaging standardisation will be achieved will be described in a 
separate scanning document.  
 
7.3 SUB-STUDY ASSESSMENTS 
There will be three main sub-studies in relation to coronary 18F-fluoride 
uptake that will assess (i) short-term reproducibility, (ii) time course, and (iii) in 
vivo plaque characterisation. These will be performed only at the lead centre 
in Edinburgh and are described in more detail in separate protocols. Any 
participant will only be involved in one sub-study that requires a repeat 18F-
fluoride positron emission tomography and computed tomography coronary 
angiogram in addition to the main PRE18FFIR study protocol. 
7.3.1 Short-term Reproducibility (PRE18FFIR-REPRO) 
Following the baseline assessments, a repeat 18F-fluoride positron emission 
tomography and computed tomography coronary angiogram will be performed 
within 21 days of the initial scan. This will allow the assessment of scan-
rescan reproducibility. This will be performed in 20 patients. 
7.3.2 Time Course (PRE18FFIR-TIME) 
Following the baseline assessments, a repeat 18F-fluoride positron emission 
tomography and computed tomography coronary angiogram will be performed 
within 6±2, 12±2, 26±2 and 52±2 weeks of the initial scan. This will allow a 
description of the natural history of 18F-fluoride uptake and positivity. This will 
be performed in four cohorts of 20 patients each. Any single patient will only 
undergo a maximum of two 18F-fluoride positron emission tomography and 
PRE18FFIR 
Version 1.0, 16th March 2015 
 
Page 23 of 41 
three computed tomography coronary angiography scans.  
7.3.3 In Vivo Plaque Characterisation (PRE18FFIR-IMAGE) 
In 80 patients, intravascular ultrasound, near infra-red spectroscopy and 
optical coherence tomography will be performed on the culprit and control 
non-culprit lesions at the time of invasive coronary angiography. This will 
permit detailed characterisation of plaque composition and structure with 
which to compare the 18F-fluoride positron emission tomography and 
computed tomography coronary angiography scans. 
8 DATA COLLECTION 
All trial data will be recorded onto paper case record forms (CRF) by a 
member of the research team and then entered an electronic database 
designed and developed by the Edinburgh Clinical Trials Unit.  
9 STATISTICS AND DATA ANALYSIS 
9.1 SAMPLE SIZE CALCULATION 
This is based on an event rate of 24% cardiac death or recurrent myocardial 
infarction at 2 years. This is a conservative estimate since in our recent 
studies [Mills et al, 2011; Mills et al, 2012], we observed a 1-year event rate of 
20% for death or recurrent myocardial infarction in consecutive unselected 
patients hospitalised with myocardial infarction. In our preliminary data [Joshi 
et al, 2014], 25-45% of patients had untreated 18F-fluoride positive plaques. 
Based on the assumption that one third of patients will have multiple 18F-
fluoride positive plaques, and that the rate of death or recurrent myocardial 
infarction is 50% greater in these patients (30% versus 20% 2-year event 
rate), we will need 700 subjects at 80% power and two-sided P<0.05.  
This power calculation is conservative as the analysis will be based on 
survival (‘time to event’) analysis techniques rather than a simple comparison 
of proportions. 
9.2 PROPOSED ANALYSES 
9.2.1 Description of Analysis Sets 
The primary analyses will be based on all patients who have undergone the 
initial CT-PET scan.  
9.2.2 Methods of Statistical Analysis 
The primary analysis will be performed by calculating Kaplan-Meier estimates 
of the ‘survival’ curves for the time to first event (cardiac death or recurrent 
myocardial infarction) during follow up, and comparing these estimates for 
patients with and without non-culprit 18F-fluoride positive plaques, using a 
log-rank test. The results will be expressed as the estimated hazard ratio with 
the corresponding 95% confidence interval and p value. Patients who die 
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during follow-up whose deaths are not classified as cardiac deaths will be 
censored in the above analysis at the time of death.  
Since 18F-fluoride uptake is a continuous measure, a potentially more 
sensitive analysis will explore the relationship between uptake and the risk of 
suffering an event (cardiac death or recurrent myocardial infarction). This will 
be performed using the Cox proportional hazards regression model, with 
(transformed) 18F-fluoride uptake as the only covariate. A range of potential 
transformations of the 18F-fluoride update will be explored, including fractional 
polynomials, to find an optimal fit to the data. 
Once an appropriate transformation for the 18F-fluoride uptake has been 
identified (as above), the Global Registry of Acute Coronary Events (GRACE) 
score will be added into the Cox proportional hazards model, to assess the 
incremental prognostic value of 18F-fluoride over and above conventional 
clinical risk markers. 
10 ADVERSE EVENTS 
The Investigator is responsible for the detection and documentation of events 
meeting the criteria and definitions detailed below.   
Full details of contraindications and side effects that have been reported 
following administration of the IMP are described in the study Investigator’s 
Brochure. 
Participants will be instructed to contact their Investigator at any time after 
consenting to join the trial if any symptoms develop.  All adverse events (AE) 
as defined in section 10.2 that occur after joining the trial must be reported in 
detail in the Case Report Form (CRF) or AE form.  In the case of an AE, the 
Investigator should initiate the appropriate treatment according to their 
medical judgment.   
10.1 DEFINITIONS 
An adverse event (AE) is any untoward medical occurrence in a clinical trial 
participant which does not necessarily have a causal relationship with an 
investigational medicinal product (IMP). 
An adverse reaction (AR) is any untoward and unintended response to an 
IMP which is related to any dose administered to that participant.  
A serious adverse event (SAE), serious adverse reaction (SAR). Any AE 
or AR that at any dose: 
• results in death of the clinical trial participant 
• is life threatening* 
• requires in-patient hospitalisation** or prolongation of existing 
hospitalisation 
• results in persistent or significant disability or incapacity 
• consists of a congenital anomaly or birth defect 
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• results in any other significant medical event not meeting the criteria 
above 
 
*Life-threatening in the definition of an SAE or SAR refers to an event where 
the participant was at risk of death at the time of the event. It does not refer to 
an event which hypothetically might have caused death if it were more severe. 
 
**Any hospitalisation that was planned prior to randomisation will not meet 
SAE criteria. Any hospitalisation that is planned post randomisation will meet 
the SAE criteria. 
 
A suspected unexpected serious adverse reaction (SUSAR) is any AR 
that is classified as serious and is suspected to be caused by the IMP, that it 
is not consistent with the information about the IMP in the Investigator’s 
Brochure. 
10.2 IDENTIFYING AEs AND SAEs 
There will be a 48 hour time window to collect and record all AEs and SAEs 
which occur as a result of the 18F-fluoride intravenous injection and which 
occur during the 18F-fluoride PET and CT angiogram scanning visits including 
administration of the beta blockade, glyceryl trinitrate, contrast agent and 
radiation exposure. Patients attending the scanning visits will be asked to 
contact the research team if they experience any untoward effects within 48 
hours of the scans. Only AEs/SAEs experienced during the scan and self-
reported within 48 hours of the PET and /or CT scan will be recorded in the 
AE log and SAE form, respectively. Any AEs or SAEs out with the above 
definitions will not be recorded during the study although data on 
hospitalisations and deaths will be collected for long-term outcomes. 
All other AEs and SAEs will be recorded from 48 hours until the last study visit 
in the medical notes. 
Participants will be asked about the occurrence of AEs/SAEs at each 
scanning visit during the study.  Open-ended and non-leading verbal 
questioning of the participant will be used to enquire about AE/SAE 
occurrence.  Participants will also be asked if they have been admitted to 
hospital, had any accidents, used any new medicines or changed concomitant 
medication regimens.  If there is any doubt as to whether a clinical 
observation is an AE, the event will be recorded. 
AEs and SAEs may also be identified via information from support 
departments e.g. laboratories.  
10.3 RECORDING AEs AND SAEs 
 
Any pre-existing medical conditions (i.e. existed prior to informed consent) are 
not adverse events but should be recorded as medical history in the CRF. A 
pre-existing medical condition should only be recorded as an adverse event if 
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the condition worsens during the study. The event term should clearly 
document that the condition has worsened from baseline. 
 
When an AE/SAE occurs, it is the responsibility of the Investigator to review 
all documentation (e.g. hospital notes, laboratory and diagnostic reports) 
related to the event.  The Investigator will then record all relevant information 
in the CRF and on the SAE form (if the AE meets the criteria of serious). 
Information to be collected includes dose, type of event, onset date, 
Investigator assessment of severity and causality, date of resolution as well as 
treatment required, investigations needed and outcome.   
10.4 ASSESSMENT OF AEs AND SAEs 
Seriousness, causality, severity and expectedness will be assessed by the 
Principal Investigator. Cases that are considered serious, possibly, probably 
or definitely related to IMP and unexpected (i.e. SUSARs) will be unblinded.  
The Investigator is responsible for assessing each AE.   
The Chief Investigator may not downgrade an event that has been assessed 
by an Investigator as an SAE or SUSAR, but can upgrade an AE to an SAE, 
SAR or SUSAR if appropriate. 
10.4.1 Assessment of Seriousness 
The Investigator will make an assessment of seriousness as defined in 
Section 10.1. 
10.4.2 Assessment of Causality 
The Investigator will make an assessment of whether the AE/SAE is likely to 
be related to the IMP according to the definitions below.   
• Unrelated: where an event is not considered to be related to the IMP. 
• Possibly Related: The nature of the event, the underlying medical 
condition, concomitant medication or temporal relationship make it 
possible that the AE has a causal relationship to the study drug. The 
assessment of causality will be made against the reference safety 
information found in the Investigator’s Brochure.  
Where non Investigational Medicinal Products (NIMPs) e.g. rescue/escape 
drugs are given:  if the AE is considered to be related to an interaction 
between the IMP and the NIMP, or where the AE might be linked to either the 
IMP or the NIMP but cannot be clearly attributed to either one of these, the 
event will be considered as an AR. Alternative causes such as natural history 
of the underlying disease, other risk factors and the temporal relationship of 
the event to the treatment should be considered and investigated. The blind 
should not be broken for the purpose of making this assessment.  
10.4.3 Assessment of Expectedness 
If an event is judged to be an AR, the evaluation of expectedness will be 
made based on knowledge of the reaction and the relevant product 
information documented in the IB. 
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The event may be classed as either: 
Expected: the AR is consistent with the toxicity of the IMP listed in the IB. 
Unexpected: the AR is not consistent with the toxicity in the IB. 
10.4.4 Assessment of Severity 
The Investigator will make an assessment of severity for each AE/SAE and 
record this on the CRF or SAE form according to one of the following 
categories: 
Mild: an event that is easily tolerated by the participant, causing minimal 
discomfort and not interfering with every day activities. 
Moderate: an event that is sufficiently discomforting to interfere with normal 
everyday activities. 
Severe: an event that prevents normal everyday activities. 
Note: the term ‘severe’, used to describe the intensity, should not be confused 
with ‘serious’ which is a regulatory definition based on participant/event 
outcome or action criteria.  For example, a headache may be severe but not 
serious, while a minor stroke is serious but may not be severe. 
10.5 REPORTING OF SAEs/SARs/SUSARs 
Once the Investigator becomes aware that an SAE has occurred in a study 
participant, the information will be reported to the ACCORD Research 
Governance & QA Office immediately or within 24 hours. If the Investigator 
does not have all information regarding an SAE, they should not wait for this 
additional information before notifying ACCORD.  The SAE report form can be 
updated when the additional information is received. 
The SAE report will provide an assessment of causality and expectedness at 
the time of the initial report to ACCORD according to Sections 10.4.2, 
Assessment of Causality and 10.4.3, Assessment of Expectedness. 
The SAE form will be transmitted by fax to ACCORD on +44 (0)131 242 9447 
or may be transmitted by hand to the office or submitted via email to 
Safety.Accord@ed.ac.uk. Only forms in a pdf format will be accepted by 
ACCORD via email. 
Where missing information has not been sent to ACCORD after an initial 
report, ACCORD will contact the investigator and request the missing 
information.  
All reports faxed to ACCORD and any follow up information will be retained by 
the Investigator in the Investigator Site File (ISF). 
10.6 REGULATORY REPORTING REQUIREMENTS 
The ACCORD Research Governance & QA Office is responsible for 
pharmacovigilance reporting on behalf of the co-sponsors (Edinburgh 
University and NHS Lothian). 
The ACCORD Research Governance & QA Office has a legal responsibility to 
notify the regulatory competent authority and relevant ethics committee 
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(Research Ethics Committee (REC) that approved the trial).  Fatal or life 
threatening SUSARs will be reported no later than 7 calendar days and all 
other SUSARs will be reported no later than 15 calendar days after ACCORD 
is first aware of the reaction.   
ACCORD will inform Investigators at participating sites of all SUSARs and any 
other arising safety information. 
An Annual Safety Report/Development Safety Update Report will be 
submitted, by ACCORD, to the regulatory authorities and RECs listing all 
SARs and SUSARs. 
10.7 FOLLOW UP PROCEDURES 
After initially recording an AE or recording and reporting an SAE, the 
Investigator should make every effort to follow each event until a final 
outcome can be recorded or reported as necessary. Follow up information on 
an SAE will be reported to the ACCORD office. 
If, after follow up, resolution of an event cannot be established, an explanation 
should be recorded on the CRF, AE log or SAE form. 
11 PREGNANCY 
Women who are pregnant, breastfeeding or of child-bearing potential (women 
who have experienced menarche, are pre-menopausal and have not been 
sterilised) will not be enrolled into the trial. 
12 TRIAL MANAGEMENT AND OVERSIGHT ARRANGEMENTS 
12.1 TRIAL MANAGEMENT GROUP 
The trial will be coordinated by a Project Management Group, consisting of 
the grant holders (Chief Investigator and Principal Investigator in Edinburgh) 
and site leads. 
The Principal Investigator will oversee the study and will be accountable to the 
Chief Investigator.  The Principal Investigator will be responsible for checking 
the CRFs for completeness, plausibility and consistency.  Any queries will be 
resolved by the Investigator or delegated member of the trial team.  
A Delegation Log will be prepared for each site, detailing the responsibilities 
of each member of staff working on the trial.   
12.2 TRIAL STEERING COMMITTEE 
A Trial Steering Committee (TSC) will be established to oversee the conduct 
and progress of the trial.  Contact details of the TSC are detailed in a separate 
TSC charter. The review of SAEs will be added to the TSC agenda to ensure 
that appropriate action is taken if any safety issues arise.   
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12.3 DATA MONITORING COMMITTEE 
This is an observational open label clinical cohort study involving an 
established radiotracer with over 40 years of experience. The result of the 
18F-fluoride positron emission tomography and computed tomography 
coronary angiogram will not be fed back to the clinical team responsible for 
the patients care (except for clinically important incidental findings). For this 
reason, an independent Data Monitoring Committee (DMC) will not be 
convened for this study and all study serious adverse events will be reported 
to the sponsor and will be discussed by the TSC. 
12.4 INSPECTION OF RECORDS 
Investigators and institutions involved in the study will permit trial related 
monitoring and audits on behalf of the sponsor, REC review, and regulatory 
inspection(s).  In the event of an audit or monitoring, the Investigator agrees to 
allow the representatives of the sponsor direct access to all study records and 
source documentation. In the event of regulatory inspection, the Investigator 
agrees to allow inspectors direct access to all study records and source 
documentation. 
12.5 RISK ASSESSMENT 
A study specific risk assessment has been performed by representatives of 
the co-sponsors, ACCORD monitors and the QA group, in accordance with 
ACCORD governance and sponsorship SOPs. Input has been sought from 
the Chief Investigator or designee. The outcomes of the risk assessment were 
the basis from which monitoring plans and audit plans were created. The risk 
assessment outcomes also indicated which risk adaptions (delete if no 
adaptations were possible) could be incorporated into to trial design. 
12.6 BENEFIT/RISK BALANCE 
12.6.1 Benefits 
Patients may also benefit from additional procedures and investigations that 
they will undergo as part of the study. This will include closer medical 
supervision and non-invasive imaging investigations that may identify 
important incidental findings. 
12.6.2 Risks 
There are some potential hazards of the non-invasive investigations that we 
will perform as part of the trial. The main issues relate to exposure to ionising 
radiation and contrast agent administration. We have a well-developed 
protocol for cardiac positron emission and computed tomography imaging that 
minimizes radiation exposure and has clear procedures for managing adverse 
contrast reactions. We anticipate that the total research protocol dose (TPRD) 
radiation exposure not exceed 32 mSv. The TRPD includes radiation 
exposure from both the positron emission tomography and computed 
tomography scans combined. The estimated associated risk of developing 
fatal cancer is proportional to dose.  Using a risk of 5% per Sv [ARSAC Notes] 
in a healthy population in this age group the estimated associated risk of 
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developing fatal cancer as a result of this exposure is in the region 1 in 650.  
This risk can be classified as moderate. It is likely that in a population of any 
patients in the age group 50+ the cancer risk is lower than 5% per Sv.  For 
comparison the average annual background radiation dose arising from 
natural sources of ionising radiation in the environment in the UK is 2.2 mSv.  
The TRPD of 32 mSv incurred in this study is approximately 14 times annual 
background radiation from natural sources.   This can be compared with other 
commonly used cardiovascular imaging techniques, such as nucleotide 
myocardial perfusion imaging (15-20 mSv) and diagnostic coronary 
angiography (7 mSv) [Einstein et al, 2007].  
The risks of exposure to the contrast medium include allergic reactions and 
impairment of kidney function. Amongst patients with moderate-to-severe 
chronic kidney disease, there is a 2-4% risk of kidney impairment after 
computed tomography angiography [Barrett et al, 2006]. The risk of contrast 
exposure in this study will be minimised by exclusion of high-risk patients who 
have significant kidney disease (estimated glomerular filtration rate <30 
mL/min/1.73m2). 
12.7 STUDY MONITORING AND AUDIT 
ACCORD clinical trial monitors, or designees, will perform monitoring activities 
in accordance with the study monitoring plan. This will involve on-site visits 
and central monitoring activities as necessary (delete where not required). 
ACCORD QA personnel, or designees, will perform study audits in 
accordance with the study audit plan. This will involve investigator site audits, 
study management audits and facility (including 3rd parties) audits as 
necessary (delete where not required).  
13 GOOD CLINICAL PRACTICE 
13.1 ETHICAL CONDUCT 
The study will be conducted in accordance with the principles of the 
International Conference on Harmonisation Tripartite Guideline for Good 
Clinical Practice (ICH GCP). 
A favorable ethical opinion will be obtained from the appropriate REC and 
local R&D approval will be obtained prior to commencement of the study. 
13.2 REGULATORY COMPLIANCE 
The study will not commence until a Clinical Trial Authorisation (CTA) is 
obtained from the appropriate Regulatory Authority. The protocol and study 
conduct will comply with the Medicines for Human Use (Clinical Trials) 
Regulations 2004, as amended. 
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13.3 INVESTIGATOR RESPONSIBILITIES 
The Investigator is responsible for the overall conduct of the study at the site 
and compliance with the protocol and any protocol amendments.  In 
accordance with the principles of ICH GCP, the following areas listed in this 
section are also the responsibility of the Investigator.  Responsibilities may be 
delegated to an appropriate member of study site staff.   
13.3.1 Informed Consent 
The Investigator is responsible for ensuring informed consent is obtained 
before any protocol specific procedures are carried out.  The decision of a 
participant to participate in clinical research is voluntary and should be based 
on a clear understanding of what is involved. 
Participants must receive adequate oral and written information – appropriate 
Participant Information and Informed Consent Forms will be provided.  The 
oral explanation to the participant will be performed by the Investigator or 
qualified delegated person, and must cover all the elements specified in the 
Participant Information Sheet and Consent Form. 
The participant must be given every opportunity to clarify any points they do 
not understand and, if necessary, ask for more information.  The participant 
must be given sufficient time to consider the information provided.  It should 
be emphasised that the participant may withdraw their consent to participate 
at any time without loss of benefits to which they otherwise would be entitled. 
The participant will be informed and agree to their medical records being 
inspected by regulatory authorities and representatives of the sponsor(s) but 
understand that their name will not be disclosed outside the hospital. 
The Investigator or delegated member of the trial team and the participant will 
sign and date the Informed Consent Form(s) to confirm that consent has been 
obtained.  The participant will receive a copy of this document and a copy filed 
in the Investigator Site File (ISF) and participant’s medical notes. 
13.3.2 Study Site Staff 
The Investigator must be familiar with the IMP, protocol and the study 
requirements.  It is the Investigator’s responsibility to ensure that all staff 
assisting with the study are adequately informed about the IMP, protocol and 
their trial related duties. 
13.3.3 Data Recording 
The Principal Investigator is responsible for the quality of the data recorded in 
the CRF at each Investigator Site. The source data plan identifies which 
source data correspond to CRF data and states which data are recorded 
directly into the CRF. 
13.3.4 Investigator Documentation 
Prior to beginning the study, each Investigator will be asked to provide 
particular essential documents to the ACCORD Research Governance & QA 
Office, including but not limited to: 
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• An original signed Investigator’s Declaration (as part of the Clinical 
Trial Agreement documents); 
• Curriculum vitae (CV) signed and dated by the Investigator indicating 
that it is accurate and current. 
The ACCORD Research Governance & QA Office will ensure all other 
documents required by ICH GCP are retained in a Trial Master File (TMF), 
where required, and that appropriate documentation is available in local ISFs. 
13.3.5 GCP Training 
All study staff will hold evidence of GCP training where appropriate.  
13.3.6 Confidentiality 
All laboratory specimens, evaluation forms, reports, and other records must 
be identified in a manner designed to maintain participant confidentiality.  All 
records must be kept in a secure storage area with limited access.  Clinical 
information will not be released without the written permission of the 
participant.  The Investigator and study site staff involved with this study may 
not disclose or use for any purpose other than performance of the study, any 
data, record, or other unpublished, confidential information disclosed to those 
individuals for the purpose of the study.  Prior written agreement from the 
sponsor or its designee must be obtained for the disclosure of any said 
confidential information to other parties. 
13.3.7 Data Protection 
All Investigators and study site staff involved with this study must comply with 
the requirements of the Data Protection Act 1998 with regard to the collection, 
storage, processing and disclosure of personal information and will uphold the 
Act’s core principles. Access to collated participant data will be restricted to 
those clinicians treating the participants, representatives of the sponsor(s) and 
representatives of regulatory authorities. 
Computers used to collate the data will have limited access measures via 
user names and passwords. 
Published results will not contain any personal data that could allow 
identification of individual participants. 
14 STUDY CONDUCT RESPONSIBILITIES 
14.1 PROTOCOL AMENDMENTS 
Any changes in research activity, except those necessary to remove an 
apparent, immediate hazard to the participant in the case of an urgent safety 
measure, must be reviewed and approved by the Chief Investigator.   
Amendments to the protocol must be submitted in writing to the appropriate 
REC, Regulatory Authority and local R&D for approval prior to participants 
being enrolled into an amended protocol. 
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14.2 PROTOCOL VIOLATIONS AND DEVIATIONS 
Prospective protocol deviations, i.e. protocol waivers, will not be approved by 
the sponsors and therefore will not be implemented, except where necessary 
to eliminate an immediate hazard to study participants. If this necessitates a 
subsequent protocol amendment, this should be submitted to the REC, 
Regulatory Authority and local R&D for review and approval if appropriate. 
Protocol deviations will be recorded in a protocol deviation log and logs will be 
submitted to the sponsors every 3 months. Each protocol violation will be 
reported to the sponsor within 3 days of becoming aware of the violation. 
14.3 SERIOUS BREACH REQUIREMENTS 
A serious breach is a breach which is likely to effect to a significant degree: 
(a) the safety or physical or mental integrity of the participants of the trial; or 
(b) the scientific value of the trial. 
If a potential serious breach is identified by the Chief investigator, Principal 
Investigator or delegates, the co-sponsors (accord.seriousbreach@ed.ac.uk) 
must be notified within 24 hours.  It is the responsibility of the co-sponsors to 
assess the impact of the breach on the scientific value of the trial, to 
determine whether the incident constitutes a serious breach and report to 
regulatory authorities and research ethics committees as necessary.  
14.4 STUDY RECORD RETENTION 
All study documentation will be kept for a minimum of 5 years from the 
protocol defined end of study point. When the minimum retention period has 
elapsed, study documentation will not be destroyed without permission from 
the sponsor. 
14.5 END OF STUDY 
It is anticipated that the study will last 4 years: two years for recruitment and 
two years of follow-up. The end of study is defined as the last participant’s last 
visit.   
The Investigators and/or the trial steering committee and/or the co-sponsor(s) 
have the right at any time to terminate the study for clinical or administrative 
reasons.  
The end of the study will be reported to the REC and Regulatory Authority 
within 90 days, or 15 days if the study is terminated prematurely.  The 
Investigators will inform participants of the premature study closure and 
ensure that the appropriate follow up is arranged for all participants involved. 
A summary report of the study will be provided to the REC and Regulatory 
Authority within 1 year of the end of the study. 
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14.6 INSURANCE AND INDEMNITY 
The co-sponsors are responsible for ensuring proper provision has been 
made for insurance or indemnity to cover their liability and the liability of the 
Chief Investigator and staff. 
The following arrangements are in place to fulfil the co-sponsors' 
responsibilities: 
• The Protocol has been designed by the Chief Investigator and 
researchers employed by the University and collaborators.  The 
University has insurance in place (which includes no-fault 
compensation) for negligent harm caused by poor protocol design by 
the Chief Investigator and researchers employed by the University. 
• Sites participating in the study will be liable for clinical negligence and 
other negligent harm to individuals taking part in the study and 
covered by the duty of care owed to them by the sites concerned.  
The co-sponsors require individual sites participating in the study to 
arrange for their own insurance or indemnity in respect of these 
liabilities. 
• Sites which are part of the United Kingdom's Nation Health Service 
will have the benefit of NHS Indemnity. 
• Sites out with the United Kingdom will be responsible for arranging 
their own indemnity or insurance for their participation in the study, as 
well as for compliance with local law applicable to their participation in 
the study. 
• The manufacturer supplying IMP has accepted limited liability related 
to the manufacturing and original packaging of the study drug and to 
the losses, damages, claims or liabilities incurred by study participants 
based on known or unknown Adverse Events which arise out of the 
manufacturing and original packaging of the study drug, but not where 
there is any modification to the study drug (including without limitation 
re-packaging and blinding). 
15 REPORTING, PUBLICATIONS AND NOTIFICATION OF RESULTS 
15.1 AUTHORSHIP POLICY 
Ownership of the data arising from this study resides with the study team.  On 
completion of the study, the study data will be analysed and tabulated, and a 
clinical study report will be prepared in accordance with ICH guidelines.  
15.2 PUBLICATION 
The clinical study report will be used for publication and presentation at 
scientific meetings. Investigators have the right to publish orally or in writing 
the results of the study. 
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Summaries of results will also be made available to Investigators for 
dissemination within their clinics (where appropriate and according to their 
discretion). 
15.3 PEER REVIEW 
The study has undergone national and international peer review by the 
Wellcome Trust. There is additional peer review from the Trial Steering 
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FIGURE 1.  Focal 18F-Fluoride Uptake in Patients with Myocardial 
Infarction and Stable Angina 
Patient with acute ST-segment elevation myocardial infarction with (A) 
proximal occlusion (red arrow) of the left anterior descending artery on 
invasive coronary angiography and (B) intense focal 18F-fluoride uptake 
(yellow-red) at the site of the culprit plaque (red arrow) on the combined 
positron emission and computed tomogram.  
Patient with anterior non-ST-segment elevation myocardial infarction with (C) 
culprit (red arrow; left anterior descending artery) and bystander non-culprit 
(white arrow; circumflex artery) lesions on invasive coronary angiography that 
were both stented during the index admission. Only the culprit lesion had 
increased 18F-fluoride uptake on combined positron emission and computed 
tomography (D) following percutaneous coronary intervention.  
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FIGURE 2.  Patients with Stable Angina and 18F-Fluoride Uptake 
Representative examples for 18F-fluoride uptake in patients with stable 
angina. Panels A-D, computed tomography coronary angiograms; panels E-H, 
18F-fluoride positron emission tomograms; and panels I-L, fused positron 
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1.1.1 Pathogenesis of Coronary Artery Disease 
Coronary plaque rupture of mildly stenotic coronary atherosclerosis is the commonest cause 
of acute coronary thrombosis and myocardial infarction [Davies, 2000]. This is the dominant 
type of plaque event causing an acute coronary syndrome, especially in men. It is closely 
linked to hypercholesterolaemia and has a dominant inflammatory phenotype. Classical 
histological features include a lipid-rich pool, thin fibrous cap, paucity of vascular smooth 
muscle cells and an intense inflammatory cell infiltrate [Davies, 2000]. 
Plaque rupture does not invariably lead to thrombotic occlusion of the coronary artery. 
Coronary plaque events are very common and the majority of such events do not cause 
coronary occlusion [Mann & Davies, 1999; Davies, 2000]. Here, plaque rupture and 
thrombosis is organised, remodelled and incorporated into the atherosclerotic plaque itself. 
Indeed, 80% of plaques that cause over 50% diameter stenosis have evidence of old healed 
plaque rupture with incorporation of thrombus into the atheroma [Mann & Davies, 1999]. This 
process contributes to the progression of coronary atherosclerosis and explains the first 
appearance, or step change in severity, of angina pectoris. 
Coronary plaque events are often not isolated. Plaque rupture can occur throughout the body 
and is not confined to a single vascular bed. Moreover, in patients with acute coronary 
syndromes, it is common for multiple plaque events to occur simultaneously and beyond the 
culprit lesion itself. Post-mortem studies indicate that, on average, 2.4 coronary thrombotic 
events occur in each patient who presents with fatal coronary heart disease [Mann & Davies, 
1999; Davies, 2000]. This suggests that systemic and generalised mechanisms and mediators 
play an important role in addition to local factors within the coronary artery wall. 
In summary, coronary atherosclerosis is characterised by multiple and recurrent plaque 
rupture events that are often sub-clinical and cause step-wise growth of the plaque as it heals 
and remodels. Patients undergoing repeated plaque rupture events are likely to be at 
increased risk of myocardial infarction, especially if such an event coincides with a period of 
increased blood thrombogenicity. If these patients can be identified then there would be a 
clear rationale for using powerful anti-platelet agents, such as ticagrelor, to dampen down 
their thrombotic potential and the risk of adverse cardiovascular events. 
1.1.2 Ticagrelor 
Ticagrelor (AZD6140) is a reversible and direct-acting oral antagonist of the adenosine 
diphosphate P2Y12 receptor. It provides faster, greater, and more consistent P2Y12 inhibition 
than clopidogrel [Gurbel et al, 2009]. In the PLATelet inhibition and patient Outcomes 
(PLATO) trial of 18,624 patients presenting with an acute coronary syndrome, ticagrelor was 
superior to clopidogrel for the prevention of cardiovascular events and death [Wallentin et al, 
2009]. It is unknown whether these anti-platelet and anti-thrombotic benefits extend to 
patients with coronary artery disease in the absence of an acute coronary syndrome. 
1.1.3 Non-invasive Imaging of the Vulnerable Plaque 
In the study of coronary artery disease, many researchers have searched for a non-invasive 
imaging biomarker of plaque vulnerability and rupture. For the first time, we have 
demonstrated that 18F-fluoride positron emission tomography can detect high-risk coronary 
plaque in patients with stable coronary artery disease [Joshi et al, 2013].  
In the vasculature, 18F-fluoride acts as a marker of novel calcification activity [Dweck et al, 
2012a; Dweck et al, 2013]. Similar to other conditions, calcification in coronary atheroma 
occurs as a healing response to intense necrotic inflammation, making 18F- fluoride a useful 
marker of high-risk atherosclerotic plaque. We have previously demonstrated increased 
uptake of this tracer in the coronary vasculature localizing to individual coronary lesions and 
identifying patients with increased cardiovascular risk factor profiles [Dweck et al, 2012b]. 
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More recently we have conducted a prospective study of 40 patients with myocardial 
infarction in whom 18F-fluoride localised to the culprit plaque (Figure 1) in over 90% of 
patients [Joshi et al, 2013]. This finding was confirmed in 12 patients with a recent stroke 
undergoing carotid endartectomy where 18F-fluoride uptake was observed at the site of 
plaque rupture in 100% of patients and this uptake correlated with increased calcification 
activity and areas of necrosis on histology. Finally we studied 40 patients with stable coronary 
artery disease. Increased uptake was observed in 45% of these patients and this again 
localized to individual coronary plaques (Figure 2). Interestingly these lesions were 
associated with multiple high-risk markers on radiofrequency and gray-scale intravascular 
ultrasound (necrotic core, positive remodeling and microcalcification). Importantly, plasma 
high-sensitivity troponin concentrations were much higher in patients with 18F-fluoride 
positive plaques compared with patients without evidence of uptake (7.89±9.34 versus 
3.10±1.89 ng/L, P=0·047; Figure 3). The latter observation is of particular interest as it 
supports the hypothesis that 18F-fluoride is detecting subclinical plaque rupture in those with 
stable disease, similar to its mechanism of activity following myocardial infarction. Moreover 
plasma troponin concentrations measured by a high-sensitivity assay also predict an adverse 
outcome amongst patients with stable coronary artery disease [Omland et al, 2013] and 
provide a useful surrogate biomarker of therapeutic efficacy. 
1.1.4 High-Sensitivity Cardiac Troponin I 
Cardiac troponins are regulatory muscle proteins that are released into the circulation 
following acute myocardial injury. Assays that quantify cardiac isoforms of troponin have 
greater specificity and sensitivity for the diagnosis of myocardial infarction than traditional 
cardiac enzymes. Indeed, we have demonstrated that this improved precision can lead to 
improved outcomes in patients with suspected acute coronary syndromes [Mills et al, 2011; 
Mills et al, 2012]. 
Recent advances have led to greatly improved assay sensitivity permitting quantification of 
extremely low concentrations of troponin with excellent precision. High-sensitivity cardiac 
troponin assays have limits of detection 10- to 100-fold lower than contemporary assays and 
are able to detect troponin in the circulation of the majority of healthy persons. Indeed, we 
have recently demonstrated important sex-specific thresholds for cardiac troponin when 
assessing patients with suspected acute coronary syndromes [Shah et al, 2013]. However, it 
is becoming increasingly recognized that plasma high-sensitivity troponin concentrations are 
powerful markers of future risk even when within the normal reference range. As previously 
indicated, plasma high-sensitivity troponin concentrations are increased in patients with high-
risk 18F-fluoride positive coronary artery plaque [Joshi et al, 2013] and appear to predict an 
adverse outcome amongst patients with stable coronary artery disease [Omland et al, 2013].  
1.2 RESEARCH HYPOTHESIS 
Ticagrelor will reduce biomarkers of myocardial injury and inhibit disease progression in 
patients with stable coronary heart disease and evidence of high-risk coronary plaque defined 
by 18F-fluoride uptake on positron emission tomography. 
1.3 RATIONALE FOR STUDY 
The rationale for this study is based on two main observations relevant to the pathogenesis of 
coronary artery disease.  
1. The majority of episodes of plaque rupture are subclinical because thrombus 
formation is non-occlusive and microembolism causes covert myocardial micro-injury 
that is insufficient to cause overt symptoms.  
2. Cycles of rupture and non-occlusive thrombus formation lead to plaque expansion 
and coronary artery disease progression.  
These two features can now be tracked using a high-sensitivity cardiac troponin I assay and 
computer tomography coronary angiography respectively. 
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Given this central role of thrombosis in atherogenesis, anti-thrombotic interventions have 
major potential to impact on the consequences and progression of atherosclerotic disease 
[Williams et al, 1997; Rioufol et al, 2004; Kwon et al, 2005]. With the advent of more potent 
platelet inhibition with ticagrelor, there is now the opportunity to assess whether dual anti-
platelet therapy can improve markers of myocardial injury and disease progression. 
To enhance the opportunity to detect such effects, we propose a stratified medicine approach 
where we will specifically select patients who have evidence of high-risk or subclinical 
ruptured coronary artery plaque identified by coronary 18F-fluoride uptake. We will then 
compare outcomes between those with and those without uptake, anticipating that only 
patients with high-risk plaque will demonstrate evidence of reduced injury and disease 
progression.  
2 STUDY OBJECTIVES 
2.1 OBJECTIVES 
2.1.1 Primary Objective 
To determine whether ticagrelor will reduce plasma high-sensitivity troponin concentrations 
compared with placebo in patients with stable coronary heart disease and high-risk coronary 
atheroma.  
2.1.2 Secondary Objectives 
a) To assess whether ticagrelor will reduce plasma high-sensitivity troponin concentrations in 
patients without increased coronary 18F-fluoride uptake. 
b) To assess whether ticagrelor will reduce plasma high-sensitivity troponin concentrations 
over a 1-year time frame. 
c) To assess whether ticagrelor will reduce coronary plaque volume or calcium score at the 
site of 18F-fluoride uptake. 
d) To confirm the reproducibility of 18F-fluoride PET positivity 
e) To assess the natural history of 18F-fluoride PET positive coronary plaque 
2.1.3 Safety Objective 
To determine whether the addition of ticagrelor to standard optimal medical therapy is safe 
and well tolerated in patients with stable coronary heart disease on optimal medical therapy. 
All bleeding events will be categorised according to the previous PLATO criteria [Wallentin et 
al, 2009] and recorded on the CRF. 
2.1.4 Exploratory Objectives 
The study design will also allow us to establish the effect of ticagrelor on disease progression. 
Using the baseline and repeat computed tomography coronary angiograms, we will be able to 
investigate changes in plaque burden, calcium score and lesion severity alongside the end 
points described above. This will be assessed throughout the coronary circulation as well as 
specifically at the site of 18F-fluoride uptake.  As a measurement of treatment compliance 
and efficacy, we will also assess platelet-monocyte aggregates before and after in vitro 
stimulation with 20 µm adenosine diphosphate [Frelinger et al, 2011]. 
2.2 ENDPOINTS 
2.2.1 Primary Endpoint 
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Plasma high sensitivity cardiac troponin I (hsTnI) concentration at 30 days in patients with 
coronary 18F-fluoride uptake. 
 
2.2.2 Secondary Endpoints 
a) Plasma hsTnI concentrations at 30 days in patients without coronary 18F-fluoride 
uptake. 
b) High sensitivity cardiac troponin I (hsTnI) concentration at 30 days in total study 
population. 
c) Plasma hsTnI concentrations at 1 year 
d) Total calcium score at 1 year 
e) Plaque volume at 1 year at the site of baseline coronary 18F-fluoride uptake 
f) Reproducibility of 18F-fluoride uptake detected on PET imaging at 1 week 
g) Natural history of 18F-fluoride uptake over 1 year 
3  STUDY DESIGN 
3.1 RATIONALE FOR STUDY DESIGN, DOSES AND CONTROL 
GROUPS 
The study will be a randomised double blind placebo-controlled trial to ensure a rigorous 
study design and the avoidance of systematic biases of outcome measures.  All recruited 
patients will undergo computed tomography coronary angiography and 18F-fluoride positron 
emission tomography (PET) scanning at baseline. Patients will then be randomized to 
ticagrelor 90 mg or matched placebo twice daily [Wallentin et al, 2009]. The dose has been 
selected on the basis of the PLATO trial [Wallentin et al, 2009]. The control groups will be 
two-fold. First there will be the active and inactive comparators of ticagrelor and placebo. 
Second we will examine for the presence and magnitude of an effect in the groups of patients 
with or without coronary 18F-fluoride uptake.  
The primary outcome will be the comparison between ticagrelor and matched placebo on the 
change in plasma troponin concentration from baseline to one month in patients with coronary 
18F-fluoride uptake. Secondary analyses will undertake the same assessment in patients 
without coronary 18F-fluoride uptake to determine whether this is particular to patients with 
high-risk coronary plaque or is seen in all patients with multivessel coronary artery disease. 
Further longitudinal comparisons of these groups will determine whether the dominant effect 
on plasma troponin concentrations is seen only in the early phase or whether potential 
benefits are seen throughout the study period. Finally, we will assess whether in comparison 
to placebo, ticagrelor will inhibit progression of coronary atheroma (calcium score and plaque 
volume) at the site of high-risk coronary plaque. 
An additional exploratory component to the study will be to assess the reproducibility and 
natural history of 18F-fluoride uptake within coronary plaques.  This will be investigated with 
repeat PET scanning within a subgroup of the total population. 
4 STUDY POPULATION 
4.1      Number Of Participants 
We will recruit 250 patients with stable coronary heart disease from the Edinburgh Heart 
Centre. 
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4.2        Inclusion Criteria 
For inclusion in the study subjects should fulfill the following criteria: 
1. Patients aged ≥40 years with angiographically proven multivessel coronary artery 
disease defined as at least two major epicardial vessels with any combination of 
either (a) >50% luminal stenosis, or (b) previous revascularization (percutaneous 
coronary intervention or coronary artery bypass graft surgery). 
2. Provision of informed consent prior to any study specific procedures 
3. Receiving aspirin 
4.3       Exclusion Criteria 
Subjects should not enter the study if any of the following exclusion criteria are fulfilled: 
1. An acute coronary syndrome within the last 12 months 
2. An indication for dual anti-platelet therapy, such as drug eluting stent 
3. Receiving thienopyridine therapy such as clopidogrel or prasugrel 
4. Percutaneous coronary intervention or coronary artery bypass graft surgery within the 
last 3 months 
5. Inability or unwilling to give informed consent 
6. Women who are pregnant, breastfeeding or of child-bearing potential (women who 
have experienced menarche, are pre-menopausal and have not been sterilised) will 
not be enrolled into the trial 
7. Known hypersensitivity to ticagrelor or one of its excipients 
8. Active pathological bleeding or bleeding diathesis 
9. Significant thrombocytopenia: platelets <100 x 109 /L 
10.  History of intracranial haemorrhage 
11. Moderate to severe liver impairment (Child’s Grade B or C) 
12. Maintenance therapy with strong CYP3A4 inhibitors, such as ketoconazole, 
nefazodone, ritonavir, indinavir, atazanavir, or clarithromycin 
13. Major intercurrent illness or life expectancy <1 year 
14. Renal dysfunction (eGFR ≤30 mL/min/1.73 m2) 
15. Contraindication to iodinated contrast agents 
16. Planned coronary revascularization or major non-cardiac surgery in the next 12 
months 
17.        Maintenance therapy with simvastatin or lovastatin at doses greater than 40mg daily 
18. Receiving oral anticoagulants including warfarin, rivaroxaban, dabigatran or 
apixaban. 
 
4.4       Co-Enrolment 
Co-enrolment with another clinical trial of an investigational medical product or of a trial 
involving the use of an additional anticoagulant (e.g. warfarin, dabigatran, rivaroxaban or 
apixaban) or antiplatelet (e.g. clopidogrel, prasugrel) will not be allowed with this study. A 
minimum of 4 months must elapse between studies of this nature prior to patient being 
eligible.   
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Co-enrolment involving trials not excluded above will be allowed provided this is not expected 
to place undue burden upon participants and their families.  Consideration will also be given 
to the total exposure to ionising radiation should additional studies require further exposure. 
 
5  PARTICIPANT SELECTION AND ENROLMENT 
5.1 IDENTIFYING PARTICIPANTS 
Patients will be identified by their usual care team from outpatient clinics and existing clinical 
databases (the Tomcat and TrakCare databases).  They will initially be approached (either 
verbally or in writing) for study recruitment by their usual care team who are based at the 
Edinburgh Heart Centre.  Patients will be provided with a Patient Information Sheet and given 
an opportunity to ask questions about participation in the trial.  
5.2 CONSENTING PARTICIPANTS 
After 2 days, patients willing to participate in the trial will be asked to attend a consent and 
screening visit at the Clinical Research Facility, Edinburgh. Written informed consent will be 
obtained by a suitably qualified member of the research team before any study related 
procedures are performed.  Patients will be advised to inform their physicians and dentists 
that they are enrolled on the study before any surgery is scheduled and before any new 
medicinal product is taken. 
5.3 SCREENING FOR ELIGIBILITY 
Screening of clinical records for eligibility will be performed after written consent is obtained.  
If eligibility cannot be confirmed based on pre-existing clinical investigations (i.e. standard 
clinical biochemical and haematological variables have not been assessed within the past 6 
months) then blood tests will be obtained to assess these variables.  Once a patient has 
agreed to participate and is deemed eligible they will be invited to attend the baseline visit. 
Baseline assessments will include clinical history and examination, review of patient records 
to confirm study eligibility and record clinical profile, standard clinical biochemical and 
haematological variables, plasma high sensitivity cardiac troponin I measurement, 12-lead 
electrocardiogram, 18F-fluoride positron emission tomography, computed tomography 
coronary calcium score and angiography, and storage of plasma, serum and DNA for future 
analysis. 
5.4 INELIGIBLE AND NON-RECRUITED PARTICIPANTS 
Ineligible and non-recruited patients will receive standard medical care. An anonymised log 
will be kept of patients who were screened for the study and subsequently found to be 
ineligible or not recruited.   
5.5 PROCEDURES FOR HANDLING SUBJECTS INCORRECTLY 
ENROLLED, RANDOMISED OR INITIATED ON INVESTIGATIONAL 
MEDICINAL PRODUCT 
Patients incorrectly randomized to the wrong treatment group will be maintained on allocated 
therapy unless blinding has been compromised. Given that this is a mechanistic study and not 
a clinical endpoint trial, they will be assigned to the treatment they actually received as part of 
the statistical analysis.  Records will be kept of the treatment they were originally assigned to, 
and the treatment they received. 
After the first 30 and 90 patients have been randomized into the trial, ECTU will check to 
ensure that minimization has achieved matching of the two treatment groups. 
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5.6 RANDOMISATION 
5.6.1 Randomisation Procedures 
Eligible patients will be randomized using a web-based randomization service to ensure 
allocation concealment. Given the modest sample size, we will minimise treatment allocation 
according to age, sex, baseline plasma troponin concentration and the presence of coronary 
18F-fluoride uptake. 
 
5.6.2 Treatment Allocation 
The placebo and active medication will be presented in numbered packages in collaboration 
with the Investigational Supplies Group (University of Edinburgh).  
5.6.3 Methods to Ensure Blinding 
The inactive placebo comparator will be presented and packaged in a form that will be 
indistinguishable from the active medication, ticagrelor. Therefore the treating clinical staff 
and patient will be blind to the allocated treatment.  An indication of treatment allocation will 
potentially be apparent with platelet-monocyte aggregate testing.  This will be undertaken by 
a dedicated technician distinct from the clinical investigational team.  Samples will be 
presented to the technician using anonymised sample codes.  Results will be stored in the 
database but not released to the study investigators until the end of the trial. 
5.6.4 Emergency Unblinding Procedures 
Web-based computer randomisation software will generate a randomisation list based on the 
values used for minimisation. This list will then be provided to the Investigational Supplies 
Group (ISG) for drug labelling purposes. The randomisation software will also contain 
unblinding codes which can only be accessed using a username and password. A username 
and password will only be provided to the Sponsor and Pharmacy department and can be 
used if emergency unblinding is required. Requests for unblinding will either go through the 
Chief or Principal Investigator and unblinding will be performed as required by the duty 
Pharmacist. 
5.6.5 Discontinuation of Investigational Medicinal Product 
The investigational product will be discontinued under the following circumstances: 
1. At the request of the patient or if the patient withdraws from the study. 
2. By the investigator or the responsible clinician if this was felt to be in the best 
interests of the patient. 
3. On completion of the study. 
Brief interruptions of therapy will be permitted (<14 days) where there is a clinical need, such 
as unavoidable surgical intervention. In such circumstances, the IMP will be withdrawn 5 days 
prior to surgery and recommenced as appropriate by the clinical team. 
5.6.6 Withdrawal of Study Participants 
Participants are free to withdraw from the study at any point or a participant can be withdrawn 
by the investigator. If withdrawal occurs, the primary reason for withdrawal will be 
documented in the participant’s case record form. The patient will have the option of 
withdrawal from (i) the repeat PET and CT sub-study only (ii) study medication with continued 
study procedures and collection of clinical and safety data (iii) all aspects of the trial but 
continued use of data collected up to that point, (iv) all aspects of the trial with removal of all 
previously collected data.   
Randomised patients who wish to be withdrawn from the study before they have provided a 
blood sample for the assessment of plasma troponin concentration at one month of the trial, 
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will be withdrawn from the study and another participant will be recruited to replace them. 
Data on the original participant will be kept on the database. 
 
 
6 INVESTIGATIONAL MEDICINAL PRODUCT AND 
PLACEBO 
6.1 STUDY DRUG 
Investigational product Dosage form and strength Manufacturer 
Ticagrelor (AZD6410) 90 mg tablet Astrazeneca 
6.1.1 Study Drug Identification 
Ticagrelor is presented as a round biconvex film-coated yellow tablet marked with Œ90¹ 
above ŒT¹ on one side. 
 
6.1.2 Study Drug Manufacturer 
AstraZeneca AB 
Gärtunavägen 
SE-151 85 Södertälje 
SWEDEN 
 





MA number EU/1/10/655/001-006 
6.1.4 Labelling and Packaging 
Astra Zeneca will supply study medication and placebo in prefilled HDPE bottles with Child 
resistant caps. The HDPE bottles will be clearly labelled for the purpose of this trial including 
the study title, trial subject number and study contact by the Investigational Supplies Group, 
Edinburgh (ISG).  
A Qualified Person from ISG will then release the study drug to the Pharmacy Department at 
the Royal Infirmary of Edinburgh. 
6.1.5 Storage 
All study medication will be kept in a secure place under appropriate storage conditions in the 
Pharmacy Department at the Royal Infirmary of Edinburgh.  
 
6.1.6 Summary of Product Characteristics or Investigators Brochure 
The Summary of Product Characteristics (SmPC) is given in Appendix 1. 
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6.2 PLACEBO 
Astra Zeneca will supply a matched placebo in prefilled HDPE bottles with Child resistant 
caps. The placebo will then be labelled by ISG and released to the Pharmacy Department at 
the Royal Infirmary of Edinburgh. 
  
6.3 DOSING REGIME 
One tablet twice daily for 12 months. 
6.4 DOSE CHANGES 
No alteration in the planned dosing regime will be allowed. 
6.5 PARTICIPANT COMPLIANCE AND ACCOUNTABILITY 
Members of the research team will assess treatment compliance at attendance of each of the 
study visits by interview and pill count. Any unused study medication will be returned to the 
Pharmacy Department at the Royal Infirmary for destruction.  
6.6 OVERDOSE 
Ticagrelor is well tolerated in single doses up to 900 mg. Gastrointestinal toxicity was dose-
limiting in a single ascending dose study. Other clinically meaningful adverse reactions which 
may occur with overdose include dyspnoea and ventricular pauses. 
  
In the event of overdose, we will observe for these potential adverse reactions and consider 
ECG monitoring. There is currently no known antidote to reverse the effects of ticagrelor and 
it is not expected to be dialysable. Treatment of overdose will follow local standard medical 
practice. The expected effect of excessive ticagrelor dosing is prolonged bleeding risk 
associated with platelet inhibition. If bleeding occurs appropriate supportive measures will be 
taken.  
If an overdose occurs in the course of the study, the investigators or other site personnel will 
inform appropriate AstraZeneca representatives within one day, ie, immediately but no later 
than the end of the next business day of when he or she becomes aware of it. 
The designated AstraZeneca representative will work with the investigator to ensure that all 
relevant information is provided to the AstraZeneca Patient Safety data entry site. 
6.7 OTHER MEDICATIONS 
6.7.1 Non-Investigational Medicinal Products 
18F-Sodium Fluoride (18F-NaF) 
 
At the time of positron emission tomography and computed tomography coronary 
angiography, patients may receive oral and/or intravenous beta-blockade, such as metoprolol 
5-100 mg, to slow the heart rate to below 65 beats per minute to maximise image quality and 
reduce radiation exposure. Glyceryl trintrate spray or tablet will be administered sublingually 
(200-400 µg) to induce coronary vasodilatation to enhance image quality of the coronary 
angiogram. 
6.7.2 Permitted Medications 
All patients will be maintained on aspirin 75 mg once daily and maximally tolerated dose of 
statin. Patients will be encouraged to be maintained on maximally tolerated doses of 
angiotensin-converting enzyme inhibition and beta-blocker therapy as clinically indicated and 
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in accordance with local guidelines. Following completion of the study, the trial medications 
will be discontinued. 
6.7.3 Prohibited Medications 
• Strong CYP3A4 inhibitors, such as ketoconazole, clarithromycin, nefazodone, 
ritonavir, atazanavir.Thienopyridines such as prasugrel, clopidogrel and ticlopidine 
• Coumarin anticoagulants such as warfarin 
• Direct thrombin inhibitors such as dabigatran 
• Factor Xa inhibitors such as rivaroxaban and apixaban 
• Ergot alkaloids 
• Cisapride 
• Simvastatin or lovastatin when taken at doses >40 mg daily 
7 STUDY ASSESSMENTS 
Trial participants will undergo 8 study visits: screening visit, baseline, randomisation and after 
1, 3, 6, 9 and 12 months. 
7.1 SAFETY ASSESSMENTS 
The study does not have any pre-specified safety outcome measures. However, all bleeding 
events will be categorized according to the previous PLATO criteria [Wallentin et al, 2009]. 
These will be reported through adverse event reporting mechanisms (see Section 10). 
7.2 STUDY ASSESSMENTS 
 
This is a prospective single-centre randomized double blind matched placebo controlled trial 
of ticagrelor 90 mg twice daily in patients with stable coronary artery disease for 1 year. 
Subjects will attend for clinical assessments at 30 days, 3, 6, 9 and 12 months with a final 
computed tomography coronary angiogram at the end of the study. The randomisation visit 
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Eligibility Criteria and 
PIS X        
Continuing eligibility 
confirmed   X X X X X  
Consent X        
Concomitant 
medications  X  X X X X X 
Clinical History  X  X X X X X 








X     X  
Blood sampling for 
hsTnI  X  X X X X X 
Blood sampling for 
PMA  X  X     
12-lead ECG  X  X X X X X 




  X  X X X  
Compliance check    X X X X X 
18F-Fluoride PET  X X  X X  X 
  Additional 18F-Fluoride PET scans will be performed in a subgroup only 
CT attenuation 
correction         
  CT attenuation correction is required prior to each PET scan for the subgroups who undergo this 
CT Calcium Score  X      X 
CT Coronary 
Angiogram  X 
Repeat CTCA scans will be performed at the time of 
each PET scan for those who are in the reproducibility 




7.2.1 Baseline Assessments 
Baseline assessments will include clinical history and examination, review of patient records 
to confirm study eligibility and record clinical profile, standard clinical biochemical and 
haematological variables, plasma high sensitivity cardiac troponin I measurement, platelet-
monocyte aggregates, 12-lead electrocardiogram, 18F-fluoride positron emission 
tomography, computed tomography coronary calcium score and angiography, and storage of 
plasma, serum and DNA for future analysis. 
7.2.2 Follow Up Assessments 
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At 1, 3, 6, 9 and 12 months, participants will undergo repeat clinical assessment, blood 
sampling, and 12-lead electrocardiogram. Compliance will be recorded by patient history and 
tablet count by a delegated member of the research team. At the final study visit (12 months), 
subjects will also undergo a repeat computed tomography coronary calcium score and 
angiography. 
7.2.3 High Sensitivity Cardiac Troponin I 
Plasma cardiac troponin I concentrations will be measured by the accredited Clinical 
Biochemistry Department of the Royal Infirmary of Edinburgh using the ARCHITECTSTAT high-
sensitive troponin I assay (Abbott Laboratories, Abbott Park, IL). This is the first commercially 
available high-sensitivity troponin I assay that has greater precision at very low concentrations 
compared with the contemporary assay. The limit of detection is 1.2 ng/L and the inter-assay 
coefficient of variation <10% at 4.7 ng/L. The upper reference limit (99th percentile) based on 
4,590 samples from healthy men and women is 34 ng/L for men and 16 ng/L for women. 
7.2.4 Positron Emission and Computed Tomography Coronary Angiography 
Study scans will be performed in the Clinical Research Imaging Centre. 
Patients with a heart rate exceeding 65 beats/min may receive intravenous or oral beta-
blockade (e.g. 5 to 100 mg metoprolol) 1 h before computed tomography. All patients will 
receive sublingual glyceryl trinitrate (200-400 µg) just prior to the computed tomography 
coronary angiography.  
All patients will undergo dual cardiac and respiratory-gated positron emission and computed 
tomography imaging of the coronary arteries with a hybrid scanner (64-multidetector Biograph 
mCT, Siemens Medical Systems, Erlangen, Germany). Study subjects will be administered a 
target dose of 250 MBq 18F-fluoride intravenously and subsequently rested in a quiet 
environment for 60 min. An attenuation correction computed tomography scan (non-enhanced 
120 kV and 50 mA) will then be performed, followed by positron emission tomography 
imaging of the thorax in list-mode for 30 min.  
Computed tomography coronary calcium score and angiography will be undertaken in the 
same visit as the 18F-floride scan and again at 1 year. With the patient lying still on the 
scanner after acquisition of the positron emission tomography scan, an electrocardiogram-
gated breath-hold computed tomography scan (non-contrast-enhanced, 40 mAs/rotation, 120 
kV; CareDose, Siemens Medical Systems) of the coronary arteries will be performed at the 
following settings: 330 ms rotation time, 100 (body mass index [BMI] <25 kg/m2) or 120 (body 
mass index >25 kg/m2) kV tube voltage, 160-245 mAs tube current, 3·8 mm/rotation table 
feed, prospective (heart rate regular and <60/min), or retrospective (heart rate >60 /min) 
electrocardiogram-gated. Depending on the BMI, a bolus of 80-100 mL of contrast (400 
mgI/mL; Iomeron, Bracco, Milan, Italy) will be injected intravenously at 5 mL/s, after 
determining the appropriate trigger delay with a test bolus of 20 mL contrast material.  
The positron emission tomography scans will be reconstructed in multiple phases of the 
cardiac cycle, with the diastolic phase (50-75%) used for analysis. The computed tomography 
coronary angiography scans will be reconstructed at 0·75 x 0·7 mm and 0·6 x 0·3 mm for 
retrospective and prospective acquisitions respectively at 60%, 65% and 70% of the cardiac 
cycle. Additional reconstructions will be undertaken as necessary. Positron emission 
tomography scans will correct for cardiac motion correction using electrocardiogram-gated 
images. 
18F-F PET Natural History Sub-study 
Using the same scan process as outlined above a sub-group of patients will be selected for 1 
additional PET scan.  In total this will involve 80 patients out of the total cohort.  The first 20 
participants to be scanned will be to assess the reproducibility of 18F-fluoride uptake and will 
undergo a second PET scan at the randomisation visit (1 week after the baseline scan).  This 
group will comprise 10 patients from both of the PET positive and PET negative samples.  
Following this we will investigate the natural history of 18F-fluoride uptake by performing 
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repeat PET scans on 60 patients in total from the initial PET positive sample with 20 patients 
scanned at the 3 month, 6 month and 12 month follow up visits.  No individual patient will 
undergo more than 2 PET scans during the course of the study.  In order to allow accurate 
co-registration of images, repeat CT coronary angiograms will be performed at the time of the 
repeat PET scans.  The additional PET scan for those in the sub-study will be performed at 
the 1 week, 3 month, 6 month or 12 month visit but the additional CTCA scan will only be 
performed at 1 week, 3 month or 6 month visits as the CTCA scan at 12 months will be 
performed on all participants irrespective of whether they are taking part in the sub-study 
7.2.5 Platelet-Monocyte Aggregates 
The effect of ticagrelor on platelet activation will be assessed before and after in vitro 
stimulation with 20µm adenosine diphosphate to assess inhibition of the P2Y12 receptor 
[Harding et al, 2007; Burdess et al, 2010; Frehling et al 2011]. This will be performed at the 
baseline visit (before study medication ingestion) and at the 30 day visit [Gurbel et al 2009; 
Frehling et al 2011]. Platelet-monocyte aggregate measurements will be performed by a 
trained technician independent to the study team to ensure blinding of treatment allocation is 
not compromised. 
Blood will be anticoagulated with D-phenylalanyl-L-prolyl-L-arginine chloromethylketone 
(PPACK; Cambridge Biosciences, UK). Five minutes after sample collection, samples will be 
stained with the following conjugated monoclonal antibodies: APC-conjugated CD14 (Becton-
Dickinson, UK);, PE-conjugated CD62P (Becton-Dickinson, UK); PE-Cy7-conjugated 
CD11b(Becton-Dickinson, UK); FITC-conjugated CD42a(Becton-Dickinson, UK); and 
appropriate control samples prepared. Once stained, samples will be incubated for 20 min at 
room temperature and fixed with FACS-Lyse (PMA analysis) or paraformaldehyde (platelet 
analysis). Samples will be analyzed using a FACScalibur flow cytometer (Becton-Dickinson, 
UK). Platelet–monocyte aggregates will be defined as monocytes staining positive for CD42a, 
as described previously [Harding et al, 2007]. Analysis will be performed using FlowJo 
(Treestar, USA). 
7.2.6 Biological Samples 
Blood samples will be collected and tested at baseline, 30 days and 3, 6, 9 and 12 months. At 
baseline, blood samples will be taken for routine clinical biochemistry and haematology 
(including full blood count, urea, creatinine and electrolytes, liver function tests, total 
cholesterol and glucose). 
Approximately 20 mL of blood will be obtained on each visit except that an additional 20 mL 
will be taken at baseline for the clinical biochemistry and haematology assessments. Blood 
will also be stored for DNA extraction for subsequent analysis as appropriate. 
Blood samples will be processed and stored in the Clinical Research Facility. Blood sample 
will be processed (plasma and serum) and stored at -80°C for later analysis of potential 
extracellular matrix and inflammatory biomarkers.  Blood will also undergo DNA extraction 
and flow cytometric assessment for platelet monocyte aggregates [Burdess et al, 2010].  
All samples will be stored in locked secure freezers and in compliance with the sponsor’s 
tissue governance policies. 
All samples will be retained unless consent is withdrawn by the participant who specifically 
requests that their samples are destroyed. 
8 DATA COLLECTION 
All trial data will be recorded onto written case record forms (CRF) by a member of the 
research team and then entered into electronic CRFs designed and developed by the 
Edinburgh Clinical Trials Unit.  
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9 STATISTICS AND DATA ANALYSIS 
9.1 SAMPLE SIZE CALCULATION 
Patients with increased 18F-fluoride activity had plasma high-sensitivity troponin 
concentrations that were more than double those patients without increased 18F-fluoride 
uptake (7.89±9.34 versus 3.10±1.89 ng/L; P=0·047) in our recent trail [Joshi et al, 2013]. 
Based upon the assumption that ticagrelor will reduce plasma high sensitivity troponin 
concentrations by one half (i.e from 7.89 to 3.95 ng/L, with standard deviations of 9.34 and 
1.89 respectively), we will require 48 patients per treatment arm at 80% power and two-sided 
P<0.05. Allowance for missing data brings this to 55 per group.  We have previously 
demonstrated that 45% of patients with advanced but stable coronary artery disease 
demonstrate increased 18F-fluoride uptake so that in total we will need to recruit 250 patients 
with positron emission tomography to identify these 110 patients with coronary uptake of 18F-
fluoride.   
The Edinburgh Heart Centre performs more than 5,000 diagnostic angiograms and 2,500 
angioplasty procedures per year.  This should allow an adequate pool of potentially suitable 
patients with angiographically proven stable coronary artery disease from which to recruit. 
9.2 PROPOSED ANALYSES 
9.2.1 Description of Analysis Sets 
The primary analysis will be to determine whether ticagrelor will reduce plasma high-
sensitivity troponin concentrations compared with placebo in patients with stable coronary 
heart disease and increased coronary 18F-fluoride uptake. For this primary analysis, we will 
exclude any patient who does not have a blood sample for estimation of the one-month 
plasma troponin concentration or whose compliance is deemed inadequate (as estimated 
from pill counts). The required level of medication compliance will be described in the 
statistical analysis plan. 
9.2.2 Methods of Statistical Analysis 
For the primary analysis, the change in plasma high-sensitivity troponin concentration from 
baseline to 30 days will be compared between the two treatment groups (ticagrelor and 
placebo) using linear regression, adjusting for the minimisation variables, in patients with 
coronary 18F-fluoride uptake. Prior to analysis, tests for normality will be undertaken and, 
where data are skewed, logarithmic transformation will be considered prior to analysis. Effect 
sizes and 95% confidence intervals will be calculated. Similar analyses will be performed for 
the assessment of troponin at 30 days in patients without coronary 18F-fluoride uptake, and in 
the study population as a whole; for troponin at 1 year; and for calcium score and plaque 
volume at 1 year at the site of baseline coronary 18F-fluoride uptake. 
Statistical analysis will be performed using SAS. A two-sided P<0·05 will be taken as 
statistically significant. A full statistical analysis plan will be documented prior to data base 
lock. This will be overseen by the trial statistician in the Edinburgh Clinical Trials Unit. 
10 ADVERSE EVENTS 
The Investigator is responsible for the detection and documentation of events meeting the 
criteria and definitions detailed below.   
Full details of contraindications and side effects that have been reported following 
administration of the IMP can be found in the relevant Summary of Product Characteristics 
(SmPC). 
Participants will be instructed to contact their Investigator at any time after consenting to join 
the trial if any symptoms develop.  All adverse events (AE) that occur after joining the trial 
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must be reported in detail in the Case Report Form (CRF) or AE form.  In the case of an AE, 
the Investigator should initiate the appropriate treatment according to their medical judgment.  
After initially recording an AE, the Investigator should follow each AE until resolution of the 





An adverse event (AE) is any untoward medical occurrence in a clinical trial participant which 
does not necessarily have a causal relationship with an investigational medicinal product 
(IMP). 
An adverse reaction (AR) is any untoward and unintended response to an IMP which is 
related to any dose administered to that participant.  
A serious adverse event (SAE), serious adverse reaction (SAR). Any AE or AR that at any 
dose: 
• results in death of the clinical trial participant; 
• is life threatening*; 
• requires in-patient hospitalisation^ or prolongation of existing hospitalisation; 
• results in persistent or significant disability or incapacity; 
• consists of a congenital anomaly or birth defect; 
• results in any other significant medical event not meeting the criteria above. 
 
*Life-threatening in the definition of an SAE or SAR refers to an event where the participant 
was at risk of death at the time of the event. It does not refer to an event which hypothetically 
might have caused death if it were more severe. 
 
^Any hospitalisation that was planned prior to randomisation will not meet SAE criteria. Any 
hospitalisation that is planned post randomisation will meet the SAE criteria. 
 
A suspected unexpected serious adverse reaction (SUSAR) is any AR that is classified as 
serious and is suspected to be caused by the IMP, that it is not consistent with the information 
about the IMP in the Summary of Product Characteristics (SmPC) or Investigators Brochure. 
10.2 IDENTIFYING AEs AND SAEs 
All AEs and SAEs will be recorded from the time a participant signs the consent form to take 
part in the study until the last study visit. 
Participants will be asked about the occurrence of AEs/SAEs at every visit during the study.  
Open-ended and non-leading verbal questioning of the participant will be used to enquire 
about AE/SAE occurrence.  Participants will also be asked if they have been admitted to 
hospital, had any accidents, used any new medicines or changed concomitant medication 
regimens.  If there is any doubt as to whether a clinical observation is an AE, the event will be 
recorded. 
AEs and SAEs may also be identified via information from support departments e.g. 
laboratories.  
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10.3 RECORDING AEs AND SAEs 
When an AE/SAE occurs, it is the responsibility of the Investigator to review all documentation 
(e.g. hospital notes, laboratory and diagnostic reports) related to the event.  The Investigator 
will then record all relevant information in the CRF and on the SAE form (if the AE meets the 
criteria of serious). 
Information to be collected includes dose, type of event, onset date, Investigator assessment 
of severity and causality, date of resolution as well as treatment required, investigations 
needed and outcome.   
10.4 ASSESSMENT OF AEs AND SAEs 
Seriousness, causality, severity and expectedness will be assessed by the Principal 
Investigator. For randomised double blind studies, AEs will be assessed as though the 
participant is taking active IMP.  Cases that are considered serious, possibly, probably or 
definitely related to IMP and unexpected (i.e. SUSARs) will be unblinded.  
The Investigator is responsible for assessing each AE.   
The Chief Investigator (CI) may not downgrade an event that has been assessed by an 
Investigator as an SAE or SUSAR, but can upgrade an AE to an SAE, SAR or SUSAR if 
appropriate. 
10.4.1 Assessment of Seriousness 
The Investigator will make an assessment of seriousness as defined in Section 10.1. 
10.4.2 Assessment of Causality 
The Investigator will make an assessment of whether the AE/SAE is likely to be related to the 
IMP according to the definitions below.   
• Unrelated: where an event is not considered to be related to the IMP. 
• Possibly Related: The nature of the event, the underlying medical condition, 
concomitant medication or temporal relationship make it possible that the AE has a 
causal relationship to the study drug. The assessment of causality will be made 
against the reference safety information found in the Summary of Product 
Characteristics. 
Where non Investigational Medicinal Products (NIMPs) e.g. rescue/escape drugs are given:  if 
the AE is considered to be related to an interaction between the IMP and the NIMP, or where 
the AE might be linked to either the IMP or the NIMP but cannot be clearly attributed to either 
one of these, the event will be considered as an AR. Alternative causes such as natural 
history of the underlying disease, other risk factors and the temporal relationship of the event 
to the treatment should be considered and investigated. The blind should not be broken for 
the purpose of making this assessment.  
10.4.3 Assessment of Expectedness 
If an event is judged to be an AR, the evaluation of expectedness will be made based on 
knowledge of the reaction and the relevant product information documented in the SmPC/IB. 
The event may be classed as either: 
Expected: the AR is consistent with the toxicity of the IMP listed in the SmPC/IB. 
Unexpected: the AR is not consistent with the toxicity in the SmPC/IB. 
10.4.4 Assessment of Severity 
The Investigator will make an assessment of severity for each AE/SAE and record this on the 
CRF or SAE form according to one of the following categories: 
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Mild: an event that is easily tolerated by the participant, causing minimal discomfort and not 
interfering with every day activities. 
Moderate: an event that is sufficiently discomforting to interfere with normal everyday 
activities. 
Severe: an event that prevents normal everyday activities. 
Note: the term ‘severe’, used to describe the intensity, should not be confused with ‘serious’ 
which is a regulatory definition based on participant/event outcome or action criteria.  For 
example, a headache may be severe but not serious, while a minor stroke is serious but may 
not be severe. 
10.5 REPORTING OF SAEs/SARs/SUSARs 
Once the Investigator becomes aware that an SAE has occurred in a study participant, the 
information will be reported to the ACCORD Research Governance & QA Office immediately 
or within 24 hours. If the Investigator does not have all information regarding an SAE, they 
should not wait for this additional information before notifying ACCORD.  The SAE report form 
can be updated when the additional information is received. 
The SAE report will provide an assessment of causality and expectedness at the time of the 
initial report to ACCORD according to Sections 10.4.2, Assessment of Causality and 10.4.3, 
Assessment of Expectedness. 
The SAE form will be transmitted by fax to ACCORD on +44 (0)131 242 9447 or may be 
transmitted by hand to the office or submitted via email to Safety.Accord@ed.ac.uk. Only 
forms in a pdf format will be accepted by ACCORD via email. 
Where missing information has not been sent to ACCORD after an initial report, ACCORD will 
contact the investigator and request the missing information.  
All reports faxed to ACCORD and any follow up information will be retained by the 
Investigator in the Investigator Site File (ISF). 
10.6 REGULATORY REPORTING REQUIREMENTS 
The ACCORD Research Governance & QA Office is responsible for pharmacovigilance 
reporting on behalf of the co-sponsors (Edinburgh University and NHS Lothian). 
The ACCORD Research Governance & QA Office has a legal responsibility to notify the 
regulatory competent authority and relevant ethics committee (Research Ethics Committee 
(REC) that approved the trial).  Fatal or life threatening SUSARs will be reported no later than 
7 calendar days and all other SUSARs will be reported no later than 15 calendar days after 
ACCORD is first aware of the reaction.   
ACCORD will inform Investigators at participating sites of all SUSARs and any other arising 
safety information. 
An Annual Safety Report/Development Safety Update Report will be submitted, by ACCORD, 
to the regulatory authorities and RECs listing all SARs and SUSARs. 
10.7 ASTRA ZENECA REPORTING REQUIREMENTS 
All SAEs will be reported to AstraZeneca within 7 days, whether or not considered causally 
related to the investigational product.   
The report will indicate, either in the SAE report or the cover page, the causality of events in 
relation to all study medications and if the SAE is related to disease progression, as 
determined by the principal investigator. 
A cover page/the SAE report will detail the following: 
• Investigator Sponsored Study (ISS) 
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• The Investigator IND number assigned by the FDA 
• The Investigator’s name and address 
• The trial name/title and AstraZeneca ISS reference number 
The SAE report will be sent [with the accompanying cover page] by fax to AstraZeneca’s 
designated fax line: 01582 838 010 or by email to: 
CRGSAERportingGlobalStudies@astrazeneca.com  
10.8 FOLLOW UP PROCEDURES 
After recording and reporting an SAE, the Investigator will follow each participant until 
resolution or death of the participant.  Follow up information on an SAE will be reported to the 
ACCORD office. 
After initially recording an AE, the Investigator should follow each AE until resolution of the 
event or until no longer medically indicated. 
11 PREGNANCY 
Woman of child-bearing potential will not be enrolled into the trial (woman who have 
experienced menarche, are pre-menopausal, have not been sterilised or who are currently 
pregnant). 
Pregnancy is not considered an AE or SAE; however, the Investigator will collect pregnancy 
information for any female participants or female partners of male participants who become 
pregnant while participating in the study.  The Investigator will record the information on a 
Pregnancy Notification Form and submit this to the ACCORD office within 14 days of being 
made aware of the pregnancy. 
All pregnant female participants and partners of male participants will be followed up until 
following the outcome of the pregnancy. 
All outcomes of pregnancy will be reported to AstraZeneca. 
12 TRIAL MANAGEMENT AND OVERSIGHT 
ARRANGEMENTS 
12.1 TRIAL MANAGEMENT GROUP 
The trial will be coordinated by a Project Management Group, consisting of the grant holders 
(Chief Investigator and Principal Investigator in Edinburgh) and a coordinating Clinical 
Research Facility nurse. 
The Principal Investigator will oversee the study and will be accountable to the Chief 
Investigator.  The Principal Investigator will be responsible for checking the CRFs for 
completeness, plausibility and consistency.  Any queries will be resolved by the Investigator 
or delegated member of the trial team.  
A Delegation Log will be prepared for each site, detailing the responsibilities of each member 
of staff working on the trial.   
12.2 TRIAL STEERING COMMITTEE 
A Trial Steering Committee (TSC) will be established to oversee the conduct and progress of 
the trial. The review of SAEs will be added to the TSC agenda to ensure that appropriate 
action is taken if any safety issues arise.   
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12.3 DATA MONITORING COMMITTEE 
In the PLATelet inhibition and patient Outcomes (PLATO) trial of 18,624 patients presenting 
with an acute coronary syndrome, ticagrelor was superior to clopidogrel for the prevention of 
cardiovascular events and death [Wallentin et al, 2009]. There were modest increases in the 
risks of bleeding and low rates of other side effects, such as dyspnoea. It is extremely unlikely 
that we will observe any substantial increased risk in our trial population given the small 
sample size of 250 patients and the very similar disease population in the PLATO trial that 
had a 100-fold larger trial population size. For this reason, an independent Data Monitoring 
Committee (DMC) will not be convened for this study and all study adverse events will be 
reported to the sponsors and AstraZeneca and will be discussed by the TSC. 
12.4 INSPECTION OF RECORDS 
Investigators and institutions involved in the study will permit trial related monitoring and 
audits on behalf of the sponsor, REC review, and regulatory inspection(s).  In the event of an 
audit or monitoring, the Investigator agrees to allow the representatives of the sponsor direct 
access to all study records and source documentation. In the event of regulatory inspection, 
the Investigator agrees to allow inspectors direct access to all study records and source 
documentation. 
12.5 RISK ASSESSMENT 
An independent risk assessment will be performed by an ACCORD Clinical Trials Monitor to 
determine if monitoring is required and if so, at what level. An independent risk assessment 
will also be carried out by the ACCORD Quality Assurance Group to determine if an audit 
should be performed before/during/after the study and if so, at what locations and at what 
frequency. 
12.6 BENEFIT/RISK BALANCE 
12.6.1 Benefits 
Patients may benefit from the treatment intervention. The benefits of ticagrelor in addition to 
standard medical therapy may include a reduction in the consequences and progression of 
coronary artery disease. In the PLATO trial [Wallentin et al, 2009], there appeared to be an 
ongoing and continuous improvement in outcomes beyond three months of an acute coronary 
syndrome. Ticagrelor may therefore have important ongoing secondary preventative benefits 
even in patients with apparently stable coronary artery disease. This is the rationale for the 
ongoing trial of the prevention of cardiovascular events in patients with prior myocardial 
infarction using ticagrelor compared with placebo on a background of aspirin: the PEGASUS 
trial (NCT01225562). 
Patients may also benefit from additional procedures and investigations that they will undergo 
as part of the study. This will include closer medical supervision and non-invasive imaging 
investigations that may identify important incidental findings. 
12.6.2 Risks 
The risks of ticagrelor principally relate to bleeding, transient bradyarrhythmias and dyspnoea. 
As with most anti-thrombotic treatments, there is a risk of excess bleeding. The incidence of 
excess major bleeding was modest and we will ensure robust exclusion criteria to prevent 
inclusion of patients at risk of bleeding. Bradyarrhythmias have been described but are 
generally transient and do not require intervention. We will record 12-lead electrocardiograms 
at subject visits and question patients regarding symptoms of dizziness and syncope. For 
dyspnea, there is a 14% rate of breathlessness associated with ticagrelor in the PLATO trial 
[Wallentin et al, 2009]. However, again this is usually mild and self-limiting, and 
discontinuation of study medication was necessary in only 1% of patients. 
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There are some potential hazards of the non-invasive investigations that we will perform as 
part of the trial. The main issues relate to exposure to ionising radiation and contrast agent 
administration. We have a well-developed protocol for cardiac positron emission and 
computed tomography imaging that minimizes radiation exposure and has clear procedures 
for managing adverse contrast reactions. We anticipate that the total research protocol dose 
(TPRD) radiation exposure will be 30 mSv. The TRPD includes radiation exposure from both 
the PET and CT scans combined.  The estimated associated risk of developing fatal cancer is 
proportional to dose.  Using a risk of 5% per Sv [ARSAC Notes] in a healthy population in this 
age group the estimated associated risk of developing fatal cancer as a result of this 
exposure is in the region 1 in 650.  This risk can be classified as moderate.  It is likely that in a 
population of any patients in the age group 40-50 years the cancer risk is approximately 5% 
per Sv (and correspondingly less than 5% per Sv as age increases above 50 years).  For 
comparison the average annual background radiation dose arising from natural sources of 
ionising radiation in the environment in the UK is 2.2 mSv.  The TRPD of 30 mSv incurred in 
this study is approximately 13-14 times annual background radiation from natural sources.   
An objective of this study is to assess reproducibility of NaF PET/CT.  A subgroup of 80 
subjects will receive a second PET/CT and additional CT coronary angiogram.  This 
increases the TRPD to 46 mSv in those subjects that have their repeat scan at the 
randomisation visit, 3 months or 6 months and to 38mSv in those that undergo their repeat 
scan at 12 months.  The associated risk of developing cancer as a result of this exposure is in 
the region of 1 in 450.  This risk can be classified as moderate.  A TRPD of 46 mSv is 
approximately 21 times annual background radiation from natural sources in the UK.  All 
subjects will have two CT coronary angiograms and those in the sub-studies returning at the 
randomisation visit, 3 months or 6 months will have 3 CT coronary angiograms.  We note that 
in occasional individual cases the effective dose from CT coronary angiography may increase 
to approximately 20 mSv, if the subject’s heart rate cannot be kept sufficiently low, requiring 
an alternative retrospective gating technique to be used. This will add approximately 12 mSv 
to the total research protocol dose for all subjects having CTCA. 
This can be compared with other commonly used cardiovascular imaging techniques, such as 
nucleotide myocardial perfusion imaging (15-20 mSv) and diagnostic coronary angiography (7 
mSv) [Einstein et al, 2007]. The risks of exposure to the contrast medium include allergic 
reactions and impairment of kidney function. Amongst patients with moderate-to-severe 
chronic kidney disease, there is a 2-4% risk of kidney impairment after computed tomography 
angiography [Barrett et al, 2006]. The risk of contrast exposure in this study will be minimised 
by exclusion of high-risk patients who have significant kidney disease (estimated glomerular 
filtration rate <30 mL/min/1.73m2). 
12.7 STUDY MONITORING AND AUDIT 
An ACCORD Clinical Trials Monitor or an appointed monitor will visit the Investigator site prior 
to the start of the study and during the course of the study if required, in accordance with the 
monitoring plan if required. Risk assessment will determine if audit, by the ACCORD QA 
group, is required. Details will be captured in an audit plan. Audit of Investigator sites, study 
management activities and study collaborative units, facilities and 3rd parties may be 
performed. 
13 GOOD CLINICAL PRACTICE 
13.1 ETHICAL CONDUCT 
The study will be conducted in accordance with the principles of the International Conference 
on Harmonisation Tripartite Guideline for Good Clinical Practice (ICH GCP). 
A favorable ethical opinion will be obtained from the appropriate REC and local R&D approval 
will be obtained prior to commencement of the study. 
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13.2 REGULATORY COMPLIANCE 
The study will not commence until a Clinical Trial Authorisation (CTA) is obtained from the 
appropriate Regulatory Authority. The protocol and study conduct will comply with the 
Medicines for Human Use (Clinical Trials) Regulations 2004, as amended. 
13.3 INVESTIGATOR RESPONSIBILITIES 
The Investigator is responsible for the overall conduct of the study at the site and compliance 
with the protocol and any protocol amendments.  In accordance with the principles of ICH 
GCP, the following areas listed in this section are also the responsibility of the Investigator.  
Responsibilities may be delegated to an appropriate member of study site staff.   
13.3.1 Informed Consent 
The Investigator is responsible for ensuring informed consent is obtained before any protocol 
specific procedures are carried out.  The decision of a participant to participate in clinical 
research is voluntary and should be based on a clear understanding of what is involved. 
Participants must receive adequate oral and written information – appropriate Participant 
Information and Informed Consent Forms will be provided.  The oral explanation to the 
participant will be performed by the Investigator or qualified delegated person, and must cover 
all the elements specified in the Participant Information Sheet and Consent Form. 
The participant must be given every opportunity to clarify any points they do not understand 
and, if necessary, ask for more information.  The participant must be given sufficient time to 
consider the information provided.  It should be emphasised that the participant may withdraw 
their consent to participate at any time without loss of benefits to which they otherwise would 
be entitled. 
The participant will be informed and agree to their medical records being inspected by 
regulatory authorities and representatives of the sponsor(s) but understand that their name 
will not be disclosed outside the hospital. 
The Investigator or delegated member of the trial team and the participant will sign and date 
the Informed Consent Form(s) to confirm that consent has been obtained.  The participant will 
receive a copy of this document and a copy filed in the Investigator Site File (ISF) and 
participant’s medical notes. 
13.3.2 Study Site Staff 
The Investigator must be familiar with the IMP, protocol and the study requirements.  It is the 
Investigator’s responsibility to ensure that all staff assisting with the study are adequately 
informed about the IMP, protocol and their trial related duties. 
13.3.3 Data Recording 
The Principle Investigator is responsible for the quality of the data recorded in the CRF at 
each Investigator Site. The source data plan identifies which source data correspond to CRF 
data and states which data are recorded directly into the CRF. 
13.3.4 Investigator Documentation 
Prior to beginning the study, each Investigator will be asked to provide particular essential 
documents to the ACCORD Research Governance & QA Office, including but not limited to: 
• An original signed Investigator’s Declaration (as part of the Clinical Trial Agreement 
documents); 
• Curriculum vitae (CV) signed and dated by the Investigator indicating that it is 
accurate and current. 
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The ACCORD Research Governance & QA Office will ensure all other documents required by 
ICH GCP are retained in a Trial Master File (TMF), where required, and that appropriate 
documentation is available in local ISFs. 
13.3.5 GCP Training 
All study staff must hold evidence of appropriate GCP training.  
13.3.6 Confidentiality 
All laboratory specimens, evaluation forms, reports, and other records must be identified in a 
manner designed to maintain participant confidentiality.  All records must be kept in a secure 
storage area with limited access.  Clinical information will not be released without the written 
permission of the participant.  The Investigator and study site staff involved with this study 
may not disclose or use for any purpose other than performance of the study, any data, 
record, or other unpublished, confidential information disclosed to those individuals for the 
purpose of the study.  Prior written agreement from the sponsor or its designee must be 
obtained for the disclosure of any said confidential information to other parties. 
13.3.7 Data Protection 
All Investigators and study site staff involved with this study must comply with the 
requirements of the Data Protection Act 1998 with regard to the collection, storage, 
processing and disclosure of personal information and will uphold the Act’s core principles. 
Access to collated participant data will be restricted to those clinicians treating the 
participants, representatives of the sponsor(s) and representatives of regulatory authorities. 
Computers used to collate the data will have limited access measures via user names and 
passwords. 
Published results will not contain any personal data that could allow identification of individual 
participants. 
14 STUDY CONDUCT RESPONSIBILITIES 
14.1 PROTOCOL AMENDMENTS 
Any changes in research activity, except those necessary to remove an apparent, immediate 
hazard to the participant in the case of a urgent safety measure, must be reviewed and 
approved by the Chief Investigator.   
Amendments to the protocol must be submitted in writing to the appropriate REC, Regulatory 
Authority and local R&D for approval prior to participants being enrolled into an amended 
protocol. 
14.2 PROTOCOL VIOLATIONS AND DEVIATIONS 
Prospective protocol deviations, i.e. protocol waivers, will not be approved by the sponsors 
and therefore will not be implemented, except where necessary to eliminate an immediate 
hazard to study participants. If this necessitates a subsequent protocol amendment, this 
should be submitted to the REC, Regulatory Authority and local R&D for review and approval 
if appropriate. 
Protocol deviations will be recorded in a protocol deviation log and logs will be submitted to 
the sponsors every 3 months. Each protocol violation will be reported to the sponsor within 3 
days of becoming aware of the violation. 
14.3 SERIOUS BREACH REQUIREMENTS 
A serious breach is a breach which is likely to effect to a significant degree: 
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(a) the safety or physical or mental integrity of the participants of the trial; or 
(b) the scientific value of the trial. 
If a potential serious breach is identified by the Chief investigator, Principal Investigator or 
delegates, the co-sponsors (accord.seriousbreach@ed.ac.uk) must be notified within 
24 hours.  It is the responsibility of the co-sponsors to assess the impact of the breach on the 
scientific value of the trial, to determine whether the incident constitutes a serious breach and 
report to regulatory authorities and research ethics committees as necessary.  
14.4 STUDY RECORD RETENTION 
All study documentation will be kept for a minimum of 5 years from the protocol defined end of 
study point. When the minimum retention period has elapsed, study documentation will not be 
destroyed without permission from the sponsor. 
14.5 END OF STUDY 
It is anticipated that the study will last 2 years: one year for recruitment and one year of 
follow-up. The end of study is defined as the last participant’s last visit.   
The Investigators and/or the trial steering committee and/or the co-sponsor(s) have the right 
at any time to terminate the study for clinical or administrative reasons.  
The end of the study will be reported to the REC and Regulatory Authority within 90 days, or 
15 days if the study is terminated prematurely.  The Investigators will inform participants of 
the premature study closure and ensure that the appropriate follow up is arranged for all 
participants involved. 
A summary report of the study will be provided to the REC and Regulatory Authority within 
1 year of the end of the study. 
14.6 CONTINUATION OF DRUG FOLLOWING THE END OF STUDY 
The study medication will not be continued at the trial conclusion as it is not currently licensed 
for use in stable coronary artery disease.  Patients will remain eligible to use ticagrelor for any 
approved indication however (i.e. for 12 months following an acute coronary syndrome). 
14.7 INSURANCE AND INDEMNITY 
The co-sponsors are responsible for ensuring proper provision has been made for insurance 
or indemnity to cover their liability and the liability of the Chief Investigator and staff. 
The following arrangements are in place to fulfil the co-sponsors' responsibilities: 
• The Protocol has been designed by the Chief Investigator and researchers 
employed by the University and collaborators.  The University has insurance in 
place (which includes no-fault compensation) for negligent harm caused by poor 
protocol design by the Chief Investigator and researchers employed by the 
University. 
• Sites participating in the study will be liable for clinical negligence and other 
negligent harm to individuals taking part in the study and covered by the duty of care 
owed to them by the sites concerned.  The co-sponsors require individual sites 
participating in the study to arrange for their own insurance or indemnity in respect 
of these liabilities. 
• Sites which are part of the United Kingdom's Nation Health Service will have the 
benefit of NHS Indemnity. 
• Sites out with the United Kingdom will be responsible for arranging their own 
indemnity or insurance for their participation in the study, as well as for compliance 
with local law applicable to their participation in the study. 
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• The manufacturer supplying IMP has accepted limited liability related to the 
manufacturing and original packaging of the study drug and to the losses, damages, 
claims or liabilities incurred by study participants based on known or unknown 
Adverse Events which arise out of the manufacturing and original packaging of the 
study drug, but not where there is any modification to the study drug (including 
without limitation re-packaging and blinding). 
15 REPORTING, PUBLICATIONS AND NOTIFICATION OF 
RESULTS 
15.1 AUTHORSHIP POLICY 
Ownership of the data arising from this study resides with the study team.  On completion of 
the study, the study data will be analysed and tabulated, and a clinical study report will be 
prepared in accordance with ICH guidelines.  
15.2 PUBLICATION 
The clinical study report will be used for publication and presentation at scientific meetings. 
Investigators have the right to publish orally or in writing the results of the study. 
Summaries of results will also be made available to Investigators for dissemination within their 
clinics (where appropriate and according to their discretion). 
15.3 PEER REVIEW 
The study protocol and outcomes data have been reviewed by AstraZeneca who have agreed 
to help support the conduct and part funding of this clinical trial.  There is additional peer 
review from the Trial Steering Committee and the Edinburgh Clinical Trials Unit statistician as 
well as the Medical Research Council. 
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FIGURE 1  Focal 18f-Fluoride Uptake in Patients with 
Myocardial Infarction and Stable Angina 
Patient with acute ST-segment elevation myocardial infarction with (A) proximal occlusion 
(red arrow) of the left anterior descending artery on invasive coronary angiography and (B) 
intense focal 18F-fluoride uptake (yellow-red) at the site of the culprit plaque (red arrow) on 
the combined positron emission and computed tomogram.  
Patient with anterior non-ST-segment elevation myocardial infarction with (C) culprit (red 
arrow; left anterior descending artery) and bystander non-culprit (white arrow; circumflex 
artery) lesions on invasive coronary angiography that were both stented during the index 
admission. Only the culprit lesion had increased 18F-fluoride uptake on combined positron 
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FIGURE 2:  Patients with Stable Angina and 18F-Fluoride 
Uptake 
Representative examples for 18F-fluoride uptake in patients with stable angina. Panels A-D, 
computed tomography coronary angiograms; panels E-H, 18F-fluoride positron emission 
tomograms; and panels I-L, fused positron emission tomograms and computed tomography 
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FIGURE 3:  High-Sensitivity Troponin I Levels in Patients With 
Stable Angina Who Have and Do Not Have Increased 
Coronary 18F-Fluoride Uptake 
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SUMMARY 
 
Abdominal aortic aneurysms have a prevalence of 5% in 65-74 year-old men and when 
ruptured, are associated with a mortality of up to 90%. Ruptured aortic aneurysms are a 
common cause of death in the United Kingdom, being the thirteenth commonest cause 
of death and accounting for 6,800 deaths each year in England and Wales.1 Open 
surgical or endovascular intervention to prevent rupture is considered when the aortic 
aneurysm diameter exceeds 55 mm or expansion rates are greater than 10 mm/year. 
 
Population screening halves the mortality associated with abdominal aortic aneurysms1 
and has led to the establishment of a national screening and surveillance programme. 
Currently, abdominal aortic aneurysm surveillance is complex because of the non-
linearity and unpredictability of expansion rates, although the best predictor of aneurysm 
expansion is the baseline aneurysm diameter. However, up to one fifth of ruptured 
abdominal aortic aneurysm are less than 55 mm in diameter2 and many patients present 
with diameters considerably greater than 55 mm without prior symptoms or rupture. 
Taken together, these data highlight the need for a more accurate method of rupture 
prediction that would better inform decisions to undertake preventative and potentially 
life-saving surgery. 
 
We have developed a novel magnetic resonance imaging method that is based upon the 
known biological processes underlying aneurysm expansion and rupture. For the first 
time, the MA3RS study proposes to assess this novel approach to identify aneurysms 
that are likely to expand more rapidly and potentially rupture. This technique would 
provide potentially important additional information to the current simplistic gold-
standard of ultrasound measurement of aneurysm diameter. 
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Aortic aneurysms frequently occur in patients with atherosclerosis and the two disease 
processes share several common risk factors. However, there are distinct differences. 
Atherosclerotic lesions are pre-dominantly located in the intima, whereas the media and 
adventitia are primarily involved in aneurysms. Aneurysm disease is also much more 
closely associated with smoking and hypertension, and has a particular predilection for 
the abdominal aorta. 
 
The formation, growth and rupture of aneurysms are now recognised to be the result of 
a complex interplay between biological and mechanical factors. Aneurysm tissue is 
characterised by excessive medial neovascularisation, infiltration of inflammatory cells 
(principally macrophages) and irreversible remodeling of the extracellular matrix. These 
pathological processes do not affect the aorta uniformly but are focal in nature.  Shear 
wall stress varies spatially within the aneurysm3 and tensile strength varies in different 
parts of the aneurysm sac.4 Focal neovascularisation occurs at the site of rupture and its 
presence corresponds to the degree of inflammation. These biological ‘hotspots’ 
represent sites of potential rupture and are putative targets for novel imaging strategies 
aiming to predict aneurysm expansion and assess the risk of rupture. In addition, tissue 
and wall stresses vary spatially within the aneurysm and tensile strength varies in 
different parts of the aneurysm sac. Synergy between these biological 'hotspots' and 
areas of intense biomechanical stress may be the focal point precipitating aneurysm 
rupture. Indeed, there is strong evidence that aneurysm rupture is seen in those patients 
with more rapid aneurysm expansion rates.5, 6  
 
1.1.1 Magnetic Resonance Imaging 
 
Magnetic resonance imaging is emerging as a useful investigative tool for 
cardiovascular disease that can distinguish the different atherosclerotic plaque 
components, such as the lipid-rich core and areas of calcification.7 Standard gadolinium-
based magnetic resonance imaging identifies areas of thrombus formation and fibrosis 
in abdominal aortic aneurysms.8 Newer contrast agents containing superparamagnetic 
particles of iron oxide (SPIO) have been developed that provide additional biological and 
functional information through the detection of cellular inflammation within tissues. 
Ultrasmall SPIO (USPIO), with particle sizes in the range 10-30 nm, escape immediate 
recognition by the reticulo-endothelial system and persist for longer in the bloodstream 
allowing them to be used to assess the accumulation of macrophages within vascular 
and lymphatic tissues.9, 10, 11, 12, 13 Current preparations are biodegradable and safe for 
clinical administration.14, 15, 16  
 
USPIO accumulate in the aortae of hypercholesterolaemic rabbits17 and in murine 
models of abdominal aortic aneurysms.18 In humans, USPIO accumulate in ruptured or 
rupture- prone carotid plaques rather than stable plaques,11, 12 and treatment with 
atorvastatin reduces both inflammation and USPIO uptake in carotid plaques.13  
 
We have recently conducted a series of magnetic resonance imaging studies in patients 
with abdominal aortic aneurysms and shown that uptake of USPIO in the aortic wall 
correlates with macrophage activity and identifies cellular inflammation.19, 20 Using a 3T 
magnetic resonance scanner, patients with asymptomatic abdominal aortic aneurysms 
(n=29; aneurysm diameter 4.0- 6.6 cm) attending our surveillance programme were 
imaged before and 24-36 hours after intravenous administration of USPIO. Histological 
examination of aneurysm tissue confirmed co-localization and uptake of USPIO in areas 
of macrophage infiltration (Figure 1).19  
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Figure 1.  Representative histological sections of the aortic wall. A, Haematoxoylin and eosin 
(x20) of the full thickness of the aortic wall including atherosclerotic plaque, adherent thrombus 
and periadventitial fatty tissue.  B, Elastin-van Gieson stain (x100) of the aortic wall showing 
complete destruction of the normal wall structure, including fibrosis (collagen, pink) of the media 
and adventitia and virtual absence of intact medial elastic fibers (black).  C, Prussian blue 
staining for iron demonstrating co-localisation of CD68-positive macrophages (x400; brown) with 
D, Ultrasmall super-paramagnetic particles of iron oxide particles (x400; blue), E, High power 
(x1000) Prussian blue staining shows intracytoplasmic accumulation of USPIO within 
macrophages. 
 
Furthermore, aortic aneurysms with mural USPIO uptake had a three-fold higher 
expansion rate when compared to abdominal aortic aneurysms with no or non-specific 
USPIO uptake despite similar baseline anteroposterior diameters (Figure 2).19 Indeed, 
one patient with substantial mural USPIO uptake died suddenly 2 months after scanning 
from presumed aneurysm rupture. We have therefore shown that this technique holds 
major promise as a new method of risk-stratification of patients with abdominal aortic 
aneurysm that extends beyond simple anatomical measurements of aneurysm diameter. 
 
 
Figure 2. USPIO uptake in the aortic wall (group 3; 45% of total population) predicted a 3-fold 
increase in aneurysm expansion rate despite similar aortic diameters. 
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To date, the assessment of USPIO uptake has been qualitative or based on relative 
changes in signal intensity within regions of interest defined by vessel quadrants.12, 13 
However, this change in signal intensity can be caused by other factors including 
imaging artifacts. During the process of our studies, we have developed a more robust 
semi-quantitative image acquisition methodology for the detection of iron nanoparticle 
accumulation in humans using 3T magnetic resonance imaging.19, 20 Here we apply a 
multi-echo gradient sequence to define the T2* value of the tissue. Images before and 
after USPIO administration are then co-registered and the difference in T2* value 
quantified. Following repeatability measurements in patients with abdominal aortic 
aneurysms, we have identified a threshold of change in signal  
intensity (59%) that defines USPIO accumulation in tissues (Figure 3).20  
 
 
Figure 3. A. Signal intensity as percentage of first echo time (4.9 ms) within the multi-echo 
sequence of pre-contrast and post- contrast images in areas of no (black circles), low (green 
triangles) and high (red squares) USPIO uptake. B. Frequency of voxels with per cent change in 
T2* for patients who did (red) or did not (blue) receive USPIO. The upper 95% threshold of per 
cent change in T2* in the absence of USPIO was 59%. 
 
1.1.2  Biomechanical Stress 
 
Another potential predictive marker of aneurysm rupture is wall tissue stress. Information 
on aneurysm geometry is provided by computed tomography and magnetic resonance 
imaging, and this can be combined with finite element analysis to enable prediction of 
tissue stresses within the aneurysm wall.3, 21 Peak wall tissue stress is higher in patients 
with symptomatic aneurysms22 and co-localises with regions of inflammation identified 
by 18F-fluorodeoxyglucose positron emission tomography.23  This suggests combining 
stress analysis with imaging of inflammation may provide added predictive value in the 
assessment of aneurysm expansion and potential rupture. 
 
1.2 RATIONALE FOR STUDY 
 
Ruptured AAA is the thirteenth commonest cause of death in the United Kingdom and 
accounts for 6,800 deaths each year in England and Wales. Population screening 
halves the mortality associated with AAA, and has led to the establishment of national 
screening and surveillance programmes. However, AAA surveillance is complex 
because of the non-linearity and unpredictability of expansion rates. Although the best 
predictor of aneurysm expansion is the aneurysm diameter, up to one fifth of ruptured 
AAA are less than 55 mm in diameter, and many patients present with diameters 
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considerably greater than 55 mm without prior symptoms or rupture. There is therefore a 
major unmet clinical need to predict aneurysm growth and rupture more accurately so 
that surgeons can better target preventative potentially life-saving surgery. We have 
developed a novel magnetic resonance imaging method that is based upon the known 
biological processes underlying aneurysm expansion and rupture. For the first time, this 
study proposes to assess this novel approach to identify aneurysms that are likely to 
expand more rapidly and potentially rupture. This technique would provide potentially 
important additional information to the current simplistic gold-standard of ultrasound 
measurement of aneurysm diameter. 
2 STUDY OBJECTIVES 
2.1 OBJECTIVES 
2.1.1 Primary Objective 
To determine whether mural uptake of USPIO provides incremental risk prediction in 
addition to standard risk markers such as aneurysm diameter, smoking and blood 
pressure. 
 
2.1.2 Secondary Objectives 
In patients under surveillance for abdominal aortic aneurysms, to determine whether 
mural uptake of USPIO: 
i. Correlates with the rate of aneurysm expansion 
ii. Occurs more commonly in patients who progress to surgery or whose 
aneurysm subsequently ruptures 
iii. Co-localises with, or relates to, areas of biomechanical stress 
iv. Occurs in a reproducible manner 
 
We will investigate other inter-related mechanisms associated with aneurysm growth. 
We will specifically explore the added value of biomechanical stress modeling as we 
suspect co-localisation of both USPIO uptake and areas of high mechanical stress could 
act synergistically and cause more marked aneurysm growth. We will also examine 
correlates with other blood biomarkers including regulators of extracellular matrix 
turnover (such as matrix metalloproteinases and tissue inhibitors of metalloproteinases) 
and vascular inflammation (such as C-reactive protein and interleukin-6). 
 
2.2 ENDPOINTS 
2.2.1 Primary Endpoint 
 
The primary end-point of the study will be the composite of aneurysm rupture or aortic 
aneurysm repair.  
 
2.2.2 Secondary Endpoints 
 
Secondary end-points will include: 
 
i. the rate of aneurysm rupture  
ii. the rate of surgical repair of the aneurysm 
iii. the aneurysm growth rate  
iv. all-cause and aneurysm-related mortality 
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We will conduct exploratory analyses examining the interactions between mural USPIO 
uptake, biomechanical stress, clinical risk factors and serum biomarkers of extracellular 
matrix turnover and inflammation. 
 
Clinicians involved directly with patient surveillance and care will be blinded to the 
magnetic resonance imaging findings of mural USPIO uptake. 
 
3 STUDY DESIGN 
The study will be a prospective observational cohort study of patients participating in 
abdominal aortic aneurysm surveillance programmes with blinded assessments of 
USPIO uptake. The study aims to recruit 350 participants in three study centres, with 
participants being followed up at six monthly intervals for 2 years.  
 
We aim to validate the findings of our previous proof-of-concept study,19 focusing on the 
relationship between baseline USPIO uptake and the subsequent clinical outcome and 
aneurysmal expansion rates. We will also look at the interplay between various risk 
factors affecting the growth rates and aneurysm-related adverse clinical events such as 
rupture, surgical repair, and death. This will lay the foundation for a large multicentre 
randomised controlled trial targeted at applying this technique to determine clinical 
management and surgical intervention. This will be particularly important given that 
screening programmes for the detection of abdominal aortic aneurysms are being rolled 
out across the United Kingdom and this is likely to increase substantially the number of 
patients being entered into surveillance programmes. 
 
Reproducibility of the technique will be assessed in a subgroup of study participants 
(from the Edinburgh study centre) who will undergo repeat magnetic resonance 
scanning and USPIO administration at 1 month and 1 year (n=20) and at 1 year only 
(n=60). Short-term (1 month) reproducibility is likely to reflect the variability in USPIO 
uptake whereas long-term (1 year) reproducibility is likely to represent the variation in 
biology of the aortic aneurysm with time. Patients recruited in Edinburgh who undergo 
elective surgery will also have AAA wall tissue collected and stored for the assessment 
of tissue resident macrophages and matrix metalloproteinases. Figure 4 shows the 
study flow chart. 
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Final 2 year assessments 
! Clinical assessment 
! Ultrasound scan 
! Computed Tomography scan 
! Blood sample collection 
! Pulse wave analysis 
 
Patients with abdominal aortic aneurysms (identified in surveillance 
program and other study site clinics) 
350 patients with abdominal aortic aneurysm > 40mm who meet 
inclusion and exclusion criteria AND who agree to take part 





! Clinical Assessment 
! Ultrasound scan (occurs as standard 
care and can occur up to 1 month prior 
to baseline assessment) 
! 3T Magnetic resonance scan 
! i.v. ferumoxytol 
! Computed Tomography scan with 
contrast (can be done on day 2) 
! Blood sample collection (can be 
done on day 2) 
! Pulse wave analysis (can be done on 
day 2) 
Day 2 (24-36 hours after Day 1): 
 
! 3T Magnetic resonance scan 
(post ferumoxytol) * 
 
6 Monthly assessments (6, 12 and 18 months) 
! Clinical assessment 
! Ultrasound scan 
! Blood sample collection (Edinburgh site only) 
! Pulse wave analysis (Edinburgh site only) 
317 Patients with 2 year follow up (allowing for drop-outs) 
* 20 patients will undergo MRI reproducibility assessments at 1 month and 1 year and 60 
will have the assessment at 1 year only. 
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4 STUDY POPULATION 
 
Participants will be identified from the clinical surveillance program and given a patient 
information leaflet about the study. Eligible participants who are interested in the study 
will attend a baseline visit where they will provide written informed consent. All other 
study assessments for this baseline visit and the visits though-out the study are detailed 
in section 7.2 
 
4.1 NUMBER OF PARTICIPANTS 
 
We will recruit 350 patients with abdominal aortic aneurysms from the clinical 
surveillance program.  Patients will be recruited from three centres; Royal Infirmary of 
Edinburgh, Western Infirmary in Glasgow and Forth Valley Royal Hospital.  Patients 
recruited from Edinburgh will undergo limited additional procedures. Full details are in 
section 7.2.  
 
4.2 INCLUSION CRITERIA 
1.   Abdominal aortic aneurysms measuring ≥40 mm in anteroposterior diameter on 
ultrasound scanning. 
2.   Age ≥40 years. Patients with abdominal aortic aneurysms less than 40 years 
may have a connective tissue disorder and a different aetiology to their disease. 
 
4.3 EXCLUSION CRITERIA 
1. Patients expected to, or already received, imminent elective or emergency 
surgical or endovascular repair. 
2.  Contraindication to magnetic resonance imaging scanning identified from 
magnetic resonance imaging safety questionnaire 
3.  Patients refusing or unable to give informed consent 
4.  Woman with child-bearing potential and who are breastfeeding will not be 
enrolled into the trial (woman who have experienced menarche, are pre-menopausal, 
have not been sterilised or who are currently pregnant). 
5. Intercurrent illness including patients with a systemic inflammatory disorder or 
underlying malignancy (life expectancy < 2 years) 
6.  Renal dysfunction (eGFR ≤30 mL/min/1.73m2)  
7.   Polycythemia 
8.  Contraindication to ferumoxytol (evidence of known iron overload, 
hemochromatosis, known hypersensitivity to ferumoxytol or its components or anaemia 
not caused by iron deficiency)9.  Contraindication to Iodine. 
10.     Patients with any known history of drug allergy (including hypersensitivity) to other 
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5 PARTICIPANT SELECTION AND ENROLMENT 
5.1 IDENTIFYING PARTICIPANTS 
Patients will be identified from the clinical surveillance programmes and databases in 
Edinburgh, Glasgow and Forth Valley. 
 
5.2 CONSENTING PARTICIPANTS 
Written informed consent will be obtained by a suitably qualified member of the research 
team at study entry.  
 
5.3 SCREENING FOR ELIGIBILITY 
Once patients have been identified from the surveillance service database, they will be 
seen at their surveillance ultrasound appointment (standard clinical care) and eligibility 
will be assessed.  Eligibility will be confirmed prior to consent. If patients are not seen in 
the ultrasound appointment, the study will be discussed with the patient over the phone 
and study information sent to them in the post. An appointment will be made for a 
baseline visit (where consent takes place) for all patients who are eligible and are 
interested in taking part. 
 
5.4 INELIGIBLE AND NON-RECRUITED PARTICIPANTS 
Ineligible and non-recruited patients will receive standard medical care. An anonymised 
log will be kept for patients who were screened for the study and subsequently found to 




Co-enrolment is permitted into the 18F-Sodium Fluoride Imaging of Abdominal Aortic 
Aneurysms (SoFIA3) substudy. Study participants at the Edinburgh site may be invited to 
take part in this sub-study, which is detailed in a separate protocol.   
Co-enrolment should not be considered with other interventional studies without prior 
discussion and agreement from the Sponsors and the Chief Investigators of both 
studies.  
 
5.6  PREMATURE WITHDRAWAL 
Participants are free to withdraw from the study at any point or a participant can be 
withdrawn by the investigator.  If withdrawal occurs, the primary reason for withdrawal 
will be documented in the participant’s Case Report Form (CRF). 
If a patient who has consented for the study states that they wish to be withdrawn from 
the study before they have been administered ferumoxytol, they will be withdrawn from 
the study and another participant will be recruited in their place.   
Clinicians should not withdraw participants who have received ferumoxytol but have not 
undergone the baseline MRI scanning protocol.  These participants should continue to 
be followed up.  
 
5.7 RANDOMISATION 
There is no randomisation in this study. 
 
6 INVESTIGATIONAL MEDICINAL PRODUCT AND PLACEBO 
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6.1 STUDY DRUG 
6.1.1 Study Drug Identification 
Rienso® (ferumoxytol) is composed of ultrasmall superparamagnetic particles of iron 
oxide (USPIOs) coated with polyglucose sorbitol carboxymethylether. It is supplied as 
an aqueous colloidal product that is formulated with mannitol and presented in single 
use vials 
 
6.1.2 Study Drug Manufacturer 
AMAG Pharmaceuticals Inc.Lexington, MA 02421, USA 
 
Takeda Italia Farmaceutici S.p.A. Via Crosa, 86, 28065 Cerano (NO), Italy are 
responsible for batch release. 
 
6.1.3 Marketing Authorisation Holder 
Takeda Pharma A/S, Langebjerg 1, DK-4000 Roskilde, Denmark 
 
6.1.4 Labelling and Packaging 
Rienso® is supplied in a labelled vial containing 510 mg of elemental iron in a volume of 
17mL of mannitol.  Each mL of the sterile colloidal solution contains 30 mg of elemental 
iron and 44 mg of mannitol. 
 
6.1.5 Storage 
Consistent with the Summary of Product Characteristics (November 2012), Rienso® will 
be stored in the original package in order to protect from light and will not be frozen. 
 
6.1.6 Summary of Product Characteristics or Investigators Brochure 
A copy of the latest version of the Summary of Product Characteristics (SmPC) is 
available in the Investigator Site File.  
 
6.2 PLACEBO 
No placebo will be used in this study. 
 
6.3 DOSING REGIME 
 
The single use vials are diluted and administered as an intravenous infusion over 15-30 
minutes.  The ferumoxytol dose (4.0 mg/kg) is diluted in sterile 0.9% sodium chloride up 
to a final concentration of 2-8 mg iron per mL. 
Patients should be reclined or in a semi-reclining position during infusion and for 30 
minutes thereafter.  Blood pressure (systolic and diastolic) will be recorded before 
ferumoxytol infusion and 30 minutes after the infusion to monitor for hypotension as 
detailed in the Summary of Product Characteristics.    
 
The single dose is given 24-36 hours before magnetic resonance imaging. 
In a subset of patients (n=20), repeated magnetic resonance imaging scans will be 
performed at 1 month and 1 year.  These patients will receive a further dose (4.0 mg/kg) 
of ferumoxytol 24 (± 6) - 36 hours before each magnetic resonance imaging (total of 3 
doses of ferumoxytol in one year).  
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A further subset of patients (n=60), repeated magnetic resonance imaging scans will be 
performed at 1 year only.  These patients will receive a further dose (4.0 mg/kg) of 
ferumoxytol 24 (± 6) - 36 hours before each magnetic resonance imaging (total of 2 
doses of ferumoxytol in one year).  
 
6.4 DOSE CHANGES 
All patients will receive the same dose (4.0 mg/kg) 24-36 hours before magnetic 
resonance imaging.   
In a subset of patients  (n=20), magnetic resonance imaging will be repeated at 1 month 
(± 1 week) and 1 year (± 1 month) to determine short and long-term reproducibility 
respectively. These patients will receive a further dose (4.0 mg/kg) of ferumoxytol 24 
(±6h) -36 hours before each magnetic resonance imaging (total of 3 doses of 
ferumoxytol in one year).  
Another subset of patients (n=60), repeated magnetic resonance imaging scans will be 
performed at 1 year (± 1 month) only.  These patients will receive a further dose (4.0 
mg/kg) of ferumoxytol 24 (± 6) - 36 hours before each magnetic resonance imaging 
(total of 2 doses of ferumoxytol in one year).  
All study participants who agree to be part of the reproducibility sub-study will consent 
for the extra scans.  Consecutive patients imaged in the Edinburgh centre will be 
approached until 20 patients have undergone repeated scanning at 1 month and 1 year 
and 60 patients have undergone repeated scanning at 1 year. 
 
6.5 PARTICIPANT COMPLIANCE 
Responsibility for the infusion of ferumoxytol will be with the research team. Timing and 
volume of administration will be noted in the CRF. Any reason for non-administration of 
the ferumoxytol will be noted. 
If intolerable side effects are experienced during the infusion of Ferumoxytol, the 




Overdose is unlikely as ferumoxytol will be prescribed and administered in the hospital. 
If accidental overdose is suspected, the patient will be followed up for signs of iron 
excess and will be referred for specialist assessment if appropriate. 
 
For 270 patients, a single dose of ferumoxytol will be administered.  In a random subset 
of patients  (n=20) magnetic resonance imaging will be repeated at 1 month (± 1 week) 
and 1 year (± 1 month) to determine short and long-term reproducibility respectively. 
These patients will receive a further dose (4.0 mg/kg) of ferumoxytol 24 (±6h) -36 hours 
before each magnetic resonance imaging (a total of 3 doses of ferumoxytol in one year 
and a total of 6 MRI scans). In a further subset of patients (n=60),  magnetic resonance 
imaging will be repeated at 1 year (± 1 month) only. These patients will receive a further 
dose (4.0 mg/kg) of ferumoxytol 24 (±6h) -36 hours before each magnetic resonance 
imaging (a total of 2 doses of ferumoxytol in one year and a total of 4 MRI scans).   The 
manufacturers have good evidence of repeated dosing of Ferumoxytol in more than 200 
patients, where repeat dosing occurred as short as 22 days, without adverse effect on 
the patient.  In addition, serial data from patients undergoing multiple MRIs over a 2-
week period, following a single dose of ferumoxytol show no residual ferumoxytol in the 
brain by 5-7 days. 
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Each dose of ferumoxytol equates to approximately 7% of total body iron. 
 
 
6.7 OTHER MEDICATIONS 
6.7.1   Buscopan 
20mg of intravenous Buscopan  (hyoscine butylbromide) will be given before each MRI 
scan.  If patients have a contraindication (allergic reaction, narrow angle glaucoma, 
paralytic ileus, myasthenia gravis, obstructive prostatic hypertrophy) to this drug they will 
not receive it but will proceed with MRI scanning. 
 
6.7.2 Permitted Medications 
Any other medication necessary for clinical care can be taken.   
 
For patients taking Metformin refer to section 7.1. 
 
6.7.3 Prohibited Medications 
Any other medication necessary for clinical care can be taken.  
For patients taking Metformin refer to section 7.1. 
7 STUDY ASSESSMENTS 
7.1 SAFETY ASSESSMENTS 
 
In patients with no history of renal disease, hypertension or diabetes, a normal eGFR 
within the last six months will be considered to be acceptable. For patients with risk 
factors for renal dysfunction or no blood tests within the last 6 months, clinical 
biochemical analysis of a blood sample will be performed prior to receiving contrast 
agent. 
 
All patients are advised to drink water prior to their scan for adequate hydration. 
For patients with a normal eGFR (60 mL/min/1.73m2) and taking Metformin they should 
continue taking the medication up until the scan.  After the scan they should withhold 
Metformin for 48 hours and then have a blood test to check renal function.  They will be 
informed when they are to restart the Metformin following the result of this. 
 
For patients with an eGFR 30 – 60  mL/min/1.73m2 and taking Metformin they will be 
advised to stop the medication for 48 hours before and 48 hours after the scan.  They 
will then have a blood test to check renal function and informed when they are to restart 
the Metformin following the result of this. 
 
These safety assessments are part of standard clinical care with regards to CT scanning 
with an intravenous contrast agent. 
 
The magnetic resonance imaging safety questionnaire will be applied to identify patients 
with a contraindication to scanning. 
Blood pressure (systolic and diastolic) will be recorded before ferumoxytol infusion and 
30 minutes after the infusion to monitor for hypotension as detailed in the Summary of 
Product Characteristics.   Patients should be reclined or in a semi-reclining position 
during infusion and for 30 minutes thereafter.   
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7.2 STUDY ASSESSMENTS 
A preliminary assessment of eligibility will be conducted by a suitably qualified member 




In patients that are to undergo elective repair of their aneurysms during the course of 
their follow-up, a repeat computed tomography scan may be performed immediately 
prior to surgery. 
 
Patients recruited in Edinburgh who undergo elective surgery will also have AAA wall 
tissue collected and stored for the assessment of tissue resident macrophages and 
matrix metalloproteinases. 
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Screening/Eligibility √       
Medical History/Demographics and concomitant 
medications 
 √      
Consent  √      
Ultrasound of AAA (Standard clinical care) √   √ √ √ √ 
Clinical Assessment  √  √ √ √ √ 
Pulse Wave analysis and velocity  √  √ ** √ ** √ ** √ 
Blood sampling  √  √ ** √ ** √ ** √ 
CT scan of AAA *  √      √ 
MRI scan of AAA (pre-ferumoxytol)  √      
i.v. administration of ferumoxytol  √      
Post ferumoxytol MRI scan of AAA   √     
AE/SAE Reporting   
SV = surveillance clinic; BV(a) = Baseline visit (occurs within 1 month of SV); BV (b) Baseline 
visit part B; 24-36 hours after part (a);  
• * Where patients are to undergo elective repair of their aneurysms during follow up, a 
repeat CT scan may be performed prior to surgery. 
• ** Bloods and pulse wave analysis will only occur every 6 months in Edinburgh only 
 

































Screening/Eligibility √          
Medical History/Demographics and 
concomitant medications 
 √         
Consent  √         
Ultrasound of AAA (Standard clinical 
care) 
√     √     
Clinical Assessment  √  √ √ √ √ √ √ √ 
Pulse Wave analysis and velocity  √    √   √ √ 
Blood sampling  √  √ √ √ √ √ √ √ 
CT scan of AAA  √        √ 
MRI scan of AAA (pre-ferumoxytol)  √  √   √  √ √ 
i.v. administration of ferumoxytol  √  √   √    
Post ferumoxytol MRI scan of AAA   √  √   √   
AE/SAE Reporting   
SV = surveillance clinic; BV (a)= Baseline visit; BV (b) Baseline visit part B; 24-36 hours after 
part (a); RP = Reproducibility visit where (b) is 24-36 hours after RP (a) 
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8 DATA COLLECTION 
 
8.1 CLINICAL ASSESSMENT 
Patients will have a full formal and standardized clinical assessment at baseline that 
will include history, examination, documentation of cardiovascular risk factor profile 
(smoking status, family history, hypertension, hyperlipidaemia, diabetes mellitus) and 
concomitant medications (anti-hypertensive medication, etc).  Concomitant medication 
will be recorded at baseline and at end of trial. 
Brachial artery systolic and diastolic blood pressure, pulse pressure, and mean arterial 
pressure will be measured after a 30-min supine rest period using an automated 
oscillometric sphygmomanometer (model 711, Omron Healthcare GmbH, Hamburg, 
Germany). The mean of three recordings will be taken.  
 
8.2 BLOOD SAMPLING 
Blood samples (20 mL on each visit) will be collected at baseline and at 24 months for 
patients for routine biochemistry and haematology (including full blood count, U&Es, 
Liver Function Tests, total cholesterol and glucose) 
For patients recruited and imaged in the Edinburgh centre a blood sample will be 
processed (plasma and serum) and stored at -80°C fo r later analysis of potential 
extracellular matrix and inflammatory biomarkers.   This will happen at baseline, 6, 
12,18 and 24 months. Full details for processing and shipment of serum biomarker 
samples will be provided in the ISF.  
 
8.3 PULSE WAVE ANALYSIS AND VELOCITY 
Pulse wave analysis and velocity will be measured in triplicate using the 
SphygmoCorTM apparatus (AtCor Medical, Sydney Australia) as previously described 
[McLeod et al, 2004]. This will facilitate the measurement of central aortic pressure to 
assist in the modelling of biomechanical stress within the aneurysm.  This will be 
measured at baseline and every 6 months (6,12,18 and 24 months) for the patients 
recruited at the Edinburgh centre. This procedure will be carried out at baseline and at 
24 months for patients in other recruiting centres.  Pulse wave analysis and velocity 
measurements should always be done before the MRI scan and CT scans (this can be 
on day 1 or day 2 of the baseline visit).  Patients will be fasted for this procedure. 
In some instances, it may not be possible to perform pulse wave analysis and pulse 
wave velocity on some of the study patients. For example, if they are in atrial fibrillation 
or a weak pulse. In these instances, we will record that it was not possible to obtain 
these measurements and no further measurements will be obtained at the relevant 
follow up timelines. 
 
8.4 ULTRASOUND OF THE ABDOMINAL AORTA 
 
Patients will undergo 6-month ultrasound imaging as part of standard care for the 
surveillance programme to measure the maximal anteroposterior diameter of the 
aneurysm (Ultrasound scans should be every 6 months ± 2 months from the last 
ultrasound scan) A 3.5-MHz linear array transducer will be used to provide standard 
real time longitudinal B-scan images of the abdominal aortic aneurysm at the point of 
maximum diameter. Maximum anteroposterior abdominal aortic aneurysm diameter 
and distensibility (pressure strain elastic modulus and stiffness) will be assessed. 
Scans will be undertaken by accredited clinical vascular scientists with interobserver 
coefficient of variation of aortic diameter measurements of 3.5% in our laboratory.24  
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8.5 COMPUTED TOMOGRAPHY OF THE ABDOMINAL AORTA 
 
Contrast enhanced images of the abdominal aorta will be obtained using a 320-
multidetector computed tomography scanner (Aquilion ONE; Toshiba) or a 64 slice 
multi-detector computed tomography detector (Brilliance 64; Philips_at baseline and 2 
years at either the Clinical Research Imaging Centre or the Western Infirmary of 
Glasgow. These data will be reconstructed into three dimensions using volumetric 
matrices to enable a more comprehensive assessment of the aneurysm geometry and 
growth than that provided by the ultrasound assessment of the unidimensional aortic 
anteroposterior diameter. In cases where study participants undergo emergency repair 
of a ruptured abdominal aortic aneurysm then a CT scan may not be performed. In the 
event of patients not receiving the CT scan at baseline (due to a CT scanner issue, or 
other clinical issue), the CT scan will be performed within 1 month of the baseline visit. 
 
8.6 MAGNETIC RESONANCE IMAGING OF THE ABDOMINAL AORTA 
 
Magnetic resonance imaging will be conducted using a 3T Siemens Magnetom Verio 
scanner (Siemens, Erlangen, Germany) before and 24-36 hours after administration of 
the USPIO in Edinburgh or Glasgow. Patients will be given intravenous buscopan 
(hyoscine butylbromide), prior to imaging to minimise bowel motion artifacts. Routine 
clinical coronal and sagittal breath-held T2-weighted multi-slice HASTE sequences will 
be used to identify the position and extent of the aneurysm following which a 
respiratory-gated, electrocardiographically-triggered T2 weighted (T2W) turbo- spin 
echo sequence will be used to acquire detailed anatomical data (TR/TE 2R-R 
intervals/72 ms; flip angle 180°; matrix 192 x 256;  field of view 400 x 400 mm; slice 
width 5 mm). A multi-echo, gradient-echo T2*W sequence (TE 4.9, 7.7, 10.5, 13.3 ms; 
TR 133 ms; flip angle 15°; matrix 192 x 256; field of view 400 x 400 mm; slice width 5 
mm) will be used to acquire contiguous axial images of the entire aneurysm (from the 
neck of the aneurysm down to the iliac bifurcation) with slice positions corresponding to 
those of the T2W images. 
 
8.7 FOLLOW UP FOR PATIENTS IN CERTAIN CIRCUMSTANCES 
If a patient undergoes an open or endovascular repair of their AAA they will not return 
routinely for US or pulse wave analysis or velocity every 6 months but  will be invited to 
return every 6 months for blood tests and at 2 years for a CT scan. 
If a patient is considered not fit for elective surgery then they would normally be 
discharged from the care of the Vascular Surgeons.  However, we will invite these 
patients to attend for the standard study assessments. 
 
9 STATISTICS AND DATA ANALYSIS 
9.1 SAMPLE SIZE CALCULATION 
The sample size is determined by the numbers required to build robust prognostic 
models for rupture and/or surgical repair, and in particular to measure the additional 
prognostic value of mural USPIO uptake when added to such a prognostic model 
based only on conventional clinical risk factors. There is a widely accepted ‘rule of 
thumb’ that one needs at least 10 and ideally 20 outcome events per covariate to be 
included in a prognostic model.25 As described in more detail below, we plan to use the 
net reclassification index (NRI) as the primary measure of the clinical relevance of the 
added prognostic value of mural USPIO uptake.26, 27 Based on two recent papers using 
the NRI,28, 29 and also taking account of the Harrell ‘rule of thumb, we estimate that we 
need to observe 130 events (i.e. the composite of rupture or surgical repair) to have 
adequate sensitivity to answer the primary question. With our estimated event rate of 
41% over the mean duration of follow-up of two years,30 this equates to 317 patients.  
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There should be very modest losses to follow up for the primary analysis, since all 
study recruits are already enrolled on a surveillance programme. Moreover we shall 
seek consent at the time of recruitment to flag the patients so that if any patients are 
lost to follow up they can be traced to identify any hospital admissions or to identify if 
they have died. In addition, some patients will drop out due to technical failure of the 
scan, such as claustrophobia or poor image quality. We have therefore conservatively 
accounted for a 10% drop-out rate and we will recruit 350 patients to the study. 
 
9.2 PROPOSED ANALYSES 
 
9.2.1 Image analysis of ultrasound 
 
Cursors will be locked onto echoes representing the anterior and posterior aortic walls 
and the movement of both tracked with each cardiac cycle. The longitudinal image will 
be used for analysis as experience with the technique and data from formal 
reproducibility studies indicates that the quality of the data obtained from a longitudinal 
section is superior to that obtained from a transverse view. Images will be captured 
digitally for later off-line core laboratory review. 
 
9.2.2 Image analysis of computed tomography 
 
Computed tomography of the abdominal aorta will be performed at baseline and 2 
years to assess regional and volumetric growth rates. These two computed 
tomography scans will be spatially co-registered so that areas of expansion and growth 
can be more accurately defined and permit correlation with areas of USPIO uptake and 
fine element analysis modeling. 
 
Three-dimensional computer models will be generated from segmented, contrast-
enhanced images allowing geometric indices to be quantified. Semi-automatic 
segmentation is achievable due to the intensity differences between the aneurysm and 
surrounding tissues and structures. Intensity thresholding will be used to identify the 
lumen. To detect the thrombus and complete the segmentation, we will use a 3-D 
deformable model approach that utilises the level set algorithm as well as modeling the 
thrombus contour as a radial function starting from the aortic centre line as calculated 
from the lumen segmentation. 
 
9.2.3 Image analysis of magnetic resonance imaging 
 
A region of interest (ROI) encompassing the aortic wall and thrombus but excluding the 
lumen will be drawn on each slice of the pre-contrast T2W image. The pre-contrast 
T2W scan will be used as the base image to which subsequent scans will be co-
registered using a semi-automatic rigid three-dimensional voxel registration protocol 
utilising a normalised mutual information algorithm. To minimise the contribution of 
bowel and abdominal wall motion in the magnetic resonance imaging datasets, a 
region for registration will include the aorta, vertebrae and spinal musculature that 
remain relatively static during the respiratory cycle but exclude the more mobile 
abdominal wall and bowel. 
 
The four echoes in the multi-echo T2*W sequence will be combined to generate T2* 
and R2* maps. The T2* value is the decay constant for the exponential decay of signal 
intensity with time (Figure 3) and its inverse is the R2* value. A 3 x 3 voxel Gaussian 
filter will be applied to the individual echoes to reduce noise, and the co-efficient of 
determination will be used to exclude data that do not have an acceptable straight line 
fit when ln(signal intensity) is plotted against echo time. Images will be co-registered to 
allow direct comparison of the pre-and post-contrast T2*W magnetic resonance 
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images. USPIO uptake will be presented visually as a colour map of per cent change in 
T2* or R2* values between pre- and post-USPIO scans, with our previously validated 




The change in T2* or R2* colour maps from the magnetic resonance images will be 
spatially co-registered to the computed tomography datasets. 
 
9.2.4 Finite element and stress analysis 
 
Using Abaqus, the vessel wall will be modeled as a constant thickness layer of 1.5 mm, 
with a hyperelastic constitutive model. Thrombus will be modeled as homogenous and 
isotropic with Young’s modulus 0.1 MPa. The model will be inflated from diastolic to 
systolic pressure using a homogeneous pressure-modeling regime. Peak wall stress 
and other rupture indices will be calculated and compared against areas of USPIO 
uptake. 
 
9.2.5 Statistical analysis 
 
The baseline assessment will include the baseline aneurysm diameter, sex, smoking 
habit and blood pressure. Using these covariates, a prognostic model predicting the 
time to the composite outcome event of rupture or surgical repair will be developed 
using Cox proportional hazards regression. The added prognostic value of adding 
mural USPIO uptake to this model will be assessed using the increase in the area 
under the receiver operator characteristic (ROC) curve, the Nagelkerke partial R2, and 
primarily, the net reclassification index.26, 27  The NCI is a direct measure of the clinical 
relevance of adding a covariate to a prognostic model. It is an overall measure of how 
many patients move from a low predicted risk to a high predicted risk when the 
covariate is added (and whether these individuals are indeed high risk), and how many 
move from a high predicted risk to a low predicted risk (and whether these individuals 
are indeed low risk). For the primary analysis, the USPIO will be taken as a binary 
covariate (as in Richards et al, 2011a), but a sensitivity analysis will explore the 
potential for including a quantification of the USPIO uptake. Some but not all of the 
patients will also have a measure of current aneurysm growth rate at baseline, and a 
further sensitivity analysis will explore using grown rate as a further prognostic factor, 
using imputation when the estimated growth rate is not available. 
 
A secondary analysis will follow a similar analytical strategy to that set out above, but 
using prognostic models to predict aneurysm growth rate. This analysis will be far more 
complex with there being serial measures of aneurysm diameter, and with these 
measurements being censored on rupture or on surgical repair. Further exploratory 
analysis will look at the predictive ability of measures of wall stress and how these 
interact with regional USPIO uptake. 
 
The analysis will be conducted by the study statistician, Catriona Graham (Senior 
Statistician Wellcome Trust Clinical Research Facility), under the supervision of 
Gordon Murray (Professor of Medical Statistics).  
 
Figure 4.  Colour map of magnetic resonance imaging 
of an abdominal aortic aneurysm.  Red and yellow 
pixels indicate areas of increase T2* value, indicative of 
USPIO uptake. 
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Reproducibility of the technique will be assessed in a subgroup of study participants 
who will undergo repeat magnetic resonance scanning and USPIO administration at 1 
month and 1 year (n=20) or at 1 year only (n=60). Short-term (1 month) repeatability is 
likely to reflect the variability in USPIO uptake whereas long-term (1 year) 
reproducibility is likely to represent the variation in biology of the aortic aneurysm with 
time. Subjects will be categorised with respect to the presence or absence of USPIO 
uptake to define the proportionate agreement, with 95% confidence intervals.   
10 ADVERSE EVENTS 
The Investigator is responsible for the detection and documentation of events meeting 
the criteria and definitions detailed below.   
Full details of contraindications and side effects that have been reported following 
administration of the IMP can be found in the relevant Summary of Product 
Characteristics (SmPC). 
Participants will be instructed to contact their Investigator at any time after consenting 
to join the study if any symptoms develop.  All adverse events (AE) that require medical 
attention (for example, visit to a GP, hospital etc) which occur after having received 
ferumoxytol must be reported in detail in the Case Report Form (CRF) or AE form.  In 
the case of an AE, the Investigator should initiate the appropriate treatment according 
to their medical judgment.  Participants with AEs present at the last visit must be 
followed up until resolution of the event.  For patients that have an aneurysm rupture or 
repair (elective or emergency), this will be recorded in the AAA case report form and 
entered into the database (this is one of secondary outcomes).  This event will not be 
recorded as an AE. 
10.1 DEFINITIONS 
An adverse event (AE) is any untoward medical occurrence in a clinical trial participant 
which does not necessarily have a causal relationship with an investigational medicinal 
product (IMP). 
An adverse reaction (AR) is any untoward or unintended response to an IMP which is 
related to any dose administered to that participant.  
An unexpected adverse reaction (UAR) is an adverse reaction that is not consistent 
with the applicable product information for the IMP, e.g. the Investigator Brochure (IB) 
for a non licensed IMP or the SmPC for a licensed product. 
A serious adverse event (SAE), serious adverse reaction (SAR) or suspected 
unexpected serious adverse reaction (SUSAR) is any AE, AR or UAR that at any 
dose: 
• results in death; 
• is life threatening* (i.e. the participant was at risk of death at the time of the 
event; it does not refer to an event which hypothetically might have caused 
death if it were more severe); 
• requires in-patient hospitalisation or prolongation of existing hospitalisation; 
• results in persistent or significant disability or incapacity; 
• is a congenital anomaly or birth defect. 
 
10.2 DETECTING AEs AND SAEs 
All AEs and SAEs will be recorded from the time a participant signs the consent form to 
take part in the study until the last study visit.  
Participants will be asked about the occurrence of AEs/SAEs at every visit during the 
study.  Open-ended and non-leading verbal questioning of the participant will be used 
to enquire about AE/SAE occurrence.  Participants will also be asked if they have been 
admitted to hospital or had any accidents. If there is any doubt as to whether a clinical 
observation is an AE, the event will be recorded. 
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AEs and SAEs may also be identified by support departments e.g. laboratories. 
 
10.3 RECORDING AEs AND SAEs 
When an AE/SAE occurs, it is the responsibility of the Investigator to review all 
documentation (e.g. hospital notes, laboratory and diagnostic reports) related to the 
event.  The Investigator will then record all relevant information in the CRF and on the 
SAE form (if the AE meets the criteria of serious). 
Information to be collected includes dose, type of event, onset date, Investigator 
assessment of severity and causality, date of resolution as well as treatment required, 
investigations needed and outcome.   
10.4 ASSESSMENT OF AEs AND SAEs 
Seriousness, causality, severity and expectedness will be assessed as though the 
participant is taking active IMP.  The Investigator is responsible for assessing each AE.   
The Chief Investigator (CI) may not downgrade an event that has been assessed by an 
Investigator as an SAE or SUSAR, but can upgrade an AE to an SAE, SAR or SUSAR 
if appropriate. 
10.4.1 Assessment of Seriousness 
The Investigator will make an assessment of seriousness as defined in Section 10.1. 
 
10.4.2 Assessment of Causality 
The Investigator will make an assessment of whether the AE/SAE is likely to be related 
to the IMP according to the definitions below.   
All AEs/SAEs judged as having a reasonable suspected causal relationship (e.g. 
possibly related or unrelated) to the IMP will be considered as related to the IMP 
(ARs/SARs).   
Where non Investigational Medicinal Products (NIMPs) e.g. rescue/escape drugs are 
given:  if the AE is considered to be related to an interaction between the IMP and the 
NIMP, or where the AE might be linked to either the IMP or the NIMP but cannot be 
clearly attributed to either one of these, the event will be considered as an AR/SAR. 
Unrelated: where an event is not considered to be related to the IMP. 
Possibly related: The nature of the event, the underlying medical condition, 
concomitant medication or temporal relationship make it possible that the AE has a 
causal relationship to the study drug. 
Probably related: The temporal relationship and absence of a more likely explanation 
suggest the event could be related to the study drug. 
Definitely related: The known effects of the study drug or its therapeutic class, or 
based on challenge testing, suggest that study drug is the most likely cause. 
Alternative causes such as natural history of the underlying disease, other risk factors 
and the temporal relationship of the event to the treatment should be considered and 
investigated.  
10.4.3 Assessment of Severity 
The Investigator will make an assessment of severity for each AE/SAE and record this 
on the CRF or AE form according to one of the following categories: 
Mild: an event that is easily tolerated by the participant, causing minimal discomfort 
and not interfering with every day activities. 
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Moderate: an event that is sufficiently discomforting to interfere with normal everyday 
activities. 
Severe: an event that prevents normal everyday activities. 
Note: the term ‘severe’, used to describe the intensity, should not be confused with 
‘serious’ which is a regulatory definition based on participant/event outcome or action 
criteria.  For example, a headache may be severe but not serious, while a minor stroke 
is serious but may not be severe. 
10.4.4 Assessment of Expectedness 
If an event is judged to be an AR/SAR, the evaluation of expectedness will be made 
based on knowledge of the reaction and the relevant product information documented 
in the SmPC/IB. 
The event may be classed as either: 
Expected: the AR is consistent with the toxicity of the IMP listed in the SmPC/IB. 
Unexpected: the AR is not consistent with the toxicity in the SmPC/IB. 
 
10.5 REPORTING OF SAEs/SARs/SUSARs 
Once the Investigator becomes aware that an SAE has occurred in a study participant, 
the information will be reported to the ACCORD Research Governance & QA Office 
immediately or within 24 hours. If the Investigator does not have all information 
regarding an SAE, they should not wait for this additional information before notifying 
ACCORD.  The SAE report form can be updated when the additional information is 
received. 
The SAE report will provide an assessment of causality and expectedness at the time 
of the initial report to ACCORD according to Sections 10.4.2, Assessment of Causality 
and 10.4.4, Assessment of Expectedness. 
The SAE form will be transmitted by fax to ACCORD on +44 (0)131 242 9447 or may 
be transmitted by hand to the office. 
All reports faxed to ACCORD and any follow up information will be retained by the 
Investigator in the Investigator Site File (ISF). 
 
10.6 REGULATORY REPORTING REQUIREMENTS 
The ACCORD Research Governance & QA Office is responsible for pharmacovigilance 
reporting on behalf of the co-sponsors (Edinburgh University and NHS Lothian). 
The ACCORD Research Governance & QA Office has a legal responsibility to notify 
the regulatory competent authority and relevant ethics committee (Research Ethics 
Committee (REC) that approved the trial).  Fatal or life threatening SUSARs will be 
reported no later than 7 calendar days and all other SUSARs will be reported no later 
than 15 calendar days after ACCORD is first aware of the reaction.   
ACCORD will inform Investigators at participating sites of all SUSARs and any other 
arising safety information. 
An Annual Safety Report will be submitted to the regulatory competent authority and 
main REC listing all SARs and SUSARs. 
 
10.7 FOLLOW UP PROCEDURES 
After initially recording an AE or recording and reporting an SAE, the Investigator will 
follow each participant until resolution or death of the participant.  Follow up information 
on an SAE will be reported to the ACCORD office. 
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AEs still present in participants at the last study visit will be monitored until resolution of 
the event or until no longer medically indicated. 
11. PREGNANCY 
Woman with child-bearing potential will not be enrolled into the trial (woman who have 
experienced menarche, are pre-menopausal, have not been sterilised or who are 
currently pregnant). 
12 TRIAL MANAGEMENT AND OVERSIGHT ARRANGEMENTS 
12.1 TRIAL MANAGEMENT GROUP 
The study will be coordinated by a Project Management Group, consisting of the grant 
holders (Chief Investigator and Principal Investigator in Edinburgh), Trial Manager and 
coordinating nurse. 
The Trial Manager will oversee the study and will be accountable to the Chief 
Investigator.  The Trial Manager will be responsible for checking the CRFs for 
completeness, plausibility and consistency.  Any queries will be resolved by the 
Investigator or delegated member of the study team.  
A Delegation Log will be prepared for each site, detailing the responsibilities of each 
member of staff working on the study.   
 
12.2 TRIAL STEERING COMMITTEE 
A Trial Steering Committee (TSC) will be established to oversee the conduct and 
progress of the study, in particular the TSC will monitor the trial event rate. The terms 
of reference of the Trial Steering Committee, the draft template for reporting and the 
names and contact details are detailed in the TSC charter. 
 
12.3 DATA MONITORING COMMITTEE 
An independent Data Monitoring Committee (DMC) will not be convened for this study. 
The investigators will report all adverse events to the Sponsor and the Trial Steering 
Committee. As there is no blinded intervention and the investigational medicinal 
product will be given to all subjects, there is no risk to the scientific integrity of the study 
or requirement for a DMC. 
 
12.4 INSPECTION OF RECORDS 
Investigators and institutions involved in the study will permit trial related monitoring 
and audits on behalf of the sponsor, REC review, and regulatory inspection(s).  In the 
event of an audit or monitoring, the Investigator agrees to allow the representatives of 
the sponsor direct access to all study records and source documentation. In the event 
of regulatory inspection, the Investigator agrees to allow inspectors direct access to all 
study records and source documentation. 
 
12.5 RISK ASSESSMENT 
An independent risk assessment will be performed by an ACCORD Clinical Trials 
Monitor to determine if monitoring is required and if so, at what level. An independent 
risk assessment will also be carried out by the ACCORD Quality Assurance Group to 
determine if an audit should be performed before/during/after the study and if so, at 
what locations and at what frequency. 
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12.5.1 RISKS 
 
The risks to the participants of the study are very modest and are mainly attributable to 
the magnetic resonance and computed tomography scans and their respective contrast 
agents. 
 
12.5.1.1 Magnetic resonance imaging 
 
Magnetic resonance imaging is a standard clinical imaging technique that is applied 
across the world. Contraindications for magnetic resonance imaging are the presence 
of certain metallic objects, electrical devices and claustrophobia. Patients with 
implanted electrical devices, such as pacemakers or defibrillators, will be excluded. We 
have the provision of a wide-bore scanner (diameter, 70 cm) that will minimise the risk 




Ferumoxytol (Rienso®) was originally developed for the treatment of iron-deficiency 
anaemia in patients with chronic kidney disease. It consists of a suspension of USPIO 
with an ultrasmall core (diameter ~7 nm) and a semi-synthetic carbohydrate coating 
giving an overall particle size of 30 nm. The size of the particle prevents any early 
redistribution outside the vascular space and therefore can act as a blood-pool imaging 
agent with a plasma elimination half-life of approximately 10 - 14 hours in humans. 
 
Herborn and colleagues examined the utility of ferumoxytol for imaging atheroma in the 
aortae of hyperlipidaemic rabbits using a 1.5T magnetic resonance scanner.31 
Susceptibility artifacts were detectable in the aortic wall at day 2 to 3 post 
administration of contrast. Signal voids were observed as a result of T2/T2* effects and 
were more homogenous than those seen in similar animals administered ferumoxtran-
10. Histology revealed the accumulation of iron particles under the endothelium and 
into the medial layer of diseased vessels.31  
 
Ferumoxytol has been administered safely as a bolus dose of 4 mg/kg for use as a 
magnetic resonance imaging contrast agent in humans.32, 33, 34, 35, 36 Most of these 
studies have examined and confirmed its utility as a blood-pool contrast agent. 
However, it has also been assessed for its use in lymph node imaging for cancer 
staging. In a study of patients with prostate cancer, ferumoxytol was administered at 4 
mg/kg and imaging performed at baseline, 5, 8 and 24 hours post dose using a 1.5 T 
scanner. Maximum signal-to-noise ratio was observed in lymph nodes at 24 hours on 
T2*-weighted MR imaging.37  
 
Ferumoxytol is generally very well tolerated. We have administered ferumoxytol to 16 
patients with abdominal aortic aneurysms, 28 patients who have undergone coronary 
artery bypass surgery and 12 patients with a recent acute myocardial infarction. None 
have experienced any significant major side-effects or serious adverse events. One 
subject did experience brief muscle cramps; a previously reported mild side effect. 
Common reported side-effects of ferumoxytol include constipation, diarrhoea, dizziness 
and nausea. Reported severe reactions include serious hypersensitivity reactions and 
hypotension, but are rare. 
 
Buscopan is an anticholinergic drug and is generally used to provide relief from spasm 
of the genito-urinary tract or gastro-intestinal tract. In this study it is used to minimise 
bowel motion during the imaging protocol of this study to decrease artefacts seen due 
to digestive movements. Any side effects reported are uncommon or rare and consist 
of dry mouth and constipation. 
 
 
MA3RS Protocol V 7 05/08/2014  
Page 30 of 37 
12.5.1.3 Computed tomography 
 
As part of the protocol, subjects will receive two extra computed tomography scans 
with intravenous contrast. This will expose the patient to ionising radiation (~6 mSv per 
scan for the Glasgow centre and 3mSv in Edinburgh centre) and the potential hazard of 
allergic reactions and transient renal dysfunction in response to the contrast agent. 
Thus the maximum total research protocol dose is 12 mSv. 
 
The level of dose is comparable to the average cumulated dose from 5 years of natural 
background radiation to the UK population. It is equal to 60% of the whole body dose 
limit for radiation workers. 
 
The associated excess risk of death from radiation induced cancer is approximately 1 
in 3000 compared with the cancer mortality rate in the UK of just over 1 in 4.  
 
The risks of exposure to the contrast medium include allergic reactions and impairment 
of kidney function. Amongst patients with moderate-to-severe chronic kidney disease, 
there is a 2-4% risk of kidney impairment after computed tomography angiography.38 
The risk of contrast exposure in this study will be minimised by exclusion of high risk 





Patients will benefit from inclusion in a clinical study that includes close clinical 
supervision. Based on our previous studies and the demographics of the study 
population, the study may identify other important clinical conditions that require 
intervention or treatment because of incidental findings on the magnetic resonance or 
computed tomography scans. This could be viewed as a potential risk but most 
patients are grateful if covert conditions are detected early and treated more promptly. 
In addition, patients will benefit from the additional and closer supervision and care that 
clinical studies deliver. 
 
Society and some of the participants will benefit if the findings of our study demonstrate 
that USPIO can successfully identify which patients are at risk of more rapid aneurysm 
expansion and clinical events. This is the main purpose of the study and we hope this 




The risks associated with the additional scans and the administration of contrast agents 
are very low and consistent with many routine clinical imaging procedures. Conversely, 
if this technique is proven to be successful, the major gains in risk stratification and 
better selection of patients with abdominal aortic aneurysms who should receive 
surgical intervention, could have major morbidity and mortality benefits. Deferring 
unnecessary major surgery or bringing forward potentially life-saving surgery will 
ensure appropriate use of limited health care resources for maximum patient benefit. 
 
12.6 STUDY MONITORING AND AUDIT 
An ACCORD Clinical Trials Monitor or an appointed monitor will visit the Investigator 
site prior to the start of the study and during the course of the study if required, in 
accordance with the monitoring plan if required. Investigator sites will be risk assessed 
by the ACCORD QA Manager, or designee, in order to determine if audit by the 
ACCORD QA group is required. 
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13 GOOD CLINICAL PRACTICE 
13.1 ETHICAL CONDUCT 
The study will be conducted in accordance with the principles of the International 
Conference on Harmonisation Tripartite Guideline for Good Clinical Practice (ICH 
GCP). 
A favorable ethical opinion will be obtained from the appropriate REC and local R&D 
approval will be obtained prior to commencement of the study. 
13.2 REGULATORY COMPLIANCE 
The study will not commence until a Clinical Trial Authorisation (CTA) is obtained from 
the appropriate Regulatory Authority. The protocol and study conduct will comply with 
the Medicines for Human Use (Clinical Trials) Regulations 2004, and any relevant 
amendments. 
13.3 INVESTIGATOR RESPONSIBILITIES 
The Investigator is responsible for the overall conduct of the study at the site and 
compliance with the protocol and any protocol amendments.  In accordance with the 
principles of ICH GCP, the following areas listed in this section are also the 
responsibility of the Investigator.  Responsibilities may be delegated to an appropriate 
member of study site staff.   
13.3.1 Informed Consent 
The Investigator is responsible for ensuring informed consent is obtained before any 
protocol specific procedures are carried out.  The decision of a participant to participate 
in clinical research is voluntary and should be based on a clear understanding of what 
is involved. 
Participants must receive adequate oral and written information – appropriate 
Participant Information and Informed Consent Forms will be provided.  The oral 
explanation to the participant will be performed by the Investigator or qualified 
delegated person, and must cover all the elements specified in the Participant 
Information Sheet and Consent Form. 
The participant must be given every opportunity to clarify any points they do not 
understand and, if necessary, ask for more information.  The participant must be given 
sufficient time to consider the information provided.  It should be emphasised that the 
participant may withdraw their consent to participate at any time without loss of benefits 
to which they otherwise would be entitled. 
The participant will be informed and agree to their medical records being inspected by 
regulatory authorities and representatives of the sponsor(s) but understand that their 
name will not be disclosed outside the research team. 
The Investigator or delegated member of the study team and the participant will sign 
and date the Informed Consent Form(s) to confirm that consent has been obtained.  
The participant will receive a copy of this document and a copy filed in the Investigator 
Site File (ISF) and participant’s medical notes. 
 
13.3.2 Study Site Staff 
The Investigator must be familiar with the IMP, protocol and the study requirements.  It 
is the Investigator’s responsibility to ensure that all staff assisting with the study are 
adequately informed about the IMP, protocol and their study related duties. 
13.3.3 Data Recording 
The Principal Investigator is responsible for the quality of the data recorded in the CRF 
at each Investigator Site. 
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13.3.4 Investigator Documentation 
Prior to beginning the study, each Investigator will be asked to provide particular 
essential documents to the ACCORD Research Governance & QA Office, including but 
not limited to: 
• An original signed Investigator’s Declaration (as part of the Clinical Trial 
Agreement documents); 
• Curriculum vitae (CV) signed and dated by the Investigator indicating that it is 
accurate and current. 
The ACCORD Research Governance & QA Office will ensure all other documents 
required by ICH GCP are retained in a Trial Master File (TMF), where required, and 
that appropriate documentation is available in local ISFs. 
 
13.3.5 GCP Training 
All study staff must hold evidence of appropriate GCP training. 
  
13.3.6 Confidentiality 
All laboratory specimens, evaluation forms, reports, and other records must be 
identified in a manner designed to maintain participant confidentiality.  All records must 
be kept in a secure storage area with limited access.  Clinical information will not be 
released without the written permission of the participant.  The Investigator and study 
site staff involved with this study may not disclose or use for any purpose other than 
performance of the study, any data, record, or other unpublished, confidential 
information disclosed to those individuals for the purpose of the study.  Prior written 
agreement from the sponsor or its designee must be obtained for the disclosure of any 
said confidential information to other parties. 
 
13.3.7 Data Protection 
All Investigators and study site staff involved with this study must comply with the 
requirements of the Data Protection Act 1998 with regard to the collection, storage, 
processing and disclosure of personal information and will uphold the Act’s core 
principles. Access to collated participant data will be restricted to those clinicians 
treating the participants. 
Computers used to collate the data will have limited access measures via user names 
and passwords. 
Published results will not contain any personal data that could allow identification of 
individual participants. 
 
13.3.8 Sharing of anonymised data 
 
Toshiba Medical Visualisation Systems (TMVS) have requested permission to use 
some of the anatomical MA3RS MRI and CT imaging data for the purposes of 
developing and evaluating registration algorithms. This will enable development of a 
framework allowing quantitative comparison of various registration algorithms and will 
only look at the anatomical/structural data that is acquired during the MA3RS imaging 
protocol. No MA3RS primary outcome data will be included.  
 
The data provided will be fully anonymised (identifiable by MA3RS study ID only).  An 
agreement will be put in place so that only TMVS members that are named on the 
agreement will be allowed to access the data provided and TMVS will not publish 
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without explicitly requesting consent.  Any further use of the data by TMVS for any 
purpose will require approval by the University of Edinburgh and the Trial Steering 
Committee. 
 
14 STUDY CONDUCT RESPONSIBILITIES 
14.1 PROTOCOL AMENDMENTS 
Any changes in research activity, except those necessary to remove an apparent, 
immediate hazard to the participant in the case of an urgent safety measure, must be 
reviewed and approved by the Chief Investigator.   
Amendments to the protocol must be submitted in writing to the appropriate REC, 
Regulatory Authority and local R&D for approval prior to participants being enrolled into 
an amended protocol. 
 
 
14.2 PROTOCOL VIOLATIONS AND DEVIATIONS 
Investigators will not implement any deviation from the protocol without agreement from 
the Chief Investigator and appropriate REC, Regulatory Authority and R&D approval 
except where necessary to eliminate an immediate hazard to study participants. 
In the event that an Investigator needs to deviate from the protocol, the nature of and 
reasons for the deviation will be recorded in the CRF.  If this necessitates a subsequent 
protocol amendment, this should be submitted to the REC, Regulatory Authority and 
local R&D for review and approval if appropriate. 
 
14.3 SERIOUS BREACH REQUIREMENTS 
A serious breach is a breach which is likely to effect to a significant degree: 
(a) the safety or physical or mental integrity of the participants of the study; or 
b) the scientific value of the study. 
If a potential serious breach is identified by the Chief investigator, Principal Investigator 
or delegates, the co-sponsors (accord.seriousbreach@ed.ac.uk) must be notified within 
24 hours.  It is the responsibility of the co-sponsors to assess the impact of the breach 
on the scientific value of the study, to determine whether the incident constitutes a 
serious breach and take the appropriate action.  
Not every violation from the protocol needs to be reported to the regulatory authority as 
a serious breach.  If the sponsor(s) deem the incident to be a violation that does not 
constitute a serious breach from the protocol when identified, corrective and 
preventative actions will be taken where appropriate and they will be recorded in file 
notes, held within the TMF and ISF. 
 
14.4 STUDY RECORD RETENTION 
All study documentation will be kept for a minimum of 5 years from the protocol defined 
end of study point. When the minimum retention period has elapsed, study 
documentation will not be destroyed without permission from the sponsor. 
 
14.5 END OF STUDY 
The end of study is defined as the last participant’s last visit.   
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The Investigators and/or the trial steering committee and/or the co-sponsor(s) have the 
right at any time to terminate the study for clinical or administrative reasons.  
The end of the study will be reported to the REC and Regulatory Authority within 90 
days, or 15 days if the study is terminated prematurely.  The Investigators will inform 
participants of the premature study closure and ensure that the appropriate follow up is 
arranged for all participants involved. 
A summary report of the study will be provided to the REC and Regulatory Authority 
within 1 year of the end of the study. 
 
14.6 CONTINUATION OF DRUG FOLLOWING THE END OF STUDY 




14.7 INSURANCE AND INDEMNITY 
The co-sponsors are responsible for ensuring proper provision has been made for 
insurance or indemnity to cover their liability and the liability of the Chief Investigator 
and staff. 
The following arrangements are in place to fulfil the co-sponsors' responsibilities: 
• The Protocol has been designed by the Chief Investigator and researchers 
employed by the University and collaborators.  The University has insurance in 
place (which includes no-fault compensation) for negligent harm caused by 
poor protocol design by the Chief Investigator and researchers employed by 
the University. 
• Sites participating in the study will be liable for clinical negligence and other 
negligent harm to individuals taking part in the study and covered by the duty 
of care owed to them by the sites concerned.  The co-sponsors require 
individual sites participating in the study to arrange for their own insurance or 
indemnity in respect of these liabilities. 
• Sites which are part of the United Kingdom's Nation Health Service will have 
the benefit of NHS Indemnity. 
Sites out with the United Kingdom will be responsible for arranging their own 
indemnity or insurance for their participation in the study, as well as for 
compliance with local law applicable to their participation in the study. 
15 REPORTING, PUBLICATIONS AND NOTIFICATION OF RESULTS 
15.1 AUTHORSHIP POLICY 
Ownership of the data arising from this study resides with the study team.  On 
completion of the study, the study data will be analysed and tabulated, and a clinical 
study report will be prepared in accordance with ICH guidelines.  
 
15.2 PUBLICATION 
The clinical study report will be used for publication and presentation at scientific 
meetings. Investigators have the right to publish orally or in writing the results of the 
study. 
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Summaries of results will also be made available to Investigators for dissemination 
within their clinics (where appropriate and according to their discretion). 
 
15.3 PEER REVIEW 
The protocol has undergone extensive peer review by the funders (Medical Research 
Council, Efficacy and Mechanism Evaluation programme) and by the Trial Steering 
Committee of the study. 
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Abstract Myocardial infarction remains the commonest
cause of premature death worldwide with coronary athero-
sclerotic plaque rupture often initiating the event. Despite an
ever-expanding repertoire of cardiovascular imaging tech-
niques, the race is still on to identify atherosclerotic lesions
at high-risk of rupture: the so-called vulnerable plaque. Con-
ventional imaging modalities such as stress testing and coro-
nary angiography have consistently failed to identify such
plaques, leading to the increasing appreciation that plaque
rupture relates to factors other than just the degree of luminal
stenosis. Indeed the focus has recently shifted to molecular
imaging, in an attempt to directly target the pathological
disease processes leading to rupture and thereby localize
high-risk lesions. Histological data indicate that inflammation,
necrosis and early stage microcalcification are key imaging
targets by which to achieve this aim. Here, we discuss how
these processes are related, focusing on the rationale and
evidence supporting 18F-fluoride positron emission tomogra-
phy as a novel non-invasive imaging technique for the iden-
tification of vulnerable atherosclerotic plaque.
Keywords Positron emission tomography . Computed
tomography . 18F-fluoride . PET-CT imaging . Coronary
atherosclerosis . Plaques
Introduction
Cardiovascular diseases remain the commonest cause of death
worldwide. The majority of these deaths are attributed to
sudden atherosclerotic plaque rupture resulting in myocardial
infarction or stroke [1]. However prediction of cardiovascular
events is difficult because most are caused by atherosclerotic
plaques that are non-flow limiting and therefore missed by
conventional diagnostic modalities such as myocardial stress
testing or invasive coronary arteriography. However, these
high-risk plaques, the so-called vulnerable plaque, do have
certain histopathological characteristics, which potentially can
be targeted using modern imaging technology. Indeed the race
is now on to identify these high-risk plaques in vivo using
both invasive and non-invasive modalities [2, 3••, 4].
The Vulnerable Plaque
The concept of the vulnerable plaque was first introduced by
James Muller in 1989 when he described ‘hemodynamically
insignificant, albeit dangerous lesions’ [5], that he believed
were at high risk of rupturing and causing myocardial infarc-
tion. Since thenmultiple observational studies have confirmed
that most of the plaques causing myocardial infarction are
non-flow limiting at the time of antecedent coronary arteriog-
raphy. However pioneeringwork over the last two decades has
now established that ruptured plaques do have certain key
histopathological features including: the presence of a large
necrotic core, a thin fibrous cap (<65 μm), a positively
remodelled vessel, macrophage infiltration resulting in plaque
inflammation, hypoxia leading to neovascularization and fi-
nally early stage microcalcification (Fig. 1) [6–11]. Moreover
it is widely postulated that intact high-risk plaques are likely to
demonstrate the same pathophysiological features immediate-
ly before a clinical plaque rupture event, so that identification
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of these characteristics may be of use prospectively. Recent
technological advances, coupled with the failure of percuta-
neous coronary intervention to reduce myocardial infarction
in patients with stable angina [12] has renewed interest in
detecting these plaques in vivo. Indeed, this has been de-
scribed by many as the ‘holy grail’ of clinical cardiology [1,
2, 3••, 13].
The Link Between Inflammation and Calcification
Inflammation plays a critical role in the formation, progres-
sion, and rupture of atherosclerotic plaques and is typically
characterized by the presence of macrophages within the
plaque lipid core (Fig. 1) [6–11]. In an attempt to clear lipid
from the vessel intima, these macrophages set up an inflam-
matory cycle that ultimately proves difficult to contain, lead-
ing to progressive matrix degradation and plaque destabiliza-
tion. Indeed ongoing macrophage infiltration and cell death
along with accelerated lipid accumulation contribute to an
enlarging necrotic core that becomes progressively more in-
flamed and hypoxic. Moreover these cells secrete pro-
inflammatory cytokines (including interleukin-1, monocyte
chemotactic protein-1 and tumour necrosis factor-alpha) and
matrix metalloproteinases, which actively weaken the fibrous
cap: the only barrier between this highly thrombogenic lipid
core and the vessel lumen. Fortunately this is where body
defence mechanisms are believed to respond, triggering a
calcific healing response that attempts to subdue and wall
off this inflamed necrotic environment, thereby reducing the
risk of plaque rupture.
Calcification occurs widely in the body and frequently
occurring as a healing response to intense necrotic inflamma-
tion. This is perhaps best exemplified by tuberculosis where
the body attempts to wall off the intense necrotic inflammation
associated with caseating granulomata using calcification.
Similar mechanisms are believed to occur within coronary
atheroma, with calcification occurring as a healing response
to intense inflammation within the necrotic core. However in
these arteries, calcification appears to have a bi-phasic re-
sponse, with each stage associated with markedly different
plaque characteristics and clinical consequences. The latter
phase of macroscopic calcification is readily imaged using
standard x-ray angiography and CT, and is widely believed
Fig. 1 The relationship between inflammation, biphasic calcific response
and adverse cardiovascular events. a Typical features of a vulnerable
plaque: The initial stages of plaque inflammation and vulnerability are
associated with macrophage influx into a large lipid core. By this stage,
other features of plaque vulnerability such as positive remodelling, thin-
ning of the fibrous cap, are observed. b Microcalcification within the
necrotic core: Cell death occurring within the lipid core as a consequence
of necrosis and apoptosis triggers microcalcification. This is a high risk
plaque type that is ripe to rupture. This can have two consequences:
successful plaque calcification by walling off the inflamed area, or
initiation of plaque rupture with subsequent thrombotic occlusion. This
is the plaque type that is believed to be have avid 18F-fluoride uptake on
PET/CT. c Plaque rupture with thrombotic occlusion of the lumen
resulting in myocardial infarction. d Plaque stabilization with successful
healing of the necrotic core with obvious macrocalcification that can be
detected with conventional imaging modalities such as computed tomog-
raphy and X-ray angiography
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to impart stability to the plaque. Indeed by this stage the
healing process has often successfully subdued inflammation
within the vessel wall and separated it from the contents of the
vascular lumen. By contrast the earlier phase of micro-
calcification is not visible using standard non-invasive imag-
ing techniques and is associated with plaque instability and an
increased risk of rupture (Table 1) [14, 15]. The likely expla-
nation is that at this early time-point the healing process has
not yet been effective and that the inflamed necrotic environ-
ment triggering calcification still exists within the plaque. This
risk of plaque rupture related to inflammation therefore per-
sists. However recent data have indicated that in addition
micro-calcification might itself increase the propensity to
rupture, acting as a focal point that intensifies mechanical
stresses on the surface of the cap. Either way a technique
capable of directly imaging active ongoing micro-
calcification and differentiating it from dormant macroscopic
areas would hold real promise as a means of improving our
understanding of plaque biology and in identifying high-risk
atheroma.
Although there have been significant advances in our un-
derstanding as to why atherosclerotic plaques calcify, the
exact molecular mechanisms underpinning this observation
remain unclear. Multiple potential pathways have been pro-
posed although often these have been established using
models of vascular medial calcification. Calcification in the
coronary arteries is almost uniquely intimal with medial and
adventitial involvement occurring only rarely in conditions
such as renal failure. Calcification activity in the intima ap-
pears to be closely related to inflammation and cell death
within the necrotic core. Several putative pathways have been
proposed linking these entities [16–21]. First and most obvi-
ously, necrosis of foam cells, vascular smooth muscle cells
and other cells in the inflammatory plaque milieu leads to the
release of large quantities of phosphate and calcium which
may lead to spontaneous dystrophic calcification (as observed
in infarctions, haematomas and scars). Second, inflammation
may trigger osteogenic metaplasia in a variety of cell types
(VSMC, endothelial cells, etc.) which make a phenotypic
switch to osteoblast like cells under the influence of RUNX-
2 transcription and become capable of roughly recapitulating
skeletal osteogenesis in the plaque matrix. Third, circulating
osteoprogenitors may be recruited to the plaque before under-
going maturation to classical osteoblasts. Fourth, cells under-
going programmed cell death within the plaque may provide
calcifying substrate through the release of apoptotic bodies.
Fifth and finally, macrophages themselves may provide the
substrate for calcification by directly releasing matrix vesicles
(the key and final executors of ordered tissue mineralization)
into the extracellular matrix. Aikawa et al. have published the
key and highly elegant longitudinal experiments in a mouse
model that have conclusively demonstrated the link between
inflammation and calcification [14]. They showed that mac-
rophage infiltration is closely associated with osteogenic ac-
tivity (as assayed by accumulation of OsteoSense; a
bisphosphonate-conjugated to a fluorescent reporter). They
(and others) have also shown that apoptotic bodies and matrix
vesicles that contain calcium orthophosphate nanocrystals
execute this early calcific process [20, 22, 23].
Positron Emission Tomography
Combined positron emission and computed tomography
(PET/CT) is a modern non-invasive imaging technique that
combines functional information from PET with the fine an-
atomical detail provided by CT, allowing the activity of spe-
cific pathological processes to be studied within even small
structures in the body. This technique has been widely used in
the clinical assessment of patients with cancer for many years,
resulting in the widespread availability of PET/CT scanners
[24]. Recent technological advances including ECG-gating,
improved PET resolution and fusion with detailed CT angi-
ography of the coronary vessels, has allowed translation of
this technology into the heart. Theoretically any pathological
process can be studied dependent on a suitable radiotracer
being developed, so that potentially each of the established
characteristics associated with high-risk plaque may be
targeted. However to date the majority of studies investigating
coronary atherosclerosis have utilized the tracers 18F-
fluorodeoxyglucose (18F-FDG) and 18F-fluoride as markers
of inflammation and micro-calcification respectively. Whilst a
comprehensive discussion of 18F-FDG activity in the vascu-
lature is beyond the scope of this review, it has become clear
that whilst an excellent tracer for imaging vascular inflamma-
tion and perhaps hypoxic inflammation in the aorta and carot-
id arteries, utilization of this tracer in the coronary arteries is
problematic. In particular, difficulty has arisen from uptake of
this tracer by the adjacent myocardium, which frequently
obscures the coronary signal. Whilst ultimately this problem
Table 1 Key differences between micro and macrocalcification
Microcalcification Macrocalcification
Size <5 μm >5 μm
Stage of calcification Early Late
Inflammation Persistent Healed
Surface area High Low
Exposed hydroxyapatite High Low







Avid binding Low binding
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may be rectified using advanced motion correction algorithms
and attempts to switch myocardial metabolism away from
glucose, further work is required before 18F-FDG is likely
to prove useful in the coronary circulation. By contrast 18F-
fluoride demonstrates an excellent signal to noise ratio in the
coronary arteries as it is not taken up by adjacent structures
and is rapidly cleared from plasma moreover it already ap-
pears capable of providing important clinical information with
respect to coronary plaque biology.
Mechanism of 18F-Fluoride PETActivity
18F-Fluoride is a PET tracer with favourable pharmaco-
kinetic properties, first introduced by Blau and co-
workers in 1962 for the study of bone disease [25–27].
After an intravenous injection, approximately 70 % of
18F-fluoride is plasma based with the remaining 30 %
found in erythrocytes. Because of its small size and
negligible protein binding, 18F-fluoride demonstrates al-
most complete clearance from the blood stream on first
pass [28–30], resulting in low blood-pool activity. This
coupled with its specificity for bone and vascular calci-
fication ensures that it provides excellent signal to noise
in these tissues with little contamination from adjacent
structures.
The mechanism of 18F-fluoride uptake in bone is well
established. First it diffuses via the capillary network into the
bone extracellular fluid. Then it exchanges with hydroxyl
groups on exposed regions of hydroxyapatite crystal on the
bone surface, forming fluoroapatite. The intensity of the signal
depends both on the bone blood flow but also upon the surface
area of exposed hydroxyapatite, which is increased in regions
of new bone formation and remodelling [25–27]. As a conse-
quence 18F-fluoride has been extensively utilized as a marker
of bone turnover and used to study various bone related
clinical conditions such as Paget’s disease [31, 32], osteopo-
rosis [33, 34], renal osteodystrophy [14], fracture healing [35],
and osteonecrosis [36]. Moreover, 18F-fluoride PET has be-
come widely established as the most sensitive imaging mo-
dality for the detection of malignant bone involvement, lead-
ing to its widespread and commercial availability [37–41].
We believe that very similar mechanisms underlie the
uptake of 18F-fluoride in the vasculature. Given the nature
of the tissue, blood supply is not likely to be a major factor.
However like bone, hydroxyapatite is also the key structural
component of vascular calcium, so that arterial 18F-fluoride
uptake is likely to relate closely to the available surface area of
this crystal. Transmission electron microscopy studies have
demonstrated that during the early stages of calcification
hydroxyapatite crystals are nanosized, very thin and long
[42]. This results in a much larger surface area of hydroxyap-
atite for 18F-fluoride binding in the early stages of
microcalcification compared to macroscopic calcification in
which much of the hydroxyapatite is internalized and not
accessible to the tracer. The hypothesis that 18F-fluoride
preferentially binds to vascular micro-calcification activity
has been strongly supported by some early yet detailed pre-
clinical work performed by our collaborators at Cambridge
University and will no doubt be the subject of intensive future
study [43].
Clinical Studies Examining Vascular 18F-Fluoride
Activity
Derlin et al. first described the vascular uptake of 18F-fluoride
in 2010 in a retrospective analysis of patients with malignancy
[44]. The authors noted increased 18F-fluoride uptake in large
vessels such as the aorta, carotids and femoral vessels in about
three quarters of the patients studied. Interestingly, only a fifth
of all calcified plaques on CT demonstrated increased 18F-
fluoride uptake, highlighting even at this early stage that 18F-
fluoride provides different information to the presence of
calcium on CT. Subsequent work by the same group retro-
spectively compared the distribution of 18F-fluoride and 18F-
FDG uptake in oncology patients [45] and suggested that 18F-
fluoride signal in the femoral vessels correlated with the
calcified plaque burden and cardiovascular risk factors [46].
Beheshti and colleagues first described 18F-fluoride activity
localizing to the heart [47] whilst we and other groups have
confirmed increased 18F-fluoride activity in the aorta and
importantly in the valves of patients with aortic stenosis
[48••, 49], where it acts as a marker of calcification activity
and predicts disease progression [50].
Coronary 18F-NaF PET Identifies High Risk Patients
We first described 18F-fluoride uptake in the coronary arteries
as a novel marker of plaque biology in subjects with and
without aortic valve disease [51••]. This demonstrated the
feasibility and excellent reproducibility of this tracer in the
coronary vasculature.Moreover increased uptake of this tracer
localized to individual coronary plaques and importantly iden-
tified patients at increased cardiovascular risk, with those
subjects having increased Framingham risk scores and prior
MACE event rates. This study also confirmed that, as in the
aorta, 18F-fluoride provided different information to the pres-
ence of coronary calcium on CT. Indeed we observed that
>40 % of patients with coronary artery calcium scores >1000
Agatston Units did not have 18F-fluoride uptake, suggesting
the ability of 18F- fluoride to distinguish between dormant
pacified calcific disease and metabolically active ongoing
micro-calcification.
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Coronary 18F-Fluoride PET as a Marker of High-Risk
Atherosclerotic Plaque
Perhaps the key incidental observation from our initial study
came from a patient with aortic stenosis admitted with an
inferior non-STelevation myocardial infarction [51••]. Intense
coronary 18F-fluoride uptake was localized to the exact site of
the culprit lesion in this patient, despite them having severe
three vessel disease and widespread coronary calcium on CT.
Based on this observation and the wider results of this pre-
liminary study, we designed a subsequent trial to investigate
18F-fluoride activity in patients with stable and unstable cor-
onary artery disease [52••]. Our hypothesis was that 18F-
fluoride would identify high-risk vulnerable plaques in pa-
tients with stable angina and ruptured plaques in patients with
myocardial infarction.
We examined 40 patients with stable angina referred for
invasive angiography, who all underwent 18F-NaF PET/CT
imaging alongside CT coronary angiography, invasive coro-
nary angiography and intravascular ultrasound. Increased
18F-fluoride activity localized to individual coronary plaques
in ~40 % of patients. These plaques had multiple high-risk
features on intravascular ultrasound and CT including micro-
calcification, positive remodelling and a large necrotic core. It
was not possible to undertake histological analysis of the 18F-
fluoride signal in these patients. However instead we demon-
strated that increased 18F-fluoride activity colocalized with
histological evidence of increased macrophage accumulation,
cell death and calcification activity in carotid endarterectomy
specimens. These data would indicate that 18F-fluoride iden-
tifies high-risk atherosclerotic plaque. However the real ques-
tion is whether these plaques go on to cause myocardial
infarction. Ultimately this will require prospective studies
but we examined this issue retrospectively, investigating
18F-fluoride uptake in 40 patients who had recently sustained
a type 1 myocardial infarction. We observed increased 18F-
fluoride uptake at the site of the culprit plaque in 93% of these
patients. Indeed activity was around 30 % higher in the culprit
plaque than the maximum activity recorded anywhere else in
the coronary vasculature and was independent of coronary
artery stenting.
Conclusions and Future Directions
In combination we believe that the clinical studies to date have
demonstrated that 18F-fluoride provides complementary in-
formation to the presence of calcium on CT and that this
technique is able to identify high-risk and ruptured coronary
atherosclerotic plaques. It therefore holds major promise as a
method of identifying vulnerable plaque and in improving
upon current methods for the prediction of myocardial infarc-
tion. Indeed if confirmed then this approach may have a
significant role to play in our future approach to the treatment
of coronary artery disease.
Two major questions still need to be addressed before the
potential of 18F-fluoride can be realized. First the mechanism
for 18F-fluoride uptake in the vasculatures needs to be con-
firmed over and above the work we have already performed in
the aortic valve and carotid arteries. Second the ability of 18F-
fluoride to predict myocardial infarction needs to be addressed
in the context of a prospective observational study, ideally in a
high-risk population.
We believe that it is improbable that all coronary plaques
with increased 18F-fluoride activity will go on to cause a
myocardial infarction. Indeed calcification is often likely to
prove successful in stabilizing the plaque and even when
rupture does occur this will be sub-clinical in the majority of
cases (Fig. 1). As a consequence individual plaque-directed
treatment strategies are also unlikely to be effective. Instead
we believe that the future role of 18F-fluoride will be in
identifying the vulnerable patient. Those subjects with evi-
dence of metabolically active coronary atheromawho are at an
increased risk of myocardial infarction and would therefore
benefit from some of the newer medical therapies that appear
to have profound effects on coronary plaque biology but do so
at great expense.
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Ruptured coronary atherosclerotic plaques commonly cause acute
myocardial infarction. It has recently been shown that active
microcalcification in the coronary arteries, one of the features that
characterizes vulnerable plaques at risk of rupture, can be imaged
using 18F-NaF PET. We aimed to determine whether a motion
correction technique applied to gated 18F-NaF PET images could
enhance image quality and improve uptake estimates. Methods:
Seventeen patients with myocardial infarction (n 5 7) or stable an-
gina (n 5 10) underwent 18F-NaF PET and prospective coronary CT
angiography. PET data were reconstructed in 4 different ways: the
first was 1 gated bin (end-diastolic phase with 25% of the counts),
the second was 4 gated bins (consecutive 25% segments), the third
was 10 gated bins (consecutive 10% segments), and the fourth was
ungated. Subsequently, with data from either 4 or 10 bins, gated
PET images were registered using a local, nonlinear motion correc-
tion method guided by the extracted coronary arteries from CT
angiography. Global noise levels and target-to-background ratios
(TBR) defined on manually delineated coronary plaque lesions were
compared to assess image quality and uptake estimates. Results:
Compared with the reference standard of using only 1 bin of PET data,
motion correction using 10 bins of PET data reduced image noise by
46% (P, 0.0001). TBR in positive lesions for 10-bin motion-corrected
data was 11% higher than for 1-bin data (1.98 [interquartile range,
1.70–2.37] vs. 1.78 [1.58–2.16], P 5 0.0027) and 33% higher than
for ungated data (1.98 [1.70–2.37] vs. 1.49 [1.39–1.88], P , 0.0001).
Conclusion: Motion correction of gated 18F-NaF PET/coronary CT
angiography is feasible, reduces image noise, and increases TBR. This
improvement may allow more reliable identification of vulnerable cor-
onary artery plaques using 18F-NaF PET.
Key Words: motion correction; 18F-sodium fluoride PET; 18F-NaF;
coronary atherosclerotic plaques; microcalcification
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Acute myocardial infarction (MI) is the leading cause of death
in the United States, with 735,000 Americans experiencing an
acute MI and about 120,000 dying as a consequence each year
(1). Acute MI most commonly results from coronary atherosclerotic
plaque rupture. Despite this cause, current treatment algorithms
make no allowance for the presence or absence of vulnerable pla-
ques at risk of rupture, and the current dogma is to treat all patients
with any atherosclerosis in the same way. An accurate, noninvasive,
a priori method for identifying such rupture-prone plaques would
challenge this dogma, allowing high-risk patients to be selectively
targeted with patient-specific therapies.
Histopathologic studies of patients who died from acute MI have
demonstrated that the plaques that have ruptured and caused acute
MI have several common characteristics. Among these, micro-
calcification is a consistent finding, believed to represent the very
early stages of the body’s attempt to heal inflamed necrotic plaque.
A recent series of studies (2–4) demonstrated that 18F-sodium fluo-
ride (18F-NaF)—an inexpensive, Food and Drug Administration–
approved, widely available PET tracer—binds preferentially to
regions of vascular microcalcification and can be used to identify
high-risk plaques and plaque rupture in the coronary arteries. In
particular, in a study by Joshi et al. increased 18F-NaF PET activity
was found to localize to the exact site of plaque rupture in more
than 90% of patients who had recently experienced an acute MI,
independent of stenting (2).
There are, however, several important limitations still to be
addressed. The difference in target-to-background ratio (TBR)
between culprit plaques (implicated in acute MI) and nonculprit
plaques in 18F-NaF PET is relatively small (;34%) because of blur-
ring of coronary uptake by cardiac, respiratory, and patient motion.
The implication is a greater risk of misclassification when this tech-
nique is applied to real-world, unselected populations. Unfortunately,
recent general-purpose motion correction methods proposed for PET
(5,6) are not applicable because of lack of clear anatomic landmarks
in the heart region on the 18F-NaF scan. To partially address the
problem of motion, only a single cardiac phase (representing about
25% of the PET data) was used in the initial study (2), at the expense
of a significant increase in noise. Although this was a useful explor-
atory strategy, the combination of an already-narrow diagnostic TBR
margin and increased noise is clearly suboptimal.
We previously developed motion correction techniques for cardiac
perfusion data from SPECT and PET, which facilitated an increase
in image contrast compared with ungated data (7,8). In the present
study, we aimed to overcome some of the current limitations of
18F-NaF PET by developing a motion correction method for coronary
18F-NaF PET to optimize this promising plaque-imaging technique.
MATERIALS AND METHODS
Patients
Patients were recruited from the Royal Infirmary of Edinburgh
between February 2012 and January 2013 in 2 cohorts: 7 patients
with acute ST-segment or non–ST-segment elevation acute MI and 10
Received Jun. 30, 2015; revision accepted Oct. 5, 2015.
For correspondence or reprints contact: Piotr J. Slomka, Artificial
Intelligence in Medicine Program, 8700 Beverly Blvd., Ste. A047N, Los
Angeles, CA 90048.
E-mail: piotr.slomka@cshs.org
Published online Oct. 15, 2015.
COPYRIGHT © 2016 by the Society of Nuclear Medicine and Molecular
Imaging, Inc.
54 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 57 • No. 1 • January 2016
by on September 15, 2016. For personal use only. jnm.snmjournals.org Downloaded from 
patients with stable angina pectoris undergoing elective invasive cor-
onary angiography. Table 1 shows the demographic and clinical char-
acteristics of these patients. All underwent a comprehensive baseline
clinical assessment, including evaluation of their cardiovascular risk
factor profile. Studies were done with the approval of the local re-
search ethics committee, in accordance with the Declaration of Hel-
sinki, and with the written informed consent of each participant.
Imaging and Analysis Protocols
All patients underwent 18F-NaF PET/CT imaging of the coronary
arteries with cardiac gating on a hybrid scanner (64-detector Biograph
mCT; Siemens Medical Systems). The subjects were administered a
target dose of 125 MBq of 18F-NaF intravenously and subsequently
rested in a quiet environment for 60 min. An attenuation correction CT
scan (nonenhanced, 120 kV and 50 mA) was then obtained, followed
by PET imaging of the thorax in list-mode for 20 min.
Prospectively gated coronary CT angiography (CCTA) was undertaken
during the same visit as the 18F-NaF scan, using a 330-ms rotation time,
a 100-kV (body mass index , 25 kg/m2) or 120-kV (body mass index
. 25 kg/m2) tube voltage, a 160- to 245-mAs tube current, and a 3.8-mm/
rotation table feed, with prospective electrocardiography triggering (heart
rate regular and , 60 beats/min), or retrospective electrocardiography gat-
ing (heart rate. 60 beats/min). Depending on the body mass index, a bolus
of 80–100 mL of contrast material (400 mg I/mL, Iomeron; Bracco) was
injected intravenously at 5 mL/s, after determining the appropriate trigger
delay with a test bolus of 20 mL of contrast material. Electrocardiography-
gated PET images were reconstructed using the Siemens Ultra-HD
algorithm (time-of-flight plus point spread function) in multiple phases of
the cardiac cycle. For this study, 4 different sets of data were reconstructed
from list-mode data: 1 bin with 25% of the counts during the end-diastolic
phase (the technique used in the original study of Joshi et al. (2)), 4 bins,
10 bins, and ungated. The PET pixel size was 2 mm. The CCTA scans were
reconstructed at 0.75 · 0.7 mm and 0.6 · 0.3 mm for retrospective and
prospective acquisitions, respectively, at 70% of the cardiac cycle.
Motion Correction
The goal of the motion correction procedure was to compensate for
coronary artery motion in the different phases of the electrocardiography-
gated PET data. Gated PETwith 4 and 10 time bins were reconstructed
from the PET list-mode files. The registration aimed to align all bins
to the end-diastolic phase position, synchronizing the registered data
to the prospective CCTA and, for comparison purposes, to the 1-bin
PET data corresponding to the end-diastolic phase (as used in the
original study). The end-diastolic phase, taken as the reference,
corresponded to bin 3 in the dataset with 4 bins and to bin 7 in the
dataset with 10 bins.
The registration of individual bins of 18F-NaF PET presents a
unique challenge because there are no clear anatomic references near
the heart, and motion of bones (where there is significant 18F-NaF
uptake) does not correlate with motion of the heart. Thus, innovative
approaches are required to deal with this problem. The procedure we
used is illustrated in Figure 1. To recover the anatomic information
that is missing in the PET data, we used the CCTA data that clearly
delineate the coronary arteries. The end-expiration position of the
CCTA allowed excellent alignment with PET data when the patient
remained in the same position. Coronary regions were first extracted
from the CCTA by vessel tracking based on Bayesian maximal paths
(9), as implemented and validated in our Autoplaq CCTA processing
software (10–12). This algorithm requires as input only proximal and
distal points for every coronary artery and automatically finds the
vessel centerline. The centerlines of the right, left circumflex, and left
anterior descending coronary arteries were extracted for every patient
in this manner.
Subsequently, the centerline coordinates were transferred to the
PET volumes to automatically extract 3-dimensional tubular volumes
of interest surrounding the coronary arteries in the gated PET images,
defined by a 20-mm radius around each centerline. This radius was
chosen to take into account the maximum displacement that can occur
during the cardiac cycle, also allowing for potential remaining mis-
registration. Techniques that did not constrain the registration by
coronary vessel regions were hampered by noise adjacent to the
coronary arteries.
Next, a nonlinear level-set algorithm (13) was applied to the
extracted coronary regions and constrained according to the expected
coronary artery motion. Every volume of interest of the PET data from
each bin was then registered to the end-diastolic reference artery re-
gion. The advantage of this method over other nonlinear registration
techniques is the computational efficiency and knowledge-based esti-
mation of the expected arterial motion. After the registration process,
all registered volumes of interest were inserted back into their original
PET image, using a linear gradient at the border between the regis-
tered volume of interest and the nonregistered original PET image to
blend both volumes and ensure smooth transition between the regions.
Finally, all registered PET images were summed into a single volume.
In this manner, we obtained static 4- and 10-bin motion-corrected PET
data.
Lesion and TBR
To define the lesions, the PET data were fused with the CCTA data
and analyzed on an OsiriX workstation (OsiriX Imaging Software)
by experienced observers masked to the clinical diagnosis. Two-
dimensional regions of interest were drawn around all major (diameter
. 2 mm) epicardial vessels on 3-mm axial slices just beyond the
discernible adventitial border. We used a previously established 95%
lower reference limit to categorize coronary plaques into 18F-NaF–
positive and –negative lesions, on the end-diastolic data as in the
original study. Focal uptake with a target-to-background ratio (TBR)
more than 25% higher than a proximal reference lesion were catego-
rized as 18F-NaF–positive plaques, whereas plaques were considered
18F-NaF–negative if these criteria were not achieved. This limit was
based on our previous study, in which plaques with high 18F-NaF
uptake had maximum TBRs that were 44% (95% confidence interval,
26–62) higher than a proximal quiescent reference lesion (3).
TABLE 1
Patients’ Demographic and Clinical Characteristics
Parameter Stable angina (n 5 10) MI (n 5 7)
Mean age ± SD (y) 67 ± 9 66 ± 7
Men (n) 9 (90%) 7 (100%)





MI 4 (40%) 0
PCI 5 (50%) 1 (14%)
CABG 5 (50%) 0
Lesions (n) 31 (61%) 20 (39%)
Positive 19 (68%) 9 (32%)
Negative 12 (52%) 11 (48%)
BMI5 body mass index; MI5 myocardial infarction; PCI 5 percu-
taneous coronary intervention; CABG 5 coronary artery bypass graft.
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TBR was defined as the ratio of the maximum activity values in the
manually defined lesion to the mean value of the background, taken to
be the blood pool in the middle of the left ventricle. This region was
positioned to include the whole blood pool region in a midventricular
slice for each patient. The noise was determined as the ratio of the
mean to the SD of the background.
Statistical Analysis
Statistical analyses were performed with Analyze-it software. For
all continuous variables, the Shapiro–Wilk test was used to assess
normality. All continuous variables were described as mean 6 SD
or median and interquartile range (IQR). Nonparametric results were
presented as median and IQR and compared using the Wilcoxon
signed-rank test as appropriate. A 2-sided P value of less than 0.05
was taken as statistically significant.
RESULTS
Patients were predominantly middle-aged men and had multi-
ple cardiovascular risk factors (Table 1). Radiation exposure for
CCTA and PET is summarized in Table 2. The algorithm successfully
registered the gated data for all studies, as assessed visually in the
cinematic display. The approximate processing time was about
1 min/study. The results were computed and compared for the
4 sets of reconstructed data: 1 single PET bin corresponding to
the end-diastolic phase, as presented in the initial trial (2); 4 and
10 bins that were motion-corrected as described above; and
ungated data. In total, 51 lesions (28 positive, 23 negative) were
delineated in the 17 patients. These lesions were distributed over
the major coronary arteries: 17 (33%) in the left anterior descend-
ing coronary artery, 21 (41%) in the right coronary artery, and
13 (26%) in the left circumflex coronary artery. The TBR in pos-
itive and negative lesions was measured in the 4 sets of data.
Activity
18F-NaF activity (expressed as TBR) in the positive lesions with
10-bin motion-corrected data was 11% higher than with 1-bin data
(1.98 [IQR, 1.70–2.37] vs. 1.78 [IQR, 1.58–2.16], P 5 0.0027)
and 33% higher than with ungated data (1.98 [IQR, 1.70–2.37] vs.
1.49 [IQR, 1.39–1.88], P, 0.0001). In contrast, no difference was
observed when comparing 1- to 4-bin motion-corrected data (1.78
[IQR, 1.58–2.16] vs. 1.75 [IQR, 1.50–2.16], P 5 0.77) (Fig. 2A).
In 18F-NaF–negative lesions, we observed some differences be-
tween 1- and 4-bin motion-corrected data (0.90 [IQR, 0.70–1.05]
vs. 0.91 [IQR, 0.76–1.09], P 5 0.006) as well as between 1- and
10-bin motion-corrected data (0.90 [IQR, 0.70–1.05] vs. 0.93
[IQR, 0.80–1.04], P 5 0.025) (Fig. 2B), but these absolute differ-
ences were much smaller than for the 18F-NaF–positive lesions.
Furthermore, the median TBRs in the 18F-NaF–negative lesions
were less than 1.0 for all techniques.
Overall, the median TBR difference between 18F-NaF–positive
and –negative lesions increased from 0.88 to 1.05 using the 10-bin
motion-corrected data, as compared with 1 bin. This technique
should therefore allow for better discrimination between positive
and negative lesions, as compared with the single end-diastolic bin
alone that was presented in the original trial (2).
Noise
Noise was significantly reduced by using the 4- or 10-bin motion
correction method as compared with the single end-diastolic bin:
0.09 [IQR, 0.08–0.12] vs. 0.18 [IQR, 0.15–0.24], P, 0.0001 (Fig. 2C).
This is an expected finding since only 25% of the PET counts were
used in the 1-bin data. Noise was essentially the same for ungated data
and motion-corrected 4- and 10-bin data since all the PET counts were
used by these 3 techniques.
Example images illustrating the noise decrease and TBR
improvement are shown in Figure 3.
FIGURE 1. Overview of the motion correction method. (1) Coronary artery
centerlines are extracted from CCTA in end-diastolic phase using CCTA
analysis software. (2) Volumes of interest surrounding coronary arteries are
extracted from 4- and 10-bin PET data using previously extracted CCTA
centerlines. (3) All bins of data are registered to the common end-diastolic
reference bin (bins 3 and 7 for 4- and 10-bin data, respectively) by nonlinear
level-set registration restricted to coronary regions. Then, registered VOIs
are inserted back into their original PET volumes, and all registered PET
images are summed into a single volume to obtain motion-corrected 4- and
10-bin data. MC 5 motion-corrected; VOI 5 volume of interest.
TABLE 2
Patients’ Radiation Exposure (mSv) During Study
Parameter 18F-NaF CCTA dose AC CT dose PET/CT 1 CCTA
Prospective
Range 2.8–3.1 1.3–5.8 0.5–1.8 4.7–9.9
Mean ± SD 2.9 ± 0.1 3.4 ± 1.2 1.0 ± 0.4 7.3 ± 1.4
Retrospective
Range 2.8–3.0 7.8–12.7 0.9–1.1 11.6–16.7
Mean ± SD 2.9 ± 0.1 9.7 ± 2.7 1.0 ± 0.1 13.6 ± 2.7
Conversion factors are 0.014 mSv/mGy⋅cm for CCTA and attenuation-corrected (AC) CT and 0.024 mSv/MBq for 18F-NaF.
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Motion
We also computed the maximal motion of plaques in the different
coronary arteries that occurred during the motion correction
process. The median end-systolic–to–end-diastolic displacement
was 17.2 mm [IQR, 14.6–19.0 mm] in the left anterior descending
coronary artery, 17.7 mm [IQR, 16.1–20.7 mm] in the left circum-
flex coronary artery, and 19.4 mm [IQR, 16.2–22 mm] in the right
coronary artery. These results agree with the range of the coro-
nary motion during the cardiac cycle that has been reported in
the literature (14).
DISCUSSION
We have developed a method to correct coronary motion in
18F-NaF PET imaging data by applying level-set–based nonlinear
PET registration of individual PET time-bins to the end-diastolic
position. This registration was constrained to the coronary regions
extracted from the coregistered CCTA data to avoid registration to
spurious noise signals outside the coronary regions. As compared
with the original method (2), the new method demonstrated in-
creased TBRs while drastically reducing noise (Fig. 3B). The best
results were obtained for the 10-bin motion-corrected data since
those data provided the best time-resolved motion correction.
Previous studies have addressed cardiac motion correction in
PET and SPECT (7,8). Dual gating (cardiac/respiratory) (15,16)
and dual correction have been reported by several groups
(5,6,17,18). However, all of these methods depend on uptake in
anatomic organs (in the case of cardiac imaging, the myocardium)
and therefore are not applicable to coronary PET. 18F-NaF PET
represents a unique challenge because there are no clear anatomic
references near the heart and because bone motion (where there is
significant 18F-NaF uptake) does not correlate with coronary mo-
tion. To our knowledge, this is the first report of motion-corrected
coronary PET by the use of such nonlinear registration methods.
Our technical development study also has several important
implications for the future of coronary 18F-NaF PET imaging,
which in its infancy has been hampered by cardiac motion, radiation
exposure, and cost. The initial approach to motion was to discard all
the PET counts when the heart was moving, resulting in high noise
in the end-diastolic PET data. This might ultimately limit the accu-
racy and clinical utility of 18F-NaF PET in distinguishing true uptake
in culprit or high-risk sites from noise-related false-positives. The
improved separation of positive from negative lesions and reduction
of noise enabled by this motion correction method will likely en-
hance the capability of 18F-NaF PET and lead to better detection of
vulnerable plaques. Our technique retains the count statistics from
the full PET acquisition and at the same time increases the TBR as
compared with the original 1-bin method. This ultimately may fa-
cilitate reduced bed times (improving scan efficiency and reducing
costs) or reduced tracer dose and radiation exposure.
In this study, CCTA scans were obtained in the original clinical
protocol for the purposes of PET uptake localization and plaque
characterization. We opted to use these scans as the anatomic
framework for PET motion correction since the data were readily
available. To our knowledge, all coronary PET studies (with 18F-NaF
or 18F-FDG) to date have used contrast CCTA for localization of
PET uptake (2,19,20). Registration methods that do not use CCTA
could be explored in the future, such as with PET/MR systems.
Alternatively, 18F-NaF PET testing could be applied in patients
who have already undergone anatomic testing with CCTA and pre-
sent abnormal results with potentially vulnerable plaques. Under
such circumstances, the prior CCTA could be reused (after coreg-
istration to the PET scan or CT attenuation scan obtained with
18F-NaF PET) to localize the 18F-NaF PET uptake and guide motion
correction without additional radiation or contrast exposure. Fur-
thermore, we have used the method of Vemuri et al. (13) for non-
linear registration of the multiple bins of PET data in the selected
coronary regions. This method is computationally efficient, which is
important since multiple volume registrations are required for each
patient. Other registration algorithms, such as the latest optical flow
methods, may have additional benefits that warrant further explo-
ration. Given our demonstration of the feasibility of a nonlinear
motion correction method for improved coronary PET imaging,
these other approaches and refinements warrant further prospective
investigation and validation in future studies.
The incorporation of the CCTA anatomic framework as proposed
here can also potentially lead to automation and reproducibility of
quantitative analysis of PET uptake, allowing less experienced
FIGURE 2. TBRs in positive (A) and negative (B) lesions and noise (C)
are shown for different PET datasets (1-bin data, ungated data, motion-
corrected data created from 4 bins, and motion-corrected data created
from 10 bins). (A) TBR in positive lesions increases with motion correc-
tion for 10-bin data, as compared with 1-bin data and ungated data. (B)
TBR in negative lesions remains below 1 using motion correction. (C)
Noise is almost halved using motion correction, as compared with 1-bin
data. MC 5 motion-corrected.
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centers to immediately implement this technique
and fostering meaningful intercenter comparisons of
the data. It is of key importance that this promising
PET technique be allowed to reach its full potential
by optimizing the image analysis techniques. The
CCTA-guided motion correction technique pro-
posed in this work will also be applicable to future
PET tracers exploring pathologic processes in the
coronary vasculature.
For patients with coronary heart disease, 18F-
NaF PET has several applications. First, it may
help assess future risk and provide added value to
the simple anatomic assessment from CCTA. This
may help inform the intensity of medical therapy
as well as plan potential coronary revasculariza-
tion, especially for intermediate lesions or multi-
vessel disease. It may also help determine risk in
the context of noncardiac interventions, such as
the planning of noncardiac surgery. Finally, it
may provide a surrogate biomarker of plaque vul-
nerability against which novel therapeutic inter-
ventions can be assessed.
This study had several limitations. Although it
clearly showed significant gains in image qual-
ity by the motion correction method applied to
18F-NaF PET imaging, there is room for improve-
ment. Indeed, we are likely to achieve further
significant enhancements in TBR by incorporat-
ing respiratory and patient motion correction, as
well as correction for partial-volume effects. We
did not perform these additional corrections in
our study because the dual gating and combined
correction for these motions is complex. Poten-
tially, PET and CCTA may be misregistered even
if CCTA is acquired in end-expiration. Therefore,
the CCTA coronary regions may not correspond
exactly to the PET regions considered in the mo-
tion correction technique. Automatic correction
for this alignment may result in further improve-
ments, since our method relies on centerline
extraction from the CCTA data, which defines
3-dimensional regions of interest in PET data.
Nevertheless, the regions that we used encom-
passed an approximate coronary artery path
neighborhood of 2 cm in diameter, which should
allow for some CCTA–PET misregistration. We
did not use standardized uptake values (SUVs)
in this study, focusing instead on TBR. In our
experience, SUV data result in greater variability
than TBRs, although this may need to be reeval-
uated when partial-volume corrections are per-
formed. We acknowledge that the study cohort
was small, reflecting the novelty of coronary im-
aging by 18F-NaF PET. Nevertheless, since there
were multiple lesions in each patient, we were
able to demonstrate the significant improvements
afforded by our technique.We focused on improve-
ment of image quality and discrimination of 18F-
NaF PET–positive lesions from 18F-NaF PET–
negative lesions, rather than on the clinical utility
of coronary 18F-NaF PET. An ongoing prospective
FIGURE 3. Noise decrease and TBR improvement in 18F-NaF PET images of 65-y-old
man. (A) On linear grayscale transaxial slices, 18F-NaF plaque uptake is seen in left
anterior descending (LAD) (red arrows) and left circumflex (LCX) (green arrows) coronary
arteries. The images show blurred lesion signal in ungated images, significant noise in
1-bin images, and high lesion signal with reduced noise in motion-corrected images. (B)
On PET (top), PET/CCTA (middle), and multiplanar-reformatted PET/CCTA (bottom) im-
ages with exponential color table and same window and level settings, vulnerable plaque
is seen in right coronary artery (RCA) (yellow arrows). Low lesion signal is seen in ungated
images, significant noise in 1-bin images (blue arrows), and high signal with less noise
in motion-corrected images. (C) 3-dimensional rendering of 1-bin image (25% of PET
counts) as in study of Joshi et al. (2) (left) and motion-corrected image (right) superimposed
on rendered CCTA volume. Increased uptake is seen in RCA, LAD, and LCX coronary arteries
in high-noise 1-bin image and remains clear in motion-corrected image.
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study (NCT02278211) aims to demonstrate the value of coronary
18F-NaF PET in predicting future myocardial infarction (21). When
this trial is completed, we plan to apply the techniques to demonstrate
improved prediction of myocardial infarction.
CONCLUSION
Motion correction of gated 18F-NaF PET/CT reduces noise and
increases TBR as compared with 1-bin imaging and further improves
TBR as compared with ungated images without a noise increase.
This improvement may allow more reliable identification of vulner-
able plaque lesions in the coronary arteries by 18F-NaF PET.
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¹⁸F-fluoride positron emission tomography for identification 
of ruptured and high-risk coronary atherosclerotic plaques: 
a prospective clinical trial
Nikhil V Joshi, Alex T Vesey, Michelle C Williams, Anoop S V Shah, Patrick A Calvert, Felicity H M Craighead, Su Ern Yeoh, William Wallace, 
Donald Salter, Alison M Fletcher, Edwin J R van Beek, Andrew D Flapan, Neal G Uren, Miles W H Behan, Nicholas L M Cruden, Nicholas L Mills, 
Keith A A Fox, James H F Rudd, Marc R Dweck*, David E Newby*
Summary
Background The use of non-invasive imaging to identify ruptured or high-risk coronary atherosclerotic plaques would 
represent a major clinical advance for prevention and treatment of coronary artery disease. We used combined PET 
and CT to identify ruptured and high-risk atherosclerotic plaques using the radioactive tracers ¹⁸F-sodium fluoride 
(¹⁸F-NaF) and ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG).
Methods In this prospective clinical trial, patients with myocardial infarction (n=40) and stable angina (n=40) 
underwent ¹⁸F-NaF and ¹⁸F-FDG PET-CT, and invasive coronary angiography. ¹⁸F-NaF uptake was compared with 
histology in carotid endarterectomy specimens from patients with symptomatic carotid disease, and with intravascular 
ultrasound in patients with stable angina. The primary endpoint was the comparison of ¹⁸F-fluoride tissue-to-
background ratios of culprit and non-culprit coronary plaques of patients with acute myocardial infarction.
Findings In 37 (93%) patients with myocardial infarction, the highest coronary ¹⁸F-NaF uptake was seen in the culprit 
plaque (median maximum tissue-to-background ratio: culprit 1·66 [IQR 1·40–2·25] vs highest non-culprit 1·24 
[1·06–1·38], p<0·0001). By contrast, coronary ¹⁸F-FDG uptake was commonly obscured by myocardial uptake and 
where discernible, there were no differences between culprit and non-culprit plaques (1·71 [1·40–2·13] vs 1·58 
[1·28–2·01], p=0·34). Marked ¹⁸F-NaF uptake occurred at the site of all carotid plaque ruptures and was associated 
with histological evidence of active calcification, macrophage infiltration, apoptosis, and necrosis. 18 (45%) patients 
with stable angina had plaques with focal ¹⁸F-NaF uptake (maximum tissue-to-background ratio 1·90 [IQR 1·61–2·17]) 
that were associated with more high-risk features on intravascular ultrasound than those without uptake: positive 
remodelling (remodelling index 1·12 [1·09–1·19] vs 1·01 [0·94–1·06]; p=0·0004), microcalcification (73% vs 21%, 
p=0·002), and necrotic core (25% [21–29] vs 18% [14–22], p=0·001).
Interpretation ¹⁸F-NaF PET-CT is the first non-invasive imaging method to identify and localise ruptured and high-
risk coronary plaque. Future studies are needed to establish whether this method can improve the management and 
treatment of patients with coronary artery disease.
Funding Chief Scientist Office Scotland and British Heart Foundation.
Introduction
Coronary atherosclerotic plaque rupture is the principal 
precipitant of acute myocardial infarction and an important 
cause of sudden cardiac death. Rupture is challenging to 
predict because most plaques are non-obstructive and are 
not identified by stress testing or coronary angiography.1,2 
Atherosclerotic lesions at risk of rupture have certain 
histopathological characteristics that include positive re-
modelling, microcalcification, and a large necrotic core.1–3 
The development of modern molecular imaging tech-
niques targeted at these features could lead to the 
identification of such high-risk plaques in vivo and guide 
the development of novel treatment strategies.4–7
Combined PET and CT is a non-invasive imaging 
technique that brings functional molecular imaging 
together with precise anatomical information. We have 
recently reported preliminary PET-CT data using the 
tracer ¹⁸F-sodium fluoride (¹⁸F-NaF) as a marker of 
valvular and vascular calcification activity in patients with 
aortic stenosis.7–9 Other studies have shown the use-
fulness of ¹⁸F-flurodeoxyglucose (¹⁸F-FDG) as a surro-
gate of vascular inflammation and macrophage 
burden.6,10–13 We therefore investigated whether, compared 
with the current non-invasive gold standard of ¹⁸F-FDG, 
¹⁸F-NaF uptake could identify ruptured and high-risk 
athero sclerotic plaques in patients with symptomatic 
coronary and carotid artery disease.
Methods
Patients
Patients were recruited from the Royal Infirmary of 
Edinburgh between February, 2012, and January, 2013, in 
three cohorts: 40 patients with acute ST-segment or non-
ST-segment elevation myocardial infarction,14 40 patients 
with stable angina pectoris undergoing elective invasive 
coronary angiography, and 12 patients (nine evaluable) 
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undergoing carotid endartectomy for symptomatic caro-
tid artery disease.15
Exclusion criteria were age younger than 50 years, 
insulin-dependent diabetes mellitus, women of child-
bearing age not receiving contraception, severe renal 
failure (serum creatinine >250 µmol/L), known contrast 
allergy, and inability to provide informed consent. Only 
patients older than 50 years were recruited in the study to 
reduce any long-term risks associated with radiation 
exposure. Uncontrolled diabetes and high blood glucose 
concentrations (>11 mmol/L) interfere with the quality 
of ¹⁸F-FDG PET imaging because of the competition 
between glucose and ¹⁸F-FDG for cellular entry. The 
convention is therefore to exclude such patients from 
vascular ¹⁸F-FDG PET studies.7,10,12,13
All patients underwent a comprehensive baseline 
clinical assessment including evaluation of their cardio-
vascular risk factor profile. Plasma troponin I concen-
trations were measured in patients with stable angina 
using the ARCHITECT STAT high-sensitivity troponin I 
assay (Abbott Laboratories, Abbott Park, IL, USA; lower 
limit of detection 1·2 ng/L; 99th percentile diagnostic 
threshold 26 ng/L). Studies were done with the approval 
of the local research ethics committee, in accordance 
with the Declaration of Helsinki, and with the written 
informed consent of each participant.
Procedures
Patients with myocardial infarction and stable angina 
underwent ¹⁸F-NaF and ¹⁸F-FDG PET-CT, CT coronary 
angiography, and CT calcium scoring (appendix).7 To 
minimise myocardial uptake, patients were instructed to 
adhere to a low-carbohydrate, high-protein, and high-fat 
diet for at least 24 h before undergoing ¹⁸F-FDG PET-CT.
Electrocardiograph-gated PET images were recon-
structed in diastole (50–75% of the R-R interval, Ultra-HD) 
using the Siemens Ultra-HD algorithm, fused with the 
CT coronary angiogram, and analysed by experienced 
observers blinded to the clinical diagnosis (NJ, MD, FC) 
using an OsiriX workstation (OsiriX version 5·5·1 64-bit; 
OsiriX Imaging Software, Geneva, Switzerland). Two-
dimensional regions of interest were drawn around all 
major (diameter >2 mm) epicardial vessels on 3 mm axial 
slices just beyond the discernible adventitial border. The 
maximum standard uptake value (the decay corrected 
tissue concentration of the tracer divided by the injected 
dose per bodyweight) was measured and corrected for 
blood pool activity in the superior vena cava to provide 
tissue-to-background ratio (TBRs) measurements. Using 
this method, we have previously shown excellent reprod-
uci bility for ¹⁸F-NaF TBR measurements in the coronary 
arteries with an intraclass correlation coefficient of 0·99.7
We used a previously established 95% lower reference 
limit to categorise coronary plaques into ¹⁸F-NaF positive 
lesions (focal uptake with a TBR more than 25% higher 
than a proximal reference lesion) and negative plaques if 
these criteria were not achieved. This limit was based on 
our previous study, where plaques with high ¹⁸F-NaF 
uptake had maximum TBRs that were 44% (95% CI 
26–62) higher than a proximal quiescent reference 
lesion.7 In patients with acute myocardial infarction, 
¹⁸F-NaF uptake in the culprit plaque was compared with 
the highest value in any of the non-culprit vessels.
Quantification of ¹⁸F-FDG uptake was performed as for 
¹⁸F-NaF uptake but restricted to the proximal and mid-
portions of the coronary arteries, and to regions where 
myocardial uptake and spillover could be confidently 
excluded.7 Again, ¹⁸F-FDG positive plaques were defined 
using the 25% threshold as described for ¹⁸F-NaF. Effective 
myocardial suppression of ¹⁸F-FDG was predefined as a 
standard uptake value of 5·0 or less in the basal ventricular 
septum (appendix) as per published data.12
In patients with stable angina, PET-CT imaging was 
prospectively used to direct greyscale and radio-
frequency intravascular ultrasound (20 MHz Eagle Eye 
Platinum Catheters [Volcano Corp, San Diago, CA, 
USA], motorised pull-back 0·5 mm/s) to the ¹⁸F-NaF 
positive and negative plaques. The interventional 
cardiologist acquiring the intravascular ultrasound data 
was blinded to the PET-CT status of the plaque.
Intravascular ultrasound analysis was done as described 
previously16 using dedicated VIAS software (Volcano 
Image Analysis Software version 3.0) by operators blinded 
to the PET data. Regions of interest were drawn around 
the external elastic membrane and luminal borders, and 
plaque area and composition (dense calcium, necrotic 
core, fibro-fatty tissue, and fibrous tissue) calculated.16–18 
The presence of microcalcification (spotty calcification in 
the absence of acoustic shadowing on three or more 
consecutive frames) and the maximum frame necrotic 
core (the highest percentage of necrotic core on a single 
frame) were recorded.19 The remodelling index was 
defined as the ratio between the external elastic mem-
brane cross-sectional area of the lesion and a proximal 
reference region in the same vessel.20 Plaques were 
classified as thin-cap fibroatheroma, thick-cap fibro-
atheroma, pathological intimal thickening, or fibrocalcific 
plaque as defined previously.18,21
CT analysis was done on a dedicated cardiovascular 
workstation (Vital Images, Minnetonka, MN, USA). 
Vessel-specific and total Agatston calcium scores were 
calculated as described previously.7 An independent 
experienced and blinded observer (MW) determined the 
stenosis severity, plaque composition (calcified, non-
calcified, mixed plaque), and presence of high-risk CT 
features (positive remodelling, microcalcification, necro-
tic core) according to standard definitions in plaques 
with and without increased ¹⁸F-NaF activity.22
Intact atherosclerotic plaques were retrieved at the 
time of carotid endarterectomy and scanned using ex-
vivo PET-CT to allow precise anatomical co localisation of 
¹⁸F-NaF activity with pathological evidence of plaque 
rupture. Plaques were divided into ¹⁸F-NaF positive and 
negative areas, and histological sections were assessed 
See Online for appendix
Articles
www.thelancet.com   Published online November 11, 2013   http://dx.doi.org/10.1016/S0140-6736(13)61754-7 3
using Movat’s pentachrome and immunohistochemistry 
to investigate calcification activity (tissue non-specific 
alkaline phosphatase and osteocalcin), macrophage 
infiltration (CD68), and cell death (apoptosis, cleaved 
caspase 3; presence of necrotic core; appendix).
Statistical analysis
The primary endpoint of the study was the comparison of 
¹⁸F-fluoride tissue-to-background ratios of culprit and non-
culprit coronary plaques of patients with acute myocardial 
infarction. The main secondary endpoints were com-
parative imaging and histol ogical characterisation of 
¹⁸F-fluoride positive and negative atherosclerotic plaques 
in patients with coronary and carotid artery disease. Based 
on our previous data,7 we required 36 patients with myo-
cardial infarction to detect a difference of 0·23 in the 
tissue-to-background ratio between culprit and non-culprit 
plaques at 90% power and two-sided p<0·05. We recruited 
40 patients to account for incomplete data and recruited a 
similar sized (n=40) comparator group of patients with 
stable angina.
Continuous data were tested for normality with the 
D’Agostino-Pearson omnibus test. Continuous para-
metric variables were expressed as mean (SD) and 
Myocardial infarction Stable angina
All (n=40)
All (n=40) STEMI (n=26) NSTEMI (n=14)
Age in years, mean (SD) 62 (8) 63 (9) 60 (8) 67 (8)
Men, n (%) 37 (93%) 24 (92%) 13 (93%) 36 (90%)
Body-mass index (kg/m²), mean (SD) 28 (5) 27 (5) 30 (4) 30 (5)
Antecedent angina (active), n (%) 9 (23%) 5 (19%) 4 (29%) 40 (100%)
Heart rate (per min), mean (SD)* 56 (7) 56 (7) 56 (7) 59 (9)
Systolic blood pressure (mm Hg), mean (SD) 132 (21) 131 (20) 121 (21) 134 (14)
Diastolic blood pressure (mm Hg), mean (SD) 76 (9) 76 (9) 76 (8) 77 (10)
Cardiovascular history, n (%)
Previous MI 5 (13%) 1 (4%) 4 (29%) 15 (38%)
Previous CVA/TIA 2 (5%) 1 (4%) 1 (7%) 4 (10%)
Previous PCI 5 (13%) 2 (8%) 3 (21%) 19 (48%)
Previous CABG 2 (5%) 2 (8%) 0 11 (28%)
Risk factors, n (%)
Smoking habit (ex or current) 25 (63%) 19 (73%) 6 (43%) 24 (60%)
Non-insulin dependent diabetes 8 (20%) 7 (27%) 1 (7%) 13 (33%)
Hypertension 17 (43%) 11 (42%) 6 (43%) 36 (90%)
Hypercholesterolaemia 19 (48%) 11 (42%) 8 (57%) 39 (98%)
Medications, n (%)†
Aspirin 40 (100%) 26 (100%) 14 (100%) 33 (83%)
Clopidogrel 39 (98%) 25 (96%) 14 (100%) 5 (13%)
Statin 39 (98%) 26 (100%) 13 (93%) 36 (90%)
β blocker 32 (80%) 20 (77%) 12 (86%) 28 (70%)
ACEI/ARB 35 (88%) 25 (96%) 10 (71%) 20 (50%)
Calcium channel blockers 2 (5%) 2 (8%) 0 16 (40%)
Other anti-hypertensive 3 (8%) 1 (4%) 2 (14%) 6 (15%)
Oral nitrates 1 (3%) 0 1 (7%) 15 (38%)
Serum biochemistry, mean (SD)
Cholesterol (mmol/L) 4·7 (1·2) 4·7 (1·3) 4·8 (1·1) 3·9 (0·8)
HDL cholesterol (mmol/L) 1·1 (0·3) 1·1 (0·3) 1·0 (0·3) 1·1 (0·3)
LDL cholesterol (mmol/L) 2·9 (1·1) 2·8 (1·1) 3·1 (1·0) 2·1 (0·7)
Triglycerides (mmol/L) 1·6 (0·8) 1·7 (0·7) 1·5 (0·7) 1·6 (0·7)
Creatinine (µmol/L) 84 (27) 86 (29) 82 (24) 85 (23)
Coronary artery calcium score (Agatston units), 
median (IQR)
159 (42–456) 176 (45–474) 122 (26–442) 599 (60–1302)
Peak troponin concentration (ng/L), median (IQR) 32 300 (10 200–50 000) 11 200 (3300–50 000) 3800 (1000–9200)
NSTEMI=non-ST elevation myocardial infarction. MI=myocardial infarction. CVA=cerebrovascular accident. TIA=transient ischaemic attack. PCI=percutaneous coronary 
intervention. ACEI=angiotensin converting enzyme inhibitor. ARB=angiotensin receptor blocker. CABG=coronary artery bypass graft. HDL=high-density lipoprotein. 
LDL=low-density lipoprotein. STEMI=ST-elevation myocardial infarction. *Heart rate at the time of CT coronary angiography. †Medications at the time of scan. 
Table 1: Baseline characteristics of patients with coronary artery disease
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compared using Student’s t tests. Non-parametric data 
were presented as median (IQR) and compared using 
Mann-Whitney U test or Wilcoxon signed-rank test as 
appropriate. Fisher’s exact test or chi-squared test was 
used for analysis of categorical variables. Statistical 
analysis was done with Graph Pad Prism version 5 
(GraphPad Software, La Jolla, CA, USA). A two-sided 
p<0·05 was taken as statistically significant.
The study was registered with ClinicalTrials.gov 
number NCT01749254.
Role of the funding source
The funding source had no role in the study design 
(except through its external peer review process), data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had access to the primary data and 
have final responsibility to submit for publication.
Results
Patients were predominantly middle-aged men and had 
multiple cardiovascular risk factors (table 1). They under-
went both ¹⁸F-NaF (60 [SD 9] min after 123 [SD 5] MBq) 
and ¹⁸F-FDG (90 [7] min after 192 [11] MBq) PET-CT 
scanning within a median of 6 (IQR 3–9) days. The 
median duration between PET-CT scanning and coronary 
angiography was 7 (IQR 1–12) days. The total effective 
radiation dose from study participation was 13·7 (SD 3·0) 
mSv (conversion factor of 0·014 mSv/mGy.cm): ¹⁸F-NaF 
(3·8 [SD 0·3] mSv) and ¹⁸F-FDG (4·9 [0·5] mSv) PET-CT, 
CT coronary angiogram (3·7 [2·1] mSv), and calcium 
score (1·3 [0·5] mSv).
The culprit vessel was the left anterior descending 
artery in 17 (42%) patients, the left circumflex artery in 
seven (18%), and the right coronary artery in 16 (40%). 
Patients underwent ¹⁸F-NaF scans 6 [IQR 3–10] days after 
hospitalisation for myocardial infarction (symp toms to 
¹⁸F-NaF scan, 8 [3–10] days). ¹⁸F-NaF activity in the culprit 
plaque was 34% higher than the maxi mum activity 
recorded anywhere else in the coronary vasculature 
(maximum TBR 1·66 [1·40–2·25] vs 1·24 [1·06–1·38], 
p<0·0001; figures 1 and 2). In 37 of the 40 patients (93%), 
increased ¹⁸F-NaF uptake was seen in the culprit plaque 
(figure 1; appendix). In the three patients without uptake, 
two were younger smokers (aged 50 and 52 years) and, in 
the third, the culprit lesion was adjudicated as the right 
coronary artery although focal increased activity was seen 
in the left circumflex artery. In five patients, increased 
¹⁸F-NaF activity was seen at multiple sites within the 
coronary circulation.
Predefined myocardial suppression of ¹⁸F-FDG uptake 
was achieved in 28 (70%) patients (median myocardial 
standard uptake value 3·92 [IQR 2·71–5·55]). However, 
coronary ¹⁸F-FDG uptake could not be distinguished 
from patchy myocardial uptake in 22 patients affecting 
52% of vessel territories. Increased uptake of ¹⁸F-FDG 
was observed in the culprit vessels of six (33%) of the 
remaining 18 patients. Overall, no significant differences 
could be shown between the maximum TBRs in the 
culprit plaques and those recorded elsewhere in the 
coronary vasculature (1·71 [IQR 1·40–2·13] vs 1·58 
[1·28–2·01], p=0·34: figure 2) with a mean difference of 
0·09 (95% CI −0·07 to 0·24).
The median duration between clinical symptoms and 
carotid endarterectomy was 17 [IQR 10–27] days (appen-
dix). Carotid endarterectomy specimens (figure 3; appen-
dix) were obtained for 12 patients, although three 
specimens could not be excised intact and were discarded. 
Ex-vivo ¹⁸F-NaF PET-CT was undertaken in nine speci-
mens and uptake was localised to the site of macroscopic 
plaque rupture in all patients (figure 3). Compared with 
sections of tissue without uptake (n=15), those with 
increased ¹⁸F-NaF uptake (n=24) had increased calcifi-
cation activity (tissue non-specific alkaline phosphatase 
4·07% [SD 3·42] vs 0·76% [0·51], p<0·0001; osteocalcin 
1·88% [IQR 0·58–4·10] vs 0·25% [0·11–0·58], p<0·0001), 
macrophage infiltration (CD68, 350 [IQR 172–840] vs 
145 [24–362] cells/mm², p=0·013), and cell death (apop-
tosis, cleaved-caspase-3, 1·23% [0·69–1·91] vs 0·09% 
[0·04–1·38], p=0·005; necrotic core, 22/24 vs 4/15; 
p<0·0001; appendix).
Patients with stable angina were older (67 [SD 8] vs 62 [8] 
years, p=0·006) and had more severe coronary artery 
disease (coronary artery calcium score 599 [IQR 60–1302] 
vs 159 [42–456] Agatston units, p=0·006) than those with 
myocardial infarction (table 1). Focal ¹⁸F-NaF uptake was 
noted in 18 patients (45%), which did not seem to be 
related to percutaneous coronary intervention and stent 
Figure 1: Focal ¹⁸F-fluoride and ¹⁸F-fluorodeoxyglucose uptake in patients 
with myocardial infarction and stable angina
Patient with acute ST-segment elevation myocardial infarction with (A) proximal 
occlusion (red arrow) of the left anterior descending artery on invasive coronary 
angiography and (B) intense focal ¹⁸F-fluoride (¹⁸F-NaF, tissue-to-background 
ratios, culprit 2·27 versus reference segment 1·09 [108% increase]) uptake 
(yellow-red) at the site of the culprit plaque (red arrow) on the combined positron 
emission and computed tomogram (PET-CT). Corresponding 
¹⁸F-fluorodeoxyglucose PET-CT image (C) showing no uptake at the site of the 
culprit plaque (¹⁸F-FDG, tissue-to-background ratios, 1·63 versus reference 
segment 1·91 [15% decrease]). Note the significant myocardial uptake overlapping 
with the coronary artery (yellow arrow) and uptake within the oesophagus 
(blue arrow). Patient with anterior non-ST-segment elevation myocardial 
infarction with (D) culprit (red arrow; left anterior descending artery) and 
bystander non-culprit (white arrow; circumflex artery) lesions on invasive coronary 
angiography that were both stented during the index admission. Only the culprit 
lesion had increased ¹⁸F-NaF uptake (¹⁸F-NaF, tissue-to-background ratios, culprit 
2·03 versus reference segment 1·08 [88% increase]) on PET-CT (E) after 
percutaneous coronary intervention. Corresponding ¹⁸F-fluorodeoxyglucose 
PET-CT showing no uptake either at the culprit (¹⁸F-FDG, tissue-to-background 
ratios, culprit 1·62 versus reference segment 1·49 [9% increase]) or the bystander 
stented lesion. Note intense uptake within the ascending aorta. In a patient with 
stable angina with previous coronary artery bypass grafting, invasive coronary 
angiography (G) showed non-obstructive disease in the right coronary artery. 
Corresponding PET-CT scan (H) showed a region of increased ¹⁸F-NaF activity 
(positive lesion, red line) in the mid-right coronary artery (tissue-to-background 
ratio, 3·13) and a region without increased uptake in the proximal vessel (negative 
lesion, yellow line). Radiofrequency intravascular ultrasound shows that the 
¹⁸F-NaF negative plaque (I) is principally composed of fibrous and fibrofatty tissue 
(green) with confluent calcium (white with acoustic shadow) but little evidence of 
necrosis. On the contrary, the ¹⁸F-NaF positive plaque (J) shows high-risk features 
such as a large necrotic core (red) and microcalcification (white).
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deployment (appendix). The maximum TBR for ¹⁸F-NaF 
positive plaques was 1·90 [IQR 1·61–2·17] and for ¹⁸F-NaF 
negative plaques was 1·02 [0·82–1·17]. ¹⁸F-NaF positive 
plaques were predominantly (72% of patients) non-
obstructive (<70% luminal stenosis) on coronary 
angiography and showed multiple high-risk features on 
radiofrequency intravascular ultrasound (positive 
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1·01 [0·94–1·06]; p<0·001, microcalcification (73 vs 21%, 
p=0·002) and necrotic core (24·6% [20·5–28·8] vs 18·0% 
[14·0–22·4]), p=0·001), with similar observations for CT 
(figure 1, table 2; appendix). Multivessel uptake was 
commonly seen: two-vessel uptake in six (15%) and three-
vessel uptake in five (13%) patients. Patients with ¹⁸F-NaF 
positive lesions had higher concentrations of plasma 
troponin at baseline (3·35 [IQR 2·35–10·20] vs 2·45 
[1·85–4·02] ng/L; p=0·047), with one individual having a 
concentration (35 ng/L) above the 99th percentile 
diagnostic threshold.
Although predefined myocardial suppression of 
¹⁸F-FDG uptake was achieved in 34 (85%) patients 
(median myocardial standard uptake value 2·60 
[IQR 1·83–3·83]), coronary ¹⁸F-FDG uptake could not be 
confidently interpreted in 45% of vessel territories. 
Increased focal ¹⁸F-FDG uptake was noted in just four 
patients: three at the site of recent coronary stenting and 
one at the ostium of a saphenous vein graft.
Discussion
We have shown that intense ¹⁸F-NaF uptake localises to 
recent plaque rupture in patients with acute myocardial 
infarction and in those with symptomatic carotid disease. 
Moreover, in patients with stable coronary artery disease, 
¹⁸F-NaF uptake seems to identify coronary plaques with 
high-risk features on intravascular ultrasound. This 
technique holds major promise as a means of identifying 
high-risk and ruptured plaque, and potentially informing 
the future management and treatment of patients with 
stable and unstable coronary artery disease.
Figure 3: Carotid ¹⁸F-fluoride uptake and carotid plaque rupture
In-vivo (A and B) and ex-vivo (C and D) positron emission and computed tomograms showing colocalisation of ¹⁸F-fluoride (¹⁸F-NaF) uptake (yellow-orange) to the 
site of plaque rupture with adherent thrombus on excised carotid endarterectomy tissue (E and F). Histology of the ¹⁸F-NaF-positive region shows a large necrotic 
core (Movat’s pentachrome, magnification 4×, G), within which increased staining for tissue non-specific alkaline phosphatase can be seen as a marker of calcification 
activity on immunohistochemistry (magnification 4×, H; magnification 10×, I).


























A B18F-sodium fluoride 18F-fluorodeoxyglucose
Figure 2: ¹⁸F-fluoride and ¹⁸F-fluorodeoxyglucose uptake in patients with myocardial infarction
¹⁸F-fluoride activity (maximum tissue-to-background ratio) was increased in the culprit plaque (red) compared 
with the maximum uptake in any of the non-culprit plaques (blue). By contrast, there was no difference in the 
activity of ¹⁸F-fluorodeoxyglucose between these regions.
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Over 90% of our patients with myocardial infarction 
had increased ¹⁸F-NaF uptake at the site of their culprit 
ruptured plaque, with TBR values that were a third 
higher than the maximum activity anywhere else in the 
coronary vasculature. These findings were not unique to 
the coronary circulation since we also noted increased 
focal ¹⁸F-NaF uptake at the site of plaque rupture in all 
excised carotid endarterectomy specimens from patients 
with symptomatic carotid disease. However, we do 
acknowledge that this was not a universal finding. Of the 
three patients with myocardial infarction who had no 
uptake, two were younger smokers with only mild under-
lying irregularities on coronary angiography, implicating 
plaque erosion and thrombosis as the mechanism of 
their infarction rather than plaque rupture.23 The third 
patient sustained an inferolateral non-ST segment 
elevation myocardial infarction and had a lesion stented 
in the right coronary artery. Increased ¹⁸F-NaF activity 
was seen in the co-dominant circumflex artery that could 
have equally explained the clinical presentation, raising 
the intriguing possibility that ¹⁸F-NaF might have a 
clinical role for patients in whom the culprit lesion is not 
readily apparent.
Focal regions of increased ¹⁸F-NaF activity were seen in 
almost a half of our patients with stable coronary artery 
disease. To understand the mechanism of uptake in these 
patients, we sought to compare plaque characteristics of 
lesions with and without increased ¹⁸F-NaF uptake. 
Because histology of the coronary arteries in this 
population is not feasible, we undertook greyscale and 
radiofrequency intravascular ultrasound, a widely used 
and validated process that provides detailed characterisation 
of plaque composition.21 This method showed that lesions 
with increased ¹⁸F-NaF uptake were associated with greater 
positive remodelling, more microcalcification, and a larger 
necrotic core. These findings were corroborated by, and 
consistent with, the findings of plaque analysis done with 
CT coronary angiography. Plasma troponin concentrations 
measured by a novel high-sensitivity assay were also 
higher in those patients with ¹⁸F-NaF positive plaques than 
in patients with ¹⁸F-NaF negative plaques, perhaps impli-
cating subclinical plaque rupture with embolisation and 
microinfarction.
Why does ¹⁸F-NaF bind to ruptured or high-risk 
plaque? Similar to the caseating granulomata of tuber-
culosis, atherosclerotic vascular calcification is a con-
trolled cellular response to an intense, necrotic, and 
chronic inflammatory stimulus. Indeed, direct links 
between inflammatory cells and osteoblastic metaplasia 
in the vasculature are well described.24,25 Hydroxyapatite 
is the central structural component of vascular calcifi-
cation and is laid down during the earliest and most 
active stages of mineralisation:24 hydroxyapatite nano-
crystals nucleate, propagate, and mineralise the extra-
cellular matrix. Fluoride ions are incorporated into the 
hydroxyapatite by ion exchange with hydroxyl groups at 
the crystal surface. This process is dependent on the 
crystal surface area that will be greatest in the earliest 
and most active nanocrystalline stages of mineralisation 
associated with plaque inflammation and necrosis. We 
believe that these processes are responsible for the 
observed ¹⁸F-NaF uptake and is consistent with our 
data showing ¹⁸F-NaF uptake in regions of necrosis, 
macrophage infiltration, apoptosis, microcalcification, 
and alkaline phosphatase and osteocalcin staining. 
Moreover, mathematical modelling indicates that micro-
calcification at the surface of thin-capped atheroma 
(figure 1) can intensify and double incident stresses.26 
Microcalcification is therefore not only a marker of acute 
plaque rupture but is implicated in its precipitation.
Coronary arterial calcification is considered patho-
gnomonic of atherosclerosis and is a powerful indepen-
dent risk predictor for cardiovascular events that can be 
further refined by the rapidity of its progression.27,28 Why 
then not rely on CT coronary calcium scoring alone as a 
biomarker? Microcalcification cannot be detected on 
CT and confluent coronary macrocalcification develops 
slowly, taking many months or years to become apparent 







Area (mm²) 9·0 (5·7–13·5) 6·7 (4·7–9·7) 0·078
Minimal diameter (mm) 2·6 (1·7–3·1) 1·9 (1·7–2·6) 0·165
Maximum diameter (mm) 4·9 (4·1–5·3) 3·6 (3·1–4·6) 0·006
Vessel
Area (mm²) 24·1 (17·2–27·1) 14·5 (11·9–18·1) 0·002
Minimal diameter (mm) 4·4 (3·4–5·2) 3·6 (3·0–4·1) 0·057
Maximum diameter (mm) 6·5 (6·0–7·1) 5·2 (4·7–5·9) 0·0001
Plaque
Length (mm) 14·2 (6·2–23·5) 15·2 (6·7–25·0) 0·941
Volume (mm³) 152·9 (99·6–289·7) 91·0 (45·8–158·2) 0·032
Burden (%)* 55·6 (48·6–64·4) 54·2 (46·3–57·3) 0·174
Remodelling index 1·12 (1·09–1·19) 1·01 (0·94–1·06) 0·0004
Plaque composition
Fibrous tissue (%) 51·0 (46·3–56·6) 58·1 (51·6–65·5) 0·015
Fibro-fatty (%) 10·9 (6·0–13·8) 12·6 (9·3–17·8) 0·092
Necrotic core (%) 24·6 (20·5–28·8) 18·0 (14·0–22·4) 0·001
Maximum frame necrotic core (%)† 35·5 (34·2–40·5) 29·2 (23·9–42·1) 0·009
Dense calcium (%) 12·6 (9·1–18·1) 10·2 (4·0–14·9) 0·092
Microcalcification, n (%) 11 (73%) 5 (21%) 0·002
Plaque classification, n (%)
Thin-cap fibroatheroma 7 (47%) 4 (16%) 0·068
Thick-cap fibroatheroma 5 (33%) 9 (38%) 1·0
Pathological intimal thickening 0 7 (29%) 0·003
Fibrocalcific plaque 3 (20%) 4 (16%) 1·0
Data are median (IQR) unless otherwise stated. *Plaque burden calculation = (average vessel area − average lumen area) 
/average vessel area. †Maximum necrotic core in any single frame in the plaque.
Table 2: Greyscale and radiofrequency intravascular ultrasound characteristics in ¹⁸F-fluoride positive and 
negative plaques of patients with stable angina
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the plaque has subsided. By identifying areas of nascent 
and ongoing calcification activity, ¹⁸F-NaF uptake allows 
us to detect regions of metabolically active plaque, thus 
providing complementary information to CT.29–32 Indeed, 
we noted large areas of coronary CT calcium in the 
absence of increased ¹⁸F-NaF uptake (figure 1) whereas 
other regions with minimal or no CT calcium had intense 
¹⁸F-NaF uptake (appendix) in keeping with previous 
observations in the aorta by Derlin and colleagues 
(panel).29,32 Moreover, given that ¹⁸F-NaF seems more 
closely aligned with the process of necrotic inflammation 
and plaque metabolic activity, we believe that it potentially 
offers major improvements to the prediction of cardio-
vascular risk compared with calcium scoring.
Our data have already established that ¹⁸F-NaF identifies 
plaque with multiple high-risk features, but prospective 
studies are now needed in a broad range of patients to 
assess whether increased coronary ¹⁸F-NaF activity will 
ultimately translate into future adverse events. If the 
results prove confirmatory then this technique has the 
potential to fundamentally alter the way we treat coronary 
artery disease: moving us away from the current framework 
based on lesion severity and ischaemia to one focused on 
plaque metabolism and inflammation. It could, for 
example, permit the identification of the vulnerable patient 
with single or multiple high-risk or silently ruptured 
plaques, providing an opportunity to treat and modify their 
risk to prevent future adverse cardiovascular events.
By contrast with ¹⁸F-NaF, ¹⁸F-FDG imaging was ham-
pered by problems related to tracer uptake in the 
myocardium. Our stringent dietary recommendations 
resulted in suppression of myocardial activity in 70–85% 
of patients: a rate that compares favourably with pre-
vious studies (57–84%).6,12,13 However, this suppression 
resulted in a patchy distribution of myocardial uptake 
that frequently obscured activity in one or more coronary 
vessels. Increased ¹⁸F-FDG uptake might possibly occur 
in the culprit plaque and we failed to show this because 
of incomplete data or the delay in scanning. However, 
given its limitations, we believe that ¹⁸F-FDG is unlikely 
to become sufficiently robust to permit its clinical appli-
cation to the coronary circulation. Nevertheless, ¹⁸F-FDG 
uptake remains an important measure of general 
vascular inflammation in the aorta and carotid arteries, 
providing complementary and distinct metabolic infor-
mation to that of ¹⁸F-NaF uptake.
We acknowledge that there are limitations of our study 
that include a lack of respiratory gating, potential partial 
volume artefacts, and the use of surrogate measures for 
coronary histology.21 However, we believe that the totality 
of our comprehensive evidence using multiple approaches 
and imaging modalities provides a robust and cogent 
argument to support our contention that ¹⁸F-fluoride 
uptake identifies vulnerable and high-risk plaques in 
patients with stable and unstable coronary heart disease. 
Further work is now needed to establish whether ¹⁸F-NaF 
PET-CT will provide a clinically useful technique capable 
of improving risk stratification, monitoring disease pro-
gression, guiding therapeutic interventions, and assessing 
novel anti-atherosclerotic therapies.
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Panel: Research in context
Systematic review
We searched PubMed using variations of the keywords “high-risk plaques”, “vulnerable 
plaques”, “ruptured plaques”, “¹⁸F-fluorodeoxyglucose positron emission tomography”, 
“¹⁸F-fluoride positron emission tomography”, and “coronary arteries”. The search was 
restricted to human studies. We assessed the quality of the evidence specifically related to 
cardiovascular disease by reviewing the patient population studied and the methodology 
for the positron emission and CT imaging.
Non-invasive imaging of carotid plaque inflammation using ¹⁸F-fluorodeoxyglucose 
positron emission tomography was reported by Rudd and colleagues in 2002.11 Since then, 
this tracer has been validated and widely used as a surrogate of large vessel inflammation.8,10 
Increased ¹⁸F-fluorodeoxyglucose in the coronary arteries has been described in patients with 
coexisting malignancy.12,33,34 Since then, three prospective studies have examined the 
feasibility and reproducibility of assessing uptake of this tracer in the coronary 
vasculature.6,7,13 Only two small studies (n=10–20)6,13 have suggested that 
¹⁸F-fluorodeoxyglucose might identify some inflamed plaques in patients with recent 
myocardial infarction, although the largest study showed that in 50% of patients with acute 
myocardial infarction, there was no uptake of ¹⁸F-fluorodeoxyglucose in the culprit plaque.13
Four retrospective studies in patients with cancer have recently reported cardiovascular 
uptake of ¹⁸F-fluoride.29,31,32,35 The aortic uptake of ¹⁸F-NaF was first reported by Derlin and 
colleagues29 and cardiac ¹⁸F-fluoride uptake by Beheshti and colleagues.31 We reported the 
coronary uptake of ¹⁸F-NaF in a prospective clinical trial involving patients with aortic 
stenosis,7,8 and these results were subsequently corroborated by Li and colleagues in their 
retrospective study of patients with cancer.30 No study has prospectively assessed this tracer 
in patients with stable or unstable coronary artery disease or validated its activity against 
histology or invasive intracoronary imaging, such as intravascular ultrasound. There are no 
previous reports of ¹⁸F-fluoride uptake in relation to plaque vulnerability or rupture.
Interpretation
There are currently no non-invasive imaging techniques that can identify high-risk and 
ruptured coronary atherosclerotic plaques in vivo in patients with coronary heart disease. For 
the first time, we have shown that ¹⁸F-fluoride positron emission tomography can identify 
culprit and ruptured plaques in patients with myocardial infarction and symptomatic carotid 
disease. Moreover, histological characterisation demonstrates that ¹⁸F-fluoride activity 
localises to regions of plaque rupture with evidence of increased inflammation, calcification 
activity, necrosis, and cell death. In patients with stable angina, ¹⁸F-fluoride is associated with 
coronary plaques that have high-risk features on intravascular ultrasound, including positive 
remodelling, microcalcification, and necrosis. Given its ability to identify high-risk or 
ruptured coronary atherosclerotic plaque, this non-invasive imaging technique has the 
potential to change how we identify, manage, and treat patients with stable and unstable 
coronary artery disease. Further work is now needed to establish whether ¹⁸F-fluoride 
positron emission tomography will provide a means of improving risk stratification, 
monitoring disease progression, guiding therapeutic interventions, and assessing novel 
anti-atherosclerotic therapies.
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A new frontier in atherosclerotic coronary imaging
Ischaemic heart disease resulting from rupture of 
atherosclerotic plaques is a major cause of death world-
wide. Precisely why a plaque ruptures remains a mystery. 
However, in The Lancet, Nikhil Joshi and colleagues’ 
findings1 suggest that we are close to being able to 
detect when rupture is about to occur.
The simple and inexpensive ¹⁸F-sodium fluoride 
(¹⁸F-NaF) PET radioisotope, used for 30 years to image 
bone formation, was found to signify metabolically 
active calcification in the aorta by Derlin and colleagues2 
and in the coronary arteries by Beheshti,3 Dweck,4 and 
Li,5 and their colleagues. In their landmark article, Joshi 
and coworkers move this nascent field much farther 
forward.1 They prospectively studied 40 patients with 
recent myocardial infarction (mean 8 days earlier) with 
invasive coronary angiography, CT coronary angiography, 
coronary calcium scoring, and cardiac gated PET-CT with 
¹⁸F-NaF and ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG). Using 
invasive coronary angiography as the gold standard 
for determining the culprit plaque, the area of greatest 
¹⁸F-NaF uptake in the coronary arteries localised the 
plaque in 37 of 40 patients (maximum tissue-to-back-
ground ratio in the culprit plaque 1·66 [1·40–2·25] vs 
highest non-culprit plaque 1·24 [1·06–1·38]). By contrast, 
interpretation of ¹⁸F-FDG PET-CT images in the same 
cohort was technically difficult because of the frequent 
overlap of myocardial ¹⁸F-FDG uptake with the adjacent 
coronary arteries. Of the 55% of vascular territories that 
were interpretable by ¹⁸F-FDG, only a weak correlation was 
seen with culprit plaque identification. 
A second cohort of 40 patients with stable angina 
underwent the same imaging tests and an intracoronary 
ultrasound. 18 patients had one or more plaques with 
high ¹⁸F-NaF uptake, defined as at least 25% greater than 
a proximal reference lesion. Intracoronary ultrasound 
identified that microcalcification, necrotic core size, and 
positive remodelling correlated strongly with plaques of 
high ¹⁸F-NaF activity.
Histological correlation was assessed in a third cohort 
of nine patients who underwent carotid endarterectomy 
at a mean of 17 days after clinical symptoms. Ex-vivo 
PET-CT was done on the removed carotid atherosclerotic 
tissue. Macroscopic plaque rupture was present in each 
patient, all localised to areas of high ¹⁸F-NaF uptake. 
Plaques with increased ¹⁸F-NaF uptake had substantially 
larger necrotic cores, more cell death and macrophage 
infiltration, and, as measured by alkaline phosphatase 
and osteocalcin staining, more active calcification than 
those that did not.
With the strong in-vivo correlates of coronary plaque 
rupture seen on intracoronary ultrasound in patients 
with stable angina, and histological confirmation of 
plaque rupture in atherosclerotic carotid tissue with 
high ¹⁸F-NaF activity, the authors can indeed state 
that of 40 patients with recent myocardial infarction 
(37 men, three women), plaque rupture can be detected 
non-invasively.
Now that we can detect plaque rupture, should 
we? Although the radioisotope ¹⁸F-NaF and PET-CT 
equipment are readily available in the developed 
world, much research needs to be done before the 
technique can become a viable clinical option. Just 
because a plaque at risk for rupture can be identified 
does not mean that we know what to do with this 
information. Prospective trials are needed to establish 
the frequency with which high ¹⁸F-NaF plaques 
rupture, and the timing of rupture. Also, does plaque 
rupture result in events or simply the rupture and 
healing cycle believed to result in a stepwise increase 
in plaque stenosis? If such trials are positive, what will 
we do with the information? Of Joshi and colleagues’ 
40 patients with stable angina, nearly all were on 
antiplatelet agents and 36 were taking statins. Despite 
this therapy, 18 patients had at least one plaque with 
high ¹⁸F-NaF uptake. However, the ability to assess 
and potentially quantitatively measure plaque at high 
risk of rupture as a continuous variable (by maximum 
standard uptake value) creates a new world of 
opportunity for the investigation of pharmacological 
and device therapy.
The technique holds greater promise in populations 
with myocardial infarction and acute coronary syndrome 
than in more stable patients. Earlier work by Joshi and 
colleagues, for example, found a strong correlation 
between patients with high NaF plaques and those 
with the more easily and inexpensively obtained total 
Agatston coronary calcium score.4
The technique also creates the opportunity to 
better assess the commonly accepted belief that most 
myocardial infarctions are caused by rupture of previously 
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non-obstructive plaques. The underpinnings of this theory 
are derived from coronary angiography that is done 
distant from the index myocardial infarction.6,7 Narula and 
colleagues8 and others have questioned this assumption. 
The predictive value for increasing non-fatal myocardial 
infarction and cardiac death consistently seen in studies of 
increasing ischaemia, as assessed by myocardial perfusion 
imaging,9 and worsening obstructive disease by coronary 
CT10 and invasive angiography, are also inconsistent with 
this assumption.
Questions to be answered include: how best to 
use information derived from an assessment of 
inflammation by ¹⁸F-FDG and active calcification 
by ¹⁸F-NaF. In large vessels without adjacent areas 
of intense ¹⁸F-FDG activity, ¹⁸F-FDG assessment is 
much less handicapped by overlapping structures 
compared with the coronary arteries. How do Joshi 
and colleagues’ findings apply to women, in whom 
plaque erosion is a much more common mechanism 
of myocardial infarction than in men? How do 
the findings apply to patients with diabetes? Does 
coronary artery bypass graft biology differ with respect 
to ¹⁸F-NaF activity? Do high ¹⁸F-NaF plaques in the 
carotid and other cerebrovascular vessels predict 
stroke and transient ischaemic attack? Joshi and 
colleagues and earlier pioneers have identified a new 
and hopefully fruitful frontier in nuclear cardiology 
and atherosclerotic coronary imaging.
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EDITOR'S COMMENT
Molecular imaging of coronary atherosclerosis;
predictive of an acute myocardial infarction?
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Coronary atherosclerosis is a leading cause of cardiovascular
morbidity and mortality worldwide. Plaque complications
occur most commonly from plaque rupture, and also from
plaque erosion and calcified nodule formation. Over the past
years, advanced structural, metabolic and molecular imaging
technologies have emerged and offer new windows into ath-
erosclerosis pathophysiology [1–4]. Molecular imaging com-
plements traditional structural plaque imaging through the use
of targeted probes that identify specific molecules and/or
biological processes in vivo [5]. Preclinical atherosclerosis
molecular imaging has successfully identified nearly all
established high-risk plaque characteristics including inflam-
mation, thrombosis, neo-vessel formation, apoptosis, and
haemorrhage. However, clinical translation of molecular im-
aging has been slow compared with the rapid growth within
the field.
Currently, clinical atherosclerosis molecular imaging is
dominated by non-invasive PET metabolism/inflammation
plaque imaging with fluorine 18 (18F)-fluorodeoxyglucose
(FDG). For the past two decades, 18F FDG has been the only
fluorine-18 radioligand approved by the US Food and Drug
Administration (FDA) for PET imaging. Coronary FDG PET
is challenging, in part owing to the small size of coronary
vessels and cardiac motion artefacts, but also because of the
intense FDG uptake of the adjacent highly metabolic myocar-
dium that obscures the coronary FDG signal. However, with
dietary myocardial suppression protocols, detection of FDG
PET signal in the left main and proximal coronary artery beds
is sometimes achievable. Recently, non-invasive coronary
FDG PET activity has been investigated in the stented culprit
lesions of 20 subjects with acute coronary syndromes (ACS)
versus seven non-ACS subjects within 1 week of stent place-
ment [6]. Using a predetermined FDG target to background
ratio of 2.0 or greater to identify FDG-positive lesions, the
ACS patients correlated positively with elevated stent FDG
signal. However, coronary FDG signal was interpretable in
only 50 % of ACS patients, implying the need for further
improvements in coronary FDG PET.
Apart from 18F FDG coronary imaging, clinically avail-
able approaches such as sodium 18F-fluoride (NaF) for PET
are emerging. Coronary calcification is a hallmark of ad-
vanced atheroma that can be detected with non-invasive NaF
PET, which has been used for the past 3 decades to detect
cancer bone metastases. As opposed to FDG, background
myocardial uptake of NaF is negligible, and therefore NaF
can determine coronary osteogenic activity. In a study by
Dweck et al. from the University of Edinburgh [7], NaF
PET molecular imaging identified sites of active coronary
calcification non-invasively by PET and may be a new thera-
peutic target. The NaF signal was elevated in proportion to
coronary CT calcium scores in 119 subjects, except in those
with the highest calcium scores that may represent end-stage
calcified plaques. From the same research group, Joshi et al.
[8] recently (Lancet November 2013) studied coronary plaque
imaging using two different radioactive tracers: 18F-NaF and
18F-FDG. The Scottish study included 40 patients with acute
myocardial infarction (AMI) and 40 patients with stable angi-
na. All patients underwent PET-CT, invasive coronary angi-
ography, CT coronary angiography, and CT calcium scoring.
Among the 40 patients with AMI, 18F-NaF PET uptake
was 34 % higher in the culprit ruptured plaque compared with
non-culprit plaques. Nearly all patients (93 %) had increased
18F-NaF uptake in the culprit plaque. With 18F-FDG, how-
ever, no differences in uptake between culprit and non-culprit
plaques were observed. Among the 40 patients with stable
angina, 45 % had plaques with increased 18F-NaF uptake.
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These plaques were mostly non-obstructive at coronary angiog-
raphy and contained more high-risk features on intravascular
ultrasound compared with plaques without tracer uptake. Con-
sequently, 18F-NaF PET may become an effective tool for
predicting anAMI, whichwould have a great impact for patients
with coronary atherosclerosis. Early detection of the atheroscle-
rotic ‘danger zones’ could include immediate instalment of
drugs such as statins or aspirin, drastic changes in lifestyle and
even inserting stents into the affected coronary artery.
The use of 18F-NaF PET-CT offers the first non-invasive
imaging method to identify and localise ruptured and high-
risk coronary plaques. A next step is to show that increased
18F-NaF predicts future adverse clinical events. Further stud-
ies are therefore needed to evaluate whether the detection of
risky plaques before rather than after an AMI has the potential
to save lives. To summarise, the addition of newer molecular
imaging tools such as NaF PET-CTwill continue to strengthen
our understanding of the in vivo biology of high-risk plaques
[9, 10]. They are increasingly being translated into clinical
use, and in combination with structural imaging they provide
more comprehensive information to build risk-prediction
tools. Ongoing efforts to improve non-invasive coronary im-
aging strategies must be pursued. Overall, with continued
advances in molecular and structural atherosclerosis imaging,
high-risk coronary atherosclerotic plaques will be brightened
as never before. The recent study in the Lancet at least sug-
gests that molecular imaging using PET-CT scanning may
provide an answer in identifying ‘ticking time bomb’ patients
at risk of an AMI.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
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CORONARY ARTERY DISEASE
Noninvasive imaging technique can identify high-risk 
coronary plaques
Atherosclerotic plaque rupture 
and subsequent acute myocardial 
infarction are well known to be a 
major cause of death worldwide. 
Prediction of plaque rupture, 
however, has proven challenging. 
A new noninvasive imaging 
technique that uses an inexpensive 
PET radioisotope, 18F-NaF, might 
prove to be the answer. Indeed, the 
investigators of a study published 
in the Lancet believe that their 
technique “holds major promise 
as a means of identifying high-
risk and ruptured plaque, and 
potentially informing the future 
management and treatment of 
patients with stable and unstable 
coronary artery disease”.
When 40 patients who had 
been hospitalized for myocardial 
infarction underwent 18F-FDG 
PET-CT scanning, no significant 
differences in maximum 18F-FDG 
uptake were observed between 
the culprit plaques and plaques 
located elsewhere in the coronary 
vasculature. By contrast, increased 
18F-NaF uptake was observed in 
the culprit plaque in 37 of the 
40 patients. 18F-NaF activity was 
found to be 34% higher in the 
culprit plaque than the maximum 
activity recorded anywhere else in 
the coronary vasculature.
Ex vivo 18F-NaF PET-CT 
and histological analysis were 
performed on carotid specimens 
obtained from nine other patients 
who had undergone carotid 
endarterectomy for symptomatic 
carotid artery disease. Compared 
with tissue that did not take 
up 18F-NaF, areas of increased 
18F-NaF uptake were found to 
have increased calcification, 
macrophage infiltration, and 
cell death. In their study report, 
Dr Nikhil Joshi and colleagues 
describe how they believe 18F-NaF 
is taken up by high-risk plaques: 
“Hydroxyapatite is the central 
structural component of vascular 
calcification and is laid down 
during the earliest and most 
active stages of mineralization ... 
Fluoride ions are incorporated 
into the hydroxyapatite by ion 
Image reprinted from Joshi, N. V. et al. 18F-fluoride 
positron emission tomography for identification 
of ruptured and high-risk coronary atherosclerotic 
plaques: a prospective clinical trial. Lancet 
doi:10.1016/S0140-6736(13)61754-7, 
Copyright (2013), with permission from Elsevier.
exchange with hydroxyl groups 
at the crystal surface.” “By 
identifying areas of nascent and 
ongoing calcification activity,” 
they explain, “18F-NaF uptake 
allows us to detect regions of 
metabolically active plaque.”
Joshi et al. also assessed coronary 
18F-NaF uptake in 40 patients with 
stable angina pectoris. Increased 
18F-NaF uptake seemed to identify 
coronary plaques that, although 
mostly shown to be nonobstructive 
on coronary angiography, 
contained high-risk features 
(increased positive remodelling, 
microcalcification, and necrotic 
core) on intravascular imaging.
“Prospective studies are 
now needed in a broad range 
of patients to assess whether 
increased coronary 18F-NaF 
activity will ultimately translate 
into future adverse events,” say the 
investigators. “If the results prove 
confirmatory, then this technique 
has the potential to fundamentally 
alter the way we treat coronary 
artery disease.”
Bryony M. Mearns
© 2013 Macmillan Publishers Limited. All rights reserved
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WHAT THIS PAPER ADDS
Comparing these techniques identifies a modest correlation but some key differences related to the spatial
distribution of 18F-FDG and USPIO uptake. This may reflect the differing elements of macrophage activity
detected by these modalities: glycolysis and phagocytosis. Further studies are needed to assess whether
identification of this varying activity will influence aneurysm growth rates and the clinical outcome.
Objectives: Inflammation is critical in the pathogenesis of abdominal aortic aneurysm (AAA) disease. Combined
18F-fludeoxyglucose (18F-FDG) positron emission tomography with computed tomography (PET-CT) and ultrasmall
superparamagnetic particles of iron oxide (USPIO)-enhanced magnetic resonance imaging (MRI) are non-invasive
methods of assessing tissue inflammation. The aim of this study was to compare these techniques in patients
with AAA.
Materials and methods: Fifteen patients with asymptomatic AAA with diameter 46 ! 7 mm underwent PET-CT
with 18F-FDG, and T2*-weighted MRI before and 24 hours after administration of USPIO. The PET-CT and MRI
data were then co-registered. Standardised uptake values (SUVs) were calculated to measure 18F-FDG activity,
and USPIO uptake was determined using the change in R2*. Comparisons between the techniques were made
using a quadrant analysis and a voxel-by-voxel evaluation.
Results: When all areas of the aneurysm were evaluated, there was a modest correlation between the SUV on
PET-CT and the change in R2* on USPIO-enhanced MRI (n ¼ 70,345 voxels; r ¼ .30; p < .0001). Although regions
of increased 18F-FDG and USPIO uptake co-localised on occasion, this was infrequent (kappa statistic 0.074; 95%
CI 0.026e0.122). 18F-FDG activity was commonly focused in the shoulder region whereas USPIO uptake was more
apparent in the main body of the aneurysm. Maximum SUV was lower in patients with mural USPIO uptake.
Conclusions: Both 18F-FDG PET-CT and USPIO-MRI uptake identify vascular inflammation associated with AAA.
Although they demonstrate a modest correlation, there are distinct differences in the pattern and distribution of
uptake, suggesting a differential detection of macrophage glycolytic and phagocytic activity respectively.
! 2015 The Authors. Published by Elsevier Ltd on behalf of European Society for Vascular Surgery. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Article history: Received 11 March 2015, Accepted 12 December 2015, Available online 23 February 2016
Keywords: Abdominal aortic aneurysms, Magnetic resonance imaging, Positron emission tomography, Computed
tomography
INTRODUCTION
Recent advances in imaging modalities have generated
considerable interest in novel molecular and cellular
techniques. In contrast to anatomical and structural ap-
proaches, molecular and cellular imaging targets the activity
of specific biochemical and cellular processes to provide
insight into the aetiology, biology, and pathogenesis of
diseased states. Moreover, this has the potential to refine
the diagnosis and risk stratification of cardiovascular disease
as well as to assess responses to specific therapeutic in-
terventions.1e5 A combination of morphological imaging
with molecular imaging has proven a particularly useful
approach.
18F-Fludeoxyglucose (18F-FDG) is used to image meta-
bolically active cells with combined positron emission and
computed tomography (PET-CT). 18F-FDG accumulates in all
e These authors contributed equally.
* Corresponding author. Centre for Cardiovascular Science, University of
Edinburgh, Little France Crescent, Edinburgh EH16 4SB, UK.
E-mail address: olivia.mcbride@ed.ac.uk (O.M.B. McBride).
1078-5884/! 2015 The Authors. Published by Elsevier Ltd on behalf of
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cells and tissues that metabolise glucose, in direct propor-
tion to their metabolic activity. In atherosclerotic arteries
and those affected by vasculitides, 18F-FDG uptake corre-
lates with the degree of arterial inflammation and is
reproducible.6e8 Furthermore, 18F-FDG uptake increases
with the number of cardiovascular risk factors present, is
predictive of future cardiovascular events,9e11 and has been
used as a biomarker to demonstrate the anti-inflammatory
effects of statins and other novel therapies.12e14 18F-FDG
accumulates in the wall of abdominal aortic aneurysms
(AAAs) and several studies have correlated uptake with
aortic vessel wall inflammation on histology.15e17 There is
evidence to suggest that 18F-FDG can discriminate between
asymptomatic and symptomatic AAA, but its potential use
as a marker of aneurysm expansion, progression, and
rupture has yet to be established.15e22
Magnetic resonance imaging (MRI) with ultrasmall
superparamagnetic particles of iron oxide (USPIO) is an
alternative approach for detecting cellular inflamma-
tion.23,24 Owing to their small particle size (diameter 10e
30 nm), USPIO escape immediate recognition by the
reticulo-endothelial system, persist in the bloodstream, and
accumulate at sites of vascular inflammation. Here they
undergo phagocytosis by tissue-resident macrophages
within which they accumulate and are detectable on T2-
and T2*-weighted MRI sequences. Within atheromatous
plaques, USPIO uptake correlates with macrophage density,
distinguishes stable from unstable carotid plaques, and is
reduced following high-dose atorvastatin therapy.25e27
USPIO uptake in the wall of AAAs has previously been
demonstrated, where it co-localises with macrophages and
is associated with a threefold higher AAA growth rate.24
Given that both 18F-FDG PET and USPIO-enhanced MRI
have been used to assess vascular inflammation in patients
with AAA, the aim of this study was to compare 18F-FDG PET
and USPIO-enhanced MRI in patients with AAAs. Specif-
ically, the spatial distribution and intensity of the inflam-
matory process using both techniques was assessed to
determine whether they provided complementary or
distinct insights into the pathology of AAAs.
MATERIALS AND METHODS
Subjects
Patients with asymptomatic AAA (diameter 30e55 mm on
duplex ultrasound examination) were recruited from the
aneurysm surveillance clinic at the Royal Infirmary of
Edinburgh. Exclusion criteria were age < 50 years, active
systemic inflammatory or malignant disease, renal
dysfunction (estimated glomerular filtration rate < 30 mL/
min, because of the risks of contrast induced renal
dysfunction), hepatic cirrhosis (ChildePugh score B or C,
because of the contrast agent not having been studied in
this group of patients), planned AAA surgery within 6
months of screening, any contraindication to MRI and
insulin-dependent diabetes mellitus (due to the confound-
ing of 18F-FDG uptake with variable blood glucose concen-
trations). Studies were performed with the approval of the
local research ethics committee, in accordance with the
Declaration of Helsinki, and with the written informed
consent of each participant.
All patients underwent a comprehensive baseline clinical
assessment, including evaluation of their cardiovascular risk
factor profile and recording of an abdominal ultrasound
scan. 18F-FDG PET-CT and USPIO-MRI data acquisition pro-
cedures are detailed in Methods I of the Supplementary
Material.
Image analysis
Registration of PET and MRI images. The accuracy of PET-CT
to Computed Tomography Aortogram (CTA) registration was
confirmed by visual assessment, and minor intra-scan pa-
tient movement was corrected using a semi-automatic rigid
3D voxel registration protocol (Analyze 11.0, Mayo Clinic,
Rochester, MN, USA). Registration of the MRI data allowed
the excellent anatomical detail on the T2W images and the
high sensitivity of T2*W images for iron to be utilised. All
MR images were registered to the pre-contrast T2W image.
The CTA and T2W MRI datasets were also co-registered. At
the end of the registration process, the pre-USPIO T2*W
MRI, the post-USPIO T2*W MRI, the CTA, and the PET-CT
were all co-registered to enable direct comparison. All
steps of registration used a semi-automatic rigid 3D voxel
registration protocol that has been previously validated and
published.24 All outputs were manually checked and opti-
mised as necessary. Two independent trained observers,
who were experienced vascular surgeons who had devel-
oped the image analysis techniques, undertook the ana-
lyses. There was excellent inter-observer agreement with
kappa statistics between 0.84 and 0.89, for all steps.
18F-FDG quantification. The maximum standardised uptake
value (SUVmax) was used to assess
18F-FDG uptake in the
aneurysm. The SUV is the decay-corrected tissue uptake
divided by the injected dose per unit body weight and is a
semi-quantitative dimensionless unit that has been previ-
ously validated and is a commonly used measure of tissue
18F-FDG uptake.5,28 The SUV in vascular structures can be
heavily influenced by variability of 18F-FDG activity in the
blood pool. Therefore, the tissue-to-background ratio (TBR)
was also calculated by dividing the tissue SUVmax by an
averaged mean SUV in the blood pool, derived from five
circular regions of interest in the centre of the inferior vena
cava. An area of 18F-FDG uptake was defined as positive if
the SUVmax or TBR was > 125% of the value obtained from
an averaged SUVmax from five randomly selected regions in
the non-aneurysmal descending thoracic aorta.29,30
USPIO quantification. Using validated in-house software
built in the Matlab environment (Mathworks, Natick, MA,
USA), all four echoes in the multi-echo T2*W sequence
were combined to generate a T2* map in which the
magnitude of each voxel represented the T2* value
(S(t) ¼ S(0)exp " (t/T2*). USPIO uptake was detected using
the change in T2* (or R2*; R2* ¼ 1/T2*) following USPIO
administration. We applied a validated image analysis
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method previously published for DT2* thresholding of AAA-
USPIO data in order to visually interpret and threshold the
UPSIO T2*-weighted data.24 Increasingly R2* (¼1/T2*) are
reported to provide a positive correlation between con-
centration of USPIO and increase in R2* values, facilitating
more straightforward data interpretation and visualisation.
Detailed USPIO quantification methodology is outlined in
Methods II of the Supplementary Material.
The correlation between 18F-FDG uptake and USPIO dis-
tribution was analysed using three methods: the signals in
different regions of the aneurysm were compared by
drawing regions of interest (ROI) around the wall and
thrombus, then the co-localisation across the aneurysm as a
whole using a voxel-by-voxel analysis was studied. Finally, a
previously defined aneurysm classification system based on
USPIO uptake on MRI24 was compared with the mean
SUVmax and TBR for the positive regions of
18F-FDG uptake
in each aneurysm.
Colour maps. Two independent observers, blinded to pa-
tient demographics and aneurysm size reviewed the DT2*
colour maps and the fused PET-CT data. Each axial slice was
divided into quadrants and each quadrant was defined as
positive if it included at least one region of increased USPIO
or 18F-FDG uptake, or negative if it did not. On the DT2*
colour maps, significant regions of USPIO accumulation
were defined as consisting of at least 10 contiguous voxels
with DT2* above the threshold of 59%.24 On the PET-CT
scans, ROI were drawn around areas of maximum uptake
in the wall and thrombus of the aneurysm and defined as
positive if the SUVmax or TBR was > 125% of the value
obtained from an averaged SUVmax from five randomly
selected regions in the non-aneurysmal descending thoracic
aorta.
In order to define the area of the aneurysm where there
was increased uptake of USPIO or 18F-FDG, the aneurysm
was divided in the axial plane into three distinct regions: on
MRI the shoulder region extended one slice (5 mm) above
and below the point at which the aorta last measured "
30 mm in diameter, whereas on PET-CT, two slices (6 mm)
were considered. The bifurcation region was defined in an
identical way but from the point where the aneurysm
reduced in diameter to " 30 mm. The area between these
two points was defined as the main body of the aneurysm.
Voxel-by-voxel analysis. The MR images were reconstructed
by down-sampling to achieve equivalent voxel sizes with the
corresponding PET images. A ROI encompassing the entire
aortic wall and thrombus was drawn on each slice of the
pre-contrast T2W image. These ROIs were then applied to
the PET images and to the calculated DR2* colour maps.
This enabled a quantitative voxel-by-voxel analysis of USPIO
and 18F-FDG uptake.
Aneurysm classification. We have previously shown that
mural USPIO uptake predicts expansion; therefore, aneu-
rysms were classified into three predefined groups by two
independent blinded observers: Group 1, no mural or
thrombus USPIO uptake, except for isolated periluminal
enhancement; Group 2, diffuse USPIO uptake, distinct from
the periluminal thrombus and aortic wall; and Group 3 focal
areas (with at least 10 contiguous voxels) of USPIO uptake
within the aortic wall of the aneurysm, distinct from the
periluminal area and thrombus.24 PET activity in regions of
increased uptake was then compared across these three
groups.
A schematic outlining the image analysis techniques un-
dertaken can be found in Methods III of the Supplementary
Material.
Statistical analysis
Normally distributed continuous variables were expressed
as mean # standard deviation. Non-parametric data were
presented as median with interquartile ranges. Correlations
between normally distributed data were performed using
Pearson’s correlation. Comparisons were undertaken with
paired or unpaired Student’s t-tests as appropriate. A two-
sided p < .05 was regarded as statistically significant. Sta-
tistical analysis was performed with the use of Graph Pad
Prism version 5 (GraphPad Software Inc., La Jolla, CA USA).
RESULTS
Fifteen predominantly elderly men with multiple cardio-
vascular risk factors and a mean AAA diameter of 46 mm
(range 34e55 mm) participated in the study (Table 1). All
patients were asymptomatic and had fusiform aneurysms
confined to the abdominal aorta. 18F-FDG PET-CT and
USPIO-enhanced MRI scans were performed a median of 7
days apart. PET imaging of the abdomen was undertaken a
median of 92 (IQR, 89e97) minutes after injection of
237 # 16 MBq of 18F-FDG. The effective radiation from
participation in the study was 10.8 mSv using a conversion
Table 1. Baseline characteristics of patients with abdominal aortic
aneurysm (n ¼ 15).








Coronary artery disease 5 (33%)
Stroke or transient ischemic attack 2 (13%)
Peripheral vascular disease 2 (13%)
Risk factors
Current smoking habit 6 (40%)
Previous smoking habit 8 (60%)




Antiplatelet agent 12 (80%)
Statin 13 (87%)
b-Blocker 6 (40%)
ACE inhibitor/ARBa 8 (53%)
Other Anti-hypertensive 2 (13%)
a Angiotensin converting enzyme (ACE) inhibitor or angiotensin II
receptor blocker (ARB).
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factor of 0.014 mSv/mGy cm. The administration of 18F-FDG
and USPIO was well tolerated with no adverse events.
18F-FDG uptake
Increased 18F-FDG uptake was observed within the wall of
13 of the 15 AAAs. In total there were 42 regions of
increased uptake and all were diffuse and involved the wall.
Although it was not possible to resolve whether this uptake
localised to the aneurysm wall or the thrombus, the ma-
jority were observed in the shoulder region of the aneurysm
(25/42, 60%), with a third (14/42) occurring within the main
body of the aneurysm and the remainder in close proximity
to the bifurcation (3/42). There was increased uptake in the
peri-luminal zone of the thrombus in all patients.
USPIO uptake
All AAA demonstrated uptake of USPIO but focal areas of
mural USPIO were primarily confined to the main body of
the aneurysm (146/271, 54%), with 28% (75/271) located in
the shoulder region and 19% (50/271) adjacent to the
bifurcation (Table 2). In keeping with our previous study,24
all patients had USPIO uptake in the periluminal area,
representing a movement of particles directly into the
thrombus from the blood pool.
Comparison between 18F-FDG and USPIO uptake
When all areas of the aneurysm were considered, there was
a modest correlation between the SUV on PET-CT and the
absolute change in R2* on MRI (r ¼ .30; 95% CI 0.29e0.31,
p < .0001; Fig. 1).
In general, the main thrombus (excluding the peri-luminal
region) did not uptake 18F-FDG or USPIO. In contrast, local
inflammation within the wall was readily identifiable but
was not reflected by a change in T2* or R2* value in the
whole aneurysm because of the associated dilutional effect
of the thrombus.
Classification of AAA according to 18F-FDG or USPIO up-
take using the quadrant technique was consistent and
reproducible with excellent inter-observer agreement and a
kappa statistic of 0.87 for 18F-FDG and 0.85 for USPIO. On
occasion, areas of increased USPIO and 18F-FDG uptake co-
localised to the same quadrant in the aortic wall, although
regions of USPIO uptake without corresponding 18F-FDG
uptake were also commonly seen (Fig. 2). Overall, co-
localisation of areas of increased USPIO and 18F-FDG up-
take were poor (kappa statistic 0.074; 95% CI 0.026e0.122)
and there were more areas of increased uptake identified
on MRI than on PET-CT (Table 3). Focal and discrete uptake
of USPIO can be readily discerned on MRI, whereas there
was more diffuse and ill-defined uptake of 18F-FDG involving
both the wall and the thrombus on PET-CT.
Based on USPIO uptake, four patients were classified into
Group 3 and 11 into Groups 1 and 2. SUVmax and TBR
appeared to be lower in those classified as Group 3 than in
those in Groups 1 and 2, but this did not reach statistical
significance (p ¼ .7884, 95% CI e2.181 to 1.690; Fig. 1).
There was no correlation between the grouping classifica-
tion and the maximum absolute change in R2* (p ¼ .4123,
95% CI e86.99 to 37.98).
DISCUSSION
In comparing 18F-FDG PET-CT with USPIO-enhanced MRI in
patients with AAA, we have identified a modest correlation
between these two imaging modalities but a number of key
differences. In particular, activity detected with these two
techniques appears to be concentrated in different regions
of the aneurysm: largely in the shoulder region with 18F-
FDG and in the body of the aneurysm using USPIO. We
believe that this reflects the different elements of inflam-
matory activity detected by these two approaches, with
PET-CT providing information related to glycolysis and
USPIO information on phagocytosis. Further studies are
now required to assess which modality will have the
greatest predictive power to determine aneurysm growth
and clinical outcome.
Inflammatory cells have a key role in the development
and progression of abdominal aortic aneurysms.17 Histo-
pathologically, the aneurysmal aortic wall is characterised
by focal medial neovascularisation, infiltration of inflam-
matory cells (principally macrophages and lymphocytes),
and fragmentation of elastin and collagen fibres within the
extracellular matrix. Both 18F-FDG and USPIO imaging aim
to detect and quantify the inflammatory cellular component
and it is therefore encouraging that a modest correlation
between these two measures was observed in this study,
confirming that ultimately both identify vascular inflam-
mation, albeit through differing pathways.
Vascular inflammatory cells are metabolically active and
take up 18F-FDG in an insulin-insensitive manner. Therefore,
Table 2. Qualitative evaluation of 18F-fludeoxyglucose (FDG) uptake on positron emission tomography and computed tomography (PET-CT)
compared to ultrasmall superparamagnetic particles of iron oxide (USPIO) uptake on magnetic resonance imaging (MRI).
18F-FDG PET-CT USPIO MRI
Spatial resolution 4e6 mm 2 mm (subject to field of view)
Periluminal enhancement Present Present
Region of uptake Predilection for shoulder region Predilection for main body of aneurysm
Definition of uptake > 125% of the averaged SUVmax from five
randomly selected regions in the non-aneurysmal
descending thoracic aorta
10 contiguous voxels with % change in T2* "59%
Functional assessment Glycolytic activity Phagocytic activity
Ionising radiation Yes No
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18F-FDG uptake in the fasted state has been proposed as a
marker of risk for aneurysm progression and rupture with
higher uptake associated with inflammation, aortic wall
instability, and clinical symptoms.15,18 However, the role of
18F-FDG PET-CT in AAA disease remains controversial.
Recent data have suggested that vascular 18F-FDG activity
may relate to more than simply macrophage burden,31 with
several studies identifying high lymphocyte counts and
leucocytes15,17,32 within the aortic wall and implicating
hypoxia as an important driver to 18F-FDG uptake.33
Furthermore, although several small studies have demon-
strated the ability of 18F-FDG to discriminate between
symptomatic and asymptomatic AAA,15e18,21 a number of
published studies have failed to verify these observations.
Palombo et al.34 showed 18F-FDG uptake was low in
asymptomatic AAAs, with a diameter close to surgical in-
dications (mean diameter, 4.9 cm), perhaps reflecting
decreased cell density in large AAAs. Tegler et al.32 found no
relationship between 18F-FDG uptake and asymptomatic
(small or large) AAAs versus controls and no correlation
between histology and uptake. Similarly, Kotze et al.20 found
an inverse relationship between 18F-FDG uptake and future
growth rate of AAA.
USPIO-enhanced MRI has been used to explore a number
of inflammatory conditions, including atherosclerotic pla-
ques and abdominal aortic aneurysms.23e25,27 USPIO are
taken up by inflammatory phagocytic cells, particularly
macrophages, and accumulate at sites of cellular
Figure 1. (A.) Comparison of standard uptake value (SUV) and absolute change in R2* in the wall of the abdominal aortic aneurysm (AAA).
When the thrombus and wall of the aneurysm are considered there is a modest correlation between the SUV and the absolute change in
R2* (r ¼ 0.30). (B) MRI group classification compared to maximum SUV (SUVmax) and tissue-to-background ratio (TBR) in the wall of the
AAA. There was no significant difference between the SUVmax (p ¼ .4696, 95% CI e1.682 to 0.8194) or TBR (p ¼ .7884, 95% CI e2.181 to
1.690) of patients in Groups 1 and 2 and those in Group 3.
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inflammation at sufficient concentrations to cause signal
changes on MRI. In addition, histological examination of
excised tissue, including aneurysm tissue, has confirmed the
co-localisation and uptake of USPIO in areas of macrophage
infiltration.24,35e37
We speculate that USPIO and 18F-FDG uptake represent
distinct markers of vascular inflammation that correspond
to differing inflammatory and macrophage activities.
Clearly, USPIO uptake is a measure of ongoing phagocytic
activity of tissue-resident macrophages and potentially
neutrophils, whereas 18F-FDG reflects glucose utilisation by
cells with high metabolic requirements including the cells
implicated in vascular inflammation.38 Moreover there is
evidence that the two techniques target different macro-
phage subsets. Macrophages exist in varying polarised
states and have different roles in vascular tissue. M1 mac-
rophages are considered more destructive, promoting the
destabilisation and rupture of atherosclerotic plaques,
whereas phagocytosis is more important in the role of M2
macrophages stimulating reparative processes, mediated by
the production of anti-inflammatory cytokines and the
suppression of pro-inflammatory signalling.39 It has been
suggested that 18F-FDG and USPIO uptake may be able to
differentiate these two distinct M1 and M2 macrophage
sub-populations respectively.40 In this study, the majority of
18F-FDG uptake was identified in the shoulder region of the
aneurysm, an area of high biomechanical stress,41,42 with a
particular tendency to rupture: perhaps related to a
destructive macrophage phenotype in this area.
Even though it has been demonstrated that our USPIO
aneurysm classification identifies aneurysms likely to prog-
ress and dilate (Group 3; distinct mural USPIO uptake) we
found no correlation between this classification and 18F-
FDG uptake nor the maximum absolute change in R2*. This
supports the suggestion that it is the location of USPIO
Figure 2. (A,B) Representative magnetic resonance imaging (MRI) (A) and fused positron emission tomography and computed tomography
(PET-CT) (B) scans from the same patient with an abdominal aortic aneurysm (AAA). Ultrasmall superparamagnetic particles of iron oxide
(USPIO) uptake, defined by percentage change in T2* is demonstrated using a colour scale. Changes in T2* value over the threshold (59%)
are presented on a graduated (yellow-red) colour scale and data below the threshold appears blue. Corresponding 18F-fludeoxyglucose
(FDG) activity (red arrow) can be seen in B. Differences in the location of regions of uptake between the techniques are apparent, as
marked by the white arrow. (C,D) are corresponding MRI and fused PET-CT slices from the same patient who has no USPIO or 18F-FDG
uptake in the wall of the AAA, with uptake limited to the peri-luminal area.
Table 3. Quadrant analysis of the aneurysm wall: Regions of
uptake identified by magnetic resonance imaging (MRI) and
positron emission tomography and computed tomography (PET-
CT). kappa statistic ¼ 0.074 (95% C.I. 0.026e0.122), representing
a poor strength of agreement.
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uptake that is crucial, rather than the degree of USPIO
uptake. However, the modest correlation that was demon-
strated between maximum absolute change in R2* and SUV
on a voxel-by-voxel basis supports the contention that these
imaging modalities are both detecting elements of macro-
phage activity, namely phagocytosis and glucose
metabolism.
Study limitations
There are important study limitations and technical con-
siderations when interpreting our findings.We acknowledge
that co-registration of the MRI and PET-CT datasets was
challenging and cannot exclude partial or incomplete co-
registration. Moreover, the limited in-plane resolution of
PET-CT makes definition of the aortic wall and thrombus
difficult and therefore challenging to locate the exact site of
activity. Indeed this may also explain the increased 18F-FDG
uptake observed in the shoulder region, which is more
prone to partial volume effects due to its angulation
through the slice. This may reduce the sensitivity of the
study in detecting 18F-FDG or USPIO activity. However, as
the thrombus uptakes little contrast agent, if thrombus was
inadvertently included in the aortic wall assessment, this
would lead to a tendency to under report uptake, thus our
findings could be considered conservative. Additionally,
there is no consensus or validated definition of quantitative
significance values for 18F-FDG or USPIO uptake and despite
the excellent inter-observer reproducibility demonstrated in
this study, this may contribute to the differences observed.
The contribution of statin therapy to the results of this
study also cannot be excluded. To date there is only
observational data showing AAA growth reduction with
statins and mechanistic data are limited.43,44 Although
statin use has been shown to suppress AAA formation in
animal models, this has not been translated to humans.45,46
The use of statins in vascular patients to reduce cerebro-
vascular and cardiovascular mortality as well as in patients
undergoing AAA surgery is well documented.47,48 Conse-
quently a clinical trial with and without statin therapy in
AAA patients would be ethically challenging. The clinical
trial was registered at ClinicalTrials.gov (NCT01749280)
Intra-individual correlation of histologic specimens from
areas of minimum and maximum uptake of contrast would
provide evidence of co-localisation of inflammatory activity
but the practicalities of such are limited with the increase in
endovascular abdominal aortic aneurysm repair (EVAR) and
the ability to sample only tissue from the anterior portion
of the aortic wall. Moreover, ex vivo 18F-FDG uptake is
limited by the need for fresh viable tissue, whereas USPIO
uptake can only be assessed when undertaken in very close
proximity to elective surgery.
This was a small study population that will require pro-
spective evaluation in larger patient cohorts. Furthermore,
this study was limited by the exclusion of AAA ! 55 mm as
aneurysm growth and rupture is unpredictable and non-
linear. Current guidelines suggest that surveillance with
selective repair is the most appropriate management
strategy.49 However, as improvements in device technology
for EVAR continues, this may change. Given this limited
sample size, we were unable to assess the relationship
between uptake of either 18F-FDG or USPIO with AAA
growth rates or clinical outcome. A number of small studies
have demonstrated the ability of 18F-FDG to differentiate
between symptomatic and asymptomatic AAAs15e18,21 and
a recent study has suggested an association between 18F-
FDG activity and future clinical events.41 A pilot study of 29
patients demonstrated that USPIO uptake in the wall of AAA
is associated with accelerated expansion rates.24 Further
datasets with long-term follow-up are therefore required to
undertake more complete evaluation of these promising
imaging approaches.
An observational surveillance trial is currently underway
at the centre to assess the relationship between mural
USPIO uptake and subsequent clinical outcomes, with the
aim of improving risk stratification of patients with AAA: the
MA3RS trial (MRI for AAA to predict rupture or surgery;
ISRCTN76413758).
In conclusion, the correlation between 18F-FDG PET-CT
and USPIO-enhanced MRI to detect vascular inflammation
in AAAs is modest and reflects the differing elements of
macrophage activity that they detect: glycolysis and
phagocytosis respectively. Whether the identification of this
varying activity will impact on aneurysm growth rates or risk
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